

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/05/97ISR Number: 100000165Report Type:Expedited (15-DaCompany Report #ZANA0319970279
 Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - PER ORAL	Coma	Health	Zanaflex	PS		ORAL
Initial or Prolonged	Hypoglycaemia	Professional	Valium	C		
	Hypokalaemia		Betaseron	C		
	Respiratory Depression		Darvocet	C		
			Tylenol	C		
			Synthroid	C		

Date:11/10/97ISR Number: 100000206Report Type:Expedited (15-DaCompany Report #ZANA0319970282
 Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Dysphagia	Health	Zanaflex	PS		ORAL
Initial or Prolonged	Muscle Spasms	Professional	Ritonavir	C		
	Urinary Retention					

Date:11/26/97ISR Number: 3002805-0Report Type:Expedited (15-DaCompany Report #ZANA0319970288
 Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 24 MG DAILY, Initial or Prolonged PER ORAL	Abdominal Pain Lower	Health	Zanaflex	PS		ORAL
	Acute Respiratory	Professional				
	Distress Syndrome		Prednisone	C		
	Anxiety		Ditropan	C		
	Constipation		Halcion	C		
	Dehydration		Zantac	C		
	Dyspnoea		Amitriptyline	C		
	Hypotension		Lasix	C		
	Pneumothorax		Multivitamins	C		
	Pulmonary Oedema		Ecotrin	C		
			Os-Cal	C		

Date:12/01/97ISR Number: 3003022-0Report Type:Expedited (15-DaCompany Report #ZANA0319970291
 Age:45 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - PER ORAL Initial or Prolonged	Convulsion	Health Professional	Zanaflex Baclofen Synthroid Naproxen Hytrin Senokot Depakote	PS C C C C C C		ORAL

Date:12/01/97ISR Number: 3003025-6Report Type:Expedited (15-DaCompany Report #ZANA0319970292
 Age:87 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Asthenia Bradycardia Depressed Level Of

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Consciousness Dyspnoea Hyperhidrosis Hypersensitivity	Report Source	Product	Role	Manufacturer	Route
2MG DAILY, PER ORAL		Hypotension	Health	Zanaflex	PS		ORAL
		Pallor	Professional				
		Pulse Pressure Decreased		Lasix	C		
				Codamine	C		
				Ticlid	C		
				Zyloprim	C		
				Cordarone	C		
				Ativan	C		
				Paxil	C		
				Pepcid	C		
				Multivitamins	C		
				Metamucil	C		
				Darvocet-N	C		
				Ambien	C		

Date:12/15/97ISR Number: 3008767-4Report Type:Expedited (15-DaCompany Report #ZANA0319970291
Age:45 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 12 MG DAILY Initial or Prolonged		Convulsion	Health	Zanaflex	PS		ORAL
		Grand Mal Convulsion	Professional	Baclofen	C		
				Synthroid	C		
				Naproxen	C		
				Hytrin	C		
				Senokot	C		
				Depakote	C		
				Dulcolax	C		

Date:12/16/97ISR Number: 3008280-4Report Type:Direct Company Report #
Age:52 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 4MG PO Q 8HR;		Condition Aggravated		Zanaflex	PS		ORAL

4MG-4MG-8MG ;

12-6-97 X 1

DOSE

Calcium Carbonate	C
Darvocet-N-100	C
Vicodin	C

Date:12/24/97ISR Number: 3048844-5Report Type:Periodic
Age:56 YR Gender:Female I/FU:I

Company Report #ZANA0319970257

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - PER ORAL		Jaundice Cholestatic	Health	Zanaflex	PS		ORAL
Initial or Prolonged			Professional	Synthroid	C		
				Prozac	C		
				Avonex	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3048847-0Report Type:Periodic
Age:73 YR Gender:Female I/FU:I

Company Report #ZANA0319970241

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Coordination Abnormal	Consumer	Zanaflex	PS		ORAL
6 MG DAILY,		Sedation					
PER ORAL		Speech Disorder		Ambien	C		
				Neurontin	C		
				Xanax	C		
				Axid	C		
				Trazodone	C		
				Zoloft	C		

Date:12/24/97ISR Number: 3048850-0Report Type:Periodic
Age:49 YR Gender:Female I/FU:I

Company Report #ZANA0319970243

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasticity	Consumer	Zanaflex	PS		ORAL
6 MG DAILY,							
PER ORAL							

Date:12/24/97ISR Number: 3048854-8Report Type:Periodic
Age:68 YR Gender:Male I/FU:I

Company Report #ZANA0319910244

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Consumer	Zanaflex	PS		ORAL
24 MG DAILY,							
PER ORAL				Diflucan	C		
				Tylenol	C		
				Aspirin	C		
				Imipramine	C		
				Glucophage	C		

Date:12/24/97ISR Number: 3048858-5Report Type:Periodic Company Report #ZANA0319970245
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasticity	Consumer	Zanaflex	PS		ORAL
PER ORAL							

Date:12/24/97ISR Number: 3048863-9Report Type:Periodic Company Report #ZANA0319970247
Age:63 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscular Weakness	Consumer	Zanaflex	PS		ORAL
PER ORAL		Oliguria		Baclofen	C		
				Nifedipine	C		
				Clonidine	C		
				Atenolol	C		

Date:12/24/97ISR Number: 3048866-4Report Type:Periodic Company Report #ZANA0319970248
Age:52 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia	Consumer	Zanaflex	PS		ORAL
PER ORAL		Coordination Abnormal		Avonex	C		
		Urinary Incontinence					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3048871-8Report Type:Periodic
Age:52 YR Gender:Female I/FU:I

Company Report #ZANA0319970251

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Medication Error	Health	Zanaflex	PS		ORAL
2MG DAILY,		Menometrorrhagia	Professional				
PER ORAL				Lasix	C		
				Zestril	C		
				Vitamins	C		

Date:12/24/97ISR Number: 3048939-6Report Type:Periodic
Age:49 YR Gender:Female I/FU:I

Company Report #ZANA0319970252

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Anorexia	Health	Zanaflex	PS		ORAL
PER ORAL		Liver Function Test Abnormal	Professional	Prednisone	C		
		Photosensitivity Reaction		Solu-Medrol	C		
		Urinary Tract Infection		Copaxone	C		
		Vasodilatation		Lo-Ovral	C		
		Weight Decreased		Cipro	C		

Date:12/24/97ISR Number: 3048946-3Report Type:Periodic
Age:41 YR Gender:Male I/FU:I

Company Report #ZANA0319970254

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypertension	Health	Zanaflex	PS		ORAL
PER ORAL		Keratoconjunctivitis Sicca	Professional	Bromfed	C		
		Lacrimation Increased		Relafen	C		
		Liver Function Test Abnormal					

Date:12/24/97ISR Number: 3048951-7Report Type:Periodic Company Report #ZANA0319970255
Age:68 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,		Sedation					
PER ORAL							
				Cardizem	C		
				Vasotec	C		
				Isosorbide	C		
				Insulin	C		

Date:12/24/97ISR Number: 3048955-4Report Type:Periodic Company Report #ZANA0319970258
Age:50 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective	Consumer	Zanaflex	PS		ORAL
PER ORAL		Dry Mouth		Baclofen	C		
		Sedation		Ativan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3048959-1Report Type:Periodic
Age:52 YR Gender:Female I/FU:I

Company Report #ZANA0319970259

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test	Health	Zanaflex	PS		ORAL
8MG DAILY,		Abnormal	Professional				
PER ORAL				Lo-Estren	C		
				Paxil	C		

Date:12/24/97ISR Number: 3048962-1Report Type:Periodic
Age:45 YR Gender:Male I/FU:I

Company Report #ZANA0319970260

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Erectile Dysfunction	Health	Zanaflex	PS		ORAL
20 MG DAILY,		Sedation	Professional				
PER ORAL				Diazepam	C		

Date:12/24/97ISR Number: 3048967-0Report Type:Periodic
Age:49 YR Gender:Female I/FU:I

Company Report #ZANA0319970261

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Constipation	Consumer	Zanaflex	PS		ORAL
PER ORAL				Prednisone	C		
				Prilosec	C		
				Macrochantin	C		
				Relafen	C		

Date:12/24/97ISR Number: 3048970-0Report Type:Periodic
Age:37 YR Gender:Female I/FU:I

Company Report #ZANA0319970262

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Other	Fatigue	Consumer	Zanaflex	PS	ORAL
2 MG DAILY,					
PER ORAL			Dantrium	C	
			Zoloft	C	
			Verapamil	C	
			Aspirin	C	

Date:12/24/97ISR Number: 3048974-8Report Type:Periodic Company Report #ZANA0319970267
 Age:45 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Fall	Consumer	Zanaflex	PS		ORAL
PER ORAL		Sedation		Oxybutynin	C		
				Daypro	C		
				Prozac	C		
				Xanax	C		

Date:12/24/97ISR Number: 3048976-1Report Type:Periodic Company Report #ZANA0319970268
 Age:46 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dyspepsia	Consumer	Zanaflex	PS		ORAL
12 MG DAILY,		Nausea					
PER ORAL				Tegretol	C		
				Glucotrol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3048979-7Report Type:Periodic
Age:24 YR Gender:Male I/FU:I

Company Report #ZANA0319970270

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose			Health	Zanaflex	PS		ORAL
Other		Dizziness	Professional				
12 MG DAILY, PER ORAL		Fatigue					
		Insomnia		Docusate	C		
				Darvocet N-100	C		

Date:12/24/97ISR Number: 3048983-9Report Type:Periodic
Age:57 YR Gender:Male I/FU:I

Company Report #ZANA0319970271

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose			Health	Zanaflex	PS		ORAL
Other		Conjunctival Hyperaemia	Professional				
12 MG DAILY, PER ORAL		Eye Irritation					
		Flushing					

Date:12/24/97ISR Number: 3048987-6Report Type:Periodic
Age:20 YR Gender:Male I/FU:I

Company Report #ZANA0319970275

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose			Health	Zanaflex	PS		ORAL
Other		Liver Function Test	Professional	Carbamazepine	C		
PER ORAL		Abnormal Sedation		Baclofen	C		
				Valproic Acid	C		
				Amantadine	C		
				Bromocriptine	C		
				Cisapride	C		

Date:12/24/97ISR Number: 3048989-XReport Type:Periodic
Age:54 YR Gender:Female I/FU:I

Company Report #ZANA0319970277

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Health	Zanaflex	PS		ORAL
10 MG DAILY,			Professional				
PER ORAL							
				Cylert	C		
				Pamelor	C		
				Betaseron	C		
				Ambien	C		
				Baclofen	C		

Date:12/24/97ISR Number: 3048992-XReport Type:Periodic Company Report #ZANA0319970278
Age:33 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Health	Zanaflex	PS		ORAL
24 MG DAILY,			Professional				
PER ORAL							
				Zestril	C		
				Cardizem	C		
				Paxil	C		
				Prozac	C		
				Ibuprofen	C		
				Klonopin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3049024-XReport Type:Periodic
Age:48 YR Gender:Female I/FU:I

Company Report #ZANA0319970280

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Condition Aggravated	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,		Dry Mouth					
PER ORAL							
				Ditropan	C		
				Baclofen	C		
				Klonopin	C		

Date:12/24/97ISR Number: 3049029-9Report Type:Periodic
Age:24 YR Gender:Male I/FU:I

Company Report #ZANA0319970281

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Nightmare	Health	Zanaflex	PS		ORAL
6 MG DAILY,			Professional				
PER ORAL							

Date:12/24/97ISR Number: 3049036-6Report Type:Periodic
Age:48 YR Gender:Female I/FU:I

Company Report #ZANA0319970283

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension	Health	Zanaflex	PS		ORAL
4 MG DAILY ,			Professional				
PER ORAL							
				Diovan	C		
				Synthroid	C		
				Premarin	C		
				Progesterone	C		
				Baclofen	C		

Date:12/24/97ISR Number: 3049039-1Report Type:Periodic
Age:55 YR Gender:Male I/FU:I

Company Report #ZANA0319970284

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test	Health	Zanaflex	PS		ORAL
26 MG DAILY,		Abnormal	Professional				
PER ORAL				Amantadine	C		
				Avonex	C		
				Advil	C		
				Synthroid	C		

Date:12/24/97ISR Number: 3049044-5Report Type:Periodic Company Report #ZANA0319970285
Age:50 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Accident		Zanaflex	PS		ORAL
12 MG DAILY,		Influenza Like Illness					
PER ORAL		Sedation		Depakote	C		
				Clonazepam	C		
				Phenobarbital	C		
				Lozol	C		
				Prilosec	C		
				Premarin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3049058-5Report Type:Periodic
Age:63 YR Gender:Male I/FU:I

Company Report #ZANA0319970286

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms	Consumer	Zanaflex	PS		ORAL
PER ORAL		Sedation		Demadex	C		
				K-Dur	C		
				Lanoxin	C		
				Quinidex	C		
				Tegretol	C		
				Aspirin	C		

Date:12/24/97ISR Number: 3049062-7Report Type:Periodic
Age: Gender:Male I/FU:I

Company Report #ZANA0319970287

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hiccups	Health	Zanaflex	PS		ORAL
16 MG DAILY,			Professional				
PER ORAL				Valium	C		
				Baclofen	C		
				Amantadine	C		
				Percocet	C		

Date:12/24/97ISR Number: 3049067-6Report Type:Periodic
Age:30 YR Gender:Female I/FU:I

Company Report #ZANA0319970289

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Condition Aggravated	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,		Hypertonia					
PER ORAL				Synthroid	C		

Date:12/24/97ISR Number: 3049070-6Report Type:Periodic
Age:62 YR Gender:Male I/FU:I

Company Report #ZANA0319970290

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscular Weakness		Zanaflex	PS		ORAL
24 MG DAILY,		Sedation					
PER ORAL				Baclofen	C		
				Klonopin	C		

Date:12/24/97ISR Number: 3049074-3Report Type:Periodic Company Report #ZANA0319970293
 Age:93 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective	Health	Zanaflex	PS		ORAL
4 MG DAILY,		Hypotension	Professional				
PER ORAL				Pepcid	C		
				Ultram	C		
				Parlodel	C		

Date:12/24/97ISR Number: 3049077-9Report Type:Periodic Company Report #ZANA0319970294
 Age:80 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension		Zanaflex	PS		ORAL
12 MG DAILY,		Sedation					
PER ORAL		Stupor		Norvasc	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Zoloft C
 Coumadin C
 Pepcid C

Date:12/24/97ISR Number: 3049127-XReport Type:Periodic
 Age:81 YR Gender:Male I/FU:I

Company Report #ZANA0319970295

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 6 MG DAILY, PER ORAL		Coma	Health	Zanaflex	PS		ORAL
		Drug Effect Decreased	Professional				
		Hypotension Lethargy		Digoxin Verapamil Haldol Phenobarbital	C C C C		

Date:12/24/97ISR Number: 3049132-3Report Type:Periodic
 Age: Gender:Male I/FU:I

Company Report #ZANA0319970296

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 16 MG DAILY, PER ORAL		Sedation	Health	Zanaflex	PS		ORAL
			Professional				
				Methadone Diazepam	C C		

Date:12/24/97ISR Number: 3049137-2Report Type:Periodic
 Age:41 YR Gender:Female I/FU:I

Company Report #ZANA0319970297

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 12 MG DAILY, PER ORAL		Dry Skin	Health	Zanaflex	PS		ORAL
			Professional				

Date:12/24/97ISR Number: 3049141-4Report Type:Periodic Company Report #ZANA0319970298
Age:36 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Headache	Health	Zanaflex	PS		ORAL
16 MG DAILY,			Professional				
PER ORAL				Baclofen	C		
				Tegretol	C		

Date:12/24/97ISR Number: 3049145-1Report Type:Periodic Company Report #ZANA0319970299
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Gamma-Glutamyltransferase	Health	Zanaflex	PS		ORAL
PER ORAL		Increased	Professional	Dilantin	C		

Date:12/24/97ISR Number: 3049149-9Report Type:Periodic Company Report #ZANA0319970300
Age:48 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hepatitis	Health	Zanaflex	PS		ORAL
PER ORAL		Pyrexia	Professional	Baclofen	SS		
		Sedation		Prozac	C		
				Wellbutrin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3049153-0Report Type:Periodic
Age: Gender:Unknown I/FU:I

Company Report #ZANA0319970301

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Triglycerides	Health	Zanaflex	PS		ORAL
PER ORAL		Increased Hyperglycaemia	Professional				

Date:12/24/97ISR Number: 3049157-8Report Type:Periodic
Age: Gender:Unknown I/FU:I

Company Report #ZANA0319970302

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Triglycerides	Health	Zanaflex	PS		ORAL
PER ORAL		Increased	Professional				

Date:12/24/97ISR Number: 3049161-XReport Type:Periodic
Age: Gender: I/FU:I

Company Report #ZANA0319970303

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Constipation	Health	Zanaflex	PS		ORAL
PER ORAL		Dysphagia Hypertonia	Professional				

Date:12/24/97ISR Number: 3049163-3Report Type:Periodic
Age:56 YR Gender:Female I/FU:I

Company Report #ZANA0319970304

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia	Consumer	Zanaflex	PS		ORAL
4 MG DAILY, PER ORAL		Sedation					
				Prozac	C		
				Prosom	C		
				Baclofen	C		

Date:12/24/97ISR Number: 3049165-7Report Type:Periodic
Age:43 YR Gender:Female I/FU:F

Company Report #ZANA0319970007

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,		Coordination Abnormal					
PER ORAL		Cyanosis		Baclofen	C		
		Sedation		Methotrexate	C		
				Tegretol	C		
				Betaseron	C		

Date:12/24/97ISR Number: 3049172-4Report Type:Periodic
Age:78 YR Gender:Female I/FU:F

Company Report #ZANA0319970177

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Chest Pain	Health	Zanaflex	PS		ORAL
4 MG DAILY,		Hypotension	Professional				
PER ORAL		Sedation		Norvasc	C		
		Stupor		Estrace	C		
				Fosamax	C		
				Prednisone	C		
				Promod	C		
				Reglan	C		

22-Aug-2005 12:09 PM

Page: 10

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/24/97ISR Number: 3049175-XReport Type:Periodic
Age:47 YR Gender:Female I/FU:F

Company Report #ZANA0319970203

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dysgeusia	Consumer	Zanaflex	PS		ORAL
PER ORAL		Hallucination		Levoxyl	C		
				Ventolin	C		
				Aerobid	C		
				Slo-Bid	C		
				Beconase	C		
				Hismanal	C		

Date:01/28/98ISR Number: 3021651-5Report Type:Direct
Age:70 YR Gender:Male I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening		Asthenia		Zanaflex	PS	Athena Neuro Sciences	ORAL
4 MG PO		Bradycardia					
		Chest Pain					
		Hypotension					

Date:01/29/98ISR Number: 3021217-7Report Type:Direct
Age:57 YR Gender:Female I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Hallucination		Tizanidine	PS		ORAL
4MG X3D; 6MG							
Initial or Prolonged							
X2 PO				Fluoxetine	C		
				Oxybutynin	C		
				Nitrofurantoin	C		
				Cipro	C		
				Diazepam	C		
				Ibuprofen	C		

Date:02/05/98ISR Number: 3024405-9Report Type:Direct
Age:67 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 6 MG PO QD ;4 Initial or Prolonged MG PO DID	Blood Pressure Decreased Heart Rate Decreased Syncope		Tizanidine Hcl	PS		ORAL

Date:02/18/98ISR Number: 3030594-2Report Type:Expedited (15-DaCompany Report #ZANA0319980328
Age:70 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 4 MG DAILY Hospitalization - PER ORAL Initial or Prolonged	Asthenia Bradycardia Chest Pain Dizziness Hypotension	Health Professional	Zanaflex	PS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/98ISR Number: 3039669-5Report Type:Expedited (15-DaCompany Report #ZANA0319980334
Age:78 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	3MG DAILY,	Shock	Foreign	Ternelin	PS		ORAL
PER ORAL			Distributor				
				Zaltoprofen	C		
				Soleton	C		

Date:03/02/98ISR Number: 3040502-6Report Type:Expedited (15-DaCompany Report #ZANA0319980333
Age:47 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	3.0 MG DAILY	Dysarthria	Foreign	Ternelin	PS		ORAL
Hospitalization -	PER ORAL	Face Oedema	Distributor				
Initial or Prolonged		Malaise		Indomethacin	C		
		Oedema Peripheral		Benzbromarone	C		
		Pulmonary Oedema		Camostat	C		
		Weight Increased		Famotidine	C		
				Triazolam	C		
				Foy	C		

Date:03/02/98ISR Number: 3040505-1Report Type:Expedited (15-DaCompany Report #ZANA0319980332
Age:31 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	2.0 MG DAILY,	Antinuclear Antibody	Foreign	Sirdalud	PS		ORAL
PER ORAL		Positive	Distributor				
		Systemic Lupus		Myolastan	C		
		Erythematosis					

Date:03/02/98ISR Number: 3040508-7Report Type:Expedited (15-DaCompany Report #ZANA0319980331
Age:5 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Convulsion	Foreign	Sirdalud	PS		ORAL
2.5 MG DAILY,						
Hospitalization -	Drug Interaction	Distributor				
PER ORAL						
Initial or Prolonged	Shock					

Date:03/05/98ISR Number: 3050056-6Report Type:Direct Company Report #
Age:40 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Anxiety		Zanaflex	PS	Athena/Sandoz	
AS DIRECTED						
	Hallucination					
	Paranoia					

Date:03/10/98ISR Number: 3054307-3Report Type:Expedited (15-DaCompany Report #ZANA0319980341
Age:22 YR Gender:Male I/FU:I

Outcome	PT
Life-Threatening	Accidental Overdose
Hospitalization -	Arrhythmia
Initial or Prolonged	Blood Bilirubin Increased
	Hepatic Function Abnormal
	Hypotonia
	Respiratory Disorder

Hospitalization -	Alanine Aminotransferase	Foreign	Trental	PS	ORAL
300 MG PO	3 MON				
Initial or Prolonged	Increased	Study	Hextol	SS	ORAL
300 MG	3 MON				
Other	Anorexia	Health	Tegretol	SS	ORAL
ORAL	1 MON				
	Aspartate	Professional	Ternelin	SS	ORAL
ORAL	1 MON				
	Aminotransferase		Basen	C	
	Increased		Kinedak	C	
	Gamma-Glutamyltransferase		Minipress	C	
	Increased				
	Haematocrit Decreased				
	Haemoglobin Decreased				
	Hepatic Function Abnormal				

Date:03/20/98ISR Number: 3057107-3Report Type:Expedited (15-DaCompany Report #ZANA0319980328
Age:70 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Asthenia	Health	Zanaflex	PS		ORAL
4 MG DAILY,						
Hospitalization -	Bradycardia	Professional				
PER ORAL						
Initial or Prolonged	Chest Pain					
	Dizziness					
	Hypotension					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/98ISR Number: 3059380-4Report Type:Expedited (15-DaCompany Report #ZANA0319980341
 Age:22 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening PER ORAL		Accidental Overdose	Foreign	Sirdalud	PS		ORAL
Hospitalization - Initial or Prolonged		Arrhythmia Asphyxia Bradycardia Hepatic Function Abnormal Hypotonia Respiratory Disorder Sedation Tachycardia	Distributor				

Date:03/30/98ISR Number: 3140701-9Report Type:Periodic Company Report #ZANA0319970306
 Age:38 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 8 MG DAILY, PER ORAL		Asthenia	Health Professional	Zanaflex	PS		ORAL
				Baclofen Ativan Tessalon Cipro	C C C C		

Date:03/30/98ISR Number: 3140712-3Report Type:Periodic Company Report #ZANA0319970307
 Age:53 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 4 MG DAILY, PER ORAL		Insomnia Sedation	Consumer	Zanaflex	PS		ORAL
				Tylenol Insulin Allegra Resulin	C C C C		

Date:03/30/98ISR Number: 3140714-7Report Type:Periodic
Age:59 YR Gender:Male I/FU:I

Company Report #ZANA0319970308

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness	Consumer	Zanaflex	PS		ORAL
16 MG DAILY,		Dry Mouth					
PER ORAL		Muscle Spasms		Valium	C		
		Oedema		Baclofen	C		
		Paraesthesia		Aspirin	C		
		Urinary Retention		Advil	C		
				Niacin	C		
				Vitamin B12	C		

Date:03/30/98ISR Number: 3140730-5Report Type:Periodic
Age:15 YR Gender:Female I/FU:I

Company Report #ZANA0319970309

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Infection	Health	Zanaflex	PS		ORAL
PER ORAL		Sedation	Professional	Valium	C		
				Vitamin C	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/98ISR Number: 3140733-0Report Type:Periodic
Age:68 YR Gender:Male I/FU:I

Company Report #ZANA0319970310

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Orthostatic Hypotension	Health	Zanaflex	PS		ORAL
PER ORAL		Sedation	Professional	Trazodone	C		
				Toprol-Xl	C		
				Cardias Mcd	C		

Date:03/30/98ISR Number: 3140735-4Report Type:Periodic
Age:53 YR Gender:Female I/FU:I

Company Report #ZANA0319970311

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms	Consumer	Zanaflex	PS		ORAL
8 MG DAILY,		Nausea					
PER ORAL				4-Aminopyridine	C		

Date:03/30/98ISR Number: 3140739-1Report Type:Periodic
Age:40 YR Gender:Female I/FU:I

Company Report #ZANA0319970312

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,							
PER ORAL							

Date:03/30/98ISR Number: 3140741-XReport Type:Periodic
Age:62 YR Gender:Male I/FU:I

Company Report #ZANA0319970313

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,		Visual Disturbance					
PER ORAL							

Prilosec C
Lactulose C
Vitamin C C

Date:03/30/98ISR Number: 3140743-3Report Type:Periodic Company Report #ZANA0319970314
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness	Consumer	Zanaflex	PS		ORAL
PER ORAL		Myasthenia Gravis		Wellbutrin	C		
				Ditropan	C		
				Colace	C		
				Axid	C		
				Hormone	C		
				Thyroid Medication	C		

Date:03/30/98ISR Number: 3140747-0Report Type:Periodic Company Report #ZANA0319970315
Age:67 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness	Consumer	Zanaflex	PS		ORAL
PER ORAL		Dry Mouth					
		Sedation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/98ISR Number: 3140773-1Report Type:Periodic
Age:58 YR Gender:Male I/FU:I

Company Report #ZANA0319970316

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abdominal Pain	Consumer	Zanaflex	PS		ORAL
24 MG DAILY,		Diarrhoea					
PER ORAL							
				Pepcid	C		
				Parnate	C		
				Meprobamate	C		
				Propantheline	C		
				Sulfonate	C		
				Tylenol	C		
				Vitamin B12	C		
				Hydrochlorothiazide	C		
				Diazepam	C		
				Avonex	C		
				Prazocin			
				Hydrochloride	C		
				Potassium Chloride	C		
				Chlorpheniramine			
				Maleate	C		

Date:03/30/98ISR Number: 3140776-7Report Type:Periodic
Age:58 YR Gender:Female I/FU:I

Company Report #ZANA0319970317

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective	Consumer	Zanaflex	PS		ORAL
PER ORAL		Sedation		Progesterone	C		

Date:03/30/98ISR Number: 3140779-2Report Type:Periodic
Age:37 YR Gender:Female I/FU:I

Company Report #ZANA0319970318

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Consumer	Zanafex)	PS		ORAL
PER ORAL		Vaginal Candidiasis		Ultram	C		
				Ibuprofen	C		

Date:03/30/98ISR Number: 3140782-2Report Type:Periodic
Age:67 YR Gender:Female I/FU:I

Company Report #ZANA0319970319

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,		Hypertension					
PER ORAL		Nausea		Desipramine	C		
				Zestril	C		
				Relafen	C		
				Neurontin	C		
				Lipitor	C		
				Clonazepam	C		

Date:03/30/98ISR Number: 3140788-3Report Type:Periodic
Age:52 YR Gender:Female I/FU:I

Company Report #ZANA0319970320

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Flatulence	Health	Zanaflex	PS		ORAL
4 MG DAILY,			Professional				
PER ORAL				Baclofen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/98ISR Number: 3140790-1Report Type:Periodic
Age: Gender: I/FU:I

Company Report #ZANA0319970321

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Anaemia	Company	Zanaflex	PS		ORAL
PER ORAL			Representative				

Date:03/30/98ISR Number: 3140794-9Report Type:Periodic
Age:58 YR Gender:Male I/FU:I

Company Report #ZANA0319980322

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Anorexia	Consumer	Zanaflex	PS		ORAL
1 MG DAILY,		Constipation					
PER ORAL		Influenza Like Illness					
		Nausea					

Date:03/30/98ISR Number: 3140798-6Report Type:Periodic
Age:77 YR Gender:Female I/FU:I

Company Report #ZANA0319980323

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms	Consumer	Zanaflex	PS		ORAL
2 MG DAILY,							
PER ORAL				Oxycontin	C		
				Baclofen	C		
				Humibid	C		

Date:03/30/98ISR Number: 3140801-3Report Type:Periodic
Age:43 YR Gender:Female I/FU:I

Company Report #ZANA0319980324

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Aphasia	Health	Zanaflex	PS		ORAL
4 MG DAILY,							

PER ORAL

Chills	Professional		
Coordination Abnormal		Baclofen	C
Diarrhoea		Klonopin	C
Dizziness		Trimpex	C
Dry Mouth			
Hyperhidrosis			
Muscle Spasms			
Sedation			

Date:03/30/98ISR Number: 3140803-7Report Type:Periodic Company Report #ZANA0319980325
 Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Twitching	Consumer	Zanaflex	PS		ORAL
4 MG DAILY,		Paraesthesia					
PER ORAL				Motrin	C		
				Tylenol	C		
				Xanax	C		
				Zantac	C		

Date:03/30/98ISR Number: 3145770-8Report Type:Periodic Company Report #ZANA0319980326
 Age:42 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

PER ORAL

Septra C
 Progesterone C

Date:03/30/98ISR Number: 3145775-7Report Type:Periodic
 Age:30 YR Gender:Female I/FU:I

Company Report #ZANA0319980327

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Oedema	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
1) 4 MG							

DAILY, PER

ORAL; 2) PER

ORAL

Vanceril C
 Proventil C
 Prednisone C
 Bactrim C

Date:03/30/98ISR Number: 3145779-4Report Type:Periodic
 Age:51 YR Gender:Female I/FU:I

Company Report #ZANA0319980329

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
1) PER ORAL;							

2) UNK

Date:03/30/98ISR Number: 3145782-4Report Type:Periodic
 Age:54 YR Gender:Female I/FU:I

Company Report #ZANA0319980335

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Constipation Liver Function Test	Consumer	Zanaflex (Tizanidine)			

PER ORAL	Abnormal	Hydrochloride)	PS	ORAL
	Nausea	Betaseron	C	
	Sedation	Baclofen	C	
		Cylert	C	
		Ambien	C	
		Nortriptyline	C	

Date:03/30/98ISR Number: 3145783-6Report Type:Periodic Company Report #ZANA0319980336
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Stupor	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL				Marcaine	C		
				Fentanyl	C		
				Valium	C		
				Narcan	C		

Date:03/30/98ISR Number: 3145784-8Report Type:Periodic Company Report #ZANA0319980337
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Apnoea	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL		Stupor		Fentanyl	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/30/98ISR Number: 3145785-XReport Type:Periodic
 Age: Gender:Female I/FU:I

Company Report #ZANA0319980338

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Pruritus	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,							
PER ORAL							

Date:03/30/98ISR Number: 3145786-1Report Type:Periodic
 Age:40 YR Gender:Female I/FU:I

Company Report #ZANA0319980339

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Dizziness	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
		Sedation Speech Disorder		Baclofen Copaxone Birth Control Pills	C C C		

Date:03/30/98ISR Number: 3145787-3Report Type:Periodic
 Age:64 YR Gender:Male I/FU:F

Company Report #ZANA0319970196

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Oliguria	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
24 MG DAILY,							
PER ORAL							
				Vitamins Sulfasalazine	C C		

Date:04/03/98ISR Number: 3061346-5Report Type:Expedited (15-DaCompany Report #ZANA0319980349
 Age:62 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Death	Myocardial Infarction	Consumer	Zanaflex	PS	ORAL
PER ORAL					
			Insulin	C	
			Baclofen	C	
			Amantadine	C	
			Isoptin	C	

Date:04/06/98ISR Number: 3062955-XReport Type:Expedited (15-DaCompany Report #ZANA0319980351
 Age:69 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 18 MG DAILY	Dizziness	Health	Zanaflex	PS		ORAL
Initial or Prolonged	Dizziness Postural Faeces Discoloured Haemoglobin Decreased Pain Ulcer	Professional	Baclofen Methotrexate Amitriptyline Solu-Medrol	C C C C		

Date:04/14/98ISR Number: 3064332-4Report Type:Expedited (15-DaCompany Report #1998-00894
 Age:65 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Blister
Initial or Prolonged	Blood Creatine Phosphokinase Increased Blood Creatinine

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Increased Blood Pressure Decreased Blood Urea Increased Dermatitis					
300 MG/PO		Eosinophil Count	Foreign	Mexitil	PS		ORAL
5 MG/PO		Increased	Health	Norvasc	SS		ORAL
40 MG/PO		Face Oedema	Professional	Lasix	SS		ORAL
3 MG/PO		Fatigue		Ternelin	SS		ORAL
1 MG/PO		Haematuria		Depas	C		ORAL
45 MG/PO		Liver Function Test		Glekay	C		ORAL
		Abnormal Purpura Pyrexia Rash Erythematous Skin Ulcer White Blood Cell Count Increased					

Date:04/17/98ISR Number: 3068702-XReport Type:Expedited (15-DaCompany Report #ZANA0319980368

Age:49 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Asthenia	Foreign	Sirdalud	PS		ORAL
2 MG DAILY, PER ORAL		Hypotonia	Distributor				

Date:04/17/98ISR Number: 3068703-1Report Type:Expedited (15-DaCompany Report #ZANA0319980369

Age:74 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Bundle Branch Block Left	Foreign	Sirdalud	PS		ORAL
4 MG DAILY, PER ORAL		Drug Level Below	Distributor				

Therapeutic

Acetyligoxin C
Cibacalcin C
Sarotin C

Date:04/17/98ISR Number: 3068704-3Report Type:Expedited (15-DaCompany Report #ZANA0319980370
Age:22 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening PER ORAL	Blood Bilirubin Increased	Foreign	Ternelin	PS		ORAL
Hospitalization - Initial or Prolonged	Blood Creatine Increased Hepatitis Fulminant Renal Failure Acute Rhabdomyolysis	Distributor	Voltaren	SS		

Date:04/17/98ISR Number: 3068973-XReport Type:Expedited (15-DaCompany Report #ZANA0319980352
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 12 MG DAILY Initial or Prolonged PER ORAL;	Asthenia Bone Pain	Health Professional	Zanaflex	PS		ORAL
	Confusional State		Morphine	C		
	Haemorrhoids		Vicodin	C		
	Hepatomegaly		Xanax	C		
	Lethargy		Glipizide	C		
	Rectal Haemorrhage		Carafate	C		
			Prozac	C		
			Plaquenil	C		

Freedom Of Information (FOI) Report

Ritalin C
 Prilosec C

Date:05/05/98ISR Number: 3073583-4Report Type:Expedited (15-DaCompany Report #98J-10112
 Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 75 MG, DAILY, Hospitalization - ORAL	Blood Bilirubin Increased	Foreign	Voltaren	PS		ORAL
Initial or Prolonged 3 MG,DAILY, ORAL	Blood Creatinine Increased Disseminated	Health Professional	Ternelin	SS		ORAL
	Intravascular Coagulation Hepatic Failure Hepatitis Hepatitis Fulminant Pallor Renal Failure Acute Rhabdomyolysis					

Date:05/15/98ISR Number: 3079752-1Report Type:Expedited (15-DaCompany Report #ZANA0319980377
 Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 360MG DAILY, Initial or Prolonged PER ORAL	Chorea	Health	Zanaflex	PS		ORAL
Other	Coma Depressed Level Of Consciousness Intentional Misuse Muscle Rigidity	Professional				

Date:05/18/98ISR Number: 3079354-7Report Type:Direct
 Age:44 YR Gender:Female I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required		Hypertension		Tizanidine	PS	Athena Labs	ORAL
2 MG BID PO							
Intervention to							
2 DOSES							
Prevent Permanent							
Impairment/Damage							

Date:05/18/98ISR Number: 3079870-8Report Type:Expedited (15-DaCompany Report #ZANA0319980370
Age:21 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Anorexia	Foreign	Ternelin	PS		ORAL
3.0 MG DAILY							
Hospitalization -							
Initial or Prolonged							
Blood Creatinine							
Increased							
Disseminated							
Intravascular Coagulation							
Hepatic Failure							
Hepatitis							
Hepatitis Fulminant							
Malaise							
Pallor							
Pyrexia							
Renal Failure Acute							
Rhabdomyolysis							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/18/98ISR Number: 3080088-3Report Type:Expedited (15-DaCompany Report #ZANA0319980379
Age:34 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 12.0 MG DAILY Initial or Prolonged PER ORAL	Complications Of Maternal Exposure To Therapeutic Drugs Small For Dates Baby	Foreign Distributor	Sirdalud	PS		ORAL

Date:05/27/98ISR Number: 3088209-3Report Type:Expedited (15-DaCompany Report #1998-000894
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 300 MG Hospitalization - Initial or Prolonged 5 MG	Blister Dermatitis Fatigue Haematuria Oedema Pyrexia Rash Erythematous	Foreign Health Professional	Mexitil Norvasc (Amlodipine Besilate) Ternelin (Tizanidine Hydrochloride) Lasix (Furosemide) Depas(Etizolam) Ternelin(Tizanidine Hydrochloride) Glakay (Menatetrenone) Depas(Etizolam)	PS SS SS C C C C		ORAL ORAL

Date:05/28/98ISR Number: 3084810-1Report Type:Expedited (15-DaCompany Report #98J--10112
Age:22 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 75 MG, DAILY Hospitalization - ORAL Initial or Prolonged 3 MG, DAILY	Disseminated Intravascular Coagulation Hepatic Failure	Foreign Health Professional	Voltaren Ternelin	PS SS		ORAL ORAL

ORAL
Hepatitis Fulminant
Pallor
Renal Failure Acute
Rhabdomyolysis

Date:06/01/98ISR Number: 3087787-8Report Type:Expedited (15-DaCompany Report #ZANA0319980383
Age:2 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Anxiety	Foreign	Ternelin	PS		ORAL
Other		Bronchospasm	Literature				
0.33 MG		Dyspnoea					
DAILY, PER		Foreign Body Aspiration		Tricloryl	SS		
ORAL		Intercostal Retraction		Antitussive Agent	C		
		Respiratory Distress		Antihistamine	C		
		Stridor		Expectorant	C		
		Vomiting					

Date:06/01/98ISR Number: 3087791-XReport Type:Expedited (15-DaCompany Report #ZANA0319980377
Age:33 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Athetosis
Initial or Prolonged	Chorea
Other	Coma

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Depressed Level Of Consciousness Depressed Mood	Report Source	Product	Role	Manufacturer	Route
12 MG DAILY, PER ORAL		Muscle Rigidity	Health	Zanaflex	PS		ORAL
		Overdose	Professional				
		Polyuria Suicide Attempt		Thorazine	C		

Date:06/01/98ISR Number: 3088607-8Report Type:Expedited (15-DaCompany Report #ZANA0319980384
Age:58 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Jaundice	Foreign	Sirdalud	PS		ORAL
6 MG DAILY, PER ORAL		Renal Failure Acute	Distributor				
				Gastrozepin	C		
				Pankreon	C		
				Chloraldurat	C		

Date:06/02/98ISR Number: 3088567-XReport Type:Expedited (15-DaCompany Report #98J--10112
Age:22 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Disseminated	Foreign	Voltaren	PS		ORAL
75 MG, DAILY, Hospitalization - ORAL		Intravascular Coagulation	Health				
Initial or Prolonged		Hepatic Failure	Professional	Ternelin	SS		ORAL
3 MG, DAILY, ORAL		Hepatitis Fulminant					
		Pallor		Stac-Eve	SS		
		Renal Failure Acute					
		Rhabdomyolysis					

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged	Chills Dermatitis Dermatitis Bullous Eosinophilia	Health Professional	Macrochantin Capsules, 100 Mg (Nitrofurantoin Macrocrystals)	PS		ORAL
100 MG Q6HR-QID-Q6HR ; ORAL	Mucous Membrane Disorder Oedema					
2 MG BID TITRATED TO 8 MG Q8; ORAL	Pharyngitis Pruritus Purpura Pyrexia		Tizanidine Hydrochloride	SS		ORAL
	Rash Erythematous Rash Maculo-Papular Stevens-Johnson Syndrome Urticaria White Blood Cell Disorder		Bisacodyl Chloral Hydrate Docusate Sodium Elase Eucerin Creme (Wool Fat) Hydrogen Peroxide Milk Of Magnesia (Magnesium Hydroxide) Multivit Oxybutynin Phenazopyridine Tizanidine	C C C C C C C C C C		

Freedom Of Information (FOI) Report

Hydrochloride	C
Tramadol	C
Tylenol (Paracetamol)	C
Zoloft (Sertraline Hydrochloride)	C

Date:06/23/98ISR Number: 3097365-2Report Type:Expedited (15-DaCompany Report #ZANA 319980391
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - PER ORAL Initial or Prolonged	Anuria Blood Creatinine Increased Overdose Renal Failure Stupor	Health Professional	Zanaflex	PS		ORAL

Date:06/29/98ISR Number: 3099561-7Report Type:Expedited (15-DaCompany Report #ZANA0319980390
Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 3.0 MG DAILY, Initial or Prolonged PER ORAL	Cyanosis Dyspnoea	Foreign Distributor	Ternelin	PS		ORAL
			Draganon	SS		
			Loxonin	C		
			Methycool	C		
			Bufferin	C		
			Trental	C		
			Nitroderm Tts	C		

Date:06/29/98ISR Number: 3099611-8Report Type:Expedited (15-DaCompany Report #ZANA0319970256
Age:73 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Life-Threatening	Agranulocytosis	Foreign	Ternelin	PS	ORAL
2 MG DAILY,					
Hospitalization -	Blood Pressure Decreased	Distributor			
PER ORAL					
Initial or Prolonged	Bronchitis Acute		Depas	SS	
	Depressed Level Of		Clinoril	SS	
	Consciousness		Cefzon	C	
	Disseminated		Lasix	C	
	Intravascular Coagulation		Theo-Dur	C	
	Haemorrhage		Noleptan	C	
	Hypotension		Ulgut	C	
	Neutropenia		Sigmart	C	
	Platelet Disorder		Cefzon	C	
	Pneumonia		Lasix	C	
	Prothrombin Time		Theo-Dur	C	
	Prolonged		Noleptan	C	
	Respiratory Disorder		Ulgut	C	
	Sepsis		Sigmart	C	
	Thrombocytopenia		Neuquinon	C	
	Vomiting				
	White Blood Cell Count				
	Decreased				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/29/98ISR Number: 3099614-3Report Type:Expedited (15-DaCompany Report #ZANA0319970264
Age:80 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 1.0 MG DAILY, Initial or Prolonged PER ORAL	Blood Pressure Systolic Increased Cold Sweat Nausea Shock	Foreign Distributor	Ternelin Soleton	PS SS		ORAL

Date:06/30/98ISR Number: 3099957-3Report Type:Expedited (15-DaCompany Report #1998-000894
Age:65 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 10 MG/CAP, Hospitalization - 300 MG PO Initial or Prolonged 5 MG/PO 40 MG/PO 1 MG/PO 3 MG/PO 45 MG/PO	Blister Blood Creatine Phosphokinase Increased Blood Lactate Dehydrogenase Increased Blood Urea Increased Dermatitis Erythema Face Oedema Fatigue Haematuria Hypotension Purpura Pyrexia Rash Papular Skin Ulcer White Blood Cell Count Increased	Foreign Health Professional	Mexitil Norvasc Lasix Depas Ternelin Glakay	PS SS SS SS SS SS		ORAL ORAL ORAL ORAL ORAL ORAL

Date:07/01/98ISR Number: 3100878-8Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319980364

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged PER ORAL	Hepatitis	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Dantrium	C		
			Baclofen	C		
			Steroids	C		
			Amitriptyline	C		
			Trental	C		
			Pepcid	C		
			Synthroid	C		
			Bumex	C		
			Lasix	C		

Date:07/01/98ISR Number: 3100880-6Report Type:Periodic
Age:43 YR Gender:Female I/FU:I

Company Report #ZANA0319980343

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Other 12 MG DAILY, PER ORAL	Hallucination	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Tegretol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/98ISR Number: 3100882-XReport Type:Periodic
 Age:43 YR Gender:Female I/FU:I

Company Report #ZANA0319980344

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Urine Abnormality	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
6 MG DAILY, PER ORAL							
				Baclofen	C		
				Clonazepam	C		
				Estrace	C		
				Tetrabenazine	C		

Date:07/01/98ISR Number: 3100883-1Report Type:Periodic
 Age:39 YR Gender:Female I/FU:I

Company Report #ZANA0319980345

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination Insomnia	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
		Paranoia		Prozac	C		
				Amitriptyline	C		
				Talacen	C		
				Baclofen	C		
				Luvox	C		

Date:07/01/98ISR Number: 3101046-6Report Type:Periodic
 Age: Gender:Male I/FU:I

Company Report #ZANA0319980346

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Speech Disorder	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
				Baclofen	C		
				Tegretol	C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Headache	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY, PER ORAL		Insomnia Muscle Spasms		Maxzide Paxil Xanax Prempro Imipramine	C C C C C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Pain	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
18 MG DAILY, PER ORAL				Amitripyline Synthroid Baclofen Prempro Fosamax	C C C C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/98ISR Number: 3101049-1Report Type:Periodic
Age:40 YR Gender:Male I/FU:I

Company Report #ZANA0319980353

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Apathy Hallucination	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY, PER ORAL							
				Amitriptyline	C		
				Baclofen	C		
				Avonex	C		
				Neurontin	C		
				Cylert	C		
				Naproxen	C		

Date:07/01/98ISR Number: 3101050-8Report Type:Periodic
Age:42 YR Gender:Male I/FU:I

Company Report #ZANA0319980354

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Acne	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY, PER ORAL							
				Xanax	C		

Date:07/01/98ISR Number: 3101052-1Report Type:Periodic
Age:69 YR Gender:Male I/FU:I

Company Report #ZANA0319980355

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Pain	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
18 MG DAILY, PER ORAL							
				Baclofen	C		
				Methotrexate	C		
				Amitriptyline	C		
				Solu-Medrol	C		

Date:07/01/98ISR Number: 3101053-3Report Type:Periodic
Age:29 YR Gender:Female I/FU:I

Company Report #ZANA0319980356

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Urinary Incontinence	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY,							
PER ORAL							

Depakote C

Date:07/01/98ISR Number: 3101054-5Report Type:Periodic
Age:56 YR Gender:Male I/FU:I

Company Report #ZANA0319980357

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dermatitis Face Oedema	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,							
PER ORAL							

Ditropan C
Lotensin C
Nitroglycerin C
Dantrium C
Daypro C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/98ISR Number: 3101056-9Report Type:Periodic
Age:61 YR Gender:Female I/FU:I

Company Report #ZANA0319980358

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY,							
PER ORAL							
				Betaseron	C		
				Procardia	C		

Date:07/01/98ISR Number: 3101060-0Report Type:Periodic
Age:51 YR Gender:Female I/FU:I

Company Report #ZANA0319980359

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Dry Mouth	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
		Hallucination		Baclofen	C		
		Pollakiuria		Glyburide	C		
				Os-Cal	C		
				Imiprmine	C		
				Didronel	C		
				Coumdin	C		

Date:07/01/98ISR Number: 3101062-4Report Type:Periodic
Age:58 YR Gender:Female I/FU:I

Company Report #ZANA0319980360

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Increased Appetite Polyuria	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY,							
PER ORAL							
		Pyrexia		Baclofen	C		
				Diabinese	C		
				Zocor	C		
				Trinex	C		
				Claritin	C		

Date:07/01/98ISR Number: 3101064-8Report Type:Periodic
Age: Gender:Male I/FU:I

Company Report #ZANA0319980365

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
16 MG DAILY, PER ORAL							

Date:07/01/98ISR Number: 3101066-1Report Type:Periodic
Age:37 YR Gender: I/FU:I

Company Report #ZANA0319980366

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Amenorrhoea	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY, PER ORAL							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/01/98ISR Number: 3101070-3Report Type:Periodic
Age:78 YR Gender:Female I/FU:I

Company Report #ZANA0319980367

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,							
PER ORAL							
				Baclofen	C		

Date:07/01/98ISR Number: 3101071-5Report Type:Periodic
Age:38 YR Gender:Female I/FU:I

Company Report #ZANA0319980371

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Amblyopia Deafness	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
		Dizziness		Zoloft	C		
		Dry Mouth		Oral Contraceptives	C		
		Nystagmus					
		Palpitations					
		Sedation					
		Stupor					
		Syncope					
		Tinnitus					
		Vertigo					

Date:07/01/98ISR Number: 3101072-7Report Type:Periodic
Age:66 YR Gender:Male I/FU:I

Company Report #ZANA0319980372

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
16 MG DAILY,							
PER ORAL							
		Sedation					

Date:07/01/98ISR Number: 3101073-9Report Type:Periodic
Age:50 YR Gender:Female I/FU:I

Company Report #ZANA0319980375

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abnormal Dreams Hyperhidrosis	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY, PER ORAL		Sedation		Zocor Synthroid Estratest Valium	C C C C		

Date:07/01/98ISR Number: 3101074-0Report Type:Periodic
Age:58 YR Gender:Female I/FU:I

Company Report #ZANA0319980378

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Insomnia	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
6 MG DAILY, PER ORAL				Hctz Procardia Allegra Motrin Hyoscyamine Premarin	C C C C C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Betaseron C

Date:07/01/98ISR Number: 3101076-4Report Type:Periodic
Age:44 YR Gender:Male I/FU:I

Company Report #ZANA0319980380

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
24 MG DAILY, PER ORAL							
				Elavil	C		
				Neurontin	C		
				Valium	C		
				Naprelan	C		

Date:07/01/98ISR Number: 3101079-XReport Type:Periodic
Age:51 YR Gender:Female I/FU:I

Company Report #ZANA0319980381

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dermatitis Glossitis Hyperhidrosis	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY, PER ORAL							
				Tegretol	C		
				Ogen	C		
				Synthroid	C		

Date:07/01/98ISR Number: 3101082-XReport Type:Periodic
Age:32 YR Gender:Female I/FU:I

Company Report #ZANA0319980386

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
16 MG DAILY, PER ORAL							

Klonopin C
Elavil C

Date:07/01/98ISR Number: 3101084-3Report Type:Periodic Company Report #ZANA0319980387
Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms Tremor	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

Date:07/01/98ISR Number: 3101085-5Report Type:Periodic Company Report #ZANA0319980388
Age:51 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Oedema	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

Dilantin C
Claritin C
Prozac C
Lorazepam C
Volmax C
Ativan C
Prilosec C
Flovent C

Freedom Of Information (FOI) Report

Flonase C

Date:07/09/98ISR Number: 3103518-7Report Type:Expedited (15-DaCompany Report #ZANA0319980393

Age:69 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dysarthria	Foreign	Sirdalud	PS		ORAL
4 MG, PER		Hypotension	Distributor				
ORAL		Malaise		Norvasc (Amlodipine			
		Pallor		Besilate)	C		
		Sedation		Zocor (Simvastatin)	C		
		Vertigo		Nootropil	C		
				Relifex (Nabumetone)	C		
				Ulceran (Ranitidine)	C		

Date:07/13/98ISR Number: 3104744-3Report Type:Expedited (15-DaCompany Report #ZANA0319980379

Age:34 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Complications Of Maternal	Foreign	Sirdalud	PS		ORAL
12 MG DAILY,		Exposure To Therapeutic	Distributor				
Initial or Prolonged		Drugs					
PER ORAL		Foetal Growth Retardation					
		Hepatitis Neonatal					
		Hypoglycaemia					
		Polycythaemia					
		Thrombocytopenia					

Date:07/21/98ISR Number: 3107331-6Report Type:Expedited (15-DaCompany Report #ZANA0319980395

Age:77 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening		Abdominal Pain	Foreign	Ternelin	PS		ORAL
1 MG DAILY							

PER ORAL	Cold Sweat	Health		
	Diarrhoea	Professional	Calslot	SS
	Hypotension	Distributor	Soleton	
	Palpitations		(Zaltoprofen)	C
	Shock		Gefanil (Gefarnate)	C

Date:07/30/98ISR Number: 3111570-8Report Type:Direct
 Age:87 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose						
Duration						
Life-Threatening	Blood Pressure Decreased		Zanaflex	PS		
TWICE A DAY						
Other	Fluid Retention					
VIA PEG TUBE						
Required			Betopic	C		
Intervention to			Sinemet	C		
Prevent Permanent			Levoxyl	C		
Impairment/Damage			Depakene	C		
			Jevity	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/03/98ISR Number: 3112645-XReport Type:Expedited (15-DaCompany Report #WAES 98070066
 Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening PO; TAB	Agranulocytosis	Other	Clinoril	PS		ORAL
Hospitalization - 2 MG/DAILY/PO Initial or Prolonged	Blood Pressure Decreased		Ternelin	SS		ORAL
	Bronchitis Acute		Depas	SS		
	C-Reactive Protein Increased		Lasix	C		
	Depressed Level Of Consciousness		Noleptan	C		
	Disseminated Intravascular Coagulation		Sigmart	C		
	Epistaxis		Theo-Dur	C		
	Laboratory Test Abnormal Platelet Count Decreased		Ulgut	C		
	Pneumonia					
	Prothrombin Time Prolonged					
	Respiratory Rate Decreased					
	Sepsis					
	Thrombocytopenia					
	Vomiting					
	White Blood Cell Count Increased					

Date:08/05/98ISR Number: 3113385-3Report Type:Expedited (15-DaCompany Report #ZANA0319980400
 Age:38 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Death ORAL	Overdose	Health Professional	Zanaflex	PS		ORAL

Date:08/21/98ISR Number: 3123365-XReport Type:Expedited (15-DaCompany Report #ZANA0319980403
 Age:19 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Blood Creatine	Health	Zanaflex	PS		
6 MG DAILY		Phosphokinase Increased	Professional	Depakene	C		
		Disseminated		Multivitamin	C		
		Intravascular Coagulation		Milk Of Magnesia	C		
		Euphoric Mood		Proventil	C		
		Haemorrhage		Biaxin	C		
		Hyperpyrexia		Entex	C		
		Hypotension					
		Oxygen Saturation					
		Decreased					
		Respiratory Distress					
		Rhabdomyolysis					
		Sepsis					
		Tachycardia					
		Tachypnoea					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/24/98ISR Number: 3120845-8Report Type:Expedited (15-DaCompany Report #ZANA0319980403
 Age:19 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Blood Creatine	Health	Zanaflex	PS		
6 MG DAILY;		Phosphokinase Increased	Professional				
GT		Disseminated		Depakene	C		
		Intravascular Coagulation		Multivitamin	C		
		Haemorrhage		Milk Of Magnesia	C		
		Hyperpyrexia		Proventil	C		
		Hypotension		Biaxin	C		
		Inappropriate Affect		Entex	C		
		Oxygen Saturation					
		Decreased					
		Respiratory Distress					
		Respiratory Rate					
		Increased					
		Rhabdomyolysis					
		Sepsis					
		Tachycardia					

Date:08/28/98ISR Number: 3122548-2Report Type:Expedited (15-DaCompany Report #ZANA0319980401
 Age:31 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Pneumonia	Health	Zanaflex	PS		ORAL
16 MG DAILY,			Professional				
Initial or Prolonged							
PER ORAL							
				Cefuroxime	C		
				Albuterol	C		
				Restoril	C		
				Klonopin	C		
				Percocet	C		
				Acetaminophen	C		
				Milk Of Magnesia	C		
				Docusate	C		
				Acetylcysteine	C		
				Silver Sulfadiazine	C		
				Guaifenesin	C		
				Bisacodyl	C		

Hydroxyzine

C

Date:09/04/98ISR Number: 3126189-2Report Type:Expedited (15-DaCompany Report #ZANA0319980407
Age:59 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 32 MG DAILY, Initial or Prolonged PER ORAL		Chest Pain	Health	Zanaflex	PS		ORAL
		Platelet Count Decreased	Professional				
UNK		Thrombocytopenia		Avonex	SS		
				Neurontin	C		
				Tranylcypromine Sulfate	C		
				Ibuprofen	C		

Date:09/04/98ISR Number: 3126387-8Report Type:Expedited (15-DaCompany Report #ZANA0319980400
Age:38 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death PER ORAL		Overdose	Health	Zanaflex	PS		ORAL
			Professional				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/23/98ISR Number: 3134020-4Report Type:Expedited (15-DaCompany Report #ZANA 0319980401

Age:31 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 16 MG DAILY, Initial or Prolonged PER ORAL	Bronchospasm	Health	Zanaflex	PS		ORAL
	Chills	Professional				
	Cough		Cefuroxime	C		
	Pneumonia		Albuterol	C		
	Productive Cough		Restoril	C		
	Rhonchi		Klonopin	C		
			Percocet	C		
			Acetaminophen	C		
			Milk Of Magnesia	C		
			Docusate	C		
			Acetylcysteine	C		
			Silver Sulfadiazine	C		
			Guaifenesin	C		
			Bisacodyl	C		
			Hydroxyzine	C		
			Ceftin	C		
			Benadryl	C		
			Baclofen Pump	C		

Date:09/23/98ISR Number: 3134214-8Report Type:Direct

Company Report #

Age:71 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose 4MG BID PO 25MG BID PO	Hypotension		Zanaflex	PS		ORAL
	Oxygen Saturation		Lopressor	SS		ORAL
	Decreased Sedation					

Date:09/23/98ISR Number: 3134477-9Report Type:Expedited (15-DaCompany Report #ZANA 319980400

Age:38 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

Death Intentional Misuse Health Zanaflex PS ORAL
ORAL Professional

Date:09/24/98ISR Number: 3134982-5Report Type:Direct Company Report #
Age:48 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness		Zanaflex	PS		ORAL
8MG, TID, PO	6 MON	Hallucination, Visual		Neuronitin	C		
600MG QID		Hypotension		Nascobal	C		
1X/WK		Sedation		Oxybutinin	C		
5MG QID				Ultram	C		
50MG QD							

Date:10/01/98ISR Number: 3136998-1Report Type:Direct Company Report #
Age:67 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Diarrhoea		Zanaflex	PS		ORAL
14MG /DAY		Pyrexia					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/98ISR Number: 3263113-6Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319980389

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
	8 MG DAILY			Antidepressant	C		

Date:10/01/98ISR Number: 3263117-3Report Type:Periodic
Age:58 YR Gender:Female I/FU:I

Company Report #ZANA0319980392

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Myasthenic Syndrome	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
	24 MG DAILY			Avonex	C		
				Valium	C		
				Tegretol	C		
				Ditropan	C		
				Tofranil	C		

Date:10/01/98ISR Number: 3263119-7Report Type:Periodic
Age:47 YR Gender:Male I/FU:I

Company Report #ZANA0319980394

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Oedema	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Methadone	C		
				Diazepam	C		
				Dalmane	C		
				Allopurinol	C		

Date:10/01/98ISR Number: 3263122-7Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319980396

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Other	Angioneurotic Oedema	Health	Zanaflex (Tizanidine	PS	ORAL
	Urticaria	Professional	Hydrochloride)	C	
			Aspirin		

Date:10/01/98ISR Number: 3263126-4Report Type:Periodic Company Report #ZANA0319980397
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dermatitis	Health	Zanaflex (Tizanidine			
		Dry Skin	Professional	Hydrochloride)	PS		ORAL
8 MG DAILY		Urticaria		Antidepressant	C		

Date:10/01/98ISR Number: 3263129-XReport Type:Periodic Company Report #ZANA0319980399
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms	Health	Zanaflex (Tizanidine			
			Professional	Hydrochloride)	PS		ORAL
36 MG DAILY							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/98ISR Number: 3263131-8Report Type:Periodic
Age:33 YR Gender:Female I/FU:I

Company Report #ZANA0319980402

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dermatitis	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY							
				Baclofen	C		
				Ambien	C		
				Bactrim	C		

Date:10/01/98ISR Number: 3263133-1Report Type:Periodic
Age:53 YR Gender:Male I/FU:I

Company Report #ZANA0319980404

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Nausea	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY							

Date:10/01/98ISR Number: 3263136-7Report Type:Periodic
Age:51 YR Gender:Female I/FU:I

Company Report #ZANA0319980405

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Herpes Zoster Sedation	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Baclofen	C		
				Prozac	C		
				Ditropan	C		
				Nitrofurantoin	C		
				Neurontin	C		
				Estrace	C		
				Prolific	C		

Date:10/01/98ISR Number: 3263139-2Report Type:Periodic
Age:42 YR Gender:Female I/FU:I

Company Report #ZANA0319980410

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Other	Dysgeusia	Health	Zanaflex (Tizanidine	PS	ORAL
	Hyperhidrosis	Professional	Hydrochloride)		
4 MG DAILY					

Date:10/01/98ISR Number: 3263140-9Report Type:Periodic Company Report #ZANA0319980411
 Age:79 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Coagulation Time	Health	Zanaflex (Tizanidine			
		Prolonged	Professional	Hydrochloride)	PS		ORAL
12 MG DAILY				Coumadin	C		
				Mevacor	C		
				Vasotec	C		

Date:10/13/98ISR Number: 3142382-7Report Type:Direct Company Report #
 Age: Gender:Male I/FU:I

Outcome	PT
Disability	Blood Pressure Decreased
	Dizziness
	Headache
	Hyperhidrosis
	Nausea

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Tremor

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
4 MG EVERY 4 HOURS		Health Professional	Zanaflex	PS		

Date:10/29/98ISR Number: 3149344-4Report Type:Expedited (15-DaCompany Report #ZANA0319980420
Age:30 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death PER ORAL		Death	Health Professional	Zanaflex	PS		ORAL
		Overdose	Professional	Oxycodone	SS		

Date:11/04/98ISR Number: 3152429-XReport Type:Expedited (15-DaCompany Report #ZANA0319980421
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 3.0 MG DAILY, Initial or Prolonged PER ORAL		Depressed Level Of Consciousness	Foreign Health Professional Distributor	Ternelin	PS		ORAL
			Professional Distributor	Disopain Aplace	SS C		

Date:11/06/98ISR Number: 3153181-4Report Type:Direct Company Report #
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required 8 MG PO Q 4 HOURS; DOSAGE Prevent Permanent INCREASED 4		Dysarthria Hypotension	Health Professional	Zanaflex	PS		ORAL

TO ADR

Docusate Sodium	C
Kcl	C
Bisacodyl	C
Multivitamins	C
Vitamin C	C
Zinc	C
Omeprazole	C
Vancomycin	C
Flagyl	C
Aztreonam	C
Baclofen	C

Date:11/17/98ISR Number: 3158794-1Report Type:Expedited (15-DaCompany Report #ZANA0319980426
Age:58 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Disability		Asthenia	Foreign	Ternelin	PS		ORAL
2 MG DAILY,		Monoparesis	Health				
PER ORAL		Muscle Atrophy	Professional	Infree	SS		
		Neuropathy Peripheral	Distributor	Chondroitin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/04/98ISR Number: 3167347-0Report Type:Expedited (15-DaCompany Report #ZANA0319980426
Age:58 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Asthenia	Foreign	Ternelin	PS		ORAL
2 MG DAILY, PER ORAL		Intervertebral Disc Protrusion Monoparesis Movement Disorder Muscle Atrophy Nerve Compression Nerve Root Injury Neuropathy Peripheral	Health Professional Distributor	Infree Chondroitin (Chpondroitin Sulfate)	SS C		

Date:12/10/98ISR Number: 3168983-8Report Type:Direct Company Report #
Age:14 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required		Convulsion	Health	Tizanidine Hcl	PS		ORAL
8 MG TID PO Intervention to Prevent Permanent Impairment/Damage		Headache Lethargy Vomiting	Professional	Amoxicillin Ibuprofen Guafenasin Divalproate	C C C C		

Date:12/15/98ISR Number: 3171078-0Report Type:Expedited (15-DaCompany Report #ZANA0319980433
Age:20 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - PER ORAL		Blood Creatine	Health	Zanaflex	PS		ORAL
Initial or Prolonged		Phosphokinase Increased Pyrexia	Professional				

Date:12/15/98ISR Number: 3171237-7Report Type:Expedited (15-DaCompany Report #ZANA0319980429
Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Hallucination	Health	Zanaflex	PS		ORAL
PER ORAL			Professional	Ms Contin Benzodiazepine	C C		

Date:12/17/98ISR Number: 3171722-8Report Type:Expedited (15-DaCompany Report #ZANA0319980429
Age:42 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - PER ORAL		Agitation	Health	Zanaflex	PS		ORAL
Initial or Prolonged Disability		Confusional State	Professional	Ms Contin	C		
		Depressed Level Of Consciousness		Smir	C		
		Disorientation		Verapamil	C		
		Hallucination		Prozac	C		
		Medication Error		Ativan	C		
		Sedation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/29/98ISR Number: 3176397-XReport Type:Expedited (15-DaCompany Report #ZANA0319980435

Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Convulsion	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

Date:01/05/99ISR Number: 3192864-7Report Type:Expedited (15-DaCompany Report #ZANA0319990441

Age:1 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization - Initial or Prolonged		Rectal Prolapse	Foreign Health Professional Distributor	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
				Lioresal (Baclofen)	SS		
				Phenobal	C		
				Erythromycin	C		
				Baktar	C		
				Biothree	C		
				Millact	C		
				Phenobal	C		
				Erythromycin	C		
				Baktar	C		
				Biothree	C		
				Millact	C		
				Mucodyne	C		
				Leftose	C		
				Bisolvone	C		
				Zaditen	C		

Date:01/06/99ISR Number: 3192622-3Report Type:Periodic Company Report #ZANA0319980432

Age:25 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperhidrosis	Health Professional	Zanaflex	PS		ORAL
PER ORAL							
			Oedema Vasodilatation				

Date:01/06/99ISR Number: 3192628-4Report Type:Periodic
Age:50 YR Gender: I/FU:I

Company Report #ZANA0319980428

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation Tremor	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

Date:01/06/99ISR Number: 3192632-6Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319980425

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG , PER							

ORAL

Coumadin	C
Depo-Provera	C
Baclofen	C
Diazepam	C
Amitriptyline	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/06/99ISR Number: 3192636-3Report Type:Periodic
Age:41 YR Gender:Male I/FU:I

Company Report #ZANA0319980424

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

Date:01/06/99ISR Number: 3192641-7Report Type:Periodic
Age:15 YR Gender:Female I/FU:I

Company Report #ZANA0319980422

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Condition Aggravated Muscle Spasms	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY, PER ORAL							

Date:01/06/99ISR Number: 3192646-6Report Type:Periodic
Age:63 YR Gender:Male I/FU:I

Company Report #ZANA0319980419

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
12 MG DAILY, PER ORAL							
				Valium	C		
				Hydrochlorothiazide	C		
				Lisinopril	C		
				Labetalol	C		

Date:01/06/99ISR Number: 3192650-8Report Type:Periodic
Age:68 YR Gender:Male I/FU:I

Company Report #ZANA0319980415

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia	Consumer	Zanaflex (Tizanidine			

10 MG DIALY,	Sedation		Hydrochloride)	PS	ORAL
PER ORAL	Urinary Incontinence				
			Morphine	C	
			Percocet	C	
			Terazosin	C	
			Lopressor	C	
			Naprosyn	C	

Date:01/06/99ISR Number: 3192656-9Report Type:Periodic Company Report #ZANA0319980413
 Age:68 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abnormal Faeces	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,							
PER ORAL							
				Percocet	C		
				Trilisate	C		
				Zoloft	C		

Date:01/06/99ISR Number: 3192661-2Report Type:Periodic Company Report #ZANA0319980412
 Age:54 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY,							

22-Aug-2005 12:09 PM
 Page: 40

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

PER ORAL

Methotrexate C
 Avonex C

Date:01/25/99ISR Number: 3185399-9Report Type:Expedited (15-DaCompany Report #JAKYO-41666
 Age:68 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Angina Pectoris	Foreign	Itraconazole	PS	Janssen	ORAL
50 MG DAILY		Back Pain	Health				
ORAL		Drug Interaction	Professional	Tizanidine			
		Drug Level Above		Hydrochloride			
		Therapeutic		(Tizanidine) Tablet	SS		ORAL
3 MG DAILY							

ORAL

Etodolac C
 Terbinafine C
 Hydrochloride C
 Misoprostol C

Date:01/29/99ISR Number: 3188604-8Report Type:Expedited (15-DaCompany Report #98J-10423
 Age:12 MON Gender: I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
		Rectal Prolapse	Foreign	Lioresal Unknown			
5 MG, DAILY,				(Baclofen)	PS		ORAL
ORAL				Ternelin Unknown			
				(Tizanidine)	SS		ORAL
1 MG, DAILY,							

ORAL

Date:02/03/99ISR Number: 3191336-3Report Type:Expedited (15-DaCompany Report #ZANA0319990440
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - PER ORAL Initial or Prolonged	Urinary Retention	Foreign	Ternelin	PS		ORAL
		Health Professional Distributor	Madopar Symmetrel (Amantadine Hydrochloride) Aspirin	C C C		

Date:02/16/99ISR Number: 3199743-XReport Type:Expedited (15-DaCompany Report #ZANA0319990442
Age:45 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - 360 MG DAILY, Initial or Prolonged PER ORAL Other	Bradycardia Cyanosis Feeling Cold Hypotension Intentional Misuse Lung Infiltration Pneumonia Aspiration Sedation	Health Professional	Zanaflex (Tizanidine Hydrochloride) Alprazolam Trazodone Dicyclomine Prozac Percocet	PS C C C C C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/99ISR Number: 3203503-0Report Type:Expedited (15-DaCompany Report #ZANA0319990443
Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged Other 284.0 MG DAILY, PER ORAL	Cardiac Failure Depressed Level Of Consciousness Drug Level Above Therapeutic Overdose Respiratory Depression	Foreign Health Professional Distributor	Ternelin (Tizandinine Hydrochloride) Myonal (Eperisone Hydrochloride)	PS SS		ORAL

Date:03/03/99ISR Number: 3211614-9Report Type:Expedited (15-DaCompany Report #ZANA0319990440
Age:69 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 3 MG DAILY PER ORAL	Abdominal Distension Abdominal Pain Decreased Appetite Urinary Retention	Foreign Health Professional Distributor	Ternelin (Tizanidine Hydrochloride) Peon (Zaltoprofen) Marzulen-S (Marzulene-S) Dasen (Serrapeptase) Madopar Baylotensin Symmetrel Aspirin Parlodel	PS SS SS C C C C C		ORAL

Date:03/03/99ISR Number: 3211617-4Report Type:Expedited (15-DaCompany Report #ZANA0319990448
Age:43 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization -	Hyperpyrexia	Health	Zanaflex (Tizanidine			

Initial or Prolonged Pneumonia Professional Hydrochloride) PS ORAL
36 MG DAILY

PER ORAL

Date:03/03/99ISR Number: 3211620-4Report Type:Expedited (15-DaCompany Report #ZANA0319990445
Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia	Consumer	Zanaflex (Tizanidine			
Initial or Prolonged	Asthenia		Hydrochloride)	PS		ORAL
PER ORAL	Coma					
	Fatigue					
	Hallucination, Visual					
	Multiple Sclerosis					
	Muscle Rigidity					
	Muscle Spasticity					
	Panic Attack					
	Visual Disturbance					

Date:03/04/99ISR Number: 3212336-0Report Type:Direct Company Report #
Age:54 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Gallbladder Disorder

22-Aug-2005 12:09 PM
Page: 42

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Hepatotoxicity Jaundice Liver Function Test	Report Source	Product	Role	Manufacturer	Route
4MG Q6 ; ON		Abnormal	Health	Zanaflex	PS		
AT HOME NOT			Professional				
SURE HOW LONG							

Date:03/04/99ISR Number: 3212864-8Report Type:Expedited (15-DaCompany Report #ZANA0319990449
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Life-Threatening	Cardio-Respiratory Arrest	Company	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL			Representative				

Date:03/12/99ISR Number: 3219247-5Report Type:Expedited (15-DaCompany Report #ZANA0319990443
Age:51 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Hospitalization - Initial or Prolonged	Cardiac Failure Depressed Level Of	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
284.0 MG	Other	Consciousness	Professional				
DAILY, PER		Electrocardiogram Qt	Distributor				
ORAL		Prolonged Electrocardiogram St Segment Elevation Hypothermia Loss Of Consciousness Nausea Overdose Respiratory Depression Suicide Attempt Vomiting		Myonal (Eperisone Hydrochloride)	SS		

Date:03/12/99ISR Number: 3219425-5Report Type:Expedited (15-DaCompany Report #ZANA0319990454
Age:61 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged PER ORAL	Abnormal Behaviour	Foreign	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL			Tramadol	SS		ORAL
			Baclofen	C		
			Diazepam	C		
			Diconal	C		
			Moduretic	C		

Date:03/12/99ISR Number: 3219466-8Report Type:Expedited (15-DaCompany Report #ZANA0319990453
Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged 12 MG DAILY, PER ORAL	Muscle Rigidity Tremor	Foreign	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Baclofen	C		
			Cinnarizine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/12/99ISR Number: 3219469-3Report Type:Expedited (15-DaCompany Report #ZANA0319990452
Age:30 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Cardiac Failure	Foreign	Zanaflex	PS		ORAL
32 MG DAILY,		Congestive					
PER ORAL		Creatine Phosphokinase Decreased Crepitations Dyspnoea Dyspnoea Paroxysmal Nocturnal		Lansoprazole	C		

Date:03/12/99ISR Number: 3219471-1Report Type:Expedited (15-DaCompany Report #ZANA0319990451
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Condition Aggravated	Foreign	Zanaflex	PS		ORAL
2-4 MG DAILY,		Muscle Spasticity					
Initial or Prolonged		Quadriplegia		Carbarmazepine Baclofen	C C		
PER ORAL							

Date:04/01/99ISR Number: 3232648-4Report Type:Periodic Company Report #ZANA0319980434
Age:71 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Urinary Incontinence	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,							
PER ORAL				Cosamin	C		

Date:04/01/99ISR Number: 3232650-2Report Type:Periodic Company Report #ZANA0319980436
Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Accident Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY, PER ORAL				Primidone	C		
				Diazepam	C		

Date:04/01/99ISR Number: 3232653-8Report Type:Periodic Company Report #ZANA0319990437
Age:47 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth Sedation	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL				Permax	C		
				Zocor	C		
				Hytrin	C		

Date:04/01/99ISR Number: 3232656-3Report Type:Periodic Company Report #ZANA0319990439
Age:49 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Nausea Pyrexia	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

2 MG DAILY,

22-Aug-2005 12:09 PM
Page: 44

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

PER ORAL

Neurontin C

Date:04/01/99ISR Number: 3232658-7Report Type:Periodic
Age:16 YR Gender:Male I/FU:I

Company Report #ZANA0319990446

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
6 MG DAILY,							

PER ORAL

Anti-Hypertensives C

Date:04/01/99ISR Number: 3232660-5Report Type:Periodic
Age:33 YR Gender:Male I/FU:I

Company Report #ZANA0319990447

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
30 MG DAILY,							

PER ORAL

Zithromax C

Date:04/01/99ISR Number: 3232661-7Report Type:Periodic
Age:44 YR Gender:Male I/FU:F

Company Report #ZANA0319980380

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
24 MG DAILY,							

PER ORAL

Elavil C
Neurontin C
Valium C
Naprelan C

Date:06/07/99ISR Number: 3277525-8Report Type:Expedited (15-DaCompany Report #ZANA0319990489

Age:36 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Fall	Health	Zanaflex (Tizanidine			
Hospitalization -		Hypotension	Professional	Hydrochloride)	PS		ORAL
16 MG DAILY,							
Initial or Prolonged		Liver Function Test					
PER ORAL		Abnormal					
		Renal Failure Acute					

Date:06/24/99ISR Number: 3291137-1Report Type:Expedited (15-DaCompany Report #JRFBEL1999000365

Age:73 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Bradycardia	Foreign	Prepulsid			
Initial or Prolonged		Cardiac Failure	Health	(Unspecified)			
MG, DAILY		Electrocardiogram Qt	Professional	(Cisapride)	PS		ORAL
ORAL		Corrected Interval					
		Prolonged		Sirdalud Retard			
				(Tizanidine			
MG, DAILY,				Hydrochloride)	SS		ORAL
ORAL							
				Sirdalud (Tizanidine			
				Hydrochloride)	SS		ORAL

22-Aug-2005 12:09 PM

Freedom Of Information (FOI) Report

ORAL

Cozaar	C
Emconcor	C
Salazopyrin	C
Digoxin	C
Furesis	C
Lanzo	C
Para-Tabs	C
Tramal	C
Cipramil	C
Fosamax	C
Progynova	C
Miacalcic Nasal	C
Tenox	C
Oxepam	C

Date:07/01/99ISR Number: 3298847-0Report Type:Expedited (15-DaCompany Report #JRFBEL1999000365
 Age:72 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 5MG 3 IN 1 DAYS (S) ORAL	Back Pain Bradycardia Cardiac Failure Electrocardiogram Qt Prolonged Fracture Heart Rate Increased	Foreign Health Professional	Prepulsid (Unspecified) (Cisapride)	PS		ORAL
MG DAILY ORAL	Osteoporosis		Sirdalud Retard (Tizanidine Hydochloride)	SS		ORAL
MG DAILY ORAL	Pain		Sirdalud	SS		ORAL
			Salazopyrin Cozaar Emconcor	C C C		

Date:07/01/99ISR Number: 3303393-1Report Type:Periodic Company Report #ZANA0319990480
 Age:48 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Other	Hypersensitivity	Consumer	Zanaflex (Tizanidine			

2 MG DAILY,	Paraesthesia	Hydrochloride)	PS	ORAL
PER ORAL	Skin Ulcer			
	Urticaria			

Date:07/01/99ISR Number: 3303406-7Report Type:Periodic Company Report #ZANA0319990481
 Age:23 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
36 MG DAILY,							
PER ORAL							

Date:07/01/99ISR Number: 3303411-0Report Type:Periodic Company Report #ZANA0319990482
 Age:81 YR Gender:I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Pruritus Rash Maculo-Papular	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,							
PER ORAL				Vasotec Biaxin	C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Digoxin C

Date:07/01/99ISR Number: 3303415-8Report Type:Periodic
Age: Gender: I/FU:I

Company Report #ZANA0319990483

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Rash Pruritic	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4-6 MG DAILY, PER ORAL							

Date:07/01/99ISR Number: 3303418-3Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319990486

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness Myasthenic Syndrome	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL; 4 MG DAILY, PER ORAL							

Date:07/01/99ISR Number: 3303421-3Report Type:Periodic
Age:50 YR Gender:Female I/FU:I

Company Report #ZANA0319990487

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia Sedation	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
6 MG DAILY, PER ORAL							
				Baclofen	C		
				Naproxen Sodium	C		
				Ditropan Excel	C		

Date:07/01/99ISR Number: 3303449-3Report Type:Periodic
Age:52 YR Gender:Female I/FU:I

Company Report #ZANA0319990490

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Pain	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

Date:07/01/99ISR Number: 3303455-9Report Type:Periodic
Age:49 YR Gender:Female I/FU:I

Company Report #ZANA0319990491

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
12 MG DAILY,							
PER ORAL							

Clonipen	C
Imuran	C
Prednisone	C

Date:07/01/99ISR Number: 3303460-2Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319990493

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness Dry Mouth	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
				Synthroid	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Provera C
 Hctz C
 Zestril C

Date:07/01/99ISR Number: 3303465-1Report Type:Periodic
 Age: Gender:Male I/FU:I

Company Report #ZANA0319990494

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Hallucination Myasthenic Syndrome	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
36 MG DAILY, PER ORAL				Baclofen	C		

Date:07/01/99ISR Number: 3303468-7Report Type:Periodic
 Age:9 YR Gender:Male I/FU:I

Company Report #ZANA0319990497

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abdominal Pain Abnormal Faeces Nausea	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL; 1.5 MG DAILY, PER ORAL							

Tegretol C
 Mysoline C
 Multivitamins C
 Calcium Gluconate C
 Milk Of Magnesia C

Date:07/09/99ISR Number: 3300473-1Report Type:Expedited (15-DaCompany Report #ZANA0319990507
 Age:75 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Pemphigoid		Zanaflex (Tizanidine			

Initial or Prolonged
PER ORAL

Hydrochloride)	PS	ORAL
Baclofen	C	
Frusemide	C	
Thyroxine	C	
Spiro lactone	C	
Amlodipine	C	
Lisinopril	C	
Simvastatin	C	
Aspirin	C	
Diazepam	C	
Hydroxyzine	C	
Praxilene	C	

Date:07/13/99ISR Number: 3302773-8Report Type:Expedited (15-DaCompany Report #ZANA0319990503
Age:73 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 6.0 MG DAILY, PER ORAL	Bradycardia Cardiac Failure Congestive	Foreign Distributor	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
UNKNOWN PER ORAL	Condition Aggravated Electrocardiogram Qt Prolonged		Sirdalud Mr Lansoprazole Prepulsid (Cisapride)	SS SS SS		ORAL ORAL

22-Aug-2005 12:09 PM
Page: 48

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Sulfasalazine C
 Cozaar C
 Bisoprolol C
 Digoxin C
 Furosemide C

Date:07/23/99ISR Number: 3309826-9Report Type:Expedited (15-DaCompany Report #ZANA0319990509
 Age:78 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Bradycardia	Health	Sirdalud (Tizanidine			
		Depressed Level Of	Professional	Hydrochloride)	PS		ORAL
3.0 MG DAILY;		Consciousness					
PER ORAL	711 DAY	Heart Rate Decreased		Lendormin	C		
		Sedation		Sedes	C		
		Sick Sinus Syndrome		Merislon	C		
				Selbex	C		

Date:07/23/99ISR Number: 3310019-XReport Type:Expedited (15-DaCompany Report #ZANA0319990509
 Age:78 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Bradycardia	Foreign	Sirdalud (Tizanidine			
		Depressed Level Of	Health	Hydrochloride)	PS		ORAL
3.0 MG DAILY,		Consciousness	Professional				
PER ORAL		Sedation	Distributor	Merislon	SS		
		Sick Sinus Syndrome		Lendormin	C		
				Selbex	C		
				Sedes	C		

Date:07/30/99ISR Number: 3315221-9Report Type:Expedited (15-DaCompany Report #ZANA0319990511
 Age:70 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
---------	----------	----	---------------	---------	------	--------------	-------

Hospitalization - Initial or Prolonged 3.0 MG DAILY, PER ORAL	Depressed Level Of Consciousness Extensor Plantar Response Hypertension Hypoxia Respiratory Failure Respiratory Rate Decreased Sedation Shock Stridor	Foreign Health Professional Distributor	Ternelin (Tizanidine Hydrochloride) Aspirine Sarpul Trental	PS C C C	ORAL
--	---	--	---	-------------------------------	------

Date:07/30/99ISR Number: 3315224-4Report Type:Expedited (15-DaCompany Report #ZANA0319990511
Age:70 YR Gender:Female I/FU:I

Outcome Hospitalization - Initial or Prolonged	PT Cerebrovascular Accident Depressed Level Of Consciousness Extensor Plantar Response Hypopnoea Hypotension Hypoxia
--	---

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Medication Error	Report Source	Product	Role	Manufacturer	Route
3.0 MG DAILY		Rash Macular Respiratory Failure	Health Professional	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
		Sedation Shock		Aspirine	C		
		Stridor		Sarpul	C		
				Trental	C		

Date:08/19/99ISR Number: 3330238-6Report Type:Expedited (15-DaCompany Report #ZANA0319990520
Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Hypotension Sudden Death	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
32 MG DAILY, PER ORAL		Syncope		Amitriptyline	C		
				Baclofen	C		

Date:08/19/99ISR Number: 3330239-8Report Type:Expedited (15-DaCompany Report #ZANA0319990518
Age: Gender:Not SpecifiI/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 36 MG DAILY, PER ORAL		Bradycardia Hallucination	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

Date:09/03/99ISR Number: 3341141-XReport Type:Expedited (15-DaCompany Report #ZANA0319990521
Age:39 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Chromaturia	Health	Zanaflex (Tizanidine			

4 MG DAILY,	Condition Aggravated	Professional	Hydrochloride)	PS	ORAL
PER ORAL	Fatigue				
	Haematuria		Baclofen	C	
	Muscle Spasms		Allopurinol	C	
			Atenolol	C	
			Tamsulosin	C	
			Fluoxetine	C	

Date:09/15/99ISR Number: 3348801-5Report Type:Expedited (15-DaCompany Report #99J--10282
Age:33 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Liver Disorder Oculomucocutaneous	Foreign Health	Voltaren Suppository (Diclofenac Sodium)	PS		
RECTAL	UNK, DAILY,	Syndrome	Professional				
RECTAL			Other	Bufferin Unknown (Bufferin)	SS		
				Mucodyne Unknown (Carbocisteine)	SS		
				Pl Granulate (Pl Granules)	SS		
				Loxonin Unknown (Loxoprofen Sodium)	SS		
				Tizanidine Hydrochloride Tablet			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

UNK, UNK,	(Tizanidine Hydrochloride)	SS	ORAL
ORAL	Klaricid Unknown (Clarithromycin)	SS	

Date:09/15/99ISR Number: 3348815-5Report Type:Expedited (15-DaCompany Report #99J--10282
 Age:33 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Liver Disorder	Foreign	Voltaren Suppository			
Initial or Prolonged	Oculomucocutaneous	Health	(Diclofenac Sodium)	PS		
RECTAL	UNK, DAILY,	Professional				
RECTAL	Syndrome	Other	Bufferin Unknown (Bufferin)	SS		
			Mucodyne Unknown (Carbocisteine)	SS		
			Tizanidine Hydrochloride Tablet (Tizanidine Hydrochloride)	SS		ORAL

UNK, UNK,

ORAL

Klaricid Unknown (Clarithromycin)	SS
P1 Granulate (P1 Granules)	SS
Loxonin Unknown (Loxoprofen Sodium)	C

Date:09/17/99ISR Number: 3350546-2Report Type:Expedited (15-DaCompany Report #ZANA0319990522
 Age:30 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Asthma	Foreign	Zanaflex (Tizanidine Hydrochloride)			
Initial or Prolonged	Dyspepsia	Health		PS		ORAL
36 MG DAILY						

PER ORAL	Dyspnoea Exertional	Professional					
				Diazepam	C		
				Salbutamol	C		
Date:09/20/99ISR Number: 3350768-0Report Type:Direct			Company Report #				
Age:44 YR	Gender:Male	I/FU:I					
Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
Required	Fatigue		Zanaflex 4mg	PS		ORAL	
4MG 1 1/2-1T							
Intervention to	Liver Function Test						
PO QD							
Prevent Permanent	Abnormal		Effexor	C			
Impairment/Damage			Motrin	C			
Date:09/22/99ISR Number: 3366706-0Report Type:Periodic			Company Report #WAES 99070025				
Age:	Gender:Unknown	I/FU:I					
Outcome	PT	Report Source	Product	Role	Manufacturer	Route	
Dose	Duration						
	Delusion	Health	Tab Vioxx	PS		ORAL	
	Drug Interaction	Professional	Zanaflex	SS			
	Hallucination	Company					
	Vomiting	Representative					
22-Aug-2005 12:09 PM							
Page: 51							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/99ISR Number: 3367908-XReport Type:Periodic
Age:22 YR Gender:Male I/FU:I

Company Report #ZANA0319990499

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Sedation					
ORAL							

Date:10/01/99ISR Number: 3367912-1Report Type:Periodic
Age:48 YR Gender:Male I/FU:I

Company Report #ZANA0319990500

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Diarrhoea	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Muscle Spasms					
20 MG DAILY,							
		Sedation	Distributor				
ORAL							
				Glatiramer Acetate	C		
				Oxybutynin	C		
				Fluoxetine			
				Hydrochloride	C		
				Amantadine	C		
				Fampridine	C		

Date:10/01/99ISR Number: 3367914-5Report Type:Periodic
Age: Gender: I/FU:I

Company Report #ZANA0319990508

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Urinary Retention	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
12 MG DAILY,							
ORAL							

Date:10/01/99ISR Number: 3367918-2Report Type:Periodic
Age:50 YR Gender:Female I/FU:I

Company Report #ZANA0319990512

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL							

Date:10/01/99ISR Number: 3367919-4Report Type:Periodic Company Report #ZANA0319990517
 Age:63 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Chills Depression Dry Mouth	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
12 MG DAILY, PER ORAL							
		Hyperhidrosis		Tranxene	C		
		Nausea		Inderal	C		
		Pollakiuria		Estrace	C		
		Sedation		Progesterone	C		
				Zoloft	C		
				Potassium	C		
				Magnesium	C		

Date:10/01/99ISR Number: 3367921-2Report Type:Periodic Company Report #ZANA0319990525
 Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Gastrointestinal Haemorrhage	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/99ISR Number: 3367923-6Report Type:Periodic
 Age:32 YR Gender:Male I/FU:I

Company Report #ZANA0319990526

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
12 MG DIALY, PER ORAL							
				Fentanyl	C		
				Oxy Ir	C		
				Reglan	C		
				Trilisate	C		
				Trazodone	C		
				Mexelitine	C		

Date:10/01/99ISR Number: 3367970-4Report Type:Periodic
 Age:70 YR Gender:Female I/FU:I

Company Report #ZANA0319990527

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
				Baclofen	C		

Date:10/01/99ISR Number: 3367971-6Report Type:Periodic
 Age: Gender: I/FU:I

Company Report #ZANA0319990528

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
				Coumadin	SS		

Date:10/01/99ISR Number: 3367973-XReport Type:Periodic
 Age:78 YR Gender:Female I/FU:I

Company Report #ZANA0319990529

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperhidrosis	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
14 MG DAILY,		Muscle Spasms					
PER ORAL		Myasthenic Syndrome					
		Sedation		Methazolamide	C		
				Clonidine	C		
				Voltaren	C		
				Prinivil	C		
				Zoloft	C		
				Percocet	C		
				Trental	C		
				Duragesic	C		
				Darvocet	C		

Date:10/01/99ISR Number: 3367976-5Report Type:Periodic Company Report #ZANA0319990530
Age:9 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Convulsion	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL				Mysoline (Primidone) Tablets	C		
				Tegretol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/01/99ISR Number: 3367978-9Report Type:Periodic
Age:46 YR Gender:Male I/FU:I

Company Report #ZANA0319990531

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY, PER ORAL							

Date:10/01/99ISR Number: 3367981-9Report Type:Periodic
Age:23 YR Gender:Male I/FU:F

Company Report #ZANA0319990481

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
36 MG DAILY, PER ORAL							

Date:11/02/99ISR Number: 3386864-1Report Type:Direct
Age:34 YR Gender:Female I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening		Alanine Aminotransferase		Zanaflex 4 Mg	PS		ORAL
1T PO QD Hospitalization - Initial or Prolonged Increased Aspartate Aminotransferase Increased Diarrhoea Pyrexia							

Date:11/04/99ISR Number: 3388803-6Report Type:Expedited (15-DaCompany Report #ZANA0319990545
Age:45 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death			Completed Suicide	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL					Codeine	C		
					Diazepam	C		
Date:11/04/99ISR Number: 3388841-3Report Type:Expedited (15-DaCompany Report #ZANA0319990545								
Age:45 YR Gender:Female I/FU:I								
Death			Completed Suicide Overdose	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL					Codeine	C		
					Diazepam	C		
Date:11/23/99ISR Number: 3405354-0Report Type:Direct Company Report #								
Age:73 YR Gender:Female I/FU:I								
Life-Threatening			Grand Mal Convulsion		Zanaflex 4mg	PS		ORAL
2TABS BID								
Hospitalization -								
ORAL								
Initial or Prolonged					Lioresal 20mg	SS		ORAL
1 TAB TID								
ORAL								
					Diltantin	C		
					Prozac	C		
					Kcl	C		
22-Aug-2005 12:09 PM								
Page: 54								

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/99ISR Number: 3431650-7Report Type:Expedited (15-DaCompany Report #99J--10454

Age:85 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	25 MG, DAILY,ORAL	Nausea Syncope	Foreign Health Professional	Voltaren Tablet (Diclofenac Sodium)	PS		ORAL
	3 MG DAILY, ORAL			Ternelin Tablet (Tizanidine)	SS		ORAL
				Persantine Tablet Ambroxol Hydrochlori Tablet Neuquinon Tablet Aldactone A Amlodipine Besilate	C C C C C		

Date:12/28/99ISR Number: 3432865-4Report Type:Periodic

Company Report #ZANA0319990553

Age:44 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	4MG DAILY PER ORAL	Liver Function Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Effexor Baclofen Claritin-D	C C C		

Date:12/28/99ISR Number: 3432884-8Report Type:Periodic

Company Report #ZANA0319990534

Age:53 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Hypertension	Consumer	Zanaflex (Tizanidine			

16MG DAILY	Hypotonia	Hydrochloride)	PS	ORAL
PER ORAL	Muscle Spasms			
	Visual Disturbance	Diazepam	C	
		Baclofen	C	

Date:12/28/99ISR Number: 3432891-5Report Type:Periodic Company Report #ZANA0319990535
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL				K-Dur	C		
				Indomethacin	C		
				Oxybutynin	C		
				Nitrofurantoin	C		
				Lactulose	C		
				Bumetide	C		

Date:12/28/99ISR Number: 3432895-2Report Type:Periodic Company Report #ZANA0319990537
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8MG DAILY PER							
ORAL	4	MON					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Celebrex C

Date:12/28/99ISR Number: 3432898-8Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319990541

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Skin Ulcer	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							

Date:12/28/99ISR Number: 3432903-9Report Type:Periodic
Age: Gender: I/FU:I

Company Report #ZANA0319990548

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL							
Distributor							

Date:12/28/99ISR Number: 3432906-4Report Type:Periodic
Age:27 YR Gender:Female I/FU:I

Company Report #ZANA0319990549

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Face Oedema Sedation	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4MG PER ORAL							
				Vioxx	C		
				Oxycontin	C		
				Orthotricyclen	C		
				...	C		
				...	C		

Date:12/28/99ISR Number: 3432907-6Report Type:Periodic
Age:82 YR Gender:Female I/FU:I

Company Report #ZANA0319990550

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Hypotension Sedation	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
6MG, PER ORAL				Requip	C		
				Norvasc	C		
				Prinivil	C		
				Microk	C		
				Furosemide	C		

Date:12/28/99ISR Number: 3432913-1Report Type:Periodic
Age:44 YR Gender:Male I/FU:I

Company Report #ZANA0319990551

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Hypertonia Paraesthesia	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8MG DIALY, PER ORAL				Neurontin	C		
				Baclofen	C		
				Dss	C		
				Flexeril	C		
				Ditropan	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/99ISR Number: 3432917-9Report Type:Periodic
Age:42 YR Gender:Female I/FU:I

Company Report #ZANA0319990552

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Anxiety	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
3MG PER ORAL							
		Asthenia					
		Dyspepsia		Elavil	C		
		Emotional Disorder		Klonopin	C		
		Pollakiuria		Avonex	C		
		Sedation		Prevacid	C		
		Visual Disturbance		Pepcid	C		
				Zyrtec	C		
				Synthroid	C		
				Robitussin	C		
				Vitamins	C		

Date:12/28/99ISR Number: 3432920-9Report Type:Periodic
Age:65 YR Gender:Female I/FU:I

Company Report #ZANA0319990555

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperhidrosis	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2MG PER ORAL							

Date:12/28/99ISR Number: 3432924-6Report Type:Periodic
Age:51 YR Gender:Male I/FU:I

Company Report #ZANA0319990557

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Paralysis	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
6MG PER ORAL							

Date:12/28/99ISR Number: 3432926-XReport Type:Periodic
Age:22 YR Gender:Female I/FU:I

Company Report #ZANA0319990558

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Other	Sedation	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS	ORAL
PER ORAL			Theophylline	C	
			Albuterol	C	

Date:12/28/99ISR Number: 3432928-3Report Type:Periodic Company Report #ZANA0319990559
 Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Malaise	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL						

Date:12/28/99ISR Number: 3432933-7Report Type:Periodic Company Report #ZANA0319990560
 Age:51 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Malaise	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
PER ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/99ISR Number: 3432937-4Report Type:Periodic
Age: Gender: I/FU:I

Company Report #ZANA0319990561

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
36MG PER ORAL							

Date:12/28/99ISR Number: 3432941-6Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA0319990562

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth Muscle Spasms	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2MG DAILY PER ORAL							
ORAL							
Paraesthesia							

Date:12/28/99ISR Number: 3432946-5Report Type:Periodic
Age:78 YR Gender:Female I/FU:F

Company Report #ZANA0319990529

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperhidrosis Muscle Spasms	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
12MG PER ORAL							
Myasthenic Syndrome							
Sedation							
				Methazolamide	C		
				Clonidine	C		
				Voltaren	C		
				Prinivil	C		
				Zoloft	C		
				Percocet	C		
				Trental	C		
				Duragesic	C		
				Darvocet	C		

Date:01/19/00ISR Number: 3445416-5Report Type:Expedited (15-DaCompany Report #ZANA0319990545 (1)
Age:45 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Other				Codeine	C		
PER ORAL				Diazepam	C		

Date:01/28/00ISR Number: 3447678-7Report Type:Direct Company Report #
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Cardiac Failure Congestive Dyspnoea		Zanaflex 14mg Talbetes-Athena Neurosciences	PS	Athena Neurosciences	ORAL
2MG PO		Pulmonary Oedema					
1/22-1/24;4MG		Respiratory Failure					
PO ON 1/25							

Date:02/02/00ISR Number: 3451148-XReport Type:Direct Company Report #
Age:58 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Bradycardia Dizziness Head Injury

22-Aug-2005 12:09 PM
Page: 58

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Syncope

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
PO			Zanaflex Athena	PS	Athena	ORAL
			Accolate	C		
			Luvox	C		
			Trazedone	C		
			Dicloxacillin	C		
			Diazepam	C		

Date:02/11/00ISR Number: 3456779-9Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 4 MG Q 8 PRN Initial or Prolonged		Coma Hypotension	Health Professional	Zanaflex	PS		

Date:03/03/00ISR Number: 3469027-0Report Type:Expedited (15-DaCompany Report #ZANA030574 (0)
Age:41 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other PER ORAL 4 MG PER ORAL		Abnormal Dreams Cold Sweat Confusional State	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Convulsion		Ultran	C		
		Coordination Abnormal		Neurontin	C		
		Dizziness		Lovox	C		
		Eye Movement Disorder		Celebrex	C		
		Fibromyalgia					
		Hallucination, Olfactory					
		Hallucinations, Mixed					
		Nausea					
		Tinnitus					
		Vision Blurred					

Outcome	PT
Other	Abnormal Dreams
	Cold Sweat
	Confusional State
	Convulsion
	Coordination Abnormal
	Dizziness
	Emotional Distress
	Eye Disorder
	Eye Movement Disorder
	Fall
	Fear Of Disease
	Hallucination, Olfactory
	Hallucinations, Mixed
	Irritability
	Multiple Sclerosis
	Nausea
	Paralysis
	Sedation
	Tinnitus

22-Aug-2005 12:09 PM

Page: 59

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Vision Blurred

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
8MG, PER ORAL; 4 MG, PER ORAL		Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Neurontin	C		
			Luvox	C		
			Celebrex	C		
			Tricor	C		

Date:03/24/00ISR Number: 3543157-7Report Type:Periodic Company Report #WAES 00021615
Age:43 YR Gender:Female I/FU:I

Outcome Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
25 MG/AM/PO;25 MG/DAILY/PO		Drug Interaction Hallucination	Consumer	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
				Zanaflex Unk	SS		

Date:03/27/00ISR Number: 3479959-5Report Type:Direct Company Report #
Age:75 YR Gender:Female I/FU:I

Outcome Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 2 MG BID Initial or Prolonged		Abdominal Pain Nausea Thrombocytopenia Vomiting	Health Professional	Tizanidine Catapres Lotensin Darvocet Prilosec Sinemet	PS C C C C C		

Evista C
 Synthroid C
 Lanoxin C
 Ativan C

Date:03/28/00ISR Number: 3480994-1Report Type:Expedited (15-DaCompany Report #ZANA030589 (0)
 Age:52 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Pressure Decreased Drug Interaction	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
TWO 4MG DOSES		Dysphagia					
DAILY, PER		Hallucination					
ORAL		Heart Rate Increased		Vioxx (Rofecoxib)	SS		
TWO 25MG		Psychotic Disorder					
DOSES DAILY							

Date:03/28/00ISR Number: 3480995-3Report Type:Expedited (15-DaCompany Report #ZANA030590 (0)
 Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Bradycardia Chest Discomfort	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY,		Dizziness					
PER ORAL		Hypotension		Vioxx	SS		
25 MG							

22-Aug-2005 12:09 PM
 Page: 60

Freedom Of Information (FOI) Report

Maxalt C

Date:03/28/00ISR Number: 3480996-5Report Type:Expedited (15-DaCompany Report #ZANA030593 (0)
 Age:38 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 4 MG DAILY, PER ORAL	Agitation Amnesia Conversion Disorder	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
	Drug Interaction Feeling Abnormal Hallucination		Zanax Soma Oxycontin Lortab	SS C C C		

Date:04/03/00ISR Number: 3483863-6Report Type:Expedited (15-DaCompany Report #00GB-10239
 Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 80 MG QD, ORAL	Agitation Cyanosis Hypoxia Respiratory Failure	Foreign Health Professional	Baclofen Unknown (Baclofen)	PS		ORAL
200 MG, DAILY, ORAL		Other	Dantrolene Unknown (Dantrolene)	SS		ORAL
10 MG DAILY, ORAL			Zanaflex Unknown (Tizanidine Hydrochloride)	SS		ORAL
			Voltarol Bisacodyl Lactulose Cefuroxime Temazepam	C C C C C		

Motilium	C
Ephedrine	C
Frusemide	C
Glycerol	C
Maxolon	C
Morphine	C
Paracetamol	C
Potassium Chloride	C
Senna	C
Cyclizine	C

Date:04/11/00ISR Number: 3486768-XReport Type:Expedited (15-DaCompany Report #ZANA030606(0)

Age:19 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 10 MG DAILY, PER ORAL	Post Procedural Complication Respiratory Failure	Foreign Health Professional	Zanaflex (Tizanidine Hydrofchloride) Baclofen Dantrolene	PS C C		ORAL

22-Aug-2005 12:09 PM

Page: 61

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/01/00ISR Number: 3494588-5Report Type:Expedited (15-DaCompany Report #ZANA030609 (0)

Age:66 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 12 MG DAILY, PER ORAL	Chromaturia Feeling Jittery Hepatic Cirrhosis Hepatic Necrosis Jaundice	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Lasix Potassium Supplement Phosphinex	C C C		

Date:05/03/00ISR Number: 3495372-9Report Type:Direct

Company Report #

Age:32 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 4MG HS ORAL Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Abdominal Pain Lower Abdominal Pain Upper Back Pain Chills Myalgia Nausea		Zanaflex	PS		ORAL

Date:05/08/00ISR Number: 3497679-8Report Type:Expedited (15-DaCompany Report #ZANA030610 (0)

Age:65 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 24MG, PER ORAL; 8MG, PER ORAL	Apnoea Coma Hypotension Sedation	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Tramadol Dipyridamole Lisinopril Diazepam	C C C C		

Lansoprazole C
Venlafaxine C
Aspirin C

Date:05/24/00ISR Number: 3504562-8Report Type:Direct
Age:40 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 2TT Q 2H	Hallucination Hypertension Intentional Misuse Tachycardia Tremor		Zanaflex 4mg (Athena Neuroscience) Duragesic Neurontin Estrace	PS C C C	Athena Neuroscience	

Date:05/31/00ISR Number: 3506521-8Report Type:Expedited (15-DaCompany Report #ZANA030626(0)
Age:45 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia Blood Bilirubin Increased Hepatic Failure Hepatic Necrosis Hepatotoxicity Liver Function Test

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Abnormal Malaise Nausea Vomiting	Report Source	Product	Role	Manufacturer	Route
PER ORAL			Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
				Thyroid Extract	C		
				Ms Contin	C		
				Dilaudid	C		
				Entex	C		
				Proventil	C		

Date:05/31/00ISR Number: 3507051-XReport Type:Expedited (15-DaCompany Report #ZANA030626(0)
Age:45 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged PER ORAL		Anorexia Blood Bilirubin Increased	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
		Hepatic Failure		Thyroid Extract	C		
		Hepatic Necrosis		Ms Contin	C		
		Hepatotoxicity		Dilaudid	C		
		Liver Function Test		Entex	C		
		Abnormal Malaise Vomiting		Proventil	C		

Date:05/31/00ISR Number: 3507235-0Report Type:Periodic Company Report #MYST0319990051(0)
Age:9 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other PER ORAL		Convulsion	Health Professional	Mysoline (Primidone)	PS	Elan Pharma International Ltd	ORAL
PER ORAL				Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
				Tegretol	C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Gait Disturbance Miosis	Health Professional	Actiq Dilaudid (Hydromorphone)	PS SS	Anesta Corp	ORAL
8 MG Q 3 HRS							
PO				Zanaflex (Tizanidine) Lorazepam Oxycontin (Oxycodone)	SS SS SS		

Outcome	PT
Hospitalization - Initial or Prolonged	Coma Dysphagia Hypothermia Nervous System Disorder

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Stupor

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
16 MG DAILY		Health	Zanaflex	PS		ORAL
PER ORAL		Professional				
			Amitriptyline	C		
			Diclofenac	C		
			Co-Proxamol	C		
			Dantrium	C		

Date:06/08/00ISR Number: 3512447-6Report Type:Expedited (15-DaCompany Report #ZANA030627(0)
Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	30-45 TABLETS	Drug Withdrawal Syndrome Hallucination	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
DAILY, PER		Hypertension					
ORAL		Hypochloraemia					
		Medication Error Overdose		Duragesic Neurontin	C C		
		Tachycardia Tremor Vomiting					

Date:06/08/00ISR Number: 3512449-XReport Type:Expedited (15-DaCompany Report #ZANA030627 (0)
Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	30-45 TABLETS	Drug Withdrawal Syndrome Hallucination	Health Professional	Zanaflex	PS		ORAL
DAILY PER		Hypertension					
ORAL		Hypochloraemia		Duragesic	C		

Insomnia
Intentional Misuse
Tachycardia
Tremor
Vomiting

Neurontin

C

Date:06/08/00ISR Number: 3512469-5Report Type:Expedited (15-DaCompany Report #ZANA030632 (0)
Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged PER ORAL	Difficulty In Walking Hypertension	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
	Joint Swelling		Elavil	C		
	Pyrexia		Klonopin	C		
	Rheumatic Fever		Morphine	C		
	Rheumatoid Arthritis		Phenergan	C		
	Systemic Lupus		Pain Medication (Unspecified)	C		
	Erythematosis		Anti-Hypertensive (Unspecified)	C		
			Steroid (Unspecified)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/00ISR Number: 3512476-2Report Type:Expedited (15-DaCompany Report #ZANA030632 (0)

Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged PER ORAL	Arthritis Difficulty In Walking	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
	Hypertension		Elavil	C		
	Joint Swelling		Klonopin	C		
	Muscle Disorder		Morphine	C		
	Pain		Phenergan	C		
	Pyrexia		Pain Medication (Unspecified)	C		
	Rheumatic Fever		Anti-Hpertensive (Unspecified)	C		
	Rheumatoid Arthritis					
	Systemic Lupus		Steroid (Unspecified)	C		
	Erythematosis					

Date:06/08/00ISR Number: 3512481-6Report Type:Expedited (15-DaCompany Report #ZANA030631 (0)

Age:21 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 4 MG THREE TIMES DAILY, PER ORAL	Muscle Disorder Sedation	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
			Elavil	C		
			Klonopin	C		
			Morphine	C		
			Phenergan	C		
			Pain Medication (Unspecified)	C		
			Anti-Hypertensive (Unspecified)	C		
			Steroid (Unspecified)	C		

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 4 MG THREE TIMES DAILY, PER ORAL	Hypertonia Muscle Disorder Sedation	Health Professional	Zanaflex (Tizanidine Hydrochloride) Elavir Klonopin Morphine Phenergan Pain Medication (Unspecified) Anti-Hypertensive (Unspecified) Steroid (Unspecified)	PS C C C C C C C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/08/00ISR Number: 3512490-7Report Type:Expedited (15-DaCompany Report #ZANA030629 (0)

Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 16 MG DAILY, PER ORAL	Depressed Level Of Consciousness Dysphagia Hypothermia	Foreign Health Professional	Zanaflex Amitriptyline Diclofenac Diclofenac Co-Proxamol Dantrium	PS C C C C C	Elan Pharma International Ltd	ORAL

Date:06/13/00ISR Number: 3512784-5Report Type:Expedited (15-DaCompany Report #ZANA030626(1)

Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged PER ORAL	Anorexia Blood Bilirubin Increased Cholangitis Cholestasis Hepatic Failure Hepatic Necrosis Hepatitis Liver Disorder Liver Function Test Abnormal Malaise Nausea Vomiting	Health Professional	Zanaflex Thyroid Extract Ms Contin Dilaudid Entex Proventil	PS C C C C C	Elan Pharma International Ltd	ORAL

Date:06/19/00ISR Number: 3515172-0Report Type:Direct

Company Report #USP 51945

Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration	Medication Error		Gabitril Zanaflex (Tizanidine)	PS	Abbott	

Date:06/23/00ISR Number: 3518601-1Report Type:Expedited (15-DaCompany Report #ZANA030638 (0)

Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Bradycardia	Health	Zanaflex	PS	Elan Pharma	
Initial or Prolonged	Overdose	Professional			International Ltd	ORAL

Date:06/27/00ISR Number: 3520910-7Report Type:Expedited (15-DaCompany Report #ZANA030639 (0)

Age:41 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Asthenia
Initial or Prolonged	Dermatitis Exfoliative Diarrhoea Hypersensitivity Inflammation Lip Dry Mucosal Inflammation Photosensitivity Reaction

22-Aug-2005 12:09 PM

Page: 66

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Pyrexia Rash Erythematous Rash Maculo-Papular					
4 MG, PER ORAL		Red Blood Cell Sedimentation Rate Increased	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
		Sedation Skin Chapped Stevens-Johnson Syndrome Sunburn Urticaria		Claritin-D Tiazac Darvocet-N 100 Vicodin Ibuprofen	C C C C C		

Date:07/27/00ISR Number: 3536575-4Report Type:Expedited (15-DaCompany Report #ZANA030651(0)
Age:45 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 10MG DAILY, PER ORAL		Hypotension Syncope	Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
				Baclofen Oxybutynin Ciprofloxacin Imipramine Mebeverine	C C C C C		

Date:07/27/00ISR Number: 3536576-6Report Type:Expedited (15-DaCompany Report #ZANA030651(0)
Age:45 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 10MG DAILY 27 DAY		Hypotension Syncope	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Baclofen Oxybutynin Ciprofloxacin Imipramine	C C C C		

Date:08/04/00ISR Number: 3542850-XReport Type:Expedited (15-DaCompany Report #ZANA030653 (0)
 Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Abdominal Pain Upper	Health	Zanaflex	PS	Elan Pharma	
Initial or Prolonged	Blood Bilirubin Increased	Professional			International Ltd	ORAL
4 MG DAILY						
PER ORAL	Hepatic Necrosis					
	International Normalised		Celebrex	C		
	Ratio Increased		Dexedrin	C		
	Liver Function Test		Climara Transdermal	C		
	Abnormal		Prilosec	C		
	Prothrombin Time					
	Prolonged					

Date:08/07/00ISR Number: 3542682-2Report Type:Direct
 Age:75 YR Gender:Male I/FU:I

Company Report #

Outcome
 Required
 Intervention to

22-Aug-2005 12:09 PM
 Page: 67

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Prevent Permanent
Impairment/Damage

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
2-4MG TID		Coma Hypotension		Tizanidine 4mg Athena Neurosciences	PS	Athena Neurosciences	ORAL
ORAL				Citalopram	C		
				Famotidine	C		
				Atenolol	C		
				Hydrochlorothiazide	C		
				Docusate Sodium	C		
				Acetaminophen	C		
				Quinipril	C		
				Riluzole	C		
				Heparin	C		

Date:08/14/00ISR Number: 3550484-6Report Type:Expedited (15-DaCompany Report #ZANA030656 (0)
Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 0.7		Accidental Exposure Hypotonia	Foreign Literature	Zanaflex	PS	Elan Pharma International Ltd	ORAL
MB/KG/DAY, PER ORAL		Medication Error Sedation	Health Professional				

Date:08/21/00ISR Number: 3554562-7Report Type:Expedited (15-DaCompany Report #ZANA030664 (0)
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 4 MG-36 MG AS NEEDED, PO		Condition Aggravated Movement Disorder Muscle Spasticity	Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
				Fentanyl	C		

Propofol	C
Suxamethonium	C
Atracurium	C
Morphine	C
Glycopyrrolate	C
Neostigmine	C
Interferon Beta	C
Co-Dydramol	C
Ibuprofen	C

Date:08/23/00ISR Number: 3556390-5Report Type:Direct
 Age:59 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 4MG 1/4 TAB	Abdominal Pain Upper Abdominal Tenderness		Zanaflex 4mg (Elan Pharmaceuticals)	PS	Elan Pharmaceuticals	
QID & 2TT	Hepatic Enzyme Increased					
TABS Q HS	International Normalised Ratio Increased Jaundice Pleural Effusion Prothrombin Time Prolonged Pyrexia		Climara Patch Dexedrine Celebrex	C C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/00ISR Number: 3568305-4Report Type:Direct
Age:36 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged TWO TABLETS ONLY AT BEDTIME	Dyspnoea Palpitations	Health Professional	Zanaflex 4mg Two Tablets	PS		

Date:09/12/00ISR Number: 3570369-9Report Type:Direct
Age:57 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Death 3 WK	Abdominal Pain Ascites Autoimmune Hepatitis Cardio-Respiratory Arrest Culture Urine Positive Escherichia Infection Jaundice Sedation Sepsis Ultrasound Scan Abnormal		Zanaflex	PS		

Date:09/15/00ISR Number: 3572038-8Report Type:Direct
Age:57 YR Gender:Male I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 4MG TID ORAL Initial or Prolonged Required Intervention to Prevent Permanent Impairment/Damage	Asthenia Bradycardia Dizziness Hypertension Hypotension		Zanaflex 4mg Prilosec Paxil Tranxene Vioxx Accupril	PS C C C C C		ORAL

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 16 MG DAILY PER ORAL	Abdominal Pain Upper Coagulopathy Encephalopathy Hepatic Necrosis Hepatotoxicity Hyperbilirubinaemia Hypoglycaemia International Normalised Ratio Decreased Jaundice Leukocytosis Liver Function Test Abnormal Pleural Effusion Prothrombin Time Prolonged Pyrexia	Health Professional	Zanaflex Celebrex Dexedrin Climara Transdermal	PS C C C	Elan Pharma International Ltd	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/27/00ISR Number: 3581462-9Report Type:Direct
Age:53 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening 2MG, 4MG 2MG Required TID 4MGQH Intervention to ORAL Prevent Permanent Impairment/Damage	Sedation		Zanaflex / 4 Mg	PS		ORAL

Date:09/29/00ISR Number: 3585127-9Report Type:Expedited (15-DaCompany Report #ZANA030680 (0)
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 24 MG DAILY, PER ORAL	Chest Pain Condition Aggravated Cough Headache Hepatic Enzyme Increased Hepatomegaly Musculoskeletal Stiffness Myalgia Nausea Nightmare Pyrexia Tachypnoea Tenderness	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL

Date:10/04/00ISR Number: 3587619-5Report Type:Direct
Age:45 YR Gender:Female I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 1/2 TABLET	Hepatitis	Health	Tizanidine	PS		

Initial or Prolonged (2MG) BID	Hepatotoxicity	Professional		
1 & 1/2	Liver Function Test		Tizanidine	SS
TABLET (6 MG)	Abnormal			
Q HS	Nausea			
	Vomiting		Morphine	C
			Hydromorphone	C
			Premarin	C
			Maxide	C
			Zyrtec	C
			Entex	C
			Triamcinolone	
			Inhaler	C
			Albuterol Inhaler	C

Date:10/06/00ISR Number: 3590648-9Report Type:Expedited (15-DaCompany Report #ZANA030681 (0)
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged PER ORAL		Hepatic Failure	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/06/00ISR Number: 3590815-4Report Type:Expedited (15-DaCompany Report #ZANA030609 (1)

Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 12 MG DAILY, PER ORAL	Ammonia Increased Chromaturia Diarrhoea	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
	Feeling Jittery		Lasix	C		
	Hepatic Cirrhosis		Potassium Supplement	C		
	Hepatic Necrosis		Phosphinex	C		
	Jaundice					
	Liver Function Test Abnormal					
	Nausea					
	Vomiting					

Date:10/12/00ISR Number: 3595567-XReport Type:Expedited (15-DaCompany Report #ZANA030626 (2)

Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 8 MG DAILY, PER ORAL	Anorexia Blood Bilirubin Increased Cholangitis	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
	Cholestasis		Thyroid Extract	C		
	Coagulopathy		Ms Contin	C		
	Encephalopathy		Dilaudid	C		
	Hepatic Failure		Entex	C		
	Hepatic Necrosis		Proventil	C		
	Hepatitis		Premarin	C		
	Jaundice		Maxzide	C		
	Liver Function Test Abnormal		Zyrtec	C		
	Malaise		Triamcinolone	C		
	Portal Hypertension		Inhaler	C		
	Vomiting					

Outcome	PT
Hospitalization -	Abdominal Pain Upper
Initial or Prolonged	Antibody Test Positive
	Chest Pain
	Chills
	Condition Aggravated
	Cough
	Cytomegalovirus Infection
	Fibromyalgia
	Gram Stain Positive
	Headache
	Hepatic Enzyme Increased
	Hepatitis
	Hepatitis Infectious
	Hepatomegaly
	Hypokalaemia
	Hypophosphataemia
	Musculoskeletal Stiffness
	Nausea
	Nightmare
	Pyrexia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
24 MG DAILY		Rash Macular Rash Pruritic Tachypnoea	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
PER ORAL		Viral Infection		Demulin	C		

Date:11/02/00ISR Number: 3607028-XReport Type:Expedited (15-DaCompany Report #ZANA030589 (1)
Age:52 YR Gender:Female I/FU:F

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	8 MG DAILY,		Blood Pressure Decreased Drug Interaction	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
PER ORAL			Dysphagia					
50 MG DAILY,			Hallucination		Vioxx (Rofecoxib)	SS		ORAL
PER ORAL			Heart Rate Increased					
			Psychotic Disorder Speech Disorder					

Date:11/09/00ISR Number: 3610122-0Report Type:Expedited (15-DaCompany Report #ZANA030701 (0)
Age: Gender:Female I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death	12 MG DAILY		Jaundice Liver Function Test	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
PER ORAL		2 MON	Abnormal					

Date:11/13/00ISR Number: 3610726-5Report Type:Expedited (15-DaCompany Report #ZANA030702(0)
Age:77 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 4 MG DAILY, PER ORAL		Asthenia Blood Pressure Decreased Condition Aggravated Confusional State Dysarthria Hypotension	Health Professional	Zanaflex Coumadin Lovenox Atenolol Vioxx Zoloft Quinine Sulfate Hydrochlorothiazide	PS C C C C C C C	Elan Pharma International Ltd	ORAL

Date:11/13/00ISR Number: 3610809-XReport Type:Expedited (15-DaCompany Report #ZANA030703 (0)
Age:62 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 24 MG DAILY, PER ORAL		Convulsion Hemiparesis Transient Ischaemic Attack Tremor	Health Professional	Zanaflex Coumadin Dilantin Baclofen Lipitor Zoloft Colace Valium	PS C C C C C C C	Elan Pharma International Ltd	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/15/00ISR Number: 3611748-0Report Type:Direct
Age:45 YR Gender:Male I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	3TTT A DAY	Balance Disorder		Zanaflex (2mg Tabs)	PS		
STARTED AT 1T		Confusional State					
PER DAY THEN		Dysarthria					
GRADUALLY		Memory Impairment					
INCREASED TO				Vicodin Es	C		

Date:11/16/00ISR Number: 3613012-2Report Type:Expedited (15-DaCompany Report #ZANA030710(0)
Age:78 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death	24 MG DAILY,	Sudden Death	Foreign Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
PER ORAL			Professional	Aspirin	C		
				Co-Amilofruse	C		
				Glibenclamide	C		
				Amitriptyline	C		

Date:11/16/00ISR Number: 3613013-4Report Type:Expedited (15-DaCompany Report #ZANA030707(0)
Age:61 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability	6 MG DAILY,	Cardiac Failure Congestive	Foreign Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
PER ORAL		Hypertension	Professional				
		Paraplegia		Ciprofloxacin	C		

Date:11/22/00ISR Number: 3617124-9Report Type:Expedited (15-DaCompany Report #ZANA030717 (0)
Age:67 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness	Foreign	Zanaflex	PS	Elan Pharma	
		Loss Of Consciousness	Health			International Ltd	ORAL
2 TO 4 MG			Professional				
DAILY, PER							
ORAL							

Date:11/22/00ISR Number: 3617809-4Report Type:Expedited (15-DaCompany Report #ZANA030663 (0)
Age:63 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Bradycardia	Health	Zanaflex	PS	Elan Pharma	
Initial or Prolonged		Condition Aggravated	Professional			International Ltd	ORAL
4 MG DAILY,		Hypertonia					
PER ORAL		Muscle Spasms		Ditropan	C		
				Diazepam	C		
				Lipitor	C		
				Aspirin	C		
				Prilosec	C		
				Restoril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/11/00ISR Number: 3626570-9Report Type:Expedited (15-DaCompany Report #ZANA030701 (1)

Age: Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Jaundice	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY,							
PER ORAL 2 MON							

Date:12/22/00ISR Number: 3636567-0Report Type:Expedited (15-DaCompany Report #ZANA000694 (0)

Age:45 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Hypertension Oedema Peripheral	Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
24 MG DAILY							
ORAL							

Date:12/22/00ISR Number: 3636621-3Report Type:Expedited (15-DaCompany Report #ZANA000722 (0)

Age:60 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Depressed Level Of Consciousness	Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DAILY							
ORAL							
				Methylprednisolone	C		
				Effexor	C		
				Thyroxine I 125	C		

Date:12/26/00ISR Number: 3637972-9Report Type:Expedited (15-DaCompany Report #PHNU2000DE01846

Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Congenital Anomaly	Abortion Spontaneous	Foreign	Voltaren	PS	Novartis
Other	Accidental Exposure	Health			Pharmaceuticals Corp
	Multiple Congenital	Professional	Sirdalud (Sanofi		
	Abnormalities	Other	Winthrop) (Ti		
			Zanidine		
			Hydrochloride,		
			Tizanidine	SS	
			Valoron "Goedecke"		
			(Tilidine		
			Hydrochloride)	SS	

Date:12/26/00ISR Number: 3637973-0Report Type:Expedited (15-DaCompany Report #PHNU2000DE01850
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose						
Duration						
Congenital Anomaly	Abortion Spontaneous	Foreign	Voltaren	PS	Novartis	
Other	Accidental Exposure	Health			Pharmaceuticals Corp	
	Foetal Disorder	Professional	Sirdalud (Sanofi			
		Other	Winthrop) (Ti			
			Zanidine			
			Hydrochloride)	SS		
			Valoron			
			"Goedecke" (Tilidine			
			Hydrochloride)	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/01ISR Number: 3641287-2Report Type:Expedited (15-DaCompany Report #ZANA000742 (0)
 Age:85 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	2 MG DAILY	Cardiac Arrest	Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
				Senna	C		
				Aspirin	C		
				Tamsulosin	C		
				Co-Danthramer	C		

Date:01/03/01ISR Number: 3641648-1Report Type:Expedited (15-DaCompany Report #001-0945-M0000196
 Age:40 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	900 MG(300 MG	Arthralgia Asthenia	Consumer	Neurontin	PS	Parke Davis Pharmaceuticals Ltd	ORAL
Other	TID):2400MG(8	Blood Potassium Decreased					
	00MG	Carpal Tunnel Syndrome					
	TID):2100MG(7	Cholelithiasis					
	00MG	Cholestasis					
	80 MG PER	Decreased Activity		Baclofen	SS		ORAL
	ORAL	Dental Caries					
	1600 MG	Depression		Ms Contin	SS		
	2500 MG	Difficulty In Walking		Propulsid	SS		
		Dry Mouth		Methadone	SS		
	1 OR 2 (Q 4 H	Fall		Percocet	SS		
	PRN)	Fatigue					

80 MG		Gallbladder Disorder	Valium	SS	
		Gallbladder Pain	Zanaflex	SS	ORAL
8 MG PER ORAL		Headache	Zoloft	SS	ORAL
200 MG PER		Hypoaesthesia			
ORAL		Hypothyroidism	Hydrochlorothiazide	SS	ORAL
100 MG PER		Joint Dislocation			
ORAL		Lethargy	Veetids	SS	ORAL
2000 MG PER		Liver Function Test			
ORAL	1	Abnormal	Synthroid	SS	
		Lymphadenopathy	Oxy Ir (Oxycodone		
		Malnutrition	Hydrochloride)	SS	
8-10 DAILY		Movement Disorder	Lasix	SS	
80 MG		Nervous System Disorder	Ritalin	SS	
80 MG		Oedema Peripheral	K-Dur	SS	
20 MCG		Osteoporosis	Seroquel	SS	
		Ovarian Cyst	Ketamine	SS	
		Pain In Extremity	Klonopin	SS	
		Pruritus	Corgard	SS	
		Skin Discolouration	Relafen	SS	
		Skin Ulcer	Celebrex	SS	
800 MG		Tendon Disorder	Carafate	SS	
4 MG		Vomiting	Dextromethorphan	SS	
200 MG		Weight Decreased	Nadolol	SS	
		Weight Increased	Tegaderm	SS	

Date:01/11/01ISR Number: 3646580-5Report Type:Expedited (15-DaCompany Report #2001010006
Age:74 YR Gender:Female I/FU:I

Outcome PT
Hospitalization - Akathisia
Initial or Prolonged Anorexia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Anxiety Delirium Movement Disorder					
15 MG/D, PO		Muscle Rigidity Pain In Extremity Restlessness	Foreign Health Professional	Doral	PS	Wallace Laboratories Div Carter Wallace Inc	ORAL
3 TABS/D, PO		Sedation Tremor		Levodopa/Benserazide Hcl Tablets	SS		ORAL
SEE IMAGE		Urinary Incontinence		Pergolide Mesylate	SS		ORAL
3 MG/D, PO				Tizanidine Hcl	SS		ORAL
PO				Etizolam	SS		ORAL
				Etilefrine	C		
				Pravastatin Sodium	C		
				Azulene Sulfonate	C		
				Sodium/L-Glutamine	C		
				Haloperidol	C		
				Tiapride Hcl	C		

Date:01/22/01ISR Number: 3652795-2Report Type:Expedited (15-DaCompany Report #ZANA000723 (0)

Age: Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Ammonia Increased Blood Urea Increased	Foreign Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
8 MG DAILY		Hypertension	Professional				
ORAL		Nephritis Interstitial Oliguria					

Date:02/01/01ISR Number: 3659383-2Report Type:Periodic Company Report #ZANA000696 (0)

Age:55 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Coagulopathy	Consumer	Zanaflex	PS	Elan Pharma	

ORAL

International Ltd ORAL

Verapamil	C
Triamterene/Hydrochl	
orothiazide	C
Propranolol	C
Esterifield	
Estrogens	C
Baclofen	C
Clonazepam	C
Donnatal	C
Aspirin	C

Date:02/01/01ISR Number: 3659384-4Report Type:Periodic
 Age: Gender:Female I/FU:I

Company Report #ZANA000698 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Diarrhoea	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
2MG DAILY							

ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659385-6Report Type:Periodic
 Age:71 YR Gender:Male I/FU:I

Company Report #ZANA000704 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension Syncope	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL				Trazodone Dilantin Dulcolax	C C C		

Date:02/01/01ISR Number: 3659386-8Report Type:Periodic
 Age: Gender:Female I/FU:I

Company Report #ZANA000705 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth Sedation	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
2-8 MG DAILY							
ORAL							

Date:02/01/01ISR Number: 3659387-XReport Type:Periodic
 Age:45 YR Gender:Female I/FU:I

Company Report #ZANA000706 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperhidrosis	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659388-1Report Type:Periodic
 Age: Gender:Male I/FU:I

Company Report #ZANA000709 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659389-3Report Type:Periodic Company Report #ZANA000713 (0)
Age:39 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Clonic Convulsion	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY							
ORAL							
				Zyrtec	C		
				Atenolol	C		
				Premarin	C		
				Fiorinal	C		
				Oxycontin	C		
				Tylenol#3	C		

Date:02/01/01ISR Number: 3659390-XReport Type:Periodic Company Report #ZANA000715 (0)
Age:33 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
2 MG DAILY							
ORAL							
				Vioxx	C		
				Oxycontin	C		
				Percocet	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659391-1Report Type:Periodic Company Report #ZANA000718 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Consumer Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12-16 MG			Professional				
DAILY ORAL				Plexeril	C		

Date:02/01/01ISR Number: 3659392-3Report Type:Periodic Company Report #ZANA000719 (0)
 Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659393-5Report Type:Periodic Company Report #ZANA000683 (0)
 Age:47 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypertonia Muscle Spasms	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
2 MG DAILY							
ORAL							

Date:02/01/01ISR Number: 3659394-7Report Type:Periodic Company Report #ZANA000684 (0)
 Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Pain	Company Representative	Zanaflex	PS	Elan Pharma International Ltd	ORAL
2 MG DAILY							

ORAL

Date:02/01/01ISR Number: 3659395-9Report Type:Periodic Company Report #ZANA000685 (0)
Age:56 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Diarrhoea	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL				Premarin	C		

Date:02/01/01ISR Number: 3659396-0Report Type:Periodic Company Report #ZANA000686 (0)
Age:63 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperhidrosis Pain	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
32 MG DAILY		Pruritus					
ORAL		Sedation		Paxil	C		
				Claritin-D 24 Hour	C		
				Prilosec	C		
				Celebrex	C		
				Hydroxyzine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659397-2Report Type:Periodic
Age:57 YR Gender:Female I/FU:I

Company Report #ZANA000687 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Facial Palsy Sedation	Consumer Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL		Speech Disorder Stupor	Professional	Norvasc Estrogen Supplement Aciphex Zovirax Vioxx	C C C C C		

Date:02/01/01ISR Number: 3659398-4Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA000688 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness Dry Mouth	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659399-6Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA000689 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Cardiovascular Disorder	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659400-XReport Type:Periodic
Age:78 YR Gender:Male I/FU:I

Company Report #ZANA000690(0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abdominal Pain Anorexia	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
6-12 MG DAILY							

ORAL

Celebrex C
Diuretic C

Date:02/01/01ISR Number: 3659401-1Report Type:Periodic Company Report #ZANA000691 (0)
Age:50 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Accident	Health	Zanaflex	PS	Elan Pharma	
		Clonic Convulsion	Professional			International Ltd	ORAL
4 MG DAILY							
		Hypertonia	Distributor				
ORAL				Luvox	SS		ORAL
200 MG DAILY							

ORAL

Anafranil C
Ambien C
Tylox C
Prempro C
Neurontin C

Date:02/01/01ISR Number: 3659402-3Report Type:Periodic Company Report #ZANA000692(0)
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Health	Zanaflex	PS	Elan Pharma	
			Professional			International Ltd	ORAL

ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659403-5Report Type:Periodic Company Report #ZANA000668 (0)
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DAILY,							
ORAL							

Date:02/01/01ISR Number: 3659404-7Report Type:Periodic Company Report #ZANA000669 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DILY							
ORAL							
				Desyrel	C		

Date:02/01/01ISR Number: 3659405-9Report Type:Periodic Company Report #ZANA000670 (0)
 Age:49 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Accident Hallucination	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DAILY							
ORAL							
		Hypotension		Norvasc	C		
				Paxil	C		
				Premarin	C		

Date:02/01/01ISR Number: 3659406-0Report Type:Periodic Company Report #ZANA000672 (0)
 Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659407-2Report Type:Periodic Company Report #ZANA000673 (0)
 Age:35 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Dizziness	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
6-8MG DILY							
ORAL							
				Oral Contraceptives	C		

Date:02/01/01ISR Number: 3659408-4Report Type:Periodic Company Report #ZANA000674 (0)
 Age:28 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms Pain	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							
				Dantrium	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659409-6Report Type:Periodic
Age:65 YR Gender:Female I/FU:I

Company Report #ZANA000675 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Creatinine Increased	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DAILY		Blood Urea Increased					
ORAL		Hyperkalaemia					

Date:02/01/01ISR Number: 3659410-2Report Type:Periodic
Age:35 YR Gender:Male I/FU:I

Company Report #ZANA000676 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Creatinine Increased		Zanaflex	PS	Elan Pharma International Ltd	ORAL
2 MG DAILY		Blood Urea Increased					
ORAL		Urinary Tract Infection		Hydrocodone	C		

Date:02/01/01ISR Number: 3659411-4Report Type:Periodic
Age: Gender:Female I/FU:I

Company Report #ZANA000678 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Pain Paraesthesia	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12MG DAILY		Sedation					
ORAL		Tremor					

Date:02/01/01ISR Number: 3659412-6Report Type:Periodic
Age: Gender:Male I/FU:I

Company Report #ZANA000682 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Other Testicular Disorder Health Professional Zanaflex PS Elan Pharma International Ltd ORAL

4 MG DAILY

ORAL

Date:02/01/01ISR Number: 3659413-8Report Type:Periodic Company Report #ZANA000648 (0)
Age:60 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Depressed Level Of Consciousness	Consumer	Zanaflex	PS	Elan Pharma International Ltd	
4 MG DAILY		Dyspnoea Hallucination Sedation		Vioxx	C		

Date:02/01/01ISR Number: 3659414-XReport Type:Periodic Company Report #ZANA000650 (0)
Age:36 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Syncope	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY							
ORAL				Methadone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659415-1Report Type:Periodic Company Report #ZANA000655 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth	Consumer Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
0.5 MG DAILY			Professional				
ORAL							

Date:02/01/01ISR Number: 3659416-3Report Type:Periodic Company Report #ZANA000657 (0)
 Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659417-5Report Type:Periodic Company Report #ZANA000658 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abnormal Dreams Dry Mouth	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL			Sedation				

Date:02/01/01ISR Number: 3659418-7Report Type:Periodic Company Report #ZANA000659 (0)
 Age:44 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Accident Muscle Spasms	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DAILY							
ORAL				Avonex	C		

Tylenol Pm C
Ditropan C
Vitamin Supplement C

Date:02/01/01ISR Number: 3659419-9Report Type:Periodic Company Report #ZANA000660 (0)
Age:50 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Clonic Convulsion	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
6 MG DAILY							

ORAL

Ambien C
Tylox C
Luvox C
Clomipramine C

Date:02/01/01ISR Number: 3659420-5Report Type:Periodic Company Report #ZANA000661 (0)
Age:40 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hiccups	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DAILY							

ORAL

Prednisone C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659421-7Report Type:Periodic
Age:42 YR Gender:Female I/FU:I

Company Report #ZANA000662 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Health	Zanaflex	PS	Elan Pharma	
		Visual Field Defect	Professional			International Ltd	ORAL
2 MG	DAILY						
ORAL							
				Duragesic Patch	C		
				Actiq	C		
				Ativan	C		
				Fiorinal	C		

Date:02/01/01ISR Number: 3659422-9Report Type:Periodic
Age:21 YR Gender:Male I/FU:I

Company Report #ZANA000665 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Consumer	Zanaflex	PS	Elan Pharma	
						International Ltd	ORAL
16 MG	DAILY						
ORAL							
				Zoloft	C		
				Oxybutynin	C		
				Contac	C		

Date:02/01/01ISR Number: 3659443-6Report Type:Periodic
Age:18 YR Gender:Female I/FU:I

Company Report #ZANA000579 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Health	Zanaflex	PS	Elan Pharma	
			Professional			International Ltd	ORAL
8 MG	DAILY						
ORAL							

Date:02/01/01ISR Number: 3659444-8Report Type:Periodic Company Report #ZANA000580 (0)

Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL				Baclofen	C		
				Wellbutrin	C		

Date:02/01/01ISR Number: 3659445-XReport Type:Periodic Company Report #ZANA000581 (0)

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypersensitivity	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
20 MG DAILY							
ORAL				Hyzaar	C		
				Prilosec	C		
				Soma	C		

Date:02/01/01ISR Number: 3659446-1Report Type:Periodic Company Report #ZANA000582 (0)

Age:32 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Akathisia	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
20 MG DAILY							

22-Aug-2005 12:09 PM

Page: 83

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

ORAL

Klonopin C
Neurontin C

Date:02/01/01ISR Number: 3659447-3Report Type:Periodic Company Report #ZANA000583 (0)
Age:77 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Arthralgia	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
		Arthritis					
8 MG DAILY							

ORAL

Date:02/01/01ISR Number: 3659448-5Report Type:Periodic Company Report #ZANA000584 (0)
Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dysphagia	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
		Myasthenic Syndrome					
36 MG DAILY							
		Rhinitis					
		Sinusitis		Baclofen	C		

ORAL

Date:02/01/01ISR Number: 3659449-7Report Type:Periodic Company Report #ZANA000585 (0)
Age:57 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
6 MG DAILY							

ORAL

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Diarrhoea	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL

2 MG DAILY

ORAL

- Diovan C
- Calcium C
- Aspirin C
- Acidophilus Tablets C
- Clonazepam C
- Estradiol C
- Pravachol C
- Albuterol C
- Azmacort C
- Serevent C
- Alpha Interferon
- Shots C
- B12 Shots C
- Multivitamins C
- Vitamin C C
- Vitamin E C
- Imodium C
- Compazine C
- Lomotil C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659451-5Report Type:Periodic
Age:57 YR Gender:Female I/FU:I

Company Report #ZANA000592 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abnormal Dreams	Health	Zanaflex	PS	Elan Pharma	
		Drug Interaction	Professional			International Ltd	ORAL
4 MG DAILY							
ORAL							
				Vioxx	SS		
50 MG DAILY							

Date:02/01/01ISR Number: 3659452-7Report Type:Periodic
Age:66 YR Gender:Male I/FU:I

Company Report #ZANA000594 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Anorexia	Consumer	Zanaflex	PS	Elan Pharma	
		Asthenia				International Ltd	ORAL
ORAL							
		Dry Mouth					
		Myasthenic Syndrome					

Date:02/01/01ISR Number: 3659453-9Report Type:Periodic
Age:42 YR Gender:Male I/FU:I

Company Report #ZANA000595(0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Urinary Retention	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
16 MG DAILY							
PRN ORAL							
				Ms Contin	C		
				Hydromorphone	C		
				Klonopin	C		

Date:02/01/01ISR Number: 3659454-0Report Type:Periodic
Age: Gender:Male I/FU:I

Company Report #ZANA000596(0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypoglycaemia	Consumer Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
16 MG DAILY			Professional				
ORAL				Glyburide	C		
				Glucose	C		

Date:02/01/01ISR Number: 3659455-2Report Type:Periodic Company Report #ZANA000597(0)
 Age:43 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY							
ORAL				Vioxx	C		
				Neurontin	C		

Date:02/01/01ISR Number: 3659456-4Report Type:Periodic Company Report #ZANA000598(0)
 Age:11 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Malaise	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL		Sedation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659457-6Report Type:Periodic
Age:73 YR Gender:Female I/FU:I

Company Report #ZANA000599(0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Cough	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
		Dyspnoea					
		Headache					

Date:02/01/01ISR Number: 3659458-8Report Type:Periodic
Age:47 YR Gender:Female I/FU:I

Company Report #ZANA000602(0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Twitching	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
				Baclofen	C		
				Prempro	C		

Date:02/01/01ISR Number: 3659459-XReport Type:Periodic
Age:61 YR Gender:Male I/FU:I

Company Report #ZANA000603(0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
				Avonex	C		
				Baclofen	C		
				Valium	C		

Date:02/01/01ISR Number: 3659460-6Report Type:Periodic
Age:59 YR Gender:Female I/FU:I

Company Report #ZANA000605(0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dyspnoea Hypertension	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
8 MG DAILY							
ORAL		Pneumonia					
				Alprazolam	C		
				Imipramine	C		
				Procyclidine	C		

Date:02/01/01ISR Number: 3659461-8Report Type:Periodic Company Report #ZANA000612(0)
Age:44 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Tongue Oedema	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							
				Soma	C		
				Lodine	C		
				Vitamin E	C		

Date:02/01/01ISR Number: 3659462-XReport Type:Periodic Company Report #ZANA000613(0)
Age:55 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							
				Premarin	C		

22-Aug-2005 12:09 PM
Page: 86

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659487-4Report Type:Periodic Company Report #ZANA000573(0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 60 MG DAILY		Hypotension	Company Representative	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL				Vioxx	SS		

Date:02/01/01ISR Number: 3659488-6Report Type:Periodic Company Report #ZANA000564(0)
 Age:36 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 8 MG DAILY		Liver Function Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL				Haldol	C		
				Prevacid	C		
				Norflex	C		
				Paxil	C		
				Colace	C		
				Restoril	C		
				Dulcolax	C		
				Benadryl	C		
				Ativan	C		
				Valium	C		

Date:02/01/01ISR Number: 3659489-8Report Type:Periodic Company Report #ZANA000565 (0)
 Age:44 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 12 MG DAILY		Myasthenic Syndrome Oedema Peripheral	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL		Paraesthesia					

Weight Increased

Lotrel	C
Depakote	C
Prednisone	C
Zyrtec	C
Synthroid	C
Prevacid	C
Singulair	C
Clonidine	C
Roxanol	C
Pulmicort	C
Atrovent Metered Dose Inhaler	C
Atrovent Nasal Spray	C
Rhinocort Nasal Spray	C

Date:02/01/01ISR Number: 3659491-6Report Type:Periodic Company Report #ZANA000567(0)
 Age:41 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Dizziness Hallucination	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
UNKNOWN ORAL		Insomnia		Vioxx	SS		ORAL
25 MG DAILY ORAL		Nausea		Neurontin	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659493-XReport Type:Periodic
 Age: Gender:Female I/FU:I

Company Report #ZANA000571 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659494-1Report Type:Periodic
 Age: Gender:Female I/FU:I

Company Report #ZANA000572 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
8 MG DAILY							
ORAL							

Date:02/01/01ISR Number: 3659495-3Report Type:Periodic
 Age:37 YR Gender:Female I/FU:I

Company Report #ZANA000575 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							
				Flexeril	C		

Date:02/01/01ISR Number: 3659497-7Report Type:Periodic
 Age: Gender:Male I/FU:I

Company Report #ZANA000576 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Laboratory Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							
				Melatonin	C		

Date:02/01/01ISR Number: 3659498-9Report Type:Periodic Company Report #ZANA000577 (0)
Age:48 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Delusion Hallucination	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL				Mirapex Elavil Prilosec Propulsid	C C C C		

Date:02/01/01ISR Number: 3659499-0Report Type:Periodic Company Report #ZANA000578 (0)
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
2 MG DAILY							
ORAL							

Date:02/01/01ISR Number: 3659530-2Report Type:Periodic Company Report #ZANA000633 (0)
Age:43 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
24 MG DAILY							

22-Aug-2005 12:09 PM
Page: 88

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

ORAL

Date:02/01/01ISR Number: 3659531-4Report Type:Periodic Company Report #ZANA000636 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness Emotional Disorder	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL		Hyperhidrosis Myalgia		Clonazepam Diovan	C C		

Date:02/01/01ISR Number: 3659533-8Report Type:Periodic Company Report #ZANA000637 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Arthralgia Muscle Spasms	Consumer	Zanaflex	PS	Elan Pharma International Ltd	
6 MG DAILY		Nausea					
ORAL		Tremor		Avonex Vicodin Soma	C C C		

Date:02/01/01ISR Number: 3659535-1Report Type:Periodic Company Report #ZANA000640 (0)
 Age:44 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY							
ORAL				Nortriptyline Celexa	C C		

Date:02/01/01ISR Number: 3659536-3Report Type:Periodic Company Report #ZANA000641 (0)
Age:55 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Convulsion Dizziness	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY		Dry Mouth					
ORAL		Headache					

Date:02/01/01ISR Number: 3659537-5Report Type:Periodic Company Report #ZANA000642 (0)
Age:39 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Deafness Dizziness	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY		Hallucination					
ORAL				Baclofen Prilosec	C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659539-9Report Type:Periodic
Age: Gender:Male I/FU:I

Company Report #ZANA000643 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness Hallucination	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
10 MG DAILY							
ORAL		Nausea		Vioxx	C		

Date:02/01/01ISR Number: 3659540-5Report Type:Periodic
Age:82 YR Gender:Female I/FU:I

Company Report #ZANA000644 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Urinary Retention	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
6 MG DAILY							
LORAL				Methadone	C		
				Celexia	C		
				Atenolol	C		
				Prinivil	C		
				Topamax	C		
				Neurontin	C		

Date:02/01/01ISR Number: 3659542-9Report Type:Periodic
Age:36 YR Gender:Male I/FU:I

Company Report #ZANA000645 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Amnesia Sedation	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
12 MG DAILY							
ORAL				Methadone	SS		
30 MG Q 6H				Ibuprofen	C		
				Viagra	C		

Potassium Chloride
(Kcl) C
Spironolactone C

Date:02/01/01ISR Number: 3659543-0Report Type:Periodic Company Report #ZANA000647 (0)
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Health	Zanaflex	PS	Elan Pharma	
		Sexual Dysfunction	Professional			International Ltd	ORAL

2 MG DAILY

ORAL

Pamelor C

Date:02/01/01ISR Number: 3659556-9Report Type:Periodic Company Report #ZANA000720 (0)
Age:77 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dizziness	Consumer	Zanaflex	PS	Elan Pharma	
						International Ltd	ORAL

4 MG DAILY

ORAL

Vioxx C
Premarin C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659557-0Report Type:Periodic Company Report #ZANA000721 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Sedation	Health	Zanaflex	PS	Elan Pharma	
		Sexual Dysfunction	Professional			International Ltd	ORAL
4 MG DAILY							
ORAL							
				Celexa	C		
				Buspar	C		
				Darvocet-N100	C		
				Pepcid Ac	C		
				Premarin	C		
				Progesterone	C		

Date:02/01/01ISR Number: 3659558-2Report Type:Periodic Company Report #ZANA000559 (1)
 Age:17 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Malaise	Health	Zanaflex	PS	Elan Pharma	
			Professional			International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659559-4Report Type:Periodic Company Report #ZANA000560 (1)
 Age:51 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperacusis	Health	Zanaflex	PS	Elan Pharma	
		Visual Disturbance	Professional			International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659560-0Report Type:Periodic Company Report #ZANA000615 (0)
 Age:46 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Myasthenic Syndrome	Consumer	Zanaflex	PS	Elan Pharma	

2 MG DAILY Sedation International Ltd ORAL

ORAL

Date:02/01/01ISR Number: 3659561-2Report Type:Periodic Company Report #ZANA000617 (0)
Age:38 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Gait Disturbance	Health	Zanaflex	PS	Elan Pharma	
		Miosis	Professional			International Ltd	ORAL

ORAL

Dilaudid	SS
Lorazepam	SS
Actiq	SS
Oxycontin	SS

Date:02/01/01ISR Number: 3659562-4Report Type:Periodic Company Report #ZANA000618 (0)
Age:61 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dysphagia	Consumer	Zanaflex	PS	Elan Pharma	
		Gait Disturbance				International Ltd	ORAL

8 MG DAILY

Sedation

ORAL

Oxyconti N	C
Vioxx	C
Pamellar	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Prempro C
 Prevacid C
 Ritalin C
 Calcium Supplement C
 Multivitamin C
 Vitamin B Complex C
 Glucosamine C

Date:02/01/01ISR Number: 3659563-6Report Type:Periodic Company Report #ZANA000620 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Date:02/01/01ISR Number: 3659564-8Report Type:Periodic Company Report #ZANA000621 (0)
 Age:46 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hyperaesthesia Vasodilatation	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
8 TABS DAILY, ORAL							

Loracet C
 Ambien C
 Elavil C

Date:02/01/01ISR Number: 3659565-XReport Type:Periodic Company Report #ZANA000622 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective	Consumer	Zanaflex	PS	Elan Pharma International Ltd	ORAL
4 MG DAILY							
ORAL							

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia Confusional State	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
3 MG DAILY							
ORAL							
		Emotional Disorder					
		Euphoric Mood		Daypro	C		
		Speech Disorder		Effexor	C		
				Xanax	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/01/01ISR Number: 3659568-5Report Type:Periodic
Age: Gender: I/FU:I

Company Report #ZANA000625 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hallucination	Health	Zanaflex	PS	Elan Pharma	
		Laboratory Test Abnormal	Professional			International Ltd	ORAL
2-4 MG DAILY							
ORAL							
				Baclofen	C		
				Neurontin	C		
				Celebrex	C		
				Pamelor	C		

Date:02/01/01ISR Number: 3659569-7Report Type:Periodic
Age:36 YR Gender:Female I/FU:I

Company Report #ZANA000630 (0)

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Insomnia	Consumer	Zanaflex	PS	Elan Pharma	
		Myalgia				International Ltd	ORAL
ORAL							
		Neck Pain					
		Tremor					

Date:02/05/01ISR Number: 3663227-2Report Type:Expedited (15-DaCompany Report #ZANA000724 (0)
Age:33 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Coma	Foreign	Zanaflex	PS	Elan Pharma	
		Convulsion	Health			International Ltd	ORAL
8 MG DAILY							
ORAL							
		Hemiparesis	Professional				
		Hypotension		Etidronate Disodium	C		
		Hypoxia		Fucidin	C		
				Paracetamol	C		
				Imodium	C		
				Heparin	C		
				Lansoprazole	C		
				Methylphenidate	C		

Date:02/15/01ISR Number: 3666462-2Report Type:Expedited (15-DaCompany Report #ZANA000726 (0)
 Age:57 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Disability	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
6 MG DAILY							
ORAL				Omeprazole	C		
				Lactulose	C		

Date:02/21/01ISR Number: 3669332-9Report Type:Expedited (15-DaCompany Report #ZANA000727 (0)
 Age:37 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Drooling Drug Interaction Drug Withdrawal Syndrome Eye Disorder Heart Rate Increased Hypertension

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Hypoaesthesia Pain Paraesthesia	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
8-12 MG DAILY		Sedation Vomiting					
ORAL				Prednisone Sulfasalazine Vioxx Prilosec Prozac Enbrel Betoptic Lorcet	C C C C C C C C		

Date:02/26/01ISR Number: 3670049-5Report Type:Direct Company Report #
 Age:71 MON Gender:Male I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	8MG Q6H PO		Bradycardia Hypotension	Health Professional	Zanaflex 8 Mg Q6h	PS		ORAL

Date:02/28/01ISR Number: 3672108-XReport Type:Expedited (15-DaCompany Report #ZANA000728 (0)
 Age: Gender:Female I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	4 MG DAILY		Hepatic Necrosis Hepatitis	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL								

Date:03/06/01ISR Number: 3674623-1Report Type:Direct Company Report #
 Age:46 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required Intervention to Prevent Permanent Impairment/Damage	24 MG PO	Adrenal Insufficiency Bradycardia Decreased Appetite Hypotension Hypothermia Hypothyroidism Lethargy		Tizanidine (Zanaflex) Synthroid Fosamax Depakote Colace Tegretol Vasotec Oscal Loestrin Mvi Senokot	PS C C C C C C C C C C		ORAL

Date:03/14/01ISR Number: 3680753-0Report Type:Direct Company Report #
Age:82 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Blood Pressure Decreased Bradycardia Heart Rate Decreased Hypotension		Zanaflex	PS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/14/01ISR Number: 3682360-2Report Type:Expedited (15-DaCompany Report #ZANA000729 (0)
 Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 12 MG DAILY	Drug Withdrawal Convulsions	Foreign Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL		Professional				
		Other	Analgesics (Unspecified)	C		

Date:03/15/01ISR Number: 3682206-2Report Type:Expedited (15-DaCompany Report #ZANA000730 (0)
 Age:22 MON Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - 2 MG ORAL Initial or Prolonged	Hyperpyrexia Tachycardia	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
			Rocephin	C		
			Erythromycin	C		
			Glycopyrrolate	C		
			Toradol	C		

Date:03/19/01ISR Number: 3684687-7Report Type:Expedited (15-DaCompany Report #ZANA000732(0)
 Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged ORAL	Rhabdomyolysis	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL

Date:03/19/01ISR Number: 3684688-9Report Type:Expedited (15-DaCompany Report #ZANA000731(0)
 Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization -	Hypotension	Company	Zanaflex	PS	Elan Pharma	

Initial or Prolonged Shock Representative International Ltd ORAL

4 MG DAILY

ORAL

Antihypertensive C

Date:03/23/01ISR Number: 3705738-7Report Type:Periodic Company Report #WAES 01011445

Age:57 YR Gender:Male I/FU:I

Outcome Dose Duration PT Report Source Product Role Manufacturer Route

25 MG/BID/PO Sedation Syncope Health Professional Vioxx PS Merck Research Laboratories Div Merck Co Inc ORAL

Tab Zanaflex Unk Acetaminophen (+) Hydrocodone SS C

Date:03/26/01ISR Number: 3689727-7Report Type:Expedited (15-DaCompany Report #ZANA000734 (0)

Age: Gender:Male I/FU:I

Outcome Dose Duration PT Report Source Product Role Manufacturer Route

Death Hospitalization - ORAL Initial or Prolonged Respiratory Distress Health Professional Zanaflex PS Elan Pharma International Ltd ORAL

Unspecified Narcotic C

22-Aug-2005 12:09 PM

Page: 95

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/01ISR Number: 3689730-7Report Type:Expedited (15-DaCompany Report #ZANA000733 (0)
Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening Hospitalization - 12 MG DAILY Initial or Prolonged ORAL	Bradycardia Hypotension	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
			Luvox	C		
			Prevacid	C		
			Fioricet	C		

Date:03/30/01ISR Number: 3706283-5Report Type:Expedited (15-DaCompany Report #PHHO2000DE01410
Age:58 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged INTRAVENOUS QMO, INTRAVENOUS	Aphasia Epilepsy	Foreign Study Health Professional	Sandoglobulin Or Placebo (Placebo Placebo)	PS		
		Other	Baclofen (Baclofen) Ds-103-282 (Tizanidine Hydrochloride)	SS		
			Orfiril (Valproate Sodium)	SS C		
			Neuromet (Oxiracetam)	C		

Date:04/05/01ISR Number: 3698357-2Report Type:Direct
Age:65 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 6 MG 1 DOSE	Blood Pressure Decreased Dysarthria		Zanaflex / 2 Mg / Athena	PS	Athena	ORAL

ORAL

Feeling Abnormal

Heart Rate Decreased
Tongue Oedema

Norvasc C
Evista C
Synthroid C
Vioxx C

Date:04/05/01ISR Number: 3700145-5Report Type:Direct
Age:67 YR Gender:Male I/FU:I

Company Report #

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 8 MG PO TID Initial or Prolonged PTA	Bradycardia Hypotension Mental Impairment		Tizanidine Fluoxetine Lansoprazole Oxycodone	PS C C C		

Date:04/10/01ISR Number: 3702337-8Report Type:Expedited (15-DaCompany Report #ZANA000758 (0)
Age:65 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Alanine Aminotransferase Increased Aspartate Aminotransferase

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Increased Bradycardia Dysarthria Feeling Abnormal	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
6 MG ORAL		Hypotension Speech Disorder		Norvasc	C		
		Tongue Oedema		Evista	C		
				Synthroid	C		

Date:04/13/01ISR Number: 3704774-4Report Type:Direct
Age:50 YR Gender:Female I/FU:I Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Liver Disorder		Zanaflex 4mg Athena	PS	Athena	ORAL
2 MG 3 TIMES				Estrogen	C		
ORAL				Artane	C		
				Neurontin	C		
				Mvi	C		
				Calcium	C		
				Ibuprofen	C		

Date:05/10/01ISR Number: 3721431-9Report Type:Expedited (15-DaCompany Report #TCI2000A02663
Age:61 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Angina Pectoris	Study	Actos	PS		ORAL
Hospitalization - 15 MG (15 MG, Initial or Prolonged 1 IN 1 D)	264 DAY	Back Pain	Health				
5 MG		Cardiomegaly	Professional	Simvastatin	SS		ORAL
1 TAB		Chest Pain		Mecobalamin	SS		ORAL
1 TAB		Malaise Palpitations		Tizanidine Hydrochloride	SS		ORAL

2.5 MG		Glibenclamide	SS	ORAL
0.6 MG		Basen (Voglibose)	SS	ORAL

Date:05/17/01ISR Number: 3724580-4Report Type:Direct Company Report #
 Age:54 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 4 MG PO TID / Initial or Prolonged SINCE BACK	Bradycardia Hypotension Syncope		Zanaflex	PS		ORAL
SURGERY			Prilosec Zoloft Baycol Vit E Calcium Vioxx Oxycotin	C C C C C C C		

Date:05/21/01ISR Number: 3726541-8Report Type:Expedited (15-DaCompany Report #ZANA000785 (0)
 Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 18 MG DAILY	Orthostatic Hypotension Rebound Hypertension Syncope		Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL						

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Zestril C
Lasix C

Date:05/23/01ISR Number: 3727129-5Report Type:Expedited (15-DaCompany Report #260011
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 1014 DAY	Anaemia		Panaldine	PS	Roche	
Initial or Prolonged			Ternelin	SS		
			Itrizole	SS		

Date:05/25/01ISR Number: 3729311-XReport Type:Expedited (15-DaCompany Report #260011
Age:60 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 100 MG DAILY	Anaemia	Foreign	Ticlid	PS	Syntex (Usa) Inc Llc	ORAL
Initial or Prolonged		Health Professional	Ternelin (Tizanidine Hydrochloride)	SS		ORAL
ORAL		Other	Itrizole (Itraconazole)	SS		ORAL
ORAL						

Date:06/04/01ISR Number: 3733084-4Report Type:Expedited (15-DaCompany Report #2000011288US
Age:39 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged	Arthralgia Dysphagia	Consumer Other	Solu-Medrol	PS	Pharmacia And Upjohn Co	
INTRAVENOUS 1 G, QD, IV	Haemorrhagic Stroke Hemiparesis		Solu-Medrol Regime #2	SS		
INTRAVENOUS 80 MG,QD, IV	Hypertension		Sol-Medrol Regime #3	SS		
INTRAVENOUS 60 MG,QD,IV	Injection Site Pain		Sol-Medrol Regimen			

INTRAVENOUS	40 MG,QD,IV	Speech Disorder	#4	SS
		Tendonitis	Prednisone	C
			Cardizem	C
			Zanaflex (Tizanidine Hydrochloride)	C

Date:06/05/01ISR Number: 3734012-8Report Type:Expedited (15-DaCompany Report #WAES 01058223
 Age:45 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Other		Asthenia Drug Interaction Fatigue	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
25 MG/DAILY		Oedema Peripheral					
PO	5	DAY					
4 MG/DAILY PO	5	DAY		Tab Tizanidine	SS		ORAL

Date:06/08/01ISR Number: 3736257-XReport Type:Expedited (15-DaCompany Report #ZANA000794 (0)
 Age:54 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 8 MG DAILY		Bradycardia Hypotension	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL		Liver Function Test					
		Abnormal Rebound Hypertension		Oxycontin Prilosec	C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Azulfidine C

Date:06/11/01ISR Number: 3737262-XReport Type:Periodic Company Report #2000-09-1047
 Age: Gender:Male I/FU:I

Outcome Dose	Duration	PT Drug Interaction Skin Disorder	Report Source Consumer	Product	Role	Manufacturer	Route
10 MG/QD	ORAL			Claritin	PS	Schering Corp Sub Schering Plough Corp	ORAL
4-8 MG/PRN				Zanaflex (Tizanidine Hcl) Tablets	SS		ORAL
ORAL				Dantrium	SS		
25 MG/TID				Procardia	SS		
10 MG/TID				Docusate Sodium	SS		ORAL
1/2-2 TSP/BID							
ORAL				Senokot Baclofen	SS SS		
20 MG/QID				Milk Of Magnesia	SS		
2 TBS/Q3D				Simethicone	SS		
80-160 MG/QID				Entex La Tablets	SS		
1/2 TAB/QID							

Date:06/12/01ISR Number: 3738765-4Report Type:Expedited (15-DaCompany Report #PHBS2001JP05015
 Age:71 YR Gender:Male I/FU:F

Outcome Dose	Duration	PT Dermatitis Exfoliative Rash Pruritic Toxic Epidermal	Report Source Foreign Health Professional	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 40 MG/DAY, ORAL				Diovan	PS	Novartis Pharmaceuticals Corp	ORAL

Necrolysis

Other

Ternelin (Tizanidine
Hydrochloride,
Tizanidine
Hydrochloride)

SS

ORAL

3 MG/DAY,

ORAL

Proheparum
(Cysteine, Choline
Bitartrate, Liver
Hydrolysate,
Inositol)

SS

ORAL

3 DF/DAY, ORAL

6 MG/DAY,

ORAL

Diazepam (Diazepam)

SS

ORAL

600 MG/DAY,

ORAL

Cimetidine
(Cimetidine)

SS

ORAL

Solon (Sofalcone)
Digestive Enzymes
(No
Ingredients/Substances)
Propacall
(Ticlopidine
Hydrochloride)

C

C

C

Date:06/12/01ISR Number: 3738806-4Report Type:Expedited (15-DaCompany Report #WAES 01058223

Age:45 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

22-Aug-2005 12:09 PM

Page: 99

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Other

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
25 MG/DAILY	5 DAY	Asthenia Drug Interaction Fatigue	Foreign Other	Vioxx	PS	Merck Research Laboratories Div Merck Co Inc	ORAL
4 MG/DAILY	5 DAY	Oedema Peripheral Sinus Bradycardia		Tab Tizanidine	SS		ORAL

Date:06/18/01ISR Number: 3741501-9Report Type:Expedited (15-DaCompany Report #ZANA000795 (0)
Age:63 YR Gender:Male I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	12 MG DAILY		Neuropathy Peripheral	Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL

Date:06/20/01ISR Number: 3742324-7Report Type:Expedited (15-DaCompany Report #260011
Age:60 YR Gender:Male I/FU:F

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 1051 DAY Initial or Prolonged	340 DAY		Anaemia		Panaldine Ternelin Itrizole	PS SS SS	Roche	

Date:06/22/01ISR Number: 3745870-5Report Type:Expedited (15-DaCompany Report #260011
Age:60 YR Gender:Male I/FU:F

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 100 MG DAILY			Anaemia	Foreign	Ticlid	PS	Syntex (Usa) Inc Llc	ORAL

Initial or Prolonged
ORAL

Health

Professional
Other

Ternelin (Tizanidine
Hydrochloride) SS

ORAL

ORAL

Itrazole
(Itraconazole) SS

ORAL

200 MG DAILY

ORAL

Date:06/28/01ISR Number: 3749927-4Report Type:Expedited (15-DaCompany Report #ZANA000798 (0)
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 8 MG DAILY		Hepatitis	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL

ORAL

Date:07/09/01ISR Number: 3754488-XReport Type:Direct Company Report #
Age:46 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 4 MG QID Initial or Prolonged		Abdominal Pain Upper Chromaturia Hepatotoxicity Jaundice Lethargy Necrosis		Tizanidine	PS		

22-Aug-2005 12:09 PM
Page: 100

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/10/01ISR Number: 3756280-9Report Type:Expedited (15-DaCompany Report #ZANA000775 (1)
 Age:30 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Acute Respiratory	Health	Zanaflex	PS	Elan Pharma	
Hospitalization -		Distress Syndrome	Professional			International Ltd	ORAL
4-28 MG DAILY							
Initial or Prolonged		Bradycardia					
ORAL							
		Culture Urine Positive		Baclofen	C		
		Hyperglycaemia		Ambien	C		
		Hypotension		Temazepam	C		
		Intentional Misuse					
		Pneumonia					
		Pulmonary Oedema					
		Pyrexia					
		Respiratory Arrest					
		Respiratory Depression					
		Respiratory Distress					
		Sedation					
		Sepsis					
		Staphylococcal Infection					

Date:07/10/01ISR Number: 3756281-0Report Type:Expedited (15-DaCompany Report #ZANA000788 (0)
 Age:46 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia	Consumer	Zanaflex	PS	Elan Pharma	
		Bradycardia				International Ltd	ORAL
16 MG DAILY							
ORAL							
		Dizziness					
		Dry Mouth		Celebrex	C		
		Fatigue		Pamelor	C		
		Headache		Darvocet-N	C		
		Heart Rate Decreased					
		Hypertension					
		Hypoaesthesia					
		Hypotension					
		Lethargy					
		Sedation					
		Skin Warm					
		Tremor					

Vision Blurred

Date:07/10/01ISR Number: 3756282-2Report Type:Expedited (15-DaCompany Report #ZANA000808 (0)

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Arthralgia	Consumer	Zanaflex	PS	Elan Pharma	
		Back Pain				International Ltd	ORAL
24 MG DAILY		Bronchospasm					
ORAL		Cognitive Disorder		Duragesic	C		
		Dermatitis		Celebrex	C		
		Diplopia		Morphine	C		
		Neck Pain					
		Neuropathy Peripheral					
		Oedema					
		Urinary Incontinence					

22-Aug-2005 12:09 PM

Page: 101

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/18/01ISR Number: 3760960-9Report Type:Expedited (15-DaCompany Report #ZANA000815 (0)
Age:72 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability	16 MG DAILY	Peripheral Ischaemia	Foreign Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL			Professional				
				Co-Proxamol	C		
				Acetylsalicylic Acid	C		
				Lactulose	C		

Date:07/20/01ISR Number: 3762665-7Report Type:Expedited (15-DaCompany Report #ZANA000818 (0)
Age:62 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Autoimmune Disorder Condition Aggravated	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							
		Diabetes Mellitus		Ditropan	C		
		Hallucination		Prozac	C		
		Hypertonia		Baclofen	C		
		Pyrexia		Betaseron	C		
				Synthroid	C		
				Insulin	C		

Date:07/26/01ISR Number: 3766155-7Report Type:Expedited (15-DaCompany Report #ZANA000821 (0)
Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	36 MG DAILY	Liver Function Test Abnormal	Foreign Health	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL							
		Malaise	Professional				
				Imipramine	C		
				Senna	C		
				Lactulose	C		
				Baclofen	C		

Prednisolone C
Arachis Oil C

Date:08/06/01ISR Number: 3772111-5Report Type:Expedited (15-DaCompany Report #ZANA000823 (0)
Age:49 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Anxiety Dizziness	Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
56 MG DAILY		Drug Dependence					
ORAL		Drug Withdrawal Syndrome		Premarin	C		
		Fall		Vicodin	C		
		Feeling Jittery		Dilaudid	C		
		Hypertension					
		Tremor					

Date:08/09/01ISR Number: 3775057-1Report Type:Expedited (15-DaCompany Report #ZANA000829 (0)
Age:16 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Pressure Decreased Bradycardia Heart Rate Decreased

22-Aug-2005 12:09 PM
Page: 102

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Hypothermia

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
2 MG DAILY		Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL			Clonazepam	C		
			Epilim	C		
			Baclofen	C		

Date:08/13/01ISR Number: 3777130-0Report Type:Expedited (15-DaCompany Report #PHBS2001JP05015
 Age:71 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - 40 MG/DAY, Initial or Prolonged ORAL		Toxic Epidermal Necrolysis	Foreign Health Professional	Diovan	PS	Novartis Pharmaceuticals Corp	ORAL
3 DF/DAY, ORAL				Proheparum (Cysteine, Choline Bitartrate, Liver Hydrolysate, Inositol)	SS		ORAL
6 MG/DAY, ORAL				Diazepam (Diazepam)	SS		ORAL
600 MG/DAY, ORAL				Cimetidine (Cimetidine)	SS		ORAL
				Solon (Sofalcon) Digestive Enzymes (No Ingredients/Substanc	SS		

3		es)	SS	ORAL
DOSAGES/DAY,				
ORAL				
0.2 MG/DAY,		Harnal (Tamsulosin Hydrochloride)	SS	ORAL
ORAL				
6		Eviprostat	SS	ORAL
DOSAGES/DAY,0				
RAL				
3 MG/DAY,		Ternelin (Tizanidine Hydrochloride, Tizanidine Hydrochloride)	SS	ORAL
ORAL				
		Propacall (Ticlopidine Hydrochloride)	C	

Date:08/15/01ISR Number: 3778252-0Report Type:Expedited (15-DaCompany Report #ZANA000828 (0)
Age:76 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	12 MG DAILY	Convulsion	Foreign Health Professional	Zanaflex	PS	Elan Pharma International Ltd	ORAL
ORAL				Prolopa Selegiline	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Levothyroxine C

Date:08/16/01ISR Number: 3779082-6Report Type:Expedited (15-DaCompany Report #ZANA000830 (0)

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability	24 MG DAILY	Difficulty In Walking	Consumer	Zanaflex	PS	Elan Pharmaceuticals	ORAL
ORAL		Hypotonia					

Date:08/17/01ISR Number: 3778997-2Report Type:Direct

Company Report #

Age:53 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	2MG 1 QHS	Muscle Spasms		Zanaflex 2mg	PS		

Date:08/17/01ISR Number: 3781222-XReport Type:Expedited (15-DaCompany Report #PHBS2001JP05015

Age:71 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization -	40 MG/DAY, Initial or Prolonged	Toxic Epidermal Necrolysis	Foreign Health	Diovan	PS	Novartis Pharmaceuticals Corp	ORAL
ORAL			Professional				
			Other	Proheparum(Cysteine, Choline Bitartrate, Liver Hydrolysate, Inositol)	SS		ORAL
3 DF/DAY, ORAL				Diazepam (Diazepam)	SS		ORAL
6 MG/DAY,							
ORAL				Cimetidine			

600 MG/DAY,	(Cimetidine)	SS	ORAL
ORAL			
	Solon(Sofalcone)	SS	
	Digestive Enzymes(No		
	Ingredients/Substanc		
3	es)	SS	ORAL
DOSAGES/DAY,			
ORAL			
	Eviprostat(Chimaphil		
	a Umbellata, Populus		
	Tremuloides, Sodium		
	Taurocholate,		
6	Pulsatilla	SS	ORAL
DOSAGES/DAY,			
ORAL			
	Ternelin(Tizanidine		
	Hydrochloride,		
	Tizanidine		
	Hydrochloride)	SS	ORAL
3 MG/DAY,			
ORAL			
	Harnal (Tamsulosin		
	Hydrochloride)	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/21/01ISR Number: 3780457-XReport Type:Direct
 Age:75 YR Gender:Male I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	2 MG PO. 4 MG	Blood Pressure Decreased Dizziness		Zanaflex 4 Mg (Sandoz)	PS	Sandoz	ORAL
PO 8 HRS		Fatigue					
LATER		Heart Rate Decreased					
		Respiratory Rate Decreased		Cardiozem	C		
		Sedation		Vasotec	C		
				Hydrodiuril	C		

Date:08/22/01ISR Number: 3781638-1Report Type:Direct
 Age:43 YR Gender:Female I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	1 TAB TAKEN	Dysphagia		Zanaflex 4 Mg	PS		
AT BEDTIME		Sedation					
				Estrace	C		

Date:08/22/01ISR Number: 3781932-4Report Type:Direct
 Age:79 YR Gender:Female I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 4 MG DAILY PO		Hepatitis		Zanaflex	PS		ORAL
Initial or Prolonged				Glucophage	C		
				Glucotrol Xl	C		
				Neurontin	C		
				Cipro	C		

Date:08/31/01ISR Number: 3786636-XReport Type:Direct
 Age:53 YR Gender:Female I/FU:I

Company Report #

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
4 MG PO Q 8H		Liver Function Test		Zanaflex 4 Mg	PS		ORAL
PRN		Abnormal					

Nitroglycerin O	C
Premarin	C
Lopressor	C
Endocet	C
Aciphex	C
Baclofen	C
Paxil	C
Levothroid	C
Lorazepam	C
Methadone Hcl	C

Date:09/12/01ISR Number: 3792306-4Report Type:Expedited (15-DaCompany Report #ZANA000835 (0)
 Age:44 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization - Initial or Prolonged ORAL		Confusional State Delirium	Other	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/17/01ISR Number: 3794327-4Report Type:Expedited (15-DaCompany Report #ZANA000834 (0)

Age:58 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 4 MG DAILY	Asthenia Hyperhidrosis	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Other ORAL	Hypotension Pallor Syncope		Sporanox Protonix Estratest Vioxx Synthroid Ditropan	C C C C C C		

Date:09/18/01ISR Number: 3795227-6Report Type:Expedited (15-DaCompany Report #ZANA000841 (0)

Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 24 MG DAILY	Alanine Aminotransferase Increased	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Other ORAL	Bradycardia Drug Withdrawal Syndrome Nausea Orthostatic Hypotension Rebound Hypertension Sedation Tremor Vomiting		Novantrone Baclofen	C C		

Date:09/21/01ISR Number: 3797301-7Report Type:Expedited (15-DaCompany Report #ZANA000843 (0)

Age:73 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening Hospitalization - ORAL	Blood Pressure Systolic Increased	Literature Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

Initial or Prolonged	Clonic Convulsion	Professional	Selegiline	C
	Loss Of Consciousness		Ropinirole	C
	Pyrexia		Bromocriptine	C
	Sinus Tachycardia		Tolcapone	C
	Vomiting		Levodopa	C
			Sinemet	C
			Amitriptyline	C
			Lorazepam	C
			Clonazepam	C
			Hydrochlorothiazide	C
			Potassium Chloride	C
			St. John'S Wort	C

Date:10/05/01ISR Number: 3806714-6Report Type:Expedited (15-DaCompany Report #ZANA000851(0)
Age:59 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 8 MG DAILY	Atrial Fibrillation	Consumer	Zanaflex	PS		ORAL
Initial or Prolonged ORAL	Hypertension					
Other	Speech Disorder		Synthroid	C		
	Transient Ischaemic Attack		Glucophage	C		
			Estradiol	C		
			Propoxyphene	C		
			Zestril	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Atenolol C

Date:10/12/01ISR Number: 3808762-9Report Type:Expedited (15-DaCompany Report #01P-151-0111184-00
Age:17 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required Intervention to Prevent Permanent Impairment/Damage 500 MG, 1 I 1		Drug Interaction Hypotension Sedation	Foreign Health Professional Other	Depakine (Depakene) (Sodium Valproate/ Valproic Acid) (Sodium	PS		ORAL
D, PER ORAL				Tizanidine Hydrochloride Paracetamil	SS		ORAL
2 MG, 1 IN 1				Paracetamol	C		
D, PER ORAL							

Date:10/12/01ISR Number: 3810672-8Report Type:Expedited (15-DaCompany Report #001-0945-M0101183
Age:51 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 300 MG PER		Amnesia Blood Pressure Increased	Consumer	Neurontin (Gabapentin)	PS		ORAL
Other ORAL		Dry Mouth Dysarthria Dysuria Fatigue Miosis Nausea		Vioxx (Rofecoxib) Zanaflex (Tizanidine)	SS SS		

Date:10/17/01ISR Number: 3810595-4Report Type:Expedited (15-DaCompany Report #ZANA000856 (0)
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Fall	Health	Zanaflex (Tizanidine			
		Hypotension	Professional	Hydrochloride)	PS		ORAL
4 MG DAILY							
ORAL		Rib Fracture					
				Antihypertensive			
				Medication	C		

Date:10/17/01ISR Number: 3810616-9Report Type:Expedited (15-DaCompany Report #ZANA000862 (0)
Age:61 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Stevens-Johnson Syndrome	Health	Sirdalud (Tizanidine			
Initial or Prolonged			Professional	Hydrochloride)	PS		ORAL
ORAL			Distributor	Ponstan (Mefenamic			
1000 MG DAILY				Acid)	SS		ORAL
ORAL				Atorvastatin	C		
				Pradif	C		

400 MG, BID
 SUBCUTANEOUS 1 INJ,
 SUBCUTANEOUS

Noroxin(Norfloxacin) SS
 Valium (Diazepam) SS
 Morphine C
 Tramadol C
 Paracetamol C
 Tetrazepam C

Date:10/18/01ISR Number: 3811501-9Report Type:Expedited (15-DaCompany Report #WAES 00050132
 Age:52 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Pressure Decreased	Health	Tab Vioxx	PS		ORAL
PO		Drug Interaction Dysphagia Hallucination Psychotic Disorder Tachycardia	Professional Other	Zanaflex	SS		

Date:10/18/01ISR Number: 3811551-2Report Type:Expedited (15-DaCompany Report #WAES 00050131
 Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Bradycardia	Health	Tab Vioxx	PS		ORAL
PO		Chest Pain Dizziness Drug Interaction Hypotension	Professional Other	Zanaflex Maxalt (Rizatriptan Benzoate	SS C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/01 ISR Number: 3812487-3 Report Type:Expedited (15-DaCompany Report #ZANA000865 (0)
 Age:55 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required Intervention to Prevent Permanent ORAL Impairment/Damage		Joint Dislocation	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Naudicelle	C		
				Desmopressin	C		

Date:10/24/01 ISR Number: 3814605-X Report Type:Expedited (15-DaCompany Report #ZANA000861 (0)
 Age:36 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability 2 MG DAILY ORAL		Abdominal Pain Diarrhoea Feeling Hot And Cold	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Gastrointestinal Disorder		Pamelor	C		
		Nightmare		Neurontin	C		
		Sleep Talking		Maxalt	C		
				Esgic	C		
				Lozol	C		
				Prilosec	C		
				Loestrin Fe 1.5/30	C		

Date:10/31/01 ISR Number: 3820271-X Report Type:Periodic Company Report #2001073793US
 Age:30 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
200 MG, QD, ORAL		Complications Of Maternal Exposure To Therapeutic Drugs	Consumer	Celebrex	PS		ORAL
750 MG, BID,				Neurontin(Gabapentin)	SS		ORAL

ORAL

Elavil
(Amitriptyline
Hydrochloride) SS
Zanaflex (Tizanidine
Hydrochloride) SS
Oral Contraceptive
Nos (Oral
Contraceptive Nos) SS

Date:11/02/01ISR Number: 3819704-4Report Type:Expedited (15-DaCompany Report #2001AP05083
Age:10 YR Gender:Male I/FU:I

Outcome PT
Hospitalization - Crying
Initial or Prolonged Depressed Level Of
Consciousness
Drug Interaction
Electrocardiogram
Abnormal
Encephalopathy
Heart Rate Increased
Hypertension
Hypotension
Joint Stiffness
Pallor

22-Aug-2005 12:09 PM
Page: 109

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Sedation

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
10	MON	Literature	Lisinopril	PS		
		Health Professional	Lisinopril	SS		
1	WK		Tizanidine	SS		
			Valium	C		
			Clonazepam	C		
			Valproic Acid	C		

Date:11/05/01ISR Number: 3821962-7Report Type:Expedited (15-DaCompany Report #ZANA000870 (0)
 Age:78 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Cerebrovascular Accident	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
24 MG DAILY				Aspirin	C		
ORAL				Co-Amilofruse	C		
				Glibenclamide	C		

Date:11/09/01ISR Number: 3823151-9Report Type:Direct Company Report #
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Erectile Dysfunction		Zanaflex	PS		
				Prevacid	C		

Date:11/13/01ISR Number: 3824881-5Report Type:Expedited (15-DaCompany Report #ZANA000875 (0)
 Age:66 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Condition Aggravated	Consumer	Zanaflex (Tizanidine			

Other	Difficulty In Walking	Hydrochloride)	PS	ORAL
4 MG DAILY				
	Dyspnoea			
ORAL				
	Muscle Spasms	Toprol Xl	C	
	Pain	Babypyrin	C	
		Lipitor	C	

Date:11/29/01ISR Number: 3832724-9Report Type:Expedited (15-DaCompany Report #001-0945-M0101183
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Amnesia	Consumer	Neurontin			
Initial or Prolonged	Blood Pressure Increased	Health	(Gabapentin)	PS		ORAL
600 MG (BID),						
Disability	Depressed Level Of	Professional				
PER ORAL						
Other	Consciousness		Vioxx (Rofecoxib)	SS		
	Dry Mouth		Zanaflex			
	Dysarthria		(Tizanidine)	SS		
	Dysuria					
	Fatigue					
	Gait Disturbance					
	Lethargy					
	Miosis					
	Nausea					
	Sedation					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/12/01ISR Number: 3839471-8Report Type:Expedited (15-DaCompany Report #ZANA000880 (0)

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 2 MG DAILY		Flushing Headache	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Migraine					
		Rebound Hypertension Tremor		Theophylline Xr (Theophylline) Albuterol (Salbutamol) Celebrex "Steroid Spinal Injections"	SS SS C C		

Date:12/13/01ISR Number: 3840412-8Report Type:Expedited (15-DaCompany Report #200111032BNE

Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 500 MG DAILY		Bradycardia	Foreign	Ciprofloxacin	PS		
		Hypotension Hypotonia	Health Professional Other	Tizanidine	SS		

Date:12/17/01ISR Number: 3840878-3Report Type:Expedited (15-DaCompany Report #ZANA000885 (0)

Age:76 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 4 MG DAILY		Electrocardiogram Qt Prolonged	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Syncope	Professional				
				Prozac Vioxx Neurontin	C C C		

Date:12/20/01ISR Number: 3843372-9Report Type:Expedited (15-DaCompany Report #HQ9319810DEC2001
Age:75 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Disability Other		Bradycardia Coma Hypotension	Foreign Health Professional Other	Cordarone (Amiodarone, Tablet) Sirdalud (Tizanidine Hydrochloride,)	PS SS		ORAL
8 MG 1 X PER							
1 DAY	1	DAY		Tramal-Slow Release (Tramadol Hydrochloride)	SS		ORAL

Date:12/24/01ISR Number: 3844568-2Report Type:Expedited (15-DaCompany Report #ZANA000891(0)
Age:60 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability 16 MG DAILY ORAL		Confusional State Disturbance In Attention Fatigue Hallucination, Visual	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

22-Aug-2005 12:09 PM
Page: 111

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/26/01ISR Number: 3844975-8Report Type:Expedited (15-DaCompany Report #ZANA000892 (1)
 Age:46 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - ORAL Initial or Prolonged ORAL	Acute Respiratory Failure Hepatic Failure Loss Of Consciousness Renal Failure Acute Respiratory Failure Rhabdomyolysis	Health Professional	Zanaflex (Tizanidine Hydrochloride) Lipitor (Atorvastatin) Atenolol Toradol Lidoderm Patch	PS SS C C C		ORAL ORAL

Date:12/26/01ISR Number: 3845205-3Report Type:Expedited (15-DaCompany Report #ZANA000892 (0)
 Age:46 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - ORAL Initial or Prolonged ORAL	Acute Respiratory Failure Coma Hepatic Failure Loss Of Consciousness Renal Failure Acute Respiratory Failure Rhabdomyolysis	Health Professional	Zanaflex (Tizanidine Hydrochloride) Lipitor (Atorvastatin) Atenolol Toradol Lidoderm Patch	PS SS C C C		ORAL ORAL

Date:12/26/01ISR Number: 3845216-8Report Type:Expedited (15-DaCompany Report #001-0945-M0101183
 Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 300 MG Disability (ONCE), PER Other ORAL	Amnesia Blood Pressure Increased Confusional State Difficulty In Walking	Consumer Health Professional	Neurontin (Gabapentin)	PS		ORAL

50 MG (ONCE),	Dysarthria	Vioxx (Rofecoxib)	SS	ORAL
PER ORAL	Dysuria			
2 MG (ONCE),	Fatigue	Zanaflex		
PER ORAL	Gait Disturbance	(Tizanidine)	SS	ORAL
	Hemiparesis			
	Lethargy	(Clopidogrel)	C	
	Loss Of Consciousness			
	Memory Impairment			
	Mental Status Changes			
	Miosis			
	Nausea			
	Photophobia			
	Somnolence			
	Speech Disorder			

Date:12/27/01ISR Number: 3864582-0Report Type:Periodic Company Report #WAES 01112908
Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Asthenia	Health	Tab Vioxx	PS		ORAL
25 MG/ PO		Drug Interaction	Professional	Ultram	SS		
		Fatigue	Company	Zanaflex	SS		
			Representative	Neurontin	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/28/01ISR Number: 3845935-3Report Type:Direct
 Age: Gender:Male I/FU:I

Company Report #CTU 157992

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability Required		Nystagmus Vertigo		Tizanidine(2 Mg) (Athena Neurosciences Inc)	PS	Athena Neurosciences	ORAL
Intervention to 2 MG QHS ORAL				Amitriptyline	C		
Prevent Permanent Impairment/Damage				Sertraline	C		
				Gabapentin	C		
				Methadone	C		

Date:12/31/01ISR Number: 3846940-3Report Type:Expedited (15-DaCompany Report #EMADSS2001007513
 Age:75 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 100 MG, 3 IN		Accidental Overdose Bradycardia	Foreign Health	Tramadol Hydrochloride	PS		ORAL
1 DAY(S), ORAL		Coma Drug Interaction	Professional				
16-OCT-2001		Hypotension Spinal Fracture		Sirdalud (Tizanidine Hydrochloride)	SS		
HE WAS FIRST GIVEN				Cordarone (Amiodarone Hydrochloride)	SS		ORAL

Date:01/07/02ISR Number: 3849534-9Report Type:Expedited (15-DaCompany Report #200111032BNE
 Age:38 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Life-Threatening 500 MG BID Other ORAL	Asthenia	Foreign	Ciprofloxacin	PS	ORAL
	Bradycardia	Health			
6 MG QID ORAL 4 YR	Drug Interaction	Professional	Tizanidine	SS	ORAL
	Potentialiation Hypotension Hypotonia Muscular Weakness	Other	Oxybutynin Mitozantrone	C C	

Date:01/08/02ISR Number: 3849864-0Report Type:Expedited (15-DaCompany Report #PHBS2001JP11095
Age:34 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Disability 125 MG/D, ORAL		Aspartate Aminotransferase Increased Blood Creatine	Foreign Health Professional Other	Lamisil (Terbinafine Hydrochloride) Tablet	PS		ORAL
4 MG/D, ORAL	10 DAY	Phosphokinase Increased Blood Lactate		Lornoxicam(Lornoxica m)	SS		ORAL
1 MG/D, ORAL	10 DAY	Dehydrogenase Increased Malaise		Ternelin (Tizanidine Hydrochloride, Tizanidine Hydrochloride)	SS		ORAL
				Mucosta (Rebamipide)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/09/02ISR Number: 3850482-9Report Type:Direct
Age:62 YR Gender:Male I/FU:I

Company Report #CTU 158728

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 4MG 2 TAB PO Initial or Prolonged TID	Hypotension		Zanaflex (4mg)	PS		
			Celebrex	C		
			Naproxen	C		
			Prilosec	C		
			Orphenadrine	C		
			Synthroid	C		
			Triam/Hctz	C		
			Atenolol	C		
			Lotrel	C		

Date:01/09/02ISR Number: 3851034-7Report Type:Expedited (15-DaCompany Report #ZANA000873 (0)
Age:44 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 24 MG DAILY ORAL	Alanine Aminotransferase Increased Aspartate Aminotransferase Increased Blood Bilirubin Increased Blood Lactate Dehydrogenase Increased Decreased Appetite Gamma-Glutamyltransferase Increased Jaundice Liver Function Test Abnormal Nausea Prothrombin Time Prolonged	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Oxybutynin	C		

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - INTRAMUSCULAR 40.00 MG	Bradycardia	Foreign	Feldene Capsules	PS		
Initial or Prolonged TOTAL:DAILY:I	Confusional State	Health				
NTRAMUSCULAR	Drug Interaction	Professional				
12.00 MG	Dysarthria		Tizanidin	SS		
TOTAL:DAILY	Dysphagia					
	Hallucination		Seropram	C		
	Hypertension		Neurontin	C		
	Hypotension		Voltaren	C		
	Hypovolaemia		Vioxx	C		

Outcome	PT
Hospitalization -	Bradycardia
Initial or Prolonged	Drug Interaction
	Hypotension
	Hypotonia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Malaise

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
1000 MG DAILY		Health Professional	Ciflox (Ciprofloxacin)	PS		ORAL
ORAL		Other				
SEE IMAGE			Sirdalud (Tizanidine Hydrochloride)	SS		ORAL
SEE IMAGE			Lioresal (Baclofen)	SS		ORAL
75 MG DAILY			Myolastan (Tetrazepam)	SS		ORAL
ORAL			Voltarene	C		
			Zyloric	C		
			Verospiron	C		
			Pantozol	C		
			L!Snesium	C		
			Melperon	C		
			Zocor	C		

Date:01/17/02ISR Number: 3854822-6Report Type:Expedited (15-DaCompany Report #ZANA000896 (0)
Age:38 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Bradycardia	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
24 MG DAILY		Drug Effect Increased	Professional				
ORAL		Drug Interaction					
1,000 MG		Hypotension		Ciproxin (Ciprofloxacin)	SS		ORAL
DAILY ORAL		Muscular Weakness					
				Oxybutynin	C		
				Mitoxantrone	C		

Date:01/17/02ISR Number: 3855884-2Report Type:Expedited (15-DaCompany Report #ZANA000897 (0)
Age:79 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Hypotension	Foreign	Zanaflex (Tizanidine			
6 MG DAILY		Sepsis	Health	Hydrochloride)	PS		ORAL
ORAL			Professional				
				Enoxaparin Sodium	C		
				Frusemide	C		
				Atenolol	C		

Date:01/25/02ISR Number: 3860390-5Report Type:Expedited (15-DaCompany Report #PHRM2002FR00519
Age:24 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Bradypnoea	Foreign	Lioresal(Baclofen)Ta			
Initial or Prolonged		Drug Interaction	Health	blet	PS		ORAL
30 MG DAILY,		Hypotension	Professional				
ORAL		Hypotonia	Other	Sirdalud(Tizanidine			
12 MG DAILY,		Malaise		Hydrochloride)	SS		ORAL
ORAL		Skin Infection					
75 MG PER				Myolastan(Tetrazepam			
DAY, ORAL)	SS		ORAL
				Ciflox(Ciprofloxacin			

22-Aug-2005 12:09 PM
Page: 115

Freedom Of Information (FOI) Report

1 G DAILY)Tablet SS
 Voltarene Lp
 (Diclofenac Sodium) C

Date:01/30/02ISR Number: 3862222-8Report Type:Expedited (15-DaCompany Report #A200378
 Age:50 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - INTRA VENOUS Initial or Prolonged TOTAL; DAILY;	40.00 MG	Bradycardia Confusional State	Foreign Health	Feldene Capsules	PS		
INTRA VENOUS 2200.00 MG TOTAL; ORAL		Drug Abuser Drug Interaction Drug Level Increased	Professional	Gabapentin	SS		ORAL
12.00 MG TOTAL; ORAL		Dysarthria Dysphagia		Tizanidine	SS		ORAL
		Hallucination Hypertension Hypotension Hypovolaemia		Seropram Voltaren Vioxx	C C C		

Date:02/04/02ISR Number: 3865091-5Report Type:Expedited (15-DaCompany Report #ZANA000901 (0)
 Age:47 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death 18 MG DAILY ORAL		Hyperpyrexia	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Neurontin Oxycontin	C C		

Age:41 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Dysphemia	Health Professional	Zanaflex (Tizandine Hydrochloride)	PS		ORAL
6 MG ORAL				Vioxx	C		

Age:34 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Disability		Aspartate Aminotransferase Increased	Foreign Health Professional	Lamisil (Terbinafine Hydrochloride) Tablet	PS		ORAL
125 MG/D, ORAL		Blood Creatine	Other				
		Phosphokinase Increased		Lornoxicam (Lornoxicam)	SS		ORAL
4 MG/D, ORAL	10 DAY	Blood Lactate					
		Dehydrogenase Increased		Ternelin (Tizanidine Hydrochloride, Tizanidine Hydrochloride)	SS		ORAL
1 MG/D, ORAL	10 DAY	Malaise		Unknown			
				Mucosta (Rebamipide)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/08/02ISR Number: 3866916-XReport Type:Direct
 Age:56 YR Gender:Female I/FU:I

Company Report #CTU 161325

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	4 MG 3X A	Bladder Pain		Zanaflex 4 Mg	PS		ORAL
Required	DAY ORAL	Blood Cholesterol					
Intervention to Prevent Permanent Impairment/Damage		Increased Blood Triglycerides					
		Increased Dysuria					
		Hepatomegaly					

Date:02/08/02ISR Number: 3867329-7Report Type:Expedited (15-DaCompany Report #PHRM2002FR00519
 Age:24 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	30 MG DAILY,	Bradycardia	Foreign Health	Lioresal (Baclofen) Tablet	PS		ORAL
ORAL		Hypotension	Professional				
		Hypotonia	Other	Sirdalud (Tizanidine Hydrochloride)			
12 MG DAILY,		Malaise		Unknown	SS		ORAL
ORAL				Myolastan (Tetrazepam)	SS		ORAL
75 MG PER DAY, ORAL							
				Ciflox (Ciprofloxacin) Tablet	SS		
1 G DAILY				Voltarene Lp (Diclofenac Sodium)	C		

Date:02/08/02ISR Number: 3868545-0Report Type:Expedited (15-DaCompany Report #ZANA000910 (0)
Age:34 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypersensitivity	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8-16 MG DAILY							

ORAL

Vicodin	C
Keflex	C
Ortho-Novum	C
Diazepam	C
Percocet	C
Ibuprofen	C

Date:02/11/02ISR Number: 3868898-3Report Type:Expedited (15-DaCompany Report #ZANA000908 (0)
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Withdrawal Syndrome Overdose	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/20/02ISR Number: 3873847-8Report Type:Expedited (15-DaCompany Report #041-0945-M0200003

Age:50 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 2200 MG (DAILY), PER ORAL		Bradycardia Confusional State	Foreign Health	Neurontin (Gabapentin)	PS		ORAL
		Drug Abuser	Professional				
		Drug Interaction					
INTRAMUSCULAR INTRAMUSCULAR	40 MG ,	Drug Level Above Therapeutic		(Piroxicam)	SS		
		Dysarthria Dysphagia		(Tizanidine Hydrochloride)	SS		ORAL
12 MG, PER ORAL		Hallucination					
		Hypertension Hypotension		(Citalopram Hydrobromide)	SS		ORAL
PER ORAL		Hypovolaemia		(Diclofenac Sodium) (Rofecoxib)	C C		

Date:02/21/02ISR Number: 3872735-0Report Type:Direct

Company Report #CTU 162008

Age:45 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 4MG PO QID Initial or Prolonged		Dizziness		Zanaflex (4mg)	PS		ORAL
		Electrocardiogram Qt Prolonged					

Date:02/22/02ISR Number: 3875053-XReport Type:Expedited (15-DaCompany Report #ZANA000914 (0)

Age:60 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Ammonia Increased	Health	Zanaflex (Tizanidine			

Hospitalization -	Hallucination, Visual	Professional	Hydrochloride)	PS	ORAL
4 - 6 MG					
Initial or Prolonged	Hepatitis				
DAILY ORAL	Hyperglycaemia		Ascriptin	C	
			Norvasc	C	
			Lopressor	C	

Date:02/28/02ISR Number: 3877971-5Report Type:Expedited (15-DaCompany Report #200211271BWH
Age:53 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Interaction	Consumer	Cipro (Ciprofloxacin			
		Fatigue	Other	Hydrochloride)	PS		ORAL
500 MG BID;		Speech Disorder					
ORAL				Zanaflex (Tizanidine			
				Hydrochloride)	SS		ORAL
4 MG DAILY;							
ORAL				Fibercon	C		
				Vit C	C		
				Multivitamin	C		
				Mevacor	C		
				Tylenol	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/28/02ISR Number: 3889406-7Report Type:Periodic
Age:59 YR Gender:Male I/FU:I

Company Report #001-0945-M0100756

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Anxiety	Consumer	Neurontin			
900 MG TID		Asthenia	Health	(Gabapentin)	PS		
		Burning Sensation	Professional	Tizanidine			
		Drug Ineffective		Hydrochloride	SS		
		Heart Rate Decreased		Voixx (Rofecoxib)	C		
		Hypoaesthesia					
		Hypotension					
		Insomnia					
		Paraesthesia					
		Pruritus					
		Tremor					

Date:03/01/02ISR Number: 3877598-5Report Type:Expedited (15-DaCompany Report #A200378
Age:50 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Bradycardia	Foreign	Feldene Capsules	PS		
INTRAMUSCULAR	40.00 MG						
Initial or Prolonged		Confusional State	Health				
TOTAL:DAILY:I							
		Drug Interaction	Professional				
NTRAMUSCULAR							
		Drug Level Above		Gabapentin	SS		ORAL
2200.00 MG							
		Therapeutic					
TOTAL:ORAL							
		Dysarthria		Tizanidine	SS		ORAL
12.00 MG							
		Dysphagia					
TOTAL:ORAL							
		Hallucination		Citalopram	SS		
20.00 MG							
		Hypertension					
TOTAL							
		Hypotension		Voltaren	C		
		Hypovolaemia		Vioxx	C		
		Medication Error					

Date:03/05/02ISR Number: 3877686-3Report Type:Expedited (15-DaCompany Report #WAES 0202CAN00128
 Age:57 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Paralysis	Health Professional	Vioxx Tizanidine Hydrochloride	PS		ORAL
9	WK				SS		ORAL
				Tolterodine Tartrate	C	Merck & Co., Inc	ORAL

Date:03/07/02ISR Number: 3881712-5Report Type:Expedited (15-DaCompany Report #ZANA000918 (0)
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening Hospitalization - 24 MG DAILY		Blood Magnesium Decreased Blood Potassium Decreased	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Initial or Prolonged ORAL		Torsade De Pointes					
		Urinary Tract Infection		Baclofen	C		
		Ventricular Tachycardia		Gabapentin	C		
				Methadone	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/08/02ISR Number: 3880927-XReport Type:Expedited (15-DaCompany Report #ZANA000919(0)

Age:35 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 32 MG DAILY		Bradycardia	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL				Interferon	C		
				Fluoxetine	C		
				Baclofen	C		

Date:03/11/02ISR Number: 3882291-9Report Type:Expedited (15-DaCompany Report #WAES0202CAN00128

Age:57 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 25 MG/DAILY		Paralysis	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
PO				Tizanidine Hydrochloride	SS		ORAL
8 MG/DAILY PO				Tolterodine Tartrate	C		

Date:03/18/02ISR Number: 3884740-9Report Type:Expedited (15-DaCompany Report #ZANA000925 (0)

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Hallucination, Auditory	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL				Percocet	C		

Date:03/19/02ISR Number: 3885517-0Report Type:Expedited (15-DaCompany Report #WAES 01058223

Age:45 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	25 MG/DAILY	Asthenia Drug Interaction	Foreign Other	Tab Vioxx (Rofecoxib)	PS		ORAL
Other PO	5 DAY	Fatigue					
4 MG/DAILY	5 DAY	Oedema Peripheral Sinus Bradycardia		Tab Tizanidine	SS		ORAL

Date:03/21/02ISR Number: 3887412-XReport Type:Expedited (15-DaCompany Report #ZANA000930 (0)
Age:30 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged ORAL		Asthenia Bacteraemia	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Cough		Low-Ogestrel	C		
		Headache		Steroid Epidural	C		
		Infection		Ibuprofen	C		
		Inflammation					
		Influenza Like Illness					
		Malaise					
		Nausea					
		Pain					
		Procedural Complication					
		Pyrexia					
		Urinary Tract Infection					
		Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/21/02ISR Number: 3887461-1Report Type:Expedited (15-DaCompany Report #ZANA000928 (0)
 Age:30 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged ORAL		Crying Headache	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Influenza Like Illness Malaise Nausea Pain Urinary Tract Infection Vomiting		Low -Ogestrel Steroid Epidural	C C		

Date:03/28/02ISR Number: 3890402-4Report Type:Direct Company Report #USP 54808
 Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Medication Error		Zanaflex Gabitril	PS SS	Athena Cephalon	

Date:04/18/02ISR Number: 3902957-1Report Type:Expedited (15-DaCompany Report #ZANA000939 (0)
 Age:59 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 16 MG DAILY ORAL		Drug Withdrawal Syndrome Rebound Hypertension	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Baclofen	C		

Date:04/19/02ISR Number: 3903930-XReport Type:Expedited (15-DaCompany Report #ZANA000910 (1)
 Age:34 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Hypersensitivity	Health	Zanaflex (Tizanidine			

Other Professional Hydrochloride) PS ORAL
8 MG DAILY

ORAL

Vicodin C
Keflex C
Ortho-Novum C

Date:04/22/02ISR Number: 3904511-4Report Type:Direct Company Report #CTU 166324
Age:58 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Confusional State		Zanaflex	PS		
TWICE/DAY		Depression		Atenolol	C		
		Disorientation		Neurontin	C		
				Lorazepam	C		
				Pravachol	C		
				Aciphex	C		

Date:04/22/02ISR Number: 3905326-3Report Type:Expedited (15-DaCompany Report #200210184BNE
Age:81 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Lymphoma	Foreign
	Skin Disorder	Health

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Professional
Other

Dose	Duration	Product	Role	Manufacturer	Route
30 MG DAILY		Nifedipine	PS		ORAL
ORAL					
100 MG DAILY		Betaxolol	SS		
		Allopurinol	SS		
10 MG DAILY		Simvastatin	SS		
20 MG DAILY		Enalapril	SS		
150 MG DAILY		Nizatidine	SS		
		Aspirin (Acetylsalicylic Acid)	SS		
75 MG DAILY		Paracetamol	SS		
		Tizanidine	SS		
2 MG DAILY		Prazosin	SS		
500 UG TID					

Date:04/25/02ISR Number: 3907853-1Report Type:Expedited (15-DaCompany Report #ZANA000941 (0)
Age:81 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Lymphoma Skin Disorder	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY							
ORAL							
OPHTHALMIC	OPHTH			Betaxolol (Betaxolol)	SS		
				Allopurinol (Allopurinol)	SS		
100 MG DAILY				Simvastatin			

10 MG DAILY	(Simvastatin)	SS
	Enalapril (Enalapril)	SS
20 MG DAILY		
	Nifedipine (Nifedipine)	SS
30 MG DAILY		
	Nizatidine (Nizatidine)	SS
150 MG DAILY		
	Aspirin (Acetylsalicylic Acid)	SS
75 MG DAILY		
	Paracetamol (Paracetamol)	SS
2 PRN		
	Prazosin (Prazosin)	SS
500 MCG DAILY		

Date:04/25/02ISR Number: 3907899-3Report Type:Expedited (15-DaCompany Report #ZANA000940 (0)
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 36 MG DAILY	Acute Psychosis Agitation	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL	Arthralgia					
	Confusional State		Baclofen	C		
	Fall		Oxycontin	C		
	Hallucination					
	Insomnia					
	Urinary Tract Infection					
	Vomiting					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/25/02ISR Number: 3907906-8Report Type:Expedited (15-DaCompany Report #ZANA000942 (0)

Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 6 MG DAILY	Urinary Tract Infection	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Baclofen	C		
			Oxycontin	C		

Date:04/26/02ISR Number: 3908302-XReport Type:Expedited (15-DaCompany Report #2002000069

Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 1.5 MG (TID)	Lymphoma	Foreign	Prazosin (Prazosin)	PS		
30 MG (DAILY)		Health Professional	Nifedipine(Nifedipin e)	SS		
100 MG (DAILY)		Other	Allopurinol	SS		
10 MG (DAILY)			Simvastatin	SS		
20 MG (DAILY)			Enalapril	SS		
OPHTHALMIC (BID)			Betaxolol	SS		
OPHTHALMIC			Acetylsalicylic Acid	SS		
75 MG (DAILY)			Paracetamol	SS		
2 MG (DAILY)			Tizanidine	SS		
150 MG (DAILY)			Nizatidine	SS		

Date:04/30/02ISR Number: 3910374-3Report Type:Expedited (15-DaCompany Report #PHBS2002JP04033
 Age:63 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 40 MG, QD, ORAL		Erythema Erythema Multiforme Face Oedema	Foreign Health Professional	Diovan (Valsartan) Tablet	PS		ORAL
100 MG, TID, ORAL		Pruritus	Other	Osteluc (Etodolac)	SS		ORAL
500 UG, TID, ORAL				Mecobamide (Mecobalamin)	SS		ORAL
0.5 MG, TID, ORAL				Ternelin (Tizanidine Hydrochloride)	SS		ORAL

Date:04/30/02ISR Number: 3911321-0Report Type:Expedited (15-DaCompany Report #TCI2002A00557
 Age:68 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death 30 MG PER ORAL	582 DAY	Abdominal Distension Abdominal Pain Hepatic Neoplasm	Study Health Professional	Actos Tablets 30 (Pioglitazone Hydrochloride)	PS		ORAL
PER ORAL	4 YR	Malignant Hepatic Steatosis		Dihydroergocristine Mesilate	SS		ORAL
PER ORAL	946 DAY			Zaltoprofen	SS		ORAL
3.5 MG / 1.25 MG 1.5 GM PER ORAL	337 DAY 946 DAY			Glibenclamide Teprenone	SS SS		ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

PER ORAL 673 DAY

Tizanidine			
Hydrochloride	SS		ORAL
Ticlopidine			
Hydrochloride	C		
Dihydroergocristine			
Mesilate	C		
Zaltoprofen	C		
Tizanidine			
Hydrochloride	C		
Teprenone	C		
Glibenclamide	C		

Date:05/13/02ISR Number: 3915665-8Report Type:Expedited (15-DaCompany Report #ZANA000954 (0)
 Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Blood Pressure Decreased	Health	Zanaflex (Tizanidine			
Initial or Prolonged	Bradycardia	Professional	Hydrochloride)	PS		ORAL
8 MG DAILY						
	Dizziness					
ORAL						
	Hallucination		Synthroid	C		
	Heart Rate Increased		Tylenol	C		
	Hypotension					

Date:05/13/02ISR Number: 3916451-5Report Type:Direct Company Report #CTU 167997
 Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization -	Hypersensitivity		Zanaflex	PS		
Initial or Prolonged			Baclofen	SS		

Date:05/14/02ISR Number: 3916935-XReport Type:Expedited (15-DaCompany Report #200211271BWH
 Age:53 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Other	Drug Interaction	Consumer	Cipro (Ciprofloxacin			

500 MG BID	Fatigue	Health	Hydrochloride)	PS	ORAL
ORAL	Speech Disorder	Professional			
4 MG DAILY		Other	Zanaflex (Tizanidine Hydrochloride)	SS	ORAL
ORAL			Fibercon	C	
			Vit C	C	
			Multivitamin	C	
			Mevacor	C	
			Clonazepam	C	
			Tylenol	C	

Date:05/17/02ISR Number: 3918751-1Report Type:Expedited (15-DaCompany Report #ZANA000955 (0)
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dry Mouth Feeling Abnormal	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
24 MG DAILY		Hallucination, Visual					
ORAL		Hypoaesthesia		Valium	C		
				Talwin	C		
				Effexor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/22/02ISR Number: 3920186-2Report Type:Direct
Age:33 YR Gender:Female I/FU:I

Company Report #USP 54846

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Medication Error		Zanaflex (Tizanidine Hydrochloride)	PS	Athena Neurosciences	
				Anaflex (Salsalate)	SS		

Date:05/22/02ISR Number: 3921212-7Report Type:Expedited (15-DaCompany Report #ZANA000956 (0)
Age:69 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	4 MG DAILY	ATRIOVENTRICULAR BLOCK FIRST DEGREE	Consumer Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		BRADYCARDIA	Professional				
		DISORIENTATION		Neurontin	C		
		DRY MOUTH		Alloprin	C		
		GAIT DISTURBANCE		Dyazide	C		
		HEART RATE INCREASED		Asa	C		
		HYPOTENSION		Vitamin Nos	C		
				Calcium	C		
				Vioxx	C		

Date:05/28/02ISR Number: 3924560-XReport Type:Expedited (15-DaCompany Report #EMADSS2002003182
Age:44 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability	800 MG, DAYS(S), ORAL	AGRANULOCYTOSIS	Foreign Health	Sporanox (Unspecified)			
		BACK PAIN	Professional	(Itraconazole)	PS		ORAL
		BACTERIAL INFECTION					
		BLOOD CULTURE POSITIVE					
		DRUG INTERACTION		Sidalud (Tizanidine)	SS		
		DRUG LEVEL INCREASED		Mst (Morphine Sulfate)	C		
		ELECTROCARDIOGRAM QT PROLONGED		Maxipime (Cefepime)	C		
		PANCYTOPENIA		Targocid(Teicoplanin			

Pyrexia
Tooth Infection

) C
Flagyl C
(Metronidazole)
Neupogene C
(Filgrastim)
Liquemine (Heparin C
Sodium)
Antra (Omeprazole) C
Frangulae-Rudolac C

Date:05/28/02ISR Number: 3925259-6Report Type:Expedited (15-DaCompany Report #ZANA000959 (0)
Age:50 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Convulsion	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY							
ORAL				Vioxx Dilantin Prempro	C C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/29/02ISR Number: 3926634-6Report Type:Expedited (15-DaCompany Report #ZANA000960(0)

Age:47 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	12 MG DAILY	Contusion Fall	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Other ORAL		Hypersomnia					
		Psychotic Disorder		Prednisone	C		
		Rib Fracture		Neurontin	C		
		Somnolence		Lopid	C		

Date:06/04/02ISR Number: 3929329-8Report Type:Expedited (15-DaCompany Report #ZANA000965 (0)

Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	2 TABS ORAL	Amnesia Catatonia	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Communication Disorder		Catapres	C		
		Dehydration		Hydrochlorothiazide	C		
		Eating Disorder					
		Mental Status Changes					

Date:06/04/02ISR Number: 3929345-6Report Type:Expedited (15-DaCompany Report #ZANA000966 (0)

Age:41 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other ORAL		Condition Aggravated Dental Caries	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Dry Mouth					

Date:06/13/02ISR Number: 3934743-0Report Type:Expedited (15-DaCompany Report #HQ2558304JUN2002

Age:82 YR Gender:Female I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - Initial or Prolonged	400MG DAILY	9 DAY	Abdominal Pain Upper Cardiac Failure Pneumonitis Respiratory Distress	Health Professional	Hyphen (Etodolac, Unspec)	PS		ORAL
	2 MG DAILY	9 DAY		Other	Tizanidine Hydrochloride (Tizanidine Hydrochloride,)	SS		ORAL
					Bendipine Hydrochloride (Benidipine Hydrochloride)	C		
					Ranitidine Hydrochloride (Ranitidine Hydrochloride)	C		
					Digestives, Incl Enzymes (Digestives, Incl Enzymes)	C		
					Lactobacillus Bifidus, Lyophilized (Lactobacillus Bifidus, Lyophilized)	C		
					Furosemide (Furosemide)	C		
					Spirolactone			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Spironolactone) C
 Misoprostol
 (Misoprostol) C

Date:06/17/02ISR Number: 3935718-8Report Type:Expedited (15-DaCompany Report #ZANA000959 (1)
 Age:50 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Convulsion	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY							
ORAL				Vioxx Dilantin Prempro	C C C		

Date:06/18/02ISR Number: 3935263-XReport Type:Direct Company Report #CTU 170348
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening		Liver Function Test Abnormal		Zanaflex 4mg Athena Neuro	PS	Athena Neuro	ORAL
1-2MG DAY							
ORAL				Accolate Tolectin Loestrin Proventil	C C C C		

Date:06/19/02ISR Number: 3936502-1Report Type:Expedited (15-DaCompany Report #ZONI000807 (0)
 Age:38 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Blood Glucose Increased Vision Blurred	Health Professional	Zonegran (Zonisamide)	PS		ORAL
200 MG DAILY							

ORAL

Zanaflex	
(Tizanidine)	SS
Altace	C
Aclovate	C
Proventil Tablet	C
Glucotrol	C
Duragesic	C
Xanax	C
Bentyl	C
Reglan	C
Zoloft	C
Lithium	C
Buspar	C

Date:06/20/02ISR Number: 3937398-4Report Type:Expedited (15-DaCompany Report #ZANA000971 (0)
 Age:35 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 12 MG DAILY	Bradycardia Drug Interaction	Health Professional Company Representative	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Birth Control Pills (Oral Contraceptive Nos)	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/20/02ISR Number: 3937433-3Report Type:Expedited (15-DaCompany Report #ZANA000974 (0)

Age:54 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 12 MG DAILY Other ORAL	Aspiration Condition Aggravated Drug Ineffective Dysphagia Eating Disorder Jaw Disorder Muscle Spasticity Weight Decreased	Consumer	Zanaflex (Tizanidine Hydrochloride) Baclofen	PS C		ORAL

Date:06/21/02ISR Number: 3937202-4Report Type:Direct

Company Report #CTU 170714

Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration	Back Pain Blood Pressure Increased Ear Infection Fatigue Gastrooesophageal Reflux Disease Sinusitis Tinnitus Visual Acuity Reduced Weight Increased		Zanaflex Vioxx	PS SS		

Date:06/24/02ISR Number: 3937897-5Report Type:Direct

Company Report #CTU 170793

Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - 1-2 TABS Initial or Prolonged Required Intervention to	Hallucination Liver Function Test Abnormal Nausea Tachycardia		Zanaflex 4mg Novartis	PS	Novartis	

Prevent Permanent Tinnitus
Impairment/Damage Vision Blurred

Date:06/24/02ISR Number: 3937899-9Report Type:Direct Company Report #CTU 170794
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Fear		Zanaflex 4mg	PS		
2-3 TABS		Hallucination					

Date:06/27/02ISR Number: 3978979-1Report Type:Periodic Company Report #WAES 0204USA02209
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
PO		Hallucination	Health	Tab Vioxx	PS		ORAL
		Somnolence	Professional Company Representative	Zanaflex	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/28/02ISR Number: 3941537-9Report Type:Direct
Age:39 YR Gender:Female I/FU:I

Company Report #CTU 171244

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Dermatitis Exfoliative		Zanaflex 4mg	PS		ORAL
ONE 3 TIMES							
ORAL							

Date:07/01/02ISR Number: 3983822-0Report Type:Periodic
Age: Gender:Female I/FU:F

Company Report #01100759

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Anaemia	Health	Novantrone Strength			
Initial or Prolonged		Infection	Professional	Unknown	PS		
Q 3 MO							
		Liver Function Test		Acetaminophen	SS		
		Abnormal		Tizanidine	SS		
		Surgery		Amantadine	C		
				Oxybutynin	C		
				Baclofen	C		
				4-Aminopyridine	C		
				Fluoxetine	C		

Date:07/09/02ISR Number: 3945469-1Report Type:Direct
Age:57 YR Gender:Female I/FU:I

Company Report #CTU 171933

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Anxiety		Zanaflex	PS		ORAL
2 TABS PO QHS							
Initial or Prolonged		Hallucination					
SINGLE DOSE							
		Insomnia		Epidural Steroid	SS		

Date:07/17/02ISR Number: 3950444-7Report Type:Expedited (15-DaCompany Report #2002000069
Age: Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Lymphoma	Foreign	Prazosin(Prazosin)	PS		
1.5 MG(TID)			Health Professional	Nifedipine(Nifedipine)	SS		
30 MG(DAILY)				Allopurinol	SS		
100 MG							
(DAILY)							
10 MG (DAILY)				Simvastatin	SS		
20 MG(DAILY)				Enalapril	SS		
OPHTHALMIC	UNK(BID),			Betaxolol	SS		
OPHTHALMIC							
75 MG(DAILY)				Acetylsalicylic Acid	SS		
				Paracetamol	SS		
2 MG (DAILY)				Tizanidine	SS		
150 MG(DAILY)				Nizatidine	SS		

Date:07/24/02ISR Number: 3954308-4Report Type:Expedited (15-DaCompany Report #ZANA000984 (0)
Age:47 YR Gender:Female I/FU:I

Outcome PT
Hospitalization - Dialysis
Initial or Prolonged Hypotension
Loss Of Consciousness
Nephritis Allergic
Rash
Renal Failure
Sepsis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Vasculitis

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
10 MG DAILY		Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Hydrochlorothiazide (Hydrochlorothiazide)	SS		ORAL
25 MG DAILY			Desyrel	C		
ORAL			Oxycontin	C		
			Celexa	C		

Date:08/09/02ISR Number: 3961479-2Report Type:Expedited (15-DaCompany Report #ZONI000844 (0)
 Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	400 MG DAILY	Blood Pressure Increased Orthostatic Hypotension	Consumer	Zonegran (Zonisamide)	PS		ORAL
ORAL		Tachycardia					
ORAL		Urinary Retention		Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
				Oxycontin	C		

Date:08/14/02ISR Number: 3963199-7Report Type:Expedited (15-DaCompany Report #ZANA000985(0)
 Age:65 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death Disability	8 MG DAILY	Gastrointestinal Haemorrhage	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

Myocardial Infarction

Professional

ORAL

Senna	C
Quinine	C
Carbamazepine	C
Docusate	C
Baclofen	C
Ipratropium	C
Aspirin	C
Paracetamol	C

Date:08/15/02ISR Number: 3962334-4Report Type:Direct
 Age:53 YR Gender:Male I/FU:I

Company Report #CTU 174198

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Interaction		Cipro (Ciprofloxacin			
		Fatigue		Hydrochloride)	PS		ORAL
500MG BID							
		Speech Disorder					
ORAL				Zanaflex (Tizanidine			
				Hydrochloride)	SS		ORAL
4MG DAILY							
ORAL				Fibercon	C		
				Vit C	C		
				Multivitamin	C		
				Mevacor	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/19/02ISR Number: 3963437-0Report Type:Direct
 Age: Gender: I/FU:I

Company Report #CTU 174417

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Pharmaceutical Product Complaint		Zanaflex 2mg (Bd) Generic And Brand Name Tizianidine (Gen)	PS SS		

Date:08/21/02ISR Number: 3965831-0Report Type:Expedited (15-DaCompany Report #ZANA000986 (0)
 Age:50 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 8 MG DAILY		Orthostatic Hypotension Syncope	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL				Effexor Fiorinal Evista Desyrel	C C C C		

Date:08/21/02ISR Number: 3965879-6Report Type:Expedited (15-DaCompany Report #ZANA000987 (0)
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 16 MG DAILY		Convulsion	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL							

Date:08/21/02ISR Number: 3966130-3Report Type:Expedited (15-DaCompany Report #ZANA000988 (0)
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Other	Cardiomyopathy	Health	Zanaflex (Tizanidine			
	Cerebrovascular Accident	Professional	Hydrochloride)	PS		ORAL

ORAL

Date:08/23/02ISR Number: 3967355-3Report Type:Expedited (15-DaCompany Report #ZANA000989 (0)
 Age:76 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose						
Hospitalization -	Anaemia	Health	Zanaflex (Tizanidine			
Initial or Prolonged	Arrhythmia	Professional	Hydrochloride)	PS		ORAL
12 MG DAILY						
	Gastric Ulcer Haemorrhage					
ORAL						
	Pain		Duragesic Patch	C		
	Torsade De Pointes		Metoprolol	C		
	Ulcer Haemorrhage		Darvocet-N	C		
	Ventricular Tachycardia					

Date:08/27/02ISR Number: 3967782-4Report Type:Direct Company Report #CTU 175180
 Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose						
	Anaphylactic Shock		Zanaflex 2mg (Bd)	PS		
	Pharmaceutical Product		Tizanidine (Gen)	SS		
	Complaint					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/03/02ISR Number: 3970040-5Report Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 175545

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability	4 MG 4 TIMES	Drug Effect Decreased Mobility Decreased	Pharmaceutical Product	Trizantadine 4 Mg Holt	PS	Holt	ORAL
DAY ORAL		Complaint					

Date:09/04/02ISR Number: 3971368-5Report Type:Expedited (15-DaCompany Report #2001076005CH
 Age: Gender: I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
200 MG, TID, ORAL		Complications Of Maternal Exposure To Therapeutic	Foreign Study	Celebrex (Celecoxib) Capsule	PS		ORAL
100 MG, QD		Drugs	Health	Doxycycline (Doxycycline)	SS		
4 MG, BID		Pregnancy	Professional Other	Sirdalud (Tizanidine Hydrochloride)	SS		
400 MG, BID				Noroxin (Norfloxacin)	SS		
SUBCUTANEOUS	1 INJ,			Valium (Diazepam)	SS		
SUBCUTANEOUS				Morphine	C		
				Tramadol	C		
				Paracetamol	C		
				Tetrazepam	C		

Date:09/09/02ISR Number: 3974562-2Report Type:Direct
 Age:45 YR Gender:Female I/FU:I

Company Report #CTU 176003

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Abdominal Pain		Zanaflex 4mg	PS		
1 1/2 TAB							
Required		Liver Function Test					
DAILY							
Intervention to		Abnormal		Phenobarbital	C		
Prevent Permanent		Malaise		Synthroid	C		
Impairment/Damage		Nausea		Zyrtec	C		

Date:09/10/02ISR Number: 3974113-2Report Type:Direct Company Report #CTU 176038
 Age:51 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Asthenia		Tizanidine			
Initial or Prolonged		Diplopia		(Zanaflex)	PS		
2MG 1ST X 3							
		Dizziness					
WEEKS; 4MG							
		Dry Mouth					
NOW							
		Dysarthria		Zantac	C		
		Paraesthesia		Vioxx	C		
				Estrogen	C		

Date:09/13/02ISR Number: 3976139-1Report Type:Expedited (15-DaCompany Report #MK200209-0108-1
 Age:53 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Movement Disorder	Foreign Study	Anafranil Capsules			
				100	PS		
				Depakene R	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Ternelin SS
Lochol SS

Date:09/16/02ISR Number: 3975911-1Report Type:Expedited (15-DaCompany Report #USA-2002-0002143
Age:44 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Drug Interaction Neuroleptic Malignant Syndrome Postoperative Infection	Health Professional	Oxyir Capsules 5 Mg (Oxycodone Hydrochloride) Ir Capsule	PS		ORAL
MG, ORAL				Zyvox (Linezolid) Tablet	SS		ORAL
MG, ORAL				Methadone (Methadone) Unknown	SS		ORAL
MG				Vancomycin (Vancomycin) Unknown	SS		
MG, ORAL				Zanaflex (Tizanidine Hydrochloride) Tablet	SS		ORAL
MG, ORAL				Remeron (Mirtazapine) Tablet	SS		ORAL
MG, ORAL				Effexor (Venlafaxine Hydrochloride) Tablet	SS		ORAL
MG, ORAL				Gabitril (Tiagabine Hydrochloride) Tablet	SS		ORAL

Date:09/20/02ISR Number: 3977881-9Report Type:Direct Company Report #USP 055217
Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
---------	----------	----	---------------	---------	------	--------------	-------

Medication Error

Tizanidine
 Hydrochloride PS Par
 Nizatidine SS Mylan

Date:09/20/02ISR Number: 3979356-XReport Type:Expedited (15-DaCompany Report #ZANA001010 (0)
 Age:37 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 24-32 MG DAILY; ORAL	Chills Hepatitis Influenza Like Illness Nausea Prothrombin Time Prolonged Serum Ferritin Increased Tremor Urinary Tract Infection Vomiting	Health Professional	Zanaflex (Tizanidine Hydrochloride) Relafen Cipro Tylenol	PS C C C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/02ISR Number: 3981881-2Report Type:Expedited (15-DaCompany Report #ZANA001013 (0)

Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose						
Hospitalization -	Cardiac Disorder	Health	Zanaflex (Tizanidine			
Initial or Prolonged	Coma	Professional	Hydrochloride)	PS		ORAL
ORAL	Rhabdomyolysis	Company Representative				

Date:09/25/02ISR Number: 3980226-1Report Type:Direct Company Report #CTU 177090

Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose						
Required	Dizziness		Zanaflex	PS		
4MG QD OR BID						
Intervention to	Hypotension		Amitryptiline	C		
Prevent Permanent			Neurontin	C		
Impairment/Damage			Bumex	C		
			Lisonopril	C		

Date:09/27/02ISR Number: 3984292-9Report Type:Expedited (15-DaCompany Report #PHBS2002JP04033

Age:63 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose						
Hospitalization -	Erythema Multiforme	Foreign	Diovan (Valsartan)			
Initial or Prolonged	Face Oedema	Health	Tablet	PS		ORAL
40 MG, QD,						
ORAL	Pruritus	Professional				
		Other	Ternelin (Tizanidine			
			Hydrochloride,			
			Tizanidine			
			Hydrochloride)			
0.5 MG, TID,			Unknown	SS		ORAL
ORAL						
			Osteluc (Etodolac)	SS		ORAL
100 MG, TID,						

ORAL

Mecobamide
(Mecobalamin)

SS

ORAL

500 UG, TID,

ORAL

Date:11/01/02ISR Number: 4005575-2Report Type:Expedited (15-DaCompany Report #2002AP03571

Age:47 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Intentional Misuse Suicide Attempt	Literature Health Professional	Metoprolol Salicylate Tizanidine	PS SS SS		

Date:11/12/02ISR Number: 4011639-XReport Type:Expedited (15-DaCompany Report #ZANA001033 (0)

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged ORAL Required Intervention to Prevent Permanent Impairment/Damage		Bradycardia Hypotension Myocardial Infarction Syncope	Health Professional	Zanaflex (Tizanidine Hydrochloride) Neurontin	PS C		ORAL

22-Aug-2005 12:09 PM

Page: 134

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/14/02ISR Number: 4012571-8Report Type:Expedited (15-DaCompany Report #ZANA000971 (1)
Age:37 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening Hospitalization - 8 MG DAILY Initial or Prolonged ORAL	Bradycardia Drug Interaction Hypotension	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		
1 TABLET DAILY			Ortho-Novum 777 (Norethindrone/ Estradiol)	SS		
			Vioxx Darvocet-N	C C		

Date:11/14/02ISR Number: 4012577-9Report Type:Expedited (15-DaCompany Report #ZANA001028 (1)
Age:50 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 6 MG DAILY Other ORAL	Akinesia Asthenia Decreased Activity Difficulty In Walking Hypotension Motor Dysfunction Somnolence Stupor	Consumer	Zanaflex (Tizanidne Hydrochloride)	PS		ORAL
			Baclofen	C		

Date:11/15/02ISR Number: 4011395-5Report Type:Direct Company Report #CTU 181034
Age:50 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening 4MG TID ORAL Hospitalization -	Anger Blood Glucose Decreased		Zanaflex 4g	PS		ORAL

Initial or Prolonged

- Chest Pain
- Flushing
- Hallucinations, Mixed
- Incoherent
- Insomnia
- Memory Impairment
- Mental Status Changes
- Nausea
- Nightmare
- Palpitations
- Psychotic Disorder
- Urinary Incontinence
- Vomiting

Date:11/19/02ISR Number: 4012850-4Report Type:Direct
 Age:70 YR Gender:Female I/FU:I

Company Report #CTU 181349

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required Intervention to 8 MG 3 TIMES Prevent Permanent DAILY Impairment/Damage		Blood Pressure Decreased Hypertension		Tizanidine 4 Mg Tablets	PS		
0.1 MG -2 DOSES				Clonidine 0.1 Mg Tablets	SS		
				Paxil Remeron	C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Colace C
 Metamucil C
 Intrathecal Pump
 (Clonidine Baclofen
 Morphine) C
 Neurontin C
 Lipitor C

Date:11/20/02ISR Number: 4012673-6Report Type:Direct
 Age:70 YR Gender:Female I/FU:I

Company Report #CTU 181395

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Required Intervention to 8MG 3 TIMES Prevent Permanent DAILY Impairment/Damage		Blood Pressure Decreased Hypertension		Tizanidine 4mg Tablets	PS		
0.1MG -2 DOSES				Clonidine 0.1mg Tablets	SS		

Paxil C
 Colace C
 Metamucil C
 Neurontin C
 Lipitor C
 Clonidine C
 Baclotch C
 Morphine C

Date:11/21/02ISR Number: 4016887-0Report Type:Expedited (15-DaCompany Report #NSADSS2002042283
 Age:37 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - Initial or Prolonged		Bradycardia Drug Interaction Hypotension	Health Professional	Ortho-Novum 7/7/7(Tablet) (Ethinylestradiol/No rethindrone)	PS		ORAL
1 TABLET,							

DAILY, ORAL

Zanaflex (Tizanidine
Hydrochloride) SS

ORAL

8 MG, 1 IN 1

DAILY, ORAL

Vioxx (Rofecoxib) C
Darvocet-N
(Di-Gesic) C

Date:11/22/02ISR Number: 4013851-2Report Type:Expedited (15-DaCompany Report #WAES 0211USA01696
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Disability		Somnolence		Vioxx [Composition Unspecified] Zanaflex	PS SS SS	Merck & Co., Inc	ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/26/02ISR Number: 4017976-7Report Type:Expedited (15-DaCompany Report #12115150

Age:47 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide	Literature	Metoprolol Tartrate	PS		ORAL
Other		Overdose	Health Professional	Salicylate (Salicylate Salts)	SS		ORAL
				Tizanidine (Tizanidine Hcl)	SS		ORAL

Date:11/26/02ISR Number: 4018026-9Report Type:Expedited (15-DaCompany Report #ZANA001039

Age:49 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	12 MG DAILY	Bradycardia Hypotension	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Loss Of Consciousness					
		Memory Impairment		Estrace (Estradiol Valerate)	SS		ORAL
				Plaquenil	C		
				Vioxx	C		
				Prozac	C		

Date:11/26/02ISR Number: 4018108-1Report Type:Expedited (15-DaCompany Report #ZANA001037

Age:44 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	16 MG DAILY	Biliary Tract Disorder Cholangitis Acute	Literature Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Eosinophilia	Professional				

Hepatic Congestion
 Hepatic Failure
 Hepatic Fibrosis
 Hepatic Haemorrhage
 Hepatic Steatosis
 Hepatocellular Damage

Oxycodone

C

Date:11/29/02ISR Number: 4018276-1Report Type:Expedited (15-DaCompany Report #ZANA001043

Age:47 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide	Literature Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Professional	Metoprolol (Metoprolol)	SS		ORAL
ORAL				Salicylate	C		

Date:11/29/02ISR Number: 4018348-1Report Type:Expedited (15-DaCompany Report #ZANA001042

Age:43 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Cardio-Respiratory Arrest Completed Suicide	Literature Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Professional				

22-Aug-2005 12:09 PM

Page: 137

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/02/02ISR Number: 4018381-XReport Type:Direct
Age:20 YR Gender:Male I/FU:I

Company Report #CTU 181893

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Required		Tardive Dyskinesia		Zanaflex	PS		
SEE Intervention to DESCRIPTION Prevent Permanent Impairment/Damage							

Date:12/04/02ISR Number: 4022020-1Report Type:Expedited (15-DaCompany Report #ZANA001045
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Ankle Fracture Dizziness	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY ORAL Fall Middle Insomnia Company Representative							

Date:12/09/02ISR Number: 4020891-6Report Type:Direct
Age:38 YR Gender:Female I/FU:I

Company Report #CTU 182319

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Drug Effect Decreased		Tizanidine 4 Mg Teva	PS	Teva	
3 PILLS EVERY NIGHT Pharmaceutical Product Complaint							

Date:12/16/02ISR Number: 4023957-XReport Type:Expedited (15-DaCompany Report #US-BRISTOL-MYERS SQUIBB COMPANY-12129474
Age:49 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization -		Bradycardia	Health	Estrace Tabs 1 Mg	PS	Apothecon	ORAL

Initial or Prolonged	Drug Interaction	Professional	Plaquenil	C	
	Hypotension		Vioxx	C	
	Loss Of Consciousness		Prozac	C	
	Memory Impairment		Zanaflex	I	ORAL

Date:12/18/02ISR Number: 4029340-5Report Type:Expedited (15-DaCompany Report #ZANA001049
Age:20 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Tardive Dyskinesia	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
24 MG DAILY							
ORAL							

Milk Of Magnesia	C
Ducolax	C
Lacri-Lube	C

Date:12/18/02ISR Number: 4029343-0Report Type:Expedited (15-DaCompany Report #ZANA001013
Age: Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Cardiac Disorder	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Initial or Prolonged		Coma					
ORAL							
		Drug Interaction					
		Nervous System Disorder					
		Respiratory Disorder					
		Rhabdomyolysis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/19/02ISR Number: 4030130-8Report Type:Expedited (15-DaCompany Report #ZANA001045
Age:54 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 6 MG DAILY Required ORAL		Ankle Fracture Dizziness Postural Fall	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Intervention to Prevent Permanent Impairment/Damage		Middle Insomnia		Klonopin Celexa Estrogen	C C C		

Date:12/24/02ISR Number: 4033743-2Report Type:Expedited (15-DaCompany Report #ZANA001052
Age:46 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 12 MG DAILY ORAL		Convulsion	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
				Effexor Depakote Vitamins Nos	C C C		

Date:12/24/02ISR Number: 4033769-9Report Type:Expedited (15-DaCompany Report #ZANA001051
Age:46 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 12 MG DAILY ORAL		Agitation Alanine Aminotransferase Increased	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Aspartate Aminotransferase Increased Convulsion Headache		Depakote Effexor Botox Prometrium Vitamins Nos	C C C C C		

Oedema Peripheral
Rebound Hypertension
Vomiting

Date:12/31/02ISR Number: 4040235-3Report Type:Expedited (15-DaCompany Report #SAG/INT-10/0/13/10/1
Age:58 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Aphasia Disease Recurrence Epilepsy Grand Mal Convulsion Multiple Sclerosis	Foreign Health Professional Other	Sandoglobulin Or Placebo (Placebo Placebo) (Sandoglobulin Or Placebo)			
INTRAVENOUS	QMO,	Relapse					PS
INTRAVENOUS		Postictal State Pyrexia		Baclofen (Baclofen) Capsule Ds 103-282 (Tizanidine Hydrochloride) Capsule Neuromet (Oxiracetam) Orfiril (Valproate Sodium)	SS SS C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/03/03ISR Number: 4039017-8Report Type:Expedited (15-DaCompany Report #ZANA001053
Age:55 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged ORAL	Blood Pressure Increased Hallucination	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
	Lethargy		Cozaar	C		
	Medication Error		Lisinopril	C		
	Neuroleptic Malignant Syndrome		Lopressor	C		

Date:01/03/03ISR Number: 4039033-6Report Type:Expedited (15-DaCompany Report #ZANA001054
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Death 4 MG DAILY ORAL	Death	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Company Representative	Opioids (Unspecified)	C		

Date:01/10/03ISR Number: 4041180-XReport Type:Expedited (15-DaCompany Report #2002AP04402
Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 2.5 MG DAILY Initial or Prolonged PO Required 50 MG DAILY Intervention to PO Prevent Permanent 50 MG DAILY Impairment/Damage PO	Autoimmune Hepatitis Tension Headache	Foreign Health Professional	Zomig	PS		ORAL
		Other	Imigran	SS		ORAL
			Imigran	SS		ORAL

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
3 MG DAILY PO				Ternelin	SS		ORAL
60 MG DAILY				Arofuto	SS		ORAL
PO							
60 MG DAILY				Migristene	C		ORAL
PO							
Date:01/23/03ISR Number: 4046403-9Report Type:Expedited (15-DaCompany Report #2002AP04402							
Age:44 YR Gender:Female I/FU:F							
Hospitalization - 2.5 MG DAILY		Autoimmune Hepatitis	Foreign	Zomig	PS		ORAL
Initial or Prolonged PO		Cholelithiasis	Health				
Required 50 MG DAILY		Chronic Hepatitis	Professional	Imigran	SS		ORAL
Intervention to PO		Hepatitis	Other				
Prevent Permanent 50 MG DAILY		Tension Headache		Imigran	SS		ORAL
Impairment/Damage PO				Migristene	SS		ORAL
60 MG DAILY							
PO							
60 MG DAILY				Arofuto	SS		ORAL
PO							
3 MG DAILY PO				Ternelin	SS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/28/03ISR Number: 4048741-2Report Type:Direct
Age:78 YR Gender:Male I/FU:I

Company Report #CTU 185382

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - 8 MG TID	Dry Mouth		Tizanidine	PS		
Initial or Prolonged Required	Hypotension		Simvastatin	C		
Intervention to Prevent Permanent Impairment/Damage			Metformin Hcl	C		
			Atenolol	C		
			Glipizide	C		
			Lisinopril	C		
			Rofecoxib	C		
			Acetaminophen	C		
			Ranitidine	C		

Date:01/28/03ISR Number: 4049722-5Report Type:Expedited (15-DaCompany Report #ZANA001053
Age:55 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Hospitalization - Initial or Prolonged UNK ORAL	Blood Pressure Increased Cerebral Infarction	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
	Convulsion		Cozaar	C		
	Escherichia Infection		Lisinopril	C		
	Hallucination		Lopressor	C		
	Lethargy					
	Medication Error					
	Nervous System Disorder					
	Pneumonia Klebsiella					
	Sinus Tachycardia					
	Status Epilepticus					
	Urinary Tract Infection					
	Vasculitis					

Date:01/28/03ISR Number: 4049768-7Report Type:Expedited (15-DaCompany Report #ZANA001033
Age:52 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Bradycardia	Health	Zanaflex (Tizanidine			

Hospitalization - 32 MG DAILY Initial or Prolonged ORAL Required Intervention to Prevent Permanent Impairment/Damage	Cardiac Arrest Hypotension Myocardial Infarction Syncope Ventricular Fibrillation	Professional	Hydrochloride)	PS	ORAL
			Neurontin Climara Klonopin	C C C	

Date:01/28/03ISR Number: 4049774-2Report Type:Expedited (15-DaCompany Report #ZANA001010
Age:37 YR Gender:Female I/FU:F

Outcome Dose Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 24-32 MG DAILY ORAL	Hepatitis Influenza Like Illness Serum Ferritin Increased Transferrin Abnormal Urinary Tract Infection	Health Professional	Zanaflex (Tizanidine Hydrochloride) Relafen Cipro Tylenol	PS C C C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/29/03ISR Number: 4050764-4Report Type:Periodic
 Age: Gender:Male I/FU:I

Company Report #ZANA000920

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 4 MG DAILY	Hypotension	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL						

Date:01/29/03ISR Number: 4050765-6Report Type:Periodic
 Age: Gender:Male I/FU:I

Company Report #ZANA000948

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 2 MG DAILY	Hypotension	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL						

Vicodin C

Date:01/29/03ISR Number: 4050769-3Report Type:Periodic
 Age: Gender:Female I/FU:I

Company Report #ZANA000981

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Other	Alanine Aminotransferase Increased	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL						

Birth Control Pills C

Date:02/03/03ISR Number: 4051426-XReport Type:Expedited (15-DaCompany Report #2002AP04402
 Age:44 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 2.5 MG DAILY	Autoimmune Hepatitis	Foreign	Zomig	PS		ORAL

Initial or Prolonged PO	Cholelithiasis	Health			
Required 50 MG DAILY	Chronic Hepatitis	Professional	Imigran	SS	ORAL
Intervention to PO	Hepatitis	Other			
Prevent Permanent 50 MG DAILY			Imigran	SS	ORAL
Impairment/Damage PO					
60 MG DAILY			Migristene	SS	ORAL
PO					
60 MG DAILY			Arofuto	SS	ORAL
PO					
3 MG DAILY PO			Ternelin	SS	ORAL

Date:02/03/03ISR Number: 4052066-9Report Type:Periodic Company Report #A0373546A
Age:44 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Required		Chest Discomfort Chest Pain	Health Professional	Lamictal (Lamotrigine)	PS		ORAL
Prevent Permanent Impairment/Damage ORAL		Skin Discolouration Swelling Face Swollen Tongue Urticaria Wheezing		Tizanidine Hydrochloride (Tizanidine Hydrochloride) Pirbuterol Acetate Tramadol Hydrochloride Fluticasone+Salmeter ol Salbutamol Sulphate	SS C C C C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/04/03ISR Number: 4052829-XReport Type:Expedited (15-DaCompany Report #ZANA001057

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - ORAL		Coma	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Initial or Prolonged		Pancreatitis					

Date:02/07/03ISR Number: 4053906-XReport Type:Expedited (15-DaCompany Report #2002AP03571

Age:47 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Intentional Misuse	Literature Health Professional	Metoprolol Salicylate Tizanidine	PS SS SS		

Date:02/07/03ISR Number: 4054749-3Report Type:Expedited (15-DaCompany Report #03-00259

Age:43 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Intentional Misuse	Literature Health Professional Other	Tizanidine	PS		

Date:02/07/03ISR Number: 4055131-5Report Type:Expedited (15-DaCompany Report #03-00225

Age:47 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death UNKNOWN	UNKNOWN	Completed Suicide Intentional Misuse	Literature Health Professional Other	Tizanidine Metoprolol Salicylate	PS C C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Depression Hyperhidrosis Insomnia	Foreign Health Professional Other	Oxycodone Hydrochloride Cr Tablets (Oxycodone Hydrochloride) Cr Tablet	PS		ORAL
20 MG, DAILY, ORAL							
				Cosaar (Losartan Potassium)	SS		ORAL
50 MG, DAILY, ORAL							
				Sirdalud (Tizanidine Hydrochloride)	SS		ORAL
8 MG, DAILY, ORAL							
				Fluoxetine (Fluoxetine)	SS		ORAL
20 MG, DAILY, ORAL							
				Pantozol (Pantoprazol e Sodium)	SS		ORAL
20 MG, DAILY, ORAL							
				Diclofenac (Diclofenac)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/19/03ISR Number: 4059873-7Report Type:Expedited (15-DaCompany Report #2003-02-0499
Age:58 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Anaphylactic Shock	Foreign Health Professional	Diprosan (Betamethasone Sodium Phosphate/Dipropionate) Injectable	PS		
1 ML				Lornoxicam (Chlorotenoxipam)	SS		
8 MG BID	2	DAY		Milgamma (Pyridoxine/Benfotiamine)	SS		
2 ML QD	3	DAY		Sirdalud	SS		
4 MG TID	10	DAY		Trental	SS		
400 MG BID	10	DAY					

Date:02/27/03ISR Number: 4067688-9Report Type:Expedited (15-DaCompany Report #ZANA001057
Age: Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - ORAL		Cholelithiasis Coma	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Initial or Prolonged		Pancreatitis					

Date:03/18/03ISR Number: 4075176-9Report Type:Direct Company Report #CTU 188897
Age:22 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Electrocardiogram Qt Prolonged		Tegaserod (Zelnorm) Samples	PS		
UNKNOWN (SAMPLES)	UNKNOWN	Syncope					

4 MG PO TID

Tizanidine
(Ranatlex) 4 Mg Tid
Prn SS

ORAL

PRN

Valium C
Xanax C
Prozac C
Nodete C
Zanatlex C
Albuterol C

Date:03/18/03ISR Number: 4078191-4Report Type:Expedited (15-DaCompany Report #PHBS2003JP02453
Age:35 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Drug Dependence	Foreign Literature Health Professional	Tizanidine Hydrochloride (Tizanidine Hydrochloride)	PS		ORAL
3 MG/DAY, ORAL			Other	Carbamazepine (Carbam azepine) Unknown	SS		ORAL
400 MG/DAY, ORAL							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/18/03ISR Number: 4079748-7Report Type:Expedited (15-DaCompany Report #US-SHR-03-001871
Age:42 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Hepatic Failure	Consumer	Betaseron			
Initial or Prolonged	Multiple Sclerosis	Health Professional	(Interferon Beta - 1b)Injection	PS		
Other						
SUBCUTANEOUS	SUBCUTANEOUS		Zanaflex(Tizanidine Hydrochloride)	SS		

Date:03/19/03ISR Number: 4076379-XReport Type:Direct Company Report #CTU 189056
Age:59 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Bradycardia		Tizanidine			
Initial or Prolonged	Dehydration		-Zanaflex-	PS		ORAL
4MG QD ORAL						
	Dizziness		Atenolol	SS		ORAL
50 QD ORAL						
	Drug Interaction		Lexapro	SS		ORAL
10MG QD ORAL						
	Hypotension		Diovan	C		
	Lethargy		Norvasc	C		
	Renal Failure		Vioxx	C		
			Aspirin	C		
			Hydrochlorothiazide	C		
			Temazepam	C		

Date:03/20/03ISR Number: 4078196-3Report Type:Direct Company Report #USP 55504
Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Other	Medication Error		Zofran	PS	Glaxo Welcome	
	Somnolence		Tizanide	SS	Eon	

Date:03/20/03ISR Number: 4080622-0Report Type:Expedited (15-DaCompany Report #USA-2002-0001447
Age:38 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged

PT
Accident
Anxiety
Arthralgia
Asthenia
Chest Pain
Chills
Coagulopathy
Confusional State
Coordination Abnormal
Cushingoid
Dehydration
Drug Withdrawal Syndrome
Duodenal Ulcer
Dyspnoea
Emotional Disorder
Emotional Distress
Feeling Of Body
Temperature Change
Hallucination
Hepatitis
Hyperhidrosis
Hypertonia
Insomnia

22-Aug-2005 12:09 PM

Page: 145

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Adverse Event	Report Source	Product	Role	Manufacturer	Route
		Liver Disorder					
		Migraine					
		Muscle Contractions					
		Involuntary	Consumer	Oxycontin Tablets			
		Muscle Twitching	Health	(Oxycodone			
		Oedema Peripheral	Professional	Hydrochloride) Cr			
40 MG, BID,		Palpitations	Other	Tablet	PS		ORAL
		Pancreatitis					
		Pyrexia		Zanaflex (Tizanidine			
		Skin Discolouration		Hydrochloride)			
		Speech Disorder		Tablet	SS		ORAL
12 MG, TID,		Syncope					
		Tremor		Depakote (Valproate			
		Vision Blurred		Semisodium) Tablet	C		
		Visual Disturbance		Motrin Tablet	C		
				Demerol (Pethidine			
				Hydrochloride)			
				Injectable	C		
				Phenergan "Wyeth-Ayer			
				st" (Promethazine			
				Hydrochloride)			
				Injectable	C		
				Elavil			
				(Amitriptyline			
				Hydrochloride)			
				Tablet	C		
				Xanax (Alprazolam)	C		
				Prednisone			
				(Prednisone) Tablet	C		
				Zyprexa (Olanzapine)			
				Tablet	C		
				Skelaxin			
				(Metaxalone) Tablet	C		
				Robaxin			
				(Methocarbamol)			
				Tablet	C		
				Bactrium			
				Ds (Sulfamethoxazole,			
				Trimethoprim) Tablet	C		
				Vicodin Tablet	C		
				Neurontin			
				(Gabapentin) Tablet	C		

Reglan Tablet	C
Stadol Ns	
(Butorphanol	
Tartrate) Spray	C
Doxepin (Doxepin)	
Tablet	C
Thorazine	
(Chlorpromazine	
Hydrochloride)	
Tablet	C
Flexeril	
(Ciclobenzaprine	
Hydrochloride)	
Tablet	C
Orphenadrine	
(Orphenadrine)	
Tablet	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/26/03ISR Number: 4084151-XReport Type:Expedited (15-DaCompany Report #ZANA001062
Age:50 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Loss Of Consciousness	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY ORAL			Other	Thyroxine Premarin Codeine	C C C		

Date:04/02/03ISR Number: 4088558-6Report Type:Expedited (15-DaCompany Report #JP-SHR-03-002988
Age:51 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Haemolytic Anaemia	Foreign Health Professional	Betaferon (Interferon Beta-1b) Injection	PS		
SUBCUTANEOUS 2 D, SUBCUTANEOUS	4 MIU, EVERY		Other	Zantac (Ranitidine Hydrochloride) Tablet	SS		ORAL
300 MG, ORAL				Mucosta (Rebamipide) Tablet	SS		ORAL
300 MG, ORAL				Ternelin (Tizanidine Hydrochloride) Tablet	SS		ORAL
2 MG, ORAL				Prednisolone Voltaren "Ciba-Geigy" (Diclofenac Sodium) Tegretol (Carbamazepine) Takepron	C C C C		

(Lansoprazole) C
 Solu-Medrol
 (Methylprednisolone
 Sodium Succinate) C
 Vitamedin S
 (Hydroxocobalamin) C
 Gaster (Famotidine) C

Date:04/03/03ISR Number: 4087134-9Report Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 190118

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other							
4 MG 1-1-1-2-		Blood Pressure Increased		Zanaflex 4 Mg	PS		ORAL
ORAL		Eye Swelling					
		Oedema		Fleets Phosphosoda Ginger Lemon Flavor	SS		ORAL
1.5 OZ TWICE							
ORAL							

Date:04/04/03ISR Number: 4090070-5Report Type:Expedited (15-DaCompany Report #PHBS2003JP02453
 Age:35 YR Gender:Male I/FU:F

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Drug Dependence	Foreign Literature

22-Aug-2005 12:09 PM
 Page: 147

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Health Professional Other	Product	Role	Manufacturer	Route
3 MG/DAY, ORAL			Tizanidine Hydrochloride (Tizanidine Hydrochloride)	PS		ORAL
SEE IMAGE			Carbamazepine (Carbamazepine)	SS		ORAL

Date:04/04/03
Age:35 YR
Gender:Male
I/FU:F

ISR Number: 4090503-4
Report Type:Expedited (15-DaCompany Report #PHBS2003JP02453

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	3 MG/DAY, ORAL		Drug Dependence	Foreign Literature Health Professional Other	Tizanidine Hydrochloride (Tizanidine Hydrochloride)Unkn	PS		ORAL
	500 MG/DAY, ORAL				Caqrbamazepine (Carbamazepine)Unkno	SS		ORAL

Date:04/22/03
Age:37 YR
Gender:Female
I/FU:I

ISR Number: 4097287-4
Report Type:Direct
Company Report #CTU 191425

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 25 MG (2 Q 8			Nausea		Xanaflex	PS		

H)

Nervousness

Pharmaceutical Product
Complaint

Date:04/22/03ISR Number: 4097289-8Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 191426

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Condition Aggravated		Tizanidine 4mg	PS		
12 Q 6 HOUR		Muscle Spasms					
PRN		Pharmaceutical Product Complaint					

Date:04/24/03ISR Number: 4102202-0Report Type:Expedited (15-DaCompany Report #200310010BYL
Age:68 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization - Initial or Prolonged		Erythema Multiforme	Foreign Health Professional	Bayaspirin (Acetylsalicylic Acid)	PS		ORAL
ORAL			Other	Celgotin S (Nicergoline)	SS		ORAL
ORAL				Enchinin (Tizanidine Hydrochloride)	SS		ORAL
ORAL				Diasera L Alfarol	C C		

Freedom Of Information (FOI) Report

Inderal C
Norvasc C

Date:04/24/03ISR Number: 4102658-3Report Type:Expedited (15-DaCompany Report #ZANA001068
Age:14 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged ORAL		Clonic Convulsion Condition Aggravated	Literature Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
INTRATRACHEAL	INTHC	Dyspnoea	Professional	Baclofen (Baclofen)	SS		
		Hyperpyrexia Mechanical Complication Of Implant Medical Device Complication Muscle Spasms Respiratory Rate Increased		Lorazepam Clonazepam	C C		

Date:04/28/03ISR Number: 4104230-8Report Type:Expedited (15-DaCompany Report #PHBS2003JP02453
Age:35 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Drug Dependence	Foreign Literature Health Professional	Tizanidine Hydrochloride (Tizanidine Hydrochloride)	PS		ORAL
3 MG/DAY, ORAL			Other	Carbamazepine (Carbamazepine)	SS		ORAL

SEE IMAGE

Date:04/30/03ISR Number: 4104792-0Report Type:Expedited (15-DaCompany Report #200310010BYL
Age:68 YR Gender:Female I/FU:F

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged			Erythema Multiforme Nasopharyngitis	Foreign Health Professional	Bayaspirin (Acetylsalicylic Acid)	PS		ORAL
ORAL				Other	Celgotin S (Nicergoline)	SS		ORAL
ORAL					Enchinin (Tizanidine Hydrochloride)	SS		ORAL
ORAL					Diasera	C		
					Alfarol	C		
					Inderal	C		
					Norvasc	C		

Date:05/01/03ISR Number: 4107308-8Report Type:Periodic Company Report #ZONI001060
Age:45 YR Gender:Male I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
			Hyperbilirubinaemia	Health Professional	Zonegran (Zonisamide)	PS		ORAL
ORAL					Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
12 MG DAILY								
ORAL					Elavil	C		

Freedom Of Information (FOI) Report

Darvocet C
Phrenilin C

Date:05/02/03ISR Number: 4106520-1Report Type:Expedited (15-DaCompany Report #ZANA001075
Age:53 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Cerebrovascular Accident	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL							

Date:05/02/03ISR Number: 4106883-7Report Type:Expedited (15-DaCompany Report #PHBS2003JP01063
Age:29 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening Hospitalization - SEE IMAGE		Alanine Aminotransferase Increased	Foreign Health	Tegretol (Carbamazepine) Tablet	PS		ORAL
Initial or Prolonged		Blood Alkaline Phosphatase Increased Gamma-Glutamyltransferase Increased Hepatic Function Abnormal Hypogammaglobulinaemia Immunodeficiency Pneumonia Productive Cough Pyrexia Rash Generalised Upper Respiratory Tract Infection	Professional Other	Ternelin (Tizanidine Hydrochloride) Gaster (Famotidine) Predonine Selbex (Teprenone) Rize (Clotiazepam)	SS SS C C C		

Date:05/02/03ISR Number: 4107150-8Report Type:Expedited (15-DaCompany Report #2002066682
Age:45 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Carpal Tunnel Syndrome	Consumer	Neurontin			

Initial or Prolonged 400 MG	Cognitive Deterioration	Health	(Gabapentin)	PS	ORAL
Other (DAILY), ORAL	Condition Aggravated	Professional			
	Confusional State		Anxiolytics	SS	
	Disturbance In Attention		Tizanidine		
	Drug Interaction		Hydrochloride		
	Encephalopathy		(Tizanidine		
			Hydrochloride)	SS	
			Tramadol		
			Hydrochloride		
			(Tramadol		
			Hydrochloride)	SS	
			Alprazolam		
			(Alprazolam)	C	
			Oxycodone		
			Hydrochloride		
			(Oxycodone		
			Hydrochloride)	C	
			Hypnotics And		
			Sedatives	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/03ISR Number: 4105660-0Report Type:Direct
 Age:37 YR Gender:Female I/FU:I

Company Report #CTU 192289

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Nausea		Xanaflex	PS		
25 MG (2 Q		Nervousness					
8H)		Pharmaceutical Product Complaint					

Date:05/06/03ISR Number: 4108799-9Report Type:Expedited (15-DaCompany Report #ZANA001077
 Age:42 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Cardiotoxicity	Literature	Zanaflex (Tizanidine			
ORAL		Ejection Fraction	Health	Hydrochloride)	PS		ORAL
		Decreased	Professional	Mitoxantrone			
				(Mitoxantrone)	SS		
				Amantadine	C		
				Indocin	C		
				Corticosteroid Nos	C		

Date:05/06/03ISR Number: 4108801-4Report Type:Expedited (15-DaCompany Report #ZANA001078
 Age:44 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Cardiotoxicity	Literature	Zanaflex (Tizanidine			
ORAL			Health	Hydrochloride)	PS		ORAL
			Professional	Mitoxantrone			
				(Mitoxantrone)	SS		
				Betaseron	C		
				Fosamax	C		
				Corticosteroid Nos	C		

12.5 MG/M2

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other		Abortion Induced Complications Of Maternal	Health Professional	Selipran	PS	Bristol-Myers Squibb Company	ORAL
YR		Exposure To Therapeutic		Seropram	SS		ORAL
YR		Drugs		Sirdalud	SS		ORAL
2 WK		Maternal Drugs Affecting		Ponstan	SS		ORAL
7 DAY		Foetus		Brufen	SS		ORAL
7 DAY		Pregnancy					

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 30 ML MONTHLY		Condition Aggravated Eosinophilia	Literature Health	Roxicodone (Oxycodone Hcl)	PS		ORAL
ORAL		Pleural Effusion	Professional				
4 MG Q 8 HR				Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
ORAL							
900 MCG DAILY				Duraclon (Clonidine Hydrochloride)	SS		
INTHC							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Morphine C
 Bupivacaine C
 Fentanyl C
 Morphine Sulfate C
 Gabapentin C
 Fluoxetine C
 Baclofen C

Date:05/13/03ISR Number: 4111637-1Report Type:Expedited (15-DaCompany Report #CLON000028
 Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged INTRATHECAL 900 MCG DAILY	Breath Sounds Decreased Diarrhoea Muscle Spasms	Literature Health Professional	Duraclon (Clonidine Hydrochloride)	PS		
INTHC 2 MG Q 8 HR	Nausea Pleural Effusion Vomiting		Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
ORAL			Morphine Bupivacaine Fentanyl	C C C		

Date:05/13/03ISR Number: 4111638-3Report Type:Expedited (15-DaCompany Report #ZANA001079
 Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 2MG Q 8 HR	Breath Sounds Decreased Condition Aggravated Diarrhoea	Literature Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL INTRATHECAL 900 MCG DAILY	Muscle Spasms Nausea Pleural Effusion		Duraclon (Clonidine Hydrochloride)	SS		
INTHC			Morphine	C		

Bupivacaine C
Fentanyl Patch C

Date:05/14/03ISR Number: 4114120-2Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 193070

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Condition Aggravated		Tizanidine (Generic)	PS		
8MG QID		Drug Ineffective		Ambien	C		
		Headache		Prevacid	C		
		Loss Of Consciousness		Oxycontin	C		
		Pancreatic Disorder		Xanax	C		
		Pharmaceutical Product		Advair	C		
		Complaint		Imitrex	C		
				Tylox	C		
				O2	C		

Date:05/15/03ISR Number: 4113569-1Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 193144

Outcome	PT
Other	Condition Aggravated
	Drug Ineffective
	Headache

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Complaint	Report Source	Product	Role	Manufacturer	Route
8 MG QID		Loss Of Consciousness Pancreatic Disorder Pharmaceutical Product		Tizanidine (Generic) Eon Lab	PS	Eon Lab	
				Ambien	C		
				Prevacid	C		
				Oxycontin	C		
				Xanax	C		
				Advair	C		
				Imitrex	C		
				Tylox	C		
				O2	C		

Date:05/21/03ISR Number: 4116375-7Report Type:Expedited (15-DaCompany Report #S03-SWI-02123-01
Age:43 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Abortion Induced Arthralgia	Foreign Other	Seropram (Citalopram Hydrobromide)	PS		
20 MG QD PO							
		Complications Of Maternal Exposure To Therapeutic Drugs		Selipran (Pravastatin Sodium)	SS		
2 MG QD PO		Drug Exposure During		Sirdalud (Tizanidine Hydrochloride)	SS		
		Pregnancy Limb Injury		Ponstan (Mefenamic Acid)	SS		
500 MG QD PO							
		Maternal Drugs Affecting Foetus		Brufen (Ibuprofen)	SS		

Date:05/27/03ISR Number: 4117342-XReport Type:Direct Company Report #CTU 194045
Age:37 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Nausea		Xanaflex	PS		
25 MG (2 Q							

8H)

Necrosis

Pharmaceutical Product
Complaint

Date:05/27/03ISR Number: 4118061-6Report Type:Expedited (15-DaCompany Report #001-0945-950345
Age: Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Discomfort
Initial or Prolonged	Anticonvulsant Drug Level
Other	Increased
	Asthenia
	Cervical Vertebral
	Fracture
	Chest Discomfort
	Convulsion
	Deafness
	Deafness Neurosensory
	Dental Plaque
	Difficulty In Walking
	Dizziness
	Dysstasia
	Feeling Abnormal
	Hypoaesthesia

22-Aug-2005 12:09 PM
Page: 153

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Injury Joint Stiffness Muscle Spasms	Report Source	Product	Role	Manufacturer	Route
UNKNOWN		Paralysis Road Traffic Accident	Consumer Health	Neurontin (Gabapentin)	PS		ORAL
(UNKNOWN),		Somnolence	Professional				
ORAL		Spinal Cord Injury					
UNKNOWN		Tinnitus Tooth Discolouration		Dilantin Kapseals (Phenytoin Sodium)	SS		ORAL
(UNKNOWN),		Tooth Disorder					
ORAL		Visual Acuity Reduced					
UNKNOWN				Zoloft	SS		ORAL
(UNKNOWN),							
ORAL							
UNKNOWN	UNKNOWN			Lamotrigine (Lamotrigine)	SS		
(UNKNOWN),							
UNKNOWN							
UNKNOWN	UNKNOWN			Topiramate (Topiramate)	SS		
(UNKNOWN),							
UNKNOWN							
UNKNOWN				Tizanidine Hydrochloride (Tizanidine Hydrochloride)	SS		ORAL
(UNKNOWN),							
ORAL							

Cefuroxime Axetil	C
Fluoxetine	
Hydrochloride	C
Citalopram	
Hydrobromide	C
Levetiracetam	C
Lactulose	C
Lorazepam	C

Date:06/02/03ISR Number: 4122164-XReport Type:Direct Company Report #USP 55884
 Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Medication Error		Zanaflex	PS	Athena Neurosciences	
TABLET				Gabitril	SS	Abbott	
TABLET							

Date:06/04/03ISR Number: 4124502-0Report Type:Expedited (15-DaCompany Report #ZANA001075
 Age: Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alopecia Blood Cholesterol	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG BID ORAL		Increased Blood Pressure Increased Cerebrovascular Accident Headache Nausea Vomiting		Lortab	C		

Neck Pain	Reglan Tablet	C
Oedema Peripheral	Stadol Ns	
Oral Intake Reduced	(Butorphanol	
Pain	Tartrate) Spray	C
Palpitations	Doxepin (Doxepin)	
Pancreatitis	Tablet	C
Prothrombin Time	Thorazine	
Prolonged	(Chlorpromazine	
Pyrexia	Hydrochloride)	
Road Traffic Accident	Tablet	C
Skin Discolouration	Flexeril	
Tremor	(Cyclobenzaprine	
Vision Blurred	Hydrochloride)	
Vomiting	Tablet	C
	Orphenadrine	
	(Orphenadrine)	
	Tablet	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/17/03ISR Number: 4130541-6Report Type:Direct
Age:43 YR Gender:Female I/FU:I

Company Report #CTU 195994

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Muscle Spasms		Tizanidine Hcl 4 Mg			
1/2 TAB AT		Pharmaceutical Product		Teva Brand	PS	Teva	
BEDTIME		Complaint					
		Tremor					

Date:06/17/03ISR Number: 4131733-2Report Type:Expedited (15-DaCompany Report #USA-2002-001447
Age:38 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Anorexia	Consumer	Oxycontin Tablets Cr	PS		ORAL
40 MG, BID,		Anxiety	Health				
Initial or Prolonged		Arthralgia	Professional	Zanaflex			
ORAL		Bile Duct Obstruction	Other	(Tizanidine			
		Chest Pain		Hydrochloride)			
		Chills		Tablet	SS		ORAL
12 MG, TID,		Condition Aggravated					
ORAL		Confusional State		Depakote (Valproate			
		Coordination Abnormal		Semisodium)	C		
		Cushingoid		Motrin	C		
		Dehydration		Demerol (Pethidine			
		Disorientation		Hydrochoride)			
		Dizziness Postural		Injectable	C		
		Drug Withdrawal Syndrome		Phenergan "Wyeth			
		Duodenal Ulcer		Ayerst"			
		Dyspnoea		(Promethazine			
		Emotional Distress		Hydrochloride)			
		Fear		Injectable	C	Wyeth Ayerst	
		Feeling Of Body		Elavil			
		Temperature Change		(Amitriptyline			
		Hallucination		Hydrochloride)			
		Hepatitis		Tablet	C		
		Hepatotoxicity		Xanax (Alprazolam)	C		
		Hyperhidrosis		Prednisone			

Insomnia	(Prednisone) Tablet	C
Intervertebral Disc Disorder	Zyprexa (Olanzapine) Tablet	C
Irritability	Skelaxin	
Migraine	(Metaxalone) Tablet	C
Muscle Contractions Involuntary	Robaxin (Methocarbamol)	
Muscle Spasms	Tablet	C
Nervousness	Bactrium Ds	
Oedema Peripheral	(Sulfamethoxazole, Trimethoprim) Tablet	C
Pain	Vicodin Tablet	C
Palpitations	Neurontin	
Pancreatitis	(Gabapentin) Tablet	C
Prothrombin Time Prolonged	Reglan Tablet	C
Pyrexia	Stadol Ns	
Road Traffic Accident	(Butorphanol Tartrate) Spray	C
Skin Discolouration	Doxepin (Doxepin) Tablet	C
Speech Disorder	Thorazine	
Syncope	(Chlorpromazine Hydrochloride) Tablet	C
Tremor		
Vision Blurred		
Visual Disturbance		

Freedom Of Information (FOI) Report

Flexeril (Cyclobenzaprine Hydrochloride) Tablet	C	
Orphenadrine (Orphenadrine) Butalbital, Acetaminophen & Caffeine (Butalbital) Zithromax	C	
(Azithromycin)	C	Pfizer

Date:06/24/03ISR Number: 4135851-4Report Type:Expedited (15-DaCompany Report #S03-USA-02601-01
Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - 10 MG QD PO Initial or Prolonged	Bradycardia Electrocardiogram Qt Prolonged Torsade De Pointes	Health Professional	Lexapro (Escitalopram) Zanaflex (Tizanidine Hydrochloride) Zanaflex (Tizanidine Hydrochloride)	PS SS SS		ORAL

Date:06/24/03ISR Number: 4135866-6Report Type:Expedited (15-DaCompany Report #USA-2002-0001447
Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Anorexia Anxiety Arthralgia Asthenia Chest Pain Chills Coagulopathy Coordination Abnormal Cushingoid Dehydration Disorientation

Dizziness Postural
Drug Withdrawal Syndrome
Duodenal Ulcer
Dysphemia
Dyspnoea
Emotional Distress
Fatigue
Fear
Feeling Of Body
Temperature Change
Hallucination
Hepatitis
Hepatotoxicity
Hyperhidrosis
Insomnia
Irritability
Migraine
Muscle Contractions

22-Aug-2005 12:09 PM

Page: 157

Reglan Tablet	C
Stadol Ns (Butorphanol Tartrate) Spray	C
Doxepin (Doxepin) Tablet	C
Thorazine (Chlorpromazine Hydrochloride) Tablet	C
Flexeril (Cyclobenzaprine Hydrochloride) Tablet	C
Orphenadrine (Orphenadrine)	C
Butalbital, Acetaminophen & Caffeine	

Freedom Of Information (FOI) Report

(Butalbital) C
 Zithromax "Pfizer"
 (Azithromycin) C

Date:06/26/03ISR Number: 4136019-8Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00020
 Age:29 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 6 DAY Initial or Prolonged	Bradycardia	Health Professional	Vioxx Tramadol Hydrochloride	PS SS	Merck & Co., Inc	ORAL
6 DAY			Tizanidine Hydrochloride	SS		ORAL

Date:07/01/03ISR Number: 4140379-1Report Type:Expedited (15-DaCompany Report #USA-2002-0001447
 Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Abdominal Pain Anorexia Anxiety Arthralgia Asthenia Bile Duct Obstruction Chest Pain Chills Coagulopathy Condition Aggravated Coordination Abnormal Cushingoid Dehydration Disorientation Dizziness Postural Drug Withdrawal Syndrome Duodenal Ulcer Dysphemia Dyspnoea Emotional Distress Fatigue Fear

Feeling Cold
Hallucination
Hepatitis
Hyperhidrosis
Insomnia
Irritability
Loss Of Consciousness
Migraine
Muscle Spasms
Muscle Twitching
Nausea
Nervousness
Oedema Peripheral
Pain
Palpitations
Pancreatitis
Pyrexia
Road Traffic Accident
Skin Discolouration
Tremor

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
	Vision Blurred Vomiting	Consumer Health Professional Other	Oxycontin Tablets(Oxycodone Hydrochloride) Cr Tablets	PS		ORAL
40 MG, BID, ORAL			Zanaflex (Tizanidine Hydrochloride) Tablet	SS		ORAL
12 MG, TID, ORAL			Depakote (Valproate Semisodium)Tablet	C		
			Motrin Tablet	C		
			Demerol (Pethidine Hydrochloride) Injectable	C		
			Phenergan "Wyeth-Ayerst" (Promethazine Hydrochloride)Inject able	C		
			Elavil (Amitriptyline Hydrochloride)Tablet	C		
			Xanax (Alprazolam) Prednisone (Prednisone)Tablet	C		
			Zyprexa (Olanzapine)Tablet	C		
			Skelaxin (Metaxalone) Tablet	C		
			Robaxin (Methocarbamol) Tablet	C		
			Bactrium Ds (Sulfamethoxazole, Trimethoprim) Tablet	C		
			Vicodin Tablet	C		
			Neurontin (Gabapentin) Tablet	C		

Reglan Tablet	C
Stadol Ns (Butorphanol Tartrate) Spray	C
Doxepin (Doxepin) Tablet	C
Thorazine (Chlorpromazine Hydrochloride) Tablet	C
Flexeril (Cyclobenzaprine Hydrochloride) Tablet	C
Orphenadrine (Orphenadrine)	C
Butalbital, Acetaminophen & Caffeine	

Freedom Of Information (FOI) Report

(Butalbital) C
 Zithromax "Pfizer"
 (Azithromycin) C
 Promethazine
 (Promethazine) C
 Cipro (Ciprofloxacin
 Hydrochloride) C
 Zydone C
 Triamterene
 (Triamterene) C

Date:07/02/03ISR Number: 4141836-4Report Type:Expedited (15-DaCompany Report #ZANA001086
 Age:49 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						
Life-Threatening	Bradycardia	Health	Zanaflex (Tizanidine			
Hospitalization -	Electrocardiogram	Professional	Hydrochloride)	PS		
Initial or Prolonged	Abnormal	Other	Lexapro			
Required	Electrocardiogram Qt		(Escitalopram)	SS		ORAL
10 MG QD ORAL						
Intervention to	Corrected Interval					
Prevent Permanent	Prolonged					
Impairment/Damage	Electrocardiogram Qt					
	Prolonged					
	Torsade De Pointes					

Date:07/10/03ISR Number: 4146698-7Report Type:Expedited (15-DaCompany Report #USA-2002-0001447
 Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Anxiety
Initial or Prolonged	Arthralgia
	Bile Duct Obstruction
	Chills
	Coordination Abnormal
	Cryptococcosis
	Cushingoid
	Dehydration
	Disorientation
	Drug Ineffective
	Drug Withdrawal Syndrome
	Duodenal Ulcer
	Dyspnoea

Emotional Distress
Fear
Hallucination
Hepatic Failure
Hepatitis
Hepatotoxicity
Hyperhidrosis
Hypoaesthesia
Insomnia
Intervertebral Disc
Protrusion
Irritability
Loss Of Consciousness
Migraine
Muscle Spasms
Muscle Twitching
Oedema Peripheral
Pain

Doxepin (Doxepin)	C
Thorazine	
(Chlorpromazine	
Hydrochloride)	C
Flexeril	
(Cyclobenzaprine	
Hydrochloride)	C
Orphenadrine	
(Orphenadrine)	C
Butalbital,	
Acetaminophen &	
Caffeine	
(Butalbital)	C
Zithromax Pfizer	
(Azithromycin)	C
Promethazine	
(Promethazine)	C
Cipro (Ciprofloxacin	
Hydrochloride)	C

Freedom Of Information (FOI) Report

Zydone C
 Triamterene
 (Triamterene) C

Date:07/16/03ISR Number: 4150486-5Report Type:Expedited (15-DaCompany Report #CH-JNJFOC-20030701841
 Age:29 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 20 GTT, ORAL		Bradycardia Drug Interaction	Foreign Health Professional	Tramal (Tramadol Hydrochloride)	PS		ORAL
50 MG, ORAL				Vioxx (Rofecoxib)	SS		ORAL
6 MG, 1 IN 1 DAY, ORAL				Sirdalud (Tizanidine Hydrochloride)	SS		ORAL

Date:07/17/03ISR Number: 4151531-3Report Type:Expedited (15-DaCompany Report #USA-2002-0001447
 Age:38 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anorexia Anxiety Arthralgia Bile Duct Obstruction Chest Pain Chills Coordination Abnormal Cushingoid Dehydration Disorientation Dizziness Postural Drug Ineffective Drug Withdrawal Syndrome Duodenal Ulcer Dysphemia Dyspnoea Emotional Distress Fatigue Fear

Feeling Cold
Gastroenteritis
Cryptococcal
Glucocorticoids Increased
Hallucination
Hepatic Failure
Hepatitis
Hepatotoxicity
Hyperhidrosis
Insomnia
Irritability
Loss Of Consciousness
Migraine
Muscle Spasms
Muscle Twitching
Oedema Peripheral
Oral Intake Reduced
Pain
Palpitations
Pancreatitis
Skin Discolouration

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Spinal Column Stenosis Spinal Osteoarthritis Tremor	Report Source	Product	Role	Manufacturer	Route
40 MG, BID, ORAL		Vision Blurred	Consumer Health Professional Other	Oxycontin Tablets (Oxycodone Hydrochloride) Cr Tablet	PS		ORAL
12 MG, TID, ORAL				Zanaflex(Tizanidine Hydrochloride)Tablet	SS		ORAL
				Naprosyn (Naproxen)	C		
				Depakote (Valproate Semisodium)Tablet	C		
				Motrin Tablet	C		
				Demeron (Pethidine Hydrochloride) Injectable	C		
				Phenergan "Wyeth-Ayerst" (Promethazine Hydrochloride)Inject able	C		
				Elavil (Amitriptyline Hydrochloride)	C		
				Xanax (Alprazolam)	C		
				Prednisone (Prednisone)Tablet	C		
				Zyprexa (Olanzaprine)Tablet	C		
				Skelaxin (Metaxalone)Tablet	C		
				Robaxin (Methocarbamol) Tablet	C		
				Bactrium Ds (Sulfamethoxazole, Trimethoprim)Tablet	C		
				Vicodin Tablet	C		
				Neurontin (Gabapentin) Tablet	C		

Reglan Tablet	C
Stadol Ns	
(Butorphanol	
Tartrate)Spray	C
Doxepin (Doxepin)	
Tablet	C
Thorazine	
(Chlorpromazine	
Hydrochloride)	
Tablet	C
Flexeril	
(Cyclobenzaprine	
Hydrochloride)	
Tablet	C
Orphenadrin	
(Orphenadrine)	C
Butalbital,	
Acetaminophen &	
Caffeine	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Butalbital) C
 Zithromax "Pfizer"
 (Azithromycin) C
 Promethazine
 (Promethazine) C
 Cipro (Ciprofloxacin
 Hydrochloride) C
 Zydone C
 Triamterene
 (Triamterene) C

Date:07/21/03ISR Number: 4150972-8Report Type:Expedited (15-DaCompany Report #WAES 0208USA00634
 Age:45 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 1 DAY	Blood Pressure Decreased		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization - Initial or Prolonged	Bradycardia Chest Pain Difficulty In Walking Dyspnoea Myocardial Infarction		Zanaflex Premarin Lidocaine Alprazolam	SS C C C		

Date:07/22/03ISR Number: 4154620-2Report Type:Expedited (15-DaCompany Report #ZANA001087
 Age:43 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Other Required ORAL Intervention to Prevent Permanent Impairment/Damage	Ectopic Pregnancy	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

Date:07/28/03ISR Number: 4158211-9Report Type:Expedited (15-DaCompany Report #001-0945-950345
 Age: Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization -	Abasia	Consumer	Neurontin			

Initial or Prolonged	Abdominal Discomfort	Health	(Gabapentin)	PS	ORAL
ORAL					
Other	Asthenia	Professional	Dilantin Kapseals		
	Chest Discomfort		(Phenytoin Sodium)	SS	ORAL
ORAL					
	Convulsion		Zoloft (Sertraline)	SS	ORAL
ORAL					
	Deafness		Lamotrigine		
	Dental Plaque		(Lamotrigine)	SS	
	Difficulty In Walking		Topiramate		
	Dizziness		(Topiramate)	SS	
	Hypoaesthesia		Tizanidine		
	Muscle Spasms		Hydrochloride		
	Paralysis		(Tizanidine		
	Road Traffic Accident		Hydrochloride)	SS	ORAL
ORAL					
	Somnolence		Cefuroxime Axetil		
	Spinal Disorder		(Cefuroxime Axetil)	C	
	Tinnitus		Fluoxetine		
	Tooth Discolouration		Hydrochloride		
	Victim Of Abuse		(Fluoxetine		
	Visual Acuity Reduced		Hydrochloride)	C	
			Citalopram		
			Hydrobromide		
			(Citalopram		
			Hydrobromide)	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Levetiracetam
(Levetiracetam) C
Lactulose
(Lactulose) C
Lorazepam
(Lorazepam) C

Date:07/29/03ISR Number: 4158537-9Report Type:Expedited (15-DaCompany Report #ZANA001013
Age:49 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - 40 MG DAILY Initial or Prolonged ORAL	Acidosis Acute Respiratory Failure Anuria Blood Urine Cardiac Disorder Coma Crepitations Depressed Level Of Consciousness Dialysis Drug Screen Positive Hyperkalaemia Hypotension Hypothermia Intentional Misuse Nervous System Disorder Pneumonia Aspiration Respiratory Rate Decreased Rhabdomyolysis Suicide Attempt	Health Professional	Zanaflex (Tizanidine Hydrochloride) Toradol (Ketorolac) Lipitor (Atorvastatin) Betapace (Sotalol) Lasix (Furosemide) Potassium (Potassium) Synthroid (Levothyroxine) Proventil Inhaler (Salbutamol) Phenergan (Promethazine)	PS SS SS C C C C C		ORAL

Date:08/04/03ISR Number: 4161088-9Report Type:Direct Company Report #USP 55987
Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration TAB	Medication Error		Zanaflex	PS	Athena Neurosciences	

Date:08/07/03ISR Number: 4165028-8Report Type:Direct
Age:43 YR Gender:Female I/FU:I

Company Report #CTU 199561

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abnormal Behaviour Conversion Disorder Crying Euphoric Mood Excitability Fall Feeling Abnormal Feeling Of Despair Formication Headache Loss Of Consciousness Self-Injurious Ideation Vertigo		Zanaflex	PS		

22-Aug-2005 12:09 PM

Page: 166

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/12/03 ISR Number: 4168515-1 Report Type:Expedited (15-DaCompany Report #2003AP02691
 Age:47 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required		Drug Interaction	Foreign	Zestril	PS		ORAL
10 MG DAILY							
Intervention to		Hypotension	Health				
Prevent Permanent			Professional	Sirdalud	SS		ORAL
2 MG DAILY PO							
Impairment/Damage			Other	Senokot	C		
				Magnesium Oxide	C		
				Amikin	C		
				Trandate	C		
				Nimotop	C		
				Well-Well	C		
				Glycerol	C		
				Mucosolvan	C		
				Clinicin	C		
				Ofloxacin	C		

Date:08/20/03 ISR Number: 4173184-0 Report Type:Expedited (15-DaCompany Report #ZANA001090
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Anaphylactic Reaction	Health	Zanaflex (Tizanidine			
Initial or Prolonged			Professional	Hydrochloride)	PS		ORAL
ORAL							

Date:08/21/03 ISR Number: 4173426-1 Report Type:Direct Company Report #CTU 200454
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Abnormal Behaviour		Zanaflex	PS		
		Crying					
		Drug Ineffective					
		Insomnia					
		Pharmaceutical Product					
		Complaint					

Date:09/05/03ISR Number: 4180645-7Report Type:Direct
Age:57 YR Gender:Female I/FU:I

Company Report #CTU 201335

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective Infection		Tizanidine (Generic Zanaflex) 4 Mg Q6	PS		ORAL
4 MG Q 6 PO		Pharmaceutical Product Complaint					

Date:09/05/03ISR Number: 4181550-2Report Type:Direct
Age:57 YR Gender:Female I/FU:I

Company Report #CTU 201346

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective Infection		Tizanidine (Generic Zanaflex) 4mg Q 6 Hrs	PS		ORAL
4MG Q 6 HRS		Pharmaceutical Product Complaint					
PO							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/03ISR Number: 4185781-7Report Type:Expedited (15-DaCompany Report #ZANA001092
Age:32 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 4 MG ORAL		Intentional Misuse Loss Of Consciousness Respiratory Rate Decreased	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

Date:09/11/03ISR Number: 4187786-9Report Type:Direct Company Report #USP 56044
Age:33 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other TABLET TABLET		Medication Error		Hydrocodone /Apap 10/325 Tizanidine 4 Mg	PS SS	Mallinckrodt Teva	

Date:09/11/03ISR Number: 4200753-1Report Type:Periodic Company Report #2003163149US
Age:61 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 10 MG, BID; ORAL		Renal Failure Acute	Health Professional	Bextra (Valdecoxib) Tablet	PS		ORAL
	365 DAY			Glucophage (Metformin Hydrochloride)	SS		ORAL
500 MG, BID; ORAL				Valium (Diazepam)	SS		ORAL
UNK, UNK; ORAL							

UNKNOWN	UNK, UNK, UNK	Baclofen (Baclofen)	SS	
		Diovan (Valsartan)	SS	
UNKNOWN	UNK, UNK, UNK	Zanaflex (Tizanidine Hydrochloride)	SS	ORAL
UNK, UNK;				
ORAL		Hydrocodone (Hydrocodone)	SS	
UNKNOWN	UNK, UNK, UNK	Niacin (Nicotinic Acid)	SS	ORAL
250 MG, QD;				
ORAL		Vasotec (Enalapril Maleate)	SS	ORAL
10 UNK, UNK;				
ORAL		Potassium Chloride (Potassium Chloride)	SS	ORAL
8 UNK, BID;				
ORAL		Tolterodine L-Tartrate	C	
		Ultram (Tramadol Hydrochloride)	C	
		Protonix (Pyratidinol)	C	
		Lasix	C	
		Norvasc (Amlodipine Besilate)	C	
		Lortab	C	

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/24/03ISR Number: 4193327-2Report Type:Expedited (15-DaCompany Report #WAES 0309ITA00012

Age:76 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Disability		Face Oedema	Health	Vioxx	PS		ORAL
4 DAY							
		Tongue Oedema	Professional	Tizanidine			
2 DAY		Urticaria		Hydrochloride	SS		ORAL
				Cozaar	C	Merck & Co., Inc	ORAL
363 DAY							

Date:09/26/03ISR Number: 4199610-9Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20030904656

Age:30 YR Gender:Unknown I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Death		Overdose	Literature	Tylox (Oxycodone/			
			Health	Acetaminophen)			
			Professional	Capsules	PS		ORAL
ORAL							
			Distributor	Oxycodone(Oxycodone)	SS		
				Tizanidine			
				(Tizanidine)	SS		

Date:10/06/03ISR Number: 4204974-3Report Type:Expedited (15-DaCompany Report #ZANA001098

Age:56 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Rebound Hypertension	Consumer	Zanaflex (Tizanidine			
		Somnolence		Hydrochloride)	PS		ORAL
10 MG DAILY							
		Tremor					
ORAL				Vioxx (Rofecoxib)	C		
				Vicodin			
				(Paracetamol)	C		
				Vicodin			
				(Paracetamol)	C		

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 8 MG DAILY		Hallucinations, Mixed	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL				Ambien (Zolpidem)	C		

Age:38 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 300 MG (TID), ORAL		Bladder Spasm Complex Regional Pain Syndrome	Health Professional	Neurontin (Gabapentin)	PS		ORAL
		Condition Aggravated Feeling Abnormal Laboratory Test Abnormal Medication Error Vaginitis Bacterial White Blood Cell Count Decreased		Zonisamide (Zonisamide) Ropinirole Hydrochloride (Ropinirole Hydrochloride) Tizanidine Hydrochloride (Tizanidine	SS SS		

Freedom Of Information (FOI) Report

Hydrochloride) SS
 Montelukast Sodium
 (Montelukast Sodium) C
 All Other
 Therapeutic Products C
 Multivitamins
 (Ergocalciferol,
 Ascorbic Acid, Folic
 Acid, Thiamine
 Hydrochloride, C
 Magnesium
 (Magnesium) C
 Calcium (Calcium) C
 Ascorbic Acid
 (Ascorbic Acid) C
 Zinc (Zinc) C
 Chromium (Chromium) C
 Policosanol
 (Policosanol) C
 Lactobacillus
 Acidophilus
 (Lactobacillus
 Acidophilus) C

Date:10/10/03ISR Number: 4208962-2Report Type:Direct
 Age:43 YR Gender:Female I/FU:I

Company Report #CTU 203594

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required 2MG-16MG QHS Intervention to ORAL Prevent Permanent Impairment/Damage		Generalised Oedema		Zanaflex 2mg	PS		ORAL

Date:10/16/03ISR Number: 4210563-7Report Type:Direct
 Age:9 YR Gender:Male I/FU:I

Company Report #CTU 203921

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 2 MG BID		Pharmaceutical Product Complaint		Tizanidine 2 Mg Baclofen	PS C		

Retching
Vomiting

Date:10/17/03ISR Number: 4214030-6Report Type:Expedited (15-DaCompany Report #ZANA001013
Age:49 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Acidosis
Hospitalization -	Acute Respiratory Failure
Initial or Prolonged	Anuria
	Blood Creatine
	Phosphokinase
	Blood Urine
	Cardiac Disorder
	Coma
	Crackles Lung
	Depressed Level Of
	Consciousness
	Dyspnoea
	Haemodynamic Instability

22-Aug-2005 12:09 PM
Page: 170

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Hyperkalaemia Hypotension Hypothermia					
40 MG DAILY		Overdose Pneumonia Aspiration Renal Failure Acute	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Rhabdomyolysis					
		Suicide Attempt Urine Abnormality		Toradol (Ketorolac) Lipitor (Atorvastatin) Betapace (Sotalol) Lasix (Furosemide) Potassium (Potassium) Synthroid (Levothyroxine) Proventil Inhaler (Salbutamol) Phenergan (Promethazine)	SS SS C C C C C C		

Date:10/21/03
Age:30 YR
Gender:Male
I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Alcohol Use Blood Bicarbonate Decreased	Literature Health Professional	Tylox (Oxycodone/Acetamino phen) Capsules	PS		ORAL
ORAL		Blood Creatine Phosphokinase Increased Blood Creatine Phosphokinase Mb Increased Blood Ph Decreased Blood Potassium Increased Blood Pressure Systolic Increased Body Temperature Increased Cardio-Respiratory Arrest	Distributor	Oxycodone (Oxycodone) Tizanidine (Tizanidine) Ethanol (Ethanol) Corticosteroid (Corticosteroids)	SS SS SS SS		

Coma
Diabetes Insipidus
Heart Rate Increased
Hypotension
Muscle Rigidity
Nausea
Overdose
Po2 Increased
Posturing
Tachycardia
Vomiting

Date:10/22/03ISR Number: 4215284-2Report Type:Direct
Age:17 YR Gender:Female I/FU:I

Company Report #CTU 204295

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Intentional Misuse		Zanaflex	PS		

22-Aug-2005 12:09 PM
Page: 171

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/03ISR Number: 4217003-2Report Type:Expedited (15-DaCompany Report #KII-2003-0002484

Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Other		Multiple Drug Overdose Suicide Attempt Tachycardia	Health Professional	Oxycodone Hcl Ir Capsules (Oxycodone Hydrochloride) Ir Capsule	PS		ORAL
5 MG, SEE TEXT, ORAL							
40 MG, ORAL							
SEE TEXT, ORAL							
				Ms Contin Tablets(Morphine Sulfate) Cr Tablet	SS		ORAL
				Zanaflex (Tizanidine Hydrochloride)	SS		ORAL

Date:10/27/03ISR Number: 4221012-7Report Type:Expedited (15-DaCompany Report #ZANA001103

Age:48 YR Gender:I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Multiple Drug Overdose	Literature Health Professional	Zanaflex (Tizanidine Hydrochloride) Propoxyphene/Acetami onophen (Dextropropoxyphene) Venlafaxine (Venlafaxine)	PS SS SS		

Date:10/30/03ISR Number: 4223831-XReport Type:Expedited (15-DaCompany Report #ZANA001106

Age:37 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Angioneurotic Oedema Hypersensitivity	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		
12 TO 24 MG							

DAILY

Complaint

Date:10/30/03ISR Number: 4223835-7Report Type:Expedited (15-DaCompany Report #ZANA001105

Age:50 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Withdrawal Syndrome	Health	Zanaflex (Tizanidine			
		Medication Error	Professional	Hydrochloride)	PS		ORAL
48 MG DAILY							
ORAL				Baclofen (Baclofen)	C		

Date:10/30/03ISR Number: 4223838-2Report Type:Expedited (15-DaCompany Report #ZANA001104

Age:56 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Blood Pressure Increased	Health	Zanaflex (Tizanidine			
Initial or Prolonged		Myocardial Infarction	Professional	Hydrochloride)	PS		ORAL
2-5 MG DAILY							
ORAL				Vioxx (Rofecoxib)	C		

22-Aug-2005 12:09 PM

Page: 172

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/30/03 ISR Number: 4223990-9 Report Type:Expedited (15-DaCompany Report #S03-USA-02601-01
 Age:49 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Bradycardia	Health Professional	Lexapro (Escitalopram)	PS		ORAL
Hospitalization - 10 MG QD PO		Electrocardiogram Qt					
Initial or Prolonged		Prolonged Torsade De Pointes		Zanaflex (Tizanidine Hydrochloride)	SS		
				Zanaflex (Tizanidine Hydrochloride)	SS		

Date:10/30/03 ISR Number: 4224110-7 Report Type:Expedited (15-DaCompany Report #OXYT000102
 Age:30 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Death Multiple Drug Overdose	Literature Health Professional	Roxicodone (Oxycodone Hcl)	PS		
				Zanaflex (Tizanidine Hydrochloride)	SS		
				Acetaminophen/Oxycodone (Acetaminophen/Oxycodone)	SS		

Date:10/30/03 ISR Number: 4224269-1 Report Type:Expedited (15-DaCompany Report #KII-2003-0003787
 Age:65 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Medication Error Respiratory Rate Increased	Health Professional	Oxycontin Tablets (Oxycodone Hydrochloride) Cr Tablet	PS		ORAL
SEE IMAGE	1 DAY			Zaroxolyn (Metolazone)	SS		ORAL

7.5 MG, SEE

TEXT, ORAL

10 MG, SEE	Lipitor (Atorvastatin)	SS	ORAL
TEXT, ORAL			
SEE TEXT,	Slow-Mag (Magnesium Chloride Anhydrous)	SS	ORAL
ORAL			
25 MG, SEE	Aldactone (Spironolactone)	SS	ORAL
TEXT, ORAL			
500 MG, SEE	Oscal (Calcium Carbonate)	SS	ORAL
TEXT, ORAL			
150 MG, SEE	Cleocin (Clindamycin Hydrochloride)	SS	ORAL
TEXT, ORAL			
20 MEQ, SEE	K-Dur (Potassium Chloride)	SS	ORAL
TEXT, ORAL			
4 MG, SEE	Zanaflex (Tizanidine Hydrochloride)	SS	ORAL
TEXT, ORAL			
160 MG, SEE	Lasix (Furosemide)	SS	ORAL
TEXT, ORAL			
	Atarax (Hydroxyzine)		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

25 MG, SEE			Hydrochloride)	SS	ORAL
TEXT, ORAL					
400 MG, SEE			Skelaxin (Metaxalone)	SS	ORAL
TEXT, ORAL					
1.25 MG, SEE			Premarin (Estrogens Conjugated)	SS	ORAL
TEXT, ORAL					
10 MG, SEE			Prozac (Fluoxetine Hydrochloride)	SS	ORAL
TEXT, ORAL					
150 MG, SEE			Zantac (Ranitidine Hydrochloride)	SS	ORAL
TEXT, ORAL					
100 MG, SEE			Colace (Docusate Sodium)	SS	ORAL
TEXT, ORAL	1	DAY			
100 MG	1	DAY	Dilantin (Phenytoin Sodium)	SS	
5 MG	1	DAY	Valium (Diazepam)	SS	
300 MG	1	DAY	Cardizem (Diltiazem Hydrochloride)	SS	
20 MG	1	DAY	Antivert (Meclozine Hydrochloride, Nicotinic Acid)	SS	
150 MG	1	DAY	Niferex (Polysaccharide-Iron Complex)	SS	
			Lovenox (Heparin-Fraction,		

SUBCUTANEOUS 30 MG,

SUBCUTANEOUS 1 DAY

Date:10/31/03ISR Number: 4224878-XReport Type:Expedited (15-DaCompany Report #KII-2003-0004112

Age:43 YR Gender:Male I/FU:I

Outcome	PT
Death	Acid Base Balance
Life-Threatening	Abnormal
Hospitalization -	Blood Glucose Abnormal
Initial or Prolonged	Blood Lactic Acid
Other	Increased
	Blood Pressure Decreased
	Blood Pressure Increased
	Body Temperature
	Increased
	Bradycardia
	Cardiac Arrest
	Coma
	Depression
	Electrocardiogram Qt
	Corrected Interval
	Prolonged
	Electroencephalogram
	Abnormal
	Heart Rate Increased
	Miosis
	Multiple Drug Overdose
	Muscle Twitching
	Mydriasis
	Posturing

22-Aug-2005 12:09 PM

Page: 174

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Pupil Fixed Respiratory Rate Decreased	Report Source	Product	Role	Manufacturer	Route
		Respiratory Rate Increased	Health Professional Other	Oxycontin Cr Methadone (Methadone)	PS		
400 MG				Trazodone(Trazodone) Gabapentin(Gabapenti n)	SS SS		
200 MG				Quetiapine(Quetiapin e)	SS		
20 MG				Citalopram(Citalopra m)	SS		
1 MG				Clonazepam (Clonazepam)	SS		
4 MG, ORAL				Zanaflex(Tizanidine Hydrochloride)	SS		ORAL
150 MG				Bupropion(Amfebutamo ne)	SS		
10 MG				Cyclobenzaprine(Cycl obenzaprine)	SS		
50 MG				Amitriptyline(Amitri ptyline)	SS		
				Estalopram()	SS		

Date:11/04/03ISR Number: 4227704-8Report Type:Direct
Age: Gender: I/FU:I

Company Report #CTU 205236

Outcome Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
2 TID		Drug Ineffective		Zanaflex 4mg	PS		
		Pharmaceutical Product Complaint					

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abnormal Behaviour		Zanaflex	PS		ORAL
4 MG BID PO		Confusional State		Aciphex	C		
		Crying		Trazodone	C		
		Feeling Abnormal		Paxil	C		
		Paranoia		Zyprexa	C		
		Urinary Tract Infection		Atenolol	C		
				Ms Contin	C		
				Neurontin	C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Alanine Aminotransferase	Foreign	Clopidogrel Sulfate	PS		ORAL
75 MG QD,		Increased	Health				
Initial or Prolonged		Aspartate	Professional	Stilnox - (Zolpidem)	SS		ORAL
ORAL		Aminotransferase	Other				
10 MG QD,		Increased		Phenhydan -			
		Stevens-Johnson Syndrome		(Phenytoin)	SS		ORAL
		Toxic Epidermal					
		Necrolysis		Ritrovil -			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
INTRAVENOUS 0.5 MG, INTRAVENOUS NOS	1 DAY			(Lonazepam)	SS		
20 MG QD, ORAL	2 DAY			Frisium - (Clobazam)	SS		ORAL
500 MG QD, ORAL	9 DAY			Clont - (Metronidazole)	SS		ORAL
500 MG QD, ORAL	9 DAY			Klacid -(Clarithromycin)	SS		ORAL
40 MG QD, ORAL	9 DAY			Pantozol - (Pantoprazole Sodium)	SS		ORAL
4 MG QD ORAL				Sirdalud - (Tizanidine Hydrochloride)- Unknown	SS		ORAL
				Metronidazole	C		
				Clarithromycin	C		
				Pantoprazole	C		

Date:11/10/03ISR Number: 4232803-0Report Type:Direct
Age: Gender:Male I/FU:I

Company Report #CTU 205667

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
ANY		Blood Pressure Decreased		Zanaflex	PS		
		Loss Of Consciousness					

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Required 35 G PO		Hepatic Failure Hepatic Necrosis Hepatic Steatosis	Foreign Literature Other	Unspecified Paracetamol Product (Paracetamol)	PS		ORAL
Intervention to PO		Nausea		Tizanidine	SS		ORAL
Prevent Permanent Impairment/Damage		Overdose Vomiting		Alcohol	SS		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Other		Drug Screen Positive Hyperhidrosis Hyperpyrexia Medication Error Multiple Drug Overdose Sinus Tachycardia Somnolence White Blood Cell Count	Study Health Professional Other	Morphine Sulfate(Similar To Nda 19-516)(Morphine Sulfate) Unknown Soma (Carisoprodol) Valium(Diazepam) Ace Inhibitor Nos() Antihistamine() Nortriptyline(Nortri ptyline) Biguandes() Anticonvulsant() Ssri() Acetaminophen(Parace	PS SS SS SS SS SS SS SS SS SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

tamol) SS
 Acetylsalicylic Acid
 (Acetylsalicylic
 Acid0 SS
 Baclofen(Baclofen) SS
 Zanaflex(Tizanidine
 Hydrochloride) SS

Date:11/14/03ISR Number: 4235450-XReport Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 206114

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Insomnia		Zanaflex 2 Mg Par	PS	Par	ORAL
1-2 TABLET 2		Restlessness					
HRS B4 BE							
ORAL							

Date:11/18/03ISR Number: 4237313-2Report Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 206352

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
4 MG ONE TID		Drug Ineffective Pharmaceutical Product		Zanaflex 4 Mg One Tid	PS		
BY MOUTH		Complaint					

Date:11/19/03ISR Number: 4238269-9Report Type:Direct
 Age:44 YR Gender:Female I/FU:I

Company Report #CTU 206452

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening		Dizziness		Zanaflex 4 Mg	PS		ORAL
4 MG PO QHS		Heart Rate Decreased					
Hospitalization - [LESS THAN 1 Initial or Prolonged WEEK]		Loss Of Consciousness					

Date:11/26/03ISR Number: 4241958-3Report Type:Expedited (15-DaCompany Report #PHBS2003JP12830
Age:59 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose				Diovan	PS	Novartis Sector:	
Other		Deafness				Pharma	ORAL
				Ternelin	SS		ORAL
				Gasmotin	C		ORAL
				Norvasc			
				/Den/	C		

Date:11/28/03ISR Number: 4245360-XReport Type:Expedited (15-DaCompany Report #2003110069
Age:38 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Bladder Spasm	Health	Neurontin			
		Feeling Abnormal	Professional	(Gabapentin)	PS		ORAL
300 MG (TID),		Nervousness					
ORAL		Vaginitis Bacterial		Zonisamide			
		White Blood Cell Count		(Zonisamide)	SS		
		Decreased		Ropinirole			
				Hydrochloride			
				(Ropinirole			
				Hydrochloride)	SS		

22-Aug-2005 12:09 PM
Page: 177

Freedom Of Information (FOI) Report

Tizanidine
 Hydrochloride
 (Tizanidine
 Hydrochloride) SS
 Montelukast Sodium
 (Montelukast Sodium) C
 All Other
 Therapeutic Products C
 Multivitamins
 (Ergocalciferol,
 Ascorbic Acid, Folic
 Acid, Thiamine
 Hydrochloride, C
 Magnesium
 (Magnesium) C
 Calcium (Calcium) C
 Ascorbic Acid
 (Ascorbic Acid) C
 Zinc (Zinc) C
 Chromium (Chromium) C
 Policosanol
 (Policosanol) C
 Lactobacillus
 Acidophilus
 (Lactobacillus
 Acidophilus) C

Date:12/02/03ISR Number: 4244848-5Report Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 207204

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abnormal Dreams Chest Discomfort		Tizanidine Hcl (Zanaflex)	PS		
2 MG Q HS, TAPERED UP TO		Convulsion					
8 MG/ SEE B5	6	MON Depression					
		Dizziness		Lipitor	C		
		Eye Pain		Vioxx	C		
		Hyperhidrosis		Toprol Xl	C		
		Movement Disorder		Aspirin	C		
		Muscle Spasms		Hctz	C		
		Muscular Weakness		Clarinx	C		

Paraesthesia
Paralysis
Rash
Somnolence
Syncope
Tinnitus
Tremor
Vision Blurred
Visual Disturbance

Date:12/02/03ISR Number: 4246497-1Report Type:Expedited (15-DaCompany Report #200306791
Age:46 YR Gender:Female I/FU:F

Outcome
Hospitalization -
Initial or Prolonged
Required
Intervention to

22-Aug-2005 12:09 PM
Page: 178

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Prevent Permanent
Impairment/Damage

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
35 G PO		Dialysis Hepatic Necrosis Hepatic Steatosis	Foreign Literature Other	Unspecified Paracetamol Product (Paracetamol)	PS		ORAL
PO		Nausea		Tizanidine	SS		ORAL
		Overdose Suicide Attempt Vomiting		Alcohol	SS		

Date:12/17/03ISR Number: 4254974-2Report Type:Expedited (15-DaCompany Report #PERC20030095
Age:30 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Alcohol Use	Literature	Percocet	PS	Endo	ORAL
PO		Life-Threatening	Health	Oxycodone	SS		ORAL
PO		Hospitalization -	Professional	Tizanidine	SS		ORAL
PO		Initial or Prolonged		Ethanol	SS		ORAL
ONCE INJ		Phosphokinase Mb		Corticosteroid	SS		
		Increased Blood Potassium Increased Blood Pressure Systolic Increased Body Temperature Increased Cardiac Arrest Coma Diabetes Insipidus Hypotension Muscle Rigidity Nausea Respiratory Arrest Tachycardia Troponin Increased Vomiting					

Date:12/17/03ISR Number: 4254987-0Report Type:Expedited (15-DaCompany Report #ZANA001112
Age:32 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Drug Interaction	Health	Zanaflex (Tizanidine			
Other		Haemolysis	Professional	Hydrochloride)	PS		ORAL
36 MG ORAL				Baclofen (Baclofen)	SS		
				Neurontin			
				(Gabapentin)	C		
				Ditropan			
				(Oxybutynin)	C		
				Prednisone			
				(Prednisone)	C		

Date:12/17/03ISR Number: 4268306-7Report Type:Periodic Company Report #USA-2003-0006530
Age:40 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Death	Accidental Overdose	Health
	Multiple Drug Overdose	Professional
		Company

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Representative
Other

Dose	Duration	Product	Role	Manufacturer	Route
20 MG, Q12H		Oxycontin Tablets (Oxycodone Hydrochloride)	PS		
10 MG, QID		Reglan (Metoclopramide)	SS		
PRN					
10 UNK, DAILY		Lexapro (Citalopram)	SS		
		Percocet (Paracetamol, Oxycodone Hydrochloride)	SS		
5 MG, Q4H PRN					
300 MG, BID,		Zantac (Ranitidine Hydrochloride)	SS		
PRN					
		Zanaflex (Tizanidine Hydrochloride)	SS		
		Flagyl (Metronidazole)	SS		
500 MG, BID					

Date:12/17/03ISR Number: 4271088-6Report Type:Periodic
Age:46 YR Gender:Female I/FU:I

Company Report #KII-2003-0004072

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Other ORAL		Bradycardia Hypertension Multiple Drug Overdose	Health Professional	Oxycontin Tablets (Oxycodone Hydrochloride)	PS		ORAL
				Tizanidine (Tizanidine)	SS		ORAL
2 MG, SEE TEXT, ORAL							

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Date:12/17/03ISR Number: 4271091-6Report Type:Periodic Company Report #KII-2003-0003784 Age:50 YR Gender:Male I/FU:I							
Hospitalization - Initial or Prolonged Other SEE TEXT		Multiple Drug Overdose	Health Professional	Oxycontin Tablets (Oxycodone Hydrochloride)	PS		
SEE TEXT				Flexeril (Cyclobenzaprine Hydrochloride)	SS		
SEE TEXT				Tizanidine (Tizandine)	SS		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Date:12/22/03ISR Number: 4256059-8Report Type:Direct Company Report #CTU 208553 Age:53 YR Gender:Female I/FU:I							
Disability 16 MG PO BID		Asthenia Dysarthria Swollen Tongue		Zanaflex 16 Mg Po Bid	PS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/03ISR Number: 4256944-7Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 208592

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability Other 1 MON		Activities Of Daily Living Impaired		Tizanidine (Athema Neurosuane)	PS	Athena Neuroscience	
		Anxiety Depression Drug Ineffective Pain Pharmaceutical Product Complaint					

Date:12/23/03ISR Number: 4258022-XReport Type:Expedited (15-DaCompany Report #200310834BCA
Age:41 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Other 500 MG, BID, ORAL SEE IMAGE		Apnoea Blood Pressure Decreased Blood Pressure Increased Coma Dehydration Heart Rate Decreased Heart Rate Increased Hypoventilation Pallor Respiratory Depression	Foreign Health Professional Other	Cipro (Ciprofloxacin Hydrochloride) Tizanidine Fucidine Altace Metoprolol Hydrochlorothiazide Zanaflex Ramipril Clindamycin	PS SS C C C C C C		ORAL

Date:12/29/03ISR Number: 4261566-8Report Type:Expedited (15-DaCompany Report #FI-JNJFOC-20031204242
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Aggression Psychiatric Symptom	Foreign Health Professional	Tramal (Tramadol Hydrochloride)	PS		

Sirdalud (Tizanidine
Hydrochloride) SS

Date:12/30/03ISR Number: 4262147-2Report Type:Expedited (15-DaCompany Report #ZANA001116
Age:38 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Diabetes Insipidus	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY							
ORAL				Copaxone (Glatiramer)	C		

Date:12/30/03ISR Number: 4262511-1Report Type:Expedited (15-DaCompany Report #ZANA001117
Age:72 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Bradycardia Fatigue Oxygen Saturation Decreased Palpitations	Foreign Health Professional Company Representative

22-Aug-2005 12:09 PM
Page: 181

Freedom Of Information (FOI) Report

Other

Dose	Duration	Product	Role	Manufacturer	Route
2 MG DAILY		Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Atenolol (Atenolol)	C		
		Aspirine (Acetylsalicylic Acid)	C		
		Nifedipine (Nifedipine)	C		
		Simvastatin (Simvastatin)	C		
		Aspirine (Acetylsalicylic Acid)	C		
		Methocarbamol (Methocarbamol)	C		

Date:01/02/04ISR Number: 4263784-1Report Type:Expedited (15-DaCompany Report #ZANA001112
 Age:32 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Glucose-6-Phosphate Dehydrogenase Deficiency	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Other		Haemolysis		Baclofen (Baclofen)	SS		
36 MG ORAL		Refusal Of Treatment By Patient		Neurontin (Gabapentin)	C		
				Ditropan (Oxybutynin)	C		
				Prednisone (Prednisone)	C		

Date:01/07/04ISR Number: 4267039-0Report Type:Expedited (15-DaCompany Report #ZANA001119
 Age:32 YR Gender:Male I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other			Acinetobacter Infection	Literature	Zanaflex (Tizanidine			
			Asthenia	Health	Hydrochloride)	PS		
			Catheter Related	Professional	Ms Contin (Morphine)	SS		ORAL
90 MG DAILY			Infection					
ORAL			Constipation					
			Faecal Incontinence					
			Myelitis Transverse					
			Paraesthesia					
			Urinary Incontinence					

Date:01/07/04ISR Number: 4267041-9Report Type:Expedited (15-DaCompany Report #ZANA001118
Age:32 YR Gender:Male I/FU:I

Outcome	Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other			Catheter Related	Literature	Zanaflex (Tizanidine			
			Infection	Health	Hydrochloride)	PS		ORAL
4 TO 8 MG PO			Dependence	Professional				
AT BEDTIME								
ORAL					Ms Contin (Morphine			
					Sulfate)	SS		ORAL
90 MG DAILY								

22-Aug-2005 12:09 PM
Page: 182

Freedom Of Information (FOI) Report

ORAL

Date:01/14/04ISR Number: 4270761-3Report Type:Expedited (15-DaCompany Report #JP-ROCHE-353443
 Age:51 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Alanine Aminotransferase	Health	Panaldine	PS	Roche	ORAL
Hospitalization -		Increased	Professional	Euglucon	SS	Roche	ORAL
Initial or Prolonged		Aspartate		Basen	SS		ORAL
		Aminotransferase		Ternelin	SS		ORAL
		Increased		Adalat L	C		ORAL
		Hepatic Function Abnormal		Takepron	C		ORAL
		Lymphocyte Stimulation		Cardenalin	C		ORAL
		Test Positive		Caltan	C		ORAL
		Pneumonia					

Date:01/23/04ISR Number: 4279306-5Report Type:Expedited (15-DaCompany Report #ZANA001125
 Age:30 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Coma	Literature	Zanaflex (Tizanidine			
		Overdose	Health	Hydrochloride)	PS		ORAL
120 MG ORAL			Professional				

Date:01/23/04ISR Number: 4279318-1Report Type:Expedited (15-DaCompany Report #ZANA001124
 Age:2 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Bradycardia	Literature	Zanaflex (Tizanidine			
		Overdose	Health	Hydrochloride)	PS		ORAL
16 MG ORAL			Professional				

Date:01/23/04ISR Number: 4279321-1Report Type:Expedited (15-DaCompany Report #ZANA001123
 Age:63 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Hypotension Overdose	Literature Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
28 MG ORAL							

Date:01/26/04ISR Number: 4278949-2Report Type:Expedited (15-DaCompany Report #JP-ROCHE-353443
Age:51 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening Hospitalization - Initial or Prolonged		Dialysis Hepatic Enzyme Increased Hepatic Function Abnormal Lymphocyte Stimulation Test Positive Pneumonia	Health Professional	Panaldine Euglucon Basen Ternelin Adalat L Takepron Cardenalin Caltan	PS SS SS SS C C C C	Roche Roche	ORAL ORAL ORAL ORAL ORAL ORAL ORAL ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/26/04ISR Number: 4278992-3Report Type:Expedited (15-DaCompany Report #WAES 0306CHE00020

Age:29 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -	6 DAY	Bradycardia	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	6 DAY		Professional	Tizanidine Hydrochloride	SS		ORAL
	6 DAY			Tramadol Hydrochloride	SS		ORAL

Date:01/27/04ISR Number: 4280390-3Report Type:Expedited (15-DaCompany Report #200322722GDDC

Age:51 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization -	0.625 MG QD	Alanine Aminotransferase Increased	Foreign Health	Glibenclamide (Euglucon) Tablets	PS		ORAL
Initial or Prolonged	PO 28 WK	Aspartate	Professional				
	200 MG/DAY PO 11 WK	Aminotransferase Increased Blood Alkaline	Other	Ticlopidine Hydrochloride (Panaldine)	SS		ORAL
	PO 28 WK	Phosphatase Increased		Voglibose (Basen)	SS		ORAL
	PO 19 WK	Blood Bilirubin Increased Dialysis Hepatic Function Abnormal		Tizanidine Hydrochloride (Ternelin)	SS		ORAL
		Lymphocyte Stimulation Test Positive Pneumonia		Nifedipine (Adalat L) Lansoprazole (Takepron) Doxazosin Mesilate (Cardenalin) Calcium Carbonate	C C C C		

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening Hospitalization - 200 MG DAILY	Carotid Artery Stenosis Cerebrovascular Accident	Health Professional	Zonegran (Zonisamide)	PS		ORAL
Initial or Prolonged ORAL	Palpitations		Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
2MG DAILY			Vioxx (Rofecoxib)	C		
ORAL			Nexium (Esomeprazole Magnesium)	C		
			Skelaxin (Metaxalone)	C		
			Ultracet (Tramadol Hydrochloride/Acetam inophen)	C		
			Ketoprofen (Ketoprofen)	C		

Outcome
PT
Irritability
Pharmaceutical Product

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Complaint

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
6 MG PO QID			Generic Zanaflex	PS		ORAL

Date:01/28/04ISR Number: 4281937-3Report Type:Expedited (15-DaCompany Report #ZANA001121
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening Required 16 MG/DAY Intervention to ORAL Prevent Permanent Impairment/Damage	Apnoea Cellulitis Coma Dehydration Hypotension Pallor Respiratory Arrest Urinary Tract Infection	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride) Ramipril (Ramipril) Metoprolol (Metoprolol) Fucidine (Fusidate Sodium) Clindamycin (Clindamycin)	PS C C C C		ORAL

Date:01/28/04ISR Number: 4281939-7Report Type:Expedited (15-DaCompany Report #ZANA001122
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening Hospitalization - 16 MG/DAY Initial or Prolonged ORAL	Apnoea Blood Pressure Increased Bradycardia Coma Pallor	Foreign Health Professional	Zanaflex (Tizanidine Hydrochloride) Ramipril (Ramipril) Metoprolol (Metoprolol) Fucidin (Fusidic Acid) Clindamycin (Clindamycin)	PS C C C C		ORAL

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Hyperreflexia	Literature	Zanaflex (Tizanidine			
Initial or Prolonged	Labile Blood Pressure	Health	Hydrochloride)	PS		ORAL
ORAL		Professional	Baclofen (Baclofen0	C		
			Senna Concentrate			
			(Senna Concentrate)	C		
			Gabapentin			
			(Gabapentin)	C		
			Calcium Carbonate			
			(Calcium Carbonate)	C		
			Glyburide			
			(Glibenclamide)	C		
			Fluoxetine			
			(Fluoxetine)	C		
			Lovastatin			
			(Lovastatin)	C		
			Aspirin "Bayer"			
			(Acetylsalicylic			
			Acid)	C		
			Ascorbic Acid			

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Ascorbic Acid) C
 Multi-Vitamins
 (Multi-Vitamins) C

Date:01/29/04ISR Number: 4283074-0Report Type:Expedited (15-DaCompany Report #ZANA001127
 Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Convulsion	Health	Zanaflex (Tizanidine			
		Drug Interaction	Professional	Hydrochloride)	PS		ORAL
ORAL		Dyskinesia	Other	Gabitril (Tiagabine)	SS		ORAL
12 MG QD ORAL		Extrapyramidal Disorder		Klonopin (Clonazepam)	C		

Date:01/30/04ISR Number: 4283016-8Report Type:Expedited (15-DaCompany Report #WAES 0401USA01663
 Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Dizziness		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Dry Mouth		Zanaflex	SS		
1 DAY		Hyperhidrosis		Ultracet	C		
		Hypotension					
		Somnolence					
		Speech Disorder					
		Vision Blurred					

Date:01/30/04ISR Number: 4289028-2Report Type:Periodic Company Report #ZANA001044
 Age:27 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Liver Function Test	Health	Zanaplex (Tizanidine			
		Abnormal	Professional	Hydrochloride)	PS		ORAL
8 MG DAILY				Neurontin			
ORAL							

(Gabapentin)	C
Albuterol	
(Salbutamol)	C
Ativan (Lorazepam)	C
Senokot (Senna)	C
Diastat (Pectin)	C
Robitussin	
(Guaifenesin)	C
Synthroid	
(Levothyroxine	
Sodium)	C
Vitamin C (Ascorbic	
Acid)	C
Magnesium (Magnesium	
Oxide)	C
Keppra	
(Levetiracetam)	C
Dulcolax (Bisacodyl)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/03/04ISR Number: 4285181-5Report Type:Direct
Age:21 YR Gender: I/FU:I

Company Report #CTU 211400

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening 1200 MG PO Hospitalization - OTO Initial or Prolonged	Alcohol Use Intentional Misuse Suicide Attempt		Paroxetine Zanaflex Rum	PS SS SS		ORAL

Date:02/04/04ISR Number: 4286811-4Report Type:Expedited (15-DaCompany Report #200322722GDDC
Age:51 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - 0.625 MG QD Initial or Prolonged PO 199 DAY	Alanine Aminotransferase Increased Aspartate	Foreign Health Professional	Glibenclamide (Euglucon) Tablets	PS		ORAL
200 MG/DAY PO 78 DAY PO 199 DAY	Aminotransferase Increased Hepatic Function Abnormal Lymphocyte Stimulation	Other	Ticlopidine Hydrochloride (Panaldine) Voglibose (Basen)	SS SS		ORAL ORAL
PO 138 DAY	Test Positive Pneumonia		Tizanidine Hydrochloride (Ternelin) Nifedipine (Adalat L) Lansoprazole (Takepron) Doxazosin Mesilate (Cardenalin) Calcium Carbonate	SS C C C C		ORAL

Date:02/12/04ISR Number: 4296016-9Report Type:Expedited (15-DaCompany Report #ZONI001246
Age:60 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - 200 MG DAILY		Asthenia Balance Disorder	Health Professional	Zonegran (Zonisamide)	PS		ORAL
Initial or Prolonged ORAL		Carotid Artery Stenosis	Company				
2 MG DAILY		Cerebrovascular Accident Coordination Abnormal	Representative	Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
ORAL		Dysarthria					
		Monoplegia		Vioxx (Rofecoxib)	C		
		Nausea		Nexium (Esomeprazole Magnesium)	C		
		Palpitations		Skelaxin (Metaxalone)	C		
				Ultracet (Tramadol Hydrochloride/Acetaminophen)	C		
				Ketoprofen (Ketoprofen)	C		

Date:02/17/04ISR Number: 4299044-2Report Type:Expedited (15-DaCompany Report #ZANA001129

Age:61 YR Gender:Female I/FU:I

Outcome	PT
Death	Myocardial Infarction Rash Urticaria

22-Aug-2005 12:09 PM

Page: 187

Freedom Of Information (FOI) Report

Ventricular Fibrillation

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
4 MG DAILY		Foreign Health Professional Distributor	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Vancocyn (Vancomycin)	C		
			Flagyl (Metronidazole)	C		
			Tylenol (Acetaminophen)	C		
			Neurontin (Gabapentin)	C		
			Ativan (Lorazepam)	C		
			Valium (Diazepam)	C		
			Diovol (Magnesium Hydroxide)	C		
			Lovenox (Enoxaparin)	C		

Date:02/24/04ISR Number: 4303810-4Report Type:Direct
 Age:37 YR Gender:Female I/FU:I

Company Report #CTU 213047

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required	4 MG 1-1 1/2	Dyspepsia		Tizanidine	PS		
Intervention to Prevent Permanent Impairment/Damage	Q4-6 HR	Nausea					
		Pharmaceutical Product Complaint Rash					

Date:02/24/04ISR Number: 4304359-5Report Type:Expedited (15-DaCompany Report #ZANA001130
 Age:50 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Blood Pressure Increased	Consumer	Zanaflex (Tizanidine			

18 MG DAILY	Chest Pain	Hydrochloride)	PS	ORAL
ORAL	Coma			
	Convulsion	Accupril (Quinapril		
	Dizziness	Hydrochloride)	C	
	Dyspepsia	Vioxx (Rofecoxib)	C	
	Epistaxis	Zocor (Simvastatin)	C	
	Feeling Abnormal			
	Hyperacusis			
	Hypoaesthesia			
	Loss Of Consciousness			
	Nasal Dryness			
	Paraesthesia			
	Rhinorrhoea			

Date:02/25/04ISR Number: 4304819-7Report Type:Direct Company Report #CTU 213181
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia		Tizanidine 52mg	PS		ORAL
1/2 PO BID		Fatigue					
AND 1 PO QHS		Feeling Abnormal					
		Pharmaceutical Product					
		Complaint					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/02/04ISR Number: 4310883-1Report Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 213607

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Asthenia		Tizanidine 2mg	PS		ORAL
1/2 PO BID		Fatigue					
AND 1 PO QHS		Feeling Abnormal					
		Pharmaceutical Product					
		Complaint					

Date:03/02/04ISR Number: 4310887-9Report Type:Direct
 Age:39 YR Gender:Female I/FU:I

Company Report #CTU 213609

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Ineffective		Zanaflex 4 Mg 1 -Bid			
4 MG PO BID		Dysuria		Ndc -59075-0594-15	PS		ORAL
		Pharmaceutical Product					
		Complaint					

Date:03/09/04ISR Number: 4315698-6Report Type:Expedited (15-DaCompany Report #US-SHR-04-021606
 Age:43 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alanine Aminotransferase	Health	Betaseron			
		Increased	Professional	(Interferon Beta-1b)			
		Aspartate		Injection, 250ug	PS		
SUBCUTANEOUS	8 MIU, EVERY	Aminotransferase					
2D,		Increased					
SUBCUTANEOUS		Blood Bilirubin Increased		Zanaflex (Tizanidine			
				Hydrochloride)	SS		ORAL
ORAL				Neurontin			
				/Unk/(Gabapentin)	SS		ORAL
ORAL							

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
ORAL				Potassium (Potassium)	SS		ORAL
Date:03/17/04ISR Number: 4320171-5Report Type:Expedited (15-DaCompany Report #ZANA001142 Age:48 YR Gender:Male I/FU:I							
Dose							
Other		Blood Pressure Increased	Foreign Consumer	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
6 MG DAILY		Cognitive Disorder					
ORAL		Hypoaesthesia Oral	Other				
		Somnolence		Flotac (Diclofenac)	C		
				Enalapril	C		
				Dexamethasone	C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Date:03/17/04ISR Number: 4320172-7Report Type:Expedited (15-DaCompany Report #ZANA001143 Age:47 YR Gender:Female I/FU:I							
Dose							
Life-Threatening		Bradycardia	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY		Dry Mouth					
ORAL		Hypotension	Professional				
			Other	Estalis (Norethisterone)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/04ISR Number: 4320215-0Report Type:Expedited (15-DaCompany Report #ZANA001134

Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Bronchopneumonia	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG DAILY			Professional				
ORAL			Other	Hypromellose (Hypromellose)	C		
				Perindopril (Perindopril)	C		
				Paracetamol (Paracetamol)	C		
				Lactulose (Lactulose)	C		

Date:03/17/04ISR Number: 4320216-2Report Type:Expedited (15-DaCompany Report #ZANA001135

Age:61 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Hepatic Function Abnormal Pruritus	Foreign Health	Ternalin (Tizanidine Hydrochloride)	PS		ORAL
3 MG DAILY			Professional				
ORAL		Rash	Other	Loxonin (Loxoprofen Sodium)	SS		ORAL
180 MG DAILY							
ORAL				Mucosta (Rebamipide)	SS		ORAL
300 MG DAILY							
ORAL				Voltaren (Diclofenac Sodium)	SS		
RECTAL	50 MG ONCE						
RECTAL				Magnesium Oxide			

2 G DAILY		(Magnesium Oxide)	SS	ORAL
ORAL				
12 MG ONCE		Pursennid (Senna)	SS	
600 MG DAILY		Juvela (Tocopheryl Nicotinate)	SS	ORAL
ORAL				
TOPICAL	TOPICAL	Mohrus	SS	
		Xylocaine (Lidocaine Hydrochloride)	C	

Date:03/17/04ISR Number: 4320217-4Report Type:Expedited (15-DaCompany Report #ZANA001136
Age:24 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 12 MG DAILY	Bradycardia Drug Interaction	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL	Hypotension	Professional				
30 MG DAILY	Hypotonia	Other	Lioresal (Baclofen)	SS		ORAL
ORAL	Malaise					
75 MG DAILY	Skin Infection		Myolastan (Tetrazepam)	SS		ORAL
ORAL						
1 G DAILY			Ciflox (Ciprofloxacin)	SS		
			Voltarene Lp (Diclofenac Sodium)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/17/04ISR Number: 4320218-6Report Type:Expedited (15-DaCompany Report #ZANA001140
Age:82 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 4 MG DAILY ORAL		Amnesia Aptyalism Dizziness Postural	Foreign Health Professional Other	Sirdalud (Tizanidine Hydrochloride) Rytmonorm (Propafenone Hydrochloride) Norvasc (Amlodipine Besilate) Ticlopidine (Ticlopidine Hydrochloride) Losartan (Losartan Potassium) Hydrochlorothiazide (Hydrochlorothiazide)	 C C C C C		ORAL

Date:03/18/04ISR Number: 4318539-6Report Type:Expedited (15-DaCompany Report #PHBS2003JP01063
Age:29 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - 200 mg, BID Initial or Prolonged	36000MIN	Hepatic Function Abnormal Hypogammaglobulinaemia		Tegretol	PS	Novartis Sector: Pharma	ORAL
200 mg, TID	5760 MIN	Immune System Disorder Pneumonia		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, QID	25920MIN	Productive Cough Pyrexia		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, TID	60480MIN	Rash Generalised Upper Respiratory Tract		Tegretol	SS	Novartis Sector: Pharma	
200 mg, BID	40320MIN	Infection		Tegretol	SS	Novartis Sector: Pharma	ORAL

UNKNOWN	Gaster	SS	
UNKNOWN	Ternelin	SS	
15 mg/day	Predonine	C	ORAL
150 mg/day	Selbex	C	ORAL
5 mg/day	Rize	C	ORAL

Date:03/19/04ISR Number: 4322313-4Report Type:Expedited (15-DaCompany Report #ZANA001144
Age:73 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 8 MG DAILY		Anaemia Gastritis	Foreign Health Professional	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Other	Oxaprozin (Oxaprozin)	SS		ORAL
1200 MG DAILY							
ORAL							

Date:03/19/04ISR Number: 4322314-6Report Type:Expedited (15-DaCompany Report #ZANA001146
Age:60 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged Other	Condition Aggravated Hepatitis B Treatment Noncompliance	Foreign Health Professional

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Other

Dose	Duration	Product	Role	Manufacturer	Route
3 MG DAILY		Ternalin (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Takepron (Lansoprazole)	C		
		Methotrexate (Methotrexate)	C		
		Foliamin (Folic Acid)	C		
		Predonine (Prednisolone)	C		
		Flucam (Ampiroxicam)	C		
		Cytotec (Misoprostol)	C		
		Depas (Etizolam)	C		
		Biofermin R (Streptococcus Faecalis)	C		
		Selbex (Teprenone)	C		
		Berizym (Enzymes Nos)	C		
		Gasmotin	C		
		Alinamin F (Fursultiamine)	C		
		Cerekinon (Trimebutine Maleate)	C		

Date:03/19/04ISR Number: 4322349-3Report Type:Expedited (15-DaCompany Report #ZANA001141
 Age:45 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Hallucination Murder	Foreign Literature	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Restlessness Suicidal Ideation	Health Professional Other				

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 1 MG DAILY		Aspartate Aminotransferase	Foreign Health	Ternalin (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Increased	Professional				
125 GM DAILY		Blood Creatine Phosphokinase Increased	Other	Lamisil (Terbinafine Hydrochloride)	SS		ORAL
ORAL		Blood Lactate					
4 MG DAILY		Dehydrogenase Increased Malaise		Lornoxicam (Lornoxicam)	SS		ORAL
ORAL				Mucosta (Rebamipide)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/19/04ISR Number: 4322351-1Report Type:Expedited (15-DaCompany Report #ZANA001136
Age:24 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged	12 MG DAILY	Bradycardia Drug Interaction	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Hypotension	Professional				
30 MG DAILY		Hypotonia	Other	Lioresal (Baclofen)	SS		ORAL
ORAL		Malaise					
75 MG DAILY				Myolastan (Tetrazepam)	SS		ORAL
ORAL							
1 G DAILY				Ciflox (Ciprofloxacin)	SS		
				Voltaren Lp (Diclofenac Sodium)	C		

Date:03/25/04ISR Number: 4327874-7Report Type:Expedited (15-DaCompany Report #ZANA001156
Age:62 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death Hospitalization - Initial or Prolonged		Drug Withdrawal Syndrome Hepatitis A Pancreatitis Acute	Foreign Health Professional Other	Sirdalud (Tizanidine Hydrochloride)	PS		
				Saroten (Amitriptyline Hydrochloride)	C		
				Seroxat "Novo Nordisk" (Paroxetine Hydrochloride)	C		

Date:03/25/04ISR Number: 4327877-2Report Type:Expedited (15-DaCompany Report #ZANA001155
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Bradycardia	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG A DAT Other ORAL			Professional				
				Digoxin (Digoxin)	SS		
				Morphine (Morphine)	C		
				Fluoxetine (Fluoxetine)	C		
				Simvastatin (Simvastatin)	C		
				Ramipril (Ramipril)	C		
				Warfarin (Warfarin)	C		
				Gabapentin (Gabapentin)	C		

Date:03/25/04
Age: Gender:Female I/FU:I

ISR Number: 4327928-5
Report Type:Expedited (15-DaCompany Report #2004017487

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Drug Withdrawal Syndrome	Health	Zoloft (Sertraline)	PS		
		Dyspnoea	Professional	Tizanidine Hydrochloride			
		Fatigue		(Tizanidine Hydrochloride)	SS		
		Myoclonic Epilepsy		Acetylsalicylic Acid (Acetylsalicylic			
		Nerve Injury					
		Pain					
		Somnolence					

22-Aug-2005 12:09 PM

Page: 193

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Acid) C
 Other Respiratory
 System Products C
 All Other
 Therapeutic Products C
 Omeprazole
 (Omeprazole) C
 Amlodipine Besilate
 (Amlodipine
 Besilate) C
 Digoxin (Digoxin) C

Date:03/25/04ISR Number: 4328337-5Report Type:Periodic Company Report #PHEH2003US08933
 Age:5 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	7 ML, Q12H,	Angioneurotic Oedema Pharyngeal Oedema Tongue Oedema	Health Professional Company Representative	Trileptal (Oxcarbazepine) Suspension	PS		ORAL
ORAL				Zanaflex (Lic. Athena) (Tizanidine Hydrochloride, Tizanidine Hydrochloride)	SS		
2, QHS				Klonopin Clonidine (Clonidine) Risperdal	C C C		

Date:03/29/04ISR Number: 4329925-2Report Type:Expedited (15-DaCompany Report #ZANA001158
 Age:70 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	6 MG DAILY	Bradycardia	Foreign Health Professional	Sirdalud (Tizanide Hydrochloride)	PS		ORAL
ORAL							

Date:03/29/04ISR Number: 4329926-4Report Type:Expedited (15-DaCompany Report #ZANA001157
Age:29 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Aspartate
	Aminotransferase
	Increased
	Blood Alkaline
	Phosphatase Increased
	Gamma-Glutamyltransferase
	Increased
	Hepatic Function Abnormal
	Hypoaesthesia
	Hypogammaglobulinaemia
	Immunodeficiency
	Multiple Sclerosis
	Pneumonia
	Rash Generalised

22-Aug-2005 12:09 PM

Page: 194

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Upper Respiratory Tract Infection	Report Source	Product	Role	Manufacturer	Route
400 MG DAILY			Foreign Health Professional Other	Ternalin (Tizanidine Hydrochloride) Tegretol (Carbamazepine) Predonine (Prednisolone) Selbex (Teprenone) Rize (Clotiazepam)	PS SS C C C		

Date:04/01/04ISR Number: 4331667-4Report Type:Direct Company Report #CTU 215739
Age:47 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required 4 MG PO TID Intervention to Prevent Permanent Impairment/Damage		Deafness Bilateral Deafness Neurosensory Tinnitus		Zanaflex 4 Mg Tid Prednisone Synthroid Premarin Nexium Lipitor Topomax Fluoxetine Toprol Xl Wellbutrin Flexeril Duragesic	PS C C C C C C C C C C C		ORAL

Date:04/02/04ISR Number: 4333989-XReport Type:Expedited (15-DaCompany Report #ZANA001158
Age:70 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 6 MG DAILY ORAL		Bradycardia Hypotension Nausea	Foreign Health Professional	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL

Other

Musaril (Tetrazepam) C

Date:04/08/04ISR Number: 4336984-XReport Type:Expedited (15-DaCompany Report #US-SHR-04-021606

Age:43 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alanine Aminotransferase Increased Aspartate Aminotransferase	Health Professional	Betaseron (Interferon Beta-1b) Injection, 250ug	PS		
SUBCUTANEOUS	8 MIU, EVERY 2D,	Increased					
SUBCUTANEOUS		Blood Bilirubin Increased Liver Function Test		Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
ORAL		Abnormal		Neurontin /Unk/ (Gabapentin)	SS		ORAL
ORAL				Potassium (Potassium)	SS		ORAL

22-Aug-2005 12:09 PM

Page: 195

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/12/04ISR Number: 4337502-2Report Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 216446

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Ventricular Extrasystoles		Tizanidine 4 Mg Tab	PS		ORAL
4MG 2 TABS							
HS ORAL							

Date:04/13/04ISR Number: 4341009-6Report Type:Expedited (15-DaCompany Report #ZANA001161
 Age:24 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abdominal Pain Body Temperature	Foreign Consumer	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
2 DF/DAY ORAL							
		Increased	Other	Vioxx (Rofecoxib)	SS		ORAL
25 MG/DAY							
ORAL							
		Dermatitis Bullous Exanthem Rash Macular					

Date:04/13/04ISR Number: 4342443-0Report Type:Expedited (15-DaCompany Report #ZANA001162
 Age:11 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization - Initial or Prolonged		Apathy Medication Error	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		OTHER
4MG							
		Somnolence	Professional				
ONCE/SINGLE							
OTHER							
			Other				

Date:04/15/04ISR Number: 4342039-0Report Type:Expedited (15-DaCompany Report #2004017487
 Age: Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Aphasia	Health	Zoloft (Sertraline)	PS		
Other		Convulsion	Professional	Tizanidine			
		Drug Withdrawal Syndrome		Hydrochloride			
		Dyskinesia		(Tizanidine			
		Dyspnoea		Hydrochloride)	SS		
		Fatigue		Acetylsalicylic Acid			
		Hypoaesthesia		(Acetylsalicylic			
		Muscle Rigidity		Acid)	C		
		Myotonia		Other Respiratory			
		Nerve Injury		System Products			
		Paraesthesia		(Other Respiratory			
		Paralysis		System Products)	C		
		Procedural Complication		Omeprazole			
		Respiratory Rate		(Omeprazole)	C		
		Increased		Amlodipine Besilate			
		Somnolence		(Amlodipine			
				Besilate)	C		
				Digoxin (Digoxin)	C		
				Trazodone			
				(Trazodone)	C		
				Oxycodone			
				Hydrochloride			
				(Oxycodone			
				Hydrochloride)	C		
				Diazepam (Diazepam)	C		
				Furosemide			
				(Furosemide)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/21/04ISR Number: 4346150-XReport Type:Expedited (15-DaCompany Report #2004024490

Age:42 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged Disability Other	Embolia Cutis Medicamentosa Gait Disturbance Injection Site Irritation Injection Site Pain	Consumer	Vistaril (Im) (Hydroxyzine Hydrochloride)	PS		
300 MG, ORAL			Neurontin (Gabapentin)	SS		ORAL
	Medication Error Muscle Spasms Necrosis		Pethidine Hydrochloride (Pethidine Hydrochloride)	SS		ORAL
ORAL			Oxycodone Hydrochloride (Oxycodone Hydrochloride)	SS		ORAL
20 MG (UNKNOWN),						
ORAL			Tizanidine Hydrochloride (Tizanidine Hydrochloride)	SS		ORAL
2 MG (UNKNOWN),						
ORAL						

Date:04/26/04ISR Number: 4349347-8Report Type:Expedited (15-DaCompany Report #ZANA001163

Age:14 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged ORAL	Drug Screen Positive Medication Error	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
	Somnolence	Professional	Rohypnol			

4 TABLETS	Other	(Flunitrazepam)	SS	ORAL
ORAL		Depas (Etizolam)	C	
		Solanax (Alprazolam)	C	
		Benzalin (Nitrazepam)	C	

Date:05/04/04ISR Number: 4355103-7Report Type:Expedited (15-DaCompany Report #200410240BYL
 Age:75 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Jaundice	Foreign Health Professional	Bayaspirin (Acetylsalicylic Acid)	PS		ORAL
ORAL			Other	Nitorol R (Isosorbide Dinitrate)	SS		ORAL
ORAL				Spelear (Fudosteine)	SS		ORAL
ORAL				Osteluc (Etodolac)	SS		ORAL
ORAL				Ternelin (Tizanidine Hydrochloride)	SS		ORAL
ORAL				Mucosta	C		
				Empynase P	C		
				Resplen	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/05/04ISR Number: 4355461-3Report Type:Expedited (15-DaCompany Report #ZANA001244
Age:52 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Hepatitis Toxic	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
Dose	12 MG/D		Other	Homeopathic Preparation (Unspecified) (Homeopathic Preparation)	C		

Date:05/05/04ISR Number: 4355931-8Report Type:Expedited (15-DaCompany Report #ZANA001216
Age:6 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Blood Uric Acid Increased	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
Hospitalization -	0.6 MG DAILY	Bronchitis					
Initial or Prolonged	ORAL	Cardio-Respiratory Arrest	Professional				
		Dehydration	Other	Hyserenin (Valproate Sodium)	C		
		Insomnia		Depas (Etizolam)	C		
		Musculoskeletal Stiffness		Theodur			
		Pyrexia		(Theophylline)	C		
		White Blood Cell Count Increased					

Date:05/12/04ISR Number: 4358565-4Report Type:Expedited (15-DaCompany Report #ZANA001156
Age:62 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Drug Withdrawal Syndrome	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
Hospitalization -	ORAL	Hepatitis A					
Initial or Prolonged		Pancreatitis Acute	Professional Other	Saroten (Amitriptyline Hydrochloride)	C		
				Seroxat "Novo			

Nordisk" (Paroxetine
Hydrochloride) C

Date:05/17/04ISR Number: 4361416-5Report Type:Expedited (15-DaCompany Report #ZANA001286
Age:29 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Rash Maculo-Papular Viral Rash	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY			Professional				
ORAL			Other	Paracetamol (Paracetamol) Citalopram (Citalopram)	C C		

Date:05/17/04ISR Number: 4362226-5Report Type:Expedited (15-DaCompany Report #ZANA001290
Age:74 YR Gender:Male I/FU:I

Outcome	PT	Report Source
Other	Jaundice Laboratory Test Abnormal	Foreign Health Professional

22-Aug-2005 12:09 PM
Page: 198

Freedom Of Information (FOI) Report

Other

Dose	Duration	Product	Role	Manufacturer	Route
2 MG DAILY		Ternelin (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Mucosta (Rebamipide)	C		
		Osteluc (Etodolac)	C		
		Nitrendipine (Nitrendipine)	C		
		Bayaspirina (Acetylsalicylic Acid)	C		
		Resplen (Eprazinone Hydrochloride)	C		
		Empynase (Pronase)	C		
		Spelear (Fudosteine)	C		

Date:05/18/04ISR Number: 4363007-9Report Type:Expedited (15-DaCompany Report #ZANA001309
 Age:32 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Confusional State Coordination Abnormal	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
2-4 MG/DAY		Disorientation	Professional				
ORAL		Drug Interaction	Other	Entumin (Clotiapine)	SS		ORAL
40-80 MG/DAY		Gait Disturbance					
ORAL				Lorazepam (Lorazepam)	SS		ORAL
4.5 MG/DAY							
ORAL				Seroquel (Quetiapine Fumarate)	SS		ORAL
50-700 MG/DAY							
ORAL							

50 MG, QD

Nozinan
(Levomepromazine) SS

ORAL

ORAL

Orfiril (Valproate
Sodium) SS

1000 MG/DAY

Date:05/18/04ISR Number: 4363008-0Report Type:Expedited (15-DaCompany Report #ZANA001216

Age:6 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Abdominal Distension	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
Hospitalization - 1.2 MG DAILY		Anuria					
Initial or Prolonged ORAL		Blood Uric Acid Increased	Professional				
		Bronchitis	Other	Hyserenin (Valproate Sodium)	C		
		Cardio-Respiratory Arrest		Depas (Etizolam)	C		
		Dehydration		Theodur			
		Insomnia		(Theophylline)	C		
		Musculoskeletal Stiffness		Phenobal			
		Ocular Hyperaemia		(Phenobarbital)	C		
		Oculogyration		Gabalon (Baclofen)	C		
		Pyrexia		Meptin (Procaterol Hydrochloride)	C		
		White Blood Cell Count Increased		Mucodyne			
				(Carbocisteine)	C		
				Tricloryl (Triclofos			

22-Aug-2005 12:09 PM

Page: 199

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Sodium) C
 Racol (Racol) C

Date:05/18/04ISR Number: 4363009-2Report Type:Expedited (15-DaCompany Report #ZANA001306
 Age:83 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 2 MG/D ORAL	Arthralgia Bacteria Urine Identified	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
20 MG/D ORAL	Diarrhoea Drug Interaction	Professional Other	Trasicor (Oxprenolol Hydrochloride)	SS		ORAL
27.5 MG, QW3 ORAL	Pyelocaliectasis Renal Failure Acute		Alzodone (Butizide)	SS		ORAL
200 MG/D ORAL			Celebrex (Celecoxib)	SS		ORAL
ORAL			Vioxx (Rofecoxib)	SS		ORAL
			Becozyme Forte (Pyridoxine)	C		
			Bioflorin (Lactobacillus Acidophilus)	C		

Date:05/20/04ISR Number: 4365769-3Report Type:Expedited (15-DaCompany Report #ZANA001307
 Age: Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged ORAL	Pneumonia Aspiration	Foreign Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

Date:05/21/04ISR Number: 4363035-3Report Type:Direct Company Report #USP 56480
 Age: Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration						

TABLET		Medication Error		Gabitril	PS	Cephalon	
				Tizanidine	SS		
TABLET							
Date:05/21/04ISR Number: 4363044-4Report Type:Direct Company Report #USP 56478							
Age:	Gender:	I/FU:I					
Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
		Medication Error		Gabitril	PS	Cephalon	
TABLET							
				Tizanidin	SS		
TABLET							
Date:05/21/04ISR Number: 4363810-5Report Type:Expedited (15-DaCompany Report #ZANA001296							
Age:74 YR	Gender:Female	I/FU:I					
Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Hepatic Fibrosis	Foreign	Sirdalud (Tizanidine			
Initial or Prolonged		Hepatocellular Damage	Health	Hydrochloride)	PS		ORAL
6 MG DAILY							
		Liver Function Test	Professional				
ORAL		Abnormal	Other	Panacod (Codeine			
				Phosphate)	C		
				Prednisone			
				(Prednisone)	C		
				Miacalcic			
				(Calcitonin, Salmon)	C		
22-Aug-2005 12:09 PM							
Page: 200							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:05/26/04ISR Number: 4366388-5Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 219597

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	4 MG 2 QID	Pharmaceutical Product Complaint		Zanaflex (Generic Only)	PS		

Date:05/26/04ISR Number: 4366390-3Report Type:Direct
Age:37 YR Gender:Female I/FU:I

Company Report #CTU 219591

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required	4 MG 1 - 1	Nausea		Tizanidine	PS		
Intervention to	1/2 Q 4-6 H	Pharmaceutical Product					
Prevent Permanent	PRN SPASMS	Complaint					
Impairment/Damage		Rash Stomach Discomfort					

Date:05/26/04ISR Number: 4372801-XReport Type:Expedited (15-DaCompany Report #ZANA001308
Age:75 YR Gender:Male I/FU:I

Company Report #ZANA001308

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -	4 MG DAILY	Delusion Hallucination	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL

ORAL

Requip (Ropinirole)	C
Sinemet (Levodopa)	C
Mirapex (Pramipexole Dihydrochloride)	C

Date:05/27/04ISR Number: 4370131-3Report Type:Expedited (15-DaCompany Report #ZANA001279
Age:77 YR Gender:Female I/FU:I

Company Report #ZANA001279

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Alanine Aminotransferase Increased	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
6 MG DAILY		Aspartate	Professional				
ORAL		Aminotransferase Increased	Other	Halfdigoxin-Ky (Digoxin)	C		
		Blood Lactate		Warfarin (Warfarin)	C		
		Dehydrogenase Increased		Tenormin (Atenolol)	C		
		Hepatic Function Abnormal					

Date:06/03/04ISR Number: 4373335-9Report Type:Expedited (15-DaCompany Report #ZANA001311
Age:53 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization - Initial or Prolonged		Confusional State	Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY		Dysarthria					
ORAL		Facial Palsy					

Date:06/08/04ISR Number: 4399760-8Report Type:Periodic Company Report #FROV000184
Age:18 YR Gender:Female I/FU:I

Outcome	PT
	Dysarthria
	Mental Impairment

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Somnolence

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
2.5 MG ORAL		Consumer	Frova (Frovatriptan Succinate)	PS		ORAL
16MG DAILY			Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
ORAL			Wellbutrin Xl (Wellbutrin Xl)	C		
			Coreg (Carvedilol)	C		

Date:06/08/04ISR Number: 4399761-XReport Type:Periodic Company Report #FROV000185
 Age:18 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose			Consumer	Frova (Frovatriptan Succinate)	PS		ORAL
2.5 MG ORAL		Dysarthria Mental Impairment		Zanaflex (Tizanidine Hydrochloride)	SS		ORAL
16 MG ORAL		Somnolence		Wellbutrin Xl (Wellbutrin Xl)	C		
				Coreg (Carvedilol)	C		

Date:06/10/04ISR Number: 4378813-4Report Type:Expedited (15-DaCompany Report #ZANA001286
 Age:29 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose			Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY		Rash Maculo-Papular Viral Rash	Professional	Paracetamol (Paracetamol)	C		
ORAL							

Citalopram
(Citalopram) C

Date:06/14/04ISR Number: 4379978-0Report Type:Expedited (15-DaCompany Report #ZANA001216
Age:6 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Death	Abdominal Distension	Foreign	Ternelin (Tizanidine			
Hospitalization -	Anuria	Health	Hydrochloride)	PS		ORAL
1.2 MG DAILY						
Initial or Prolonged	Blood Uric Acid Increased	Professional				
ORAL						
	Bronchitis	Other	Hyserenin (Valproate			
	Cardio-Respiratory Arrest		Sodium)	C		
	Cardiovascular Disorder		Depas (Etizolam)	C		
	Dehydration		Theodur			
	General Physical		(Theophylline)	C		
	Condition Abnormal		Phenobal			
	Insomnia		(Phenobarbital)	C		
	Musculoskeletal Stiffness		Gabalon (Baclofen)	C		
	Ocular Hyperaemia		Meptin (Procaterol			
	Oculogyration		Hydrochloride)	C		
			Mucodyne			
			(Carbocisteine)	C		
			Tricloryl (Triclofos			
			Sodium)	C		
			Racol (Racol)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/04ISR Number: 4381931-8Report Type:Expedited (15-DaCompany Report #ZANA001315
Age:38 YR Gender: I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 2 MG DAILY	Dehydration Fatigue	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL	Liver Function Test Abnormal Somnolence	Professional	Baclofen (Baclofen) Oxybutynin (Oxybutynin) Carbamazepine (Carbamazepine) Pyridoxine (Pyridoxine) Isoniazid (Isoniazid) Ascorbic Acid (Ascorbic Acid) Warfarin (Warfarin) Zinc Sulphate (Zinc Sulphate)	C C C C C		

Date:06/15/04ISR Number: 4381932-XReport Type:Expedited (15-DaCompany Report #ZANA001314
Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 2 MG DAILY	Blood Pressure Decreased Dizziness	Foreign Consumer	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL	Jaundice Tachycardia	Other				

Date:06/15/04ISR Number: 4382207-5Report Type:Expedited (15-DaCompany Report #ZANA001313
Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization -	Abnormal Dreams	Consumer	Zanaflex (Tizanidine			

Initial or Prolonged ORAL	Heart Rate Irregular	Health	Hydrochloride)	PS	ORAL
	Nasal Dryness Orthostatic Hypotension Respiratory Disorder Tachycardia	Professional	Evoxac (Cevimeline Hydrochloride)	C	

Date:06/16/04ISR Number: 4380826-3Report Type:Expedited (15-DaCompany Report #ZANA001317
Age:52 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 12 MG DAILY ORAL		Alpha 1 Foetoprotein Increased Hepatitis Serum Ferritin Increased	Foreign Health Professional Other	Sirdalud (Tizanidine Hydrochloride) Mercurius Solution (Mercurous Nitrate)	PS C		ORAL

Date:06/16/04ISR Number: 4381375-9Report Type:Expedited (15-DaCompany Report #ZONI001444
Age:55 YR Gender:Male I/FU:I

Outcome Other	PT Agitation Asthenia
------------------	-----------------------------

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Confusional State Disturbance In Attention Dry Mouth	Report Source				
200 MG DAILY		Dysgeusia Dysphasia	Consumer	Zonegran (Zonisamide)	PS		ORAL
ORAL		Irritability					
		Memory Impairment Mental Impairment Pruritus Somnolence Vision Blurred		Zanaflex (Tizanidine Hydrochloride) Clonidine (Clonidine) Avinza (Morphine Sulafte) Provigil (Modafinil) Melatonin (Melatonin) Androgel (Testosterone Gel)	SS C C C C		

Date:06/18/04ISR Number: 4383593-2Report Type:Expedited (15-DaCompany Report #ZANA001318
Age:77 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 18 MG DAILY		Drug Interaction Hepatitis Acute	Foreign Health Professional	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Other	Noroxin (Norfloxacin) Lioresal (Baclofen) Daonil (Glibenclamide) Metformin (Metformin) Spasmo-Urgenin N (Trospium Chloride) Valium (Diazepam) Aspirine (Acetylsalicylic Acid) Blopess	SS C C C C C C		

(Candesartan
Cilexetil) C
Borage Oil (Borage
Oil) C

Date:06/18/04ISR Number: 4383596-8Report Type:Expedited (15-DaCompany Report #ZANA001316
Age:55 YR Gender:Male I/FU:I

Outcome PT
Other Agitation
Asthenia
Confusional State
Disturbance In Attention
Dry Mouth
Dysgeusia
Hyperaesthesia
Irritability
Memory Impairment
Pruritus
Somnolence

22-Aug-2005 12:09 PM
Page: 204

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Speech Disorder Vision Blurred	Report Source	Product	Role	Manufacturer	Route
100 MG ORAL			Consumer	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
200 MG ORAL				Zonegran (Zonisamide)	SS		ORAL
				Clonidine (Clonidine)	C		
				Provigil (Modafinil)	C		
				Melatonin (Melatonin)	C		
				Avinza (Morphine Sulfate)	C		
				Androgel (Testosterone)	C		

Date:06/28/04ISR Number: 4389302-5Report Type:Expedited (15-DaCompany Report #ZANA001313
Age: Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged ORAL		Abnormal Dreams Blood Pressure	Consumer Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
		Orthostatic Decreased Dehydration Nasal Dryness Pulse Abnormal Respiration Abnormal Tachycardia	Professional	Evoxac (Cevimeline Hydrochloride)	C		
				Bentyl (Dicycloverine)	C		
				Synthroid (Levothyroxine)	C		
				Extex Pse (Guaifenesin)	C		
				Prevacid (Lansoprazole)	C		
				Lipitor (Atorvastatin)	C		

Date:06/29/04ISR Number: 4388210-3Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 221765

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose				Tizanidine	PS		
Other		Condition Aggravated		Ambien	C		
		Pharmaceutical Product		Nexium	C		
		Complaint		Xanax	C		
		Unevaluable Event		Oxycontin	C		
				Tylox	C		
				Advair	C		
				Valium	C		

Date:07/07/04ISR Number: 4394843-0Report Type:Expedited (15-DaCompany Report #ZANA001321
Age:37 YR Gender:Female I/FU:I

Outcome	PT
Other	Amnesia
	Crying
	Feeling Cold
	Lethargy
	Sedation

22-Aug-2005 12:09 PM
Page: 205

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Self-Medication Somnolence	Report Source	Product	Role	Manufacturer	Route
2 DF/D; ORAL			Foreign Other	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
				Bromazepam	C		
				Cipramil (Citalopram Hydrobromide)	C		
				Omeprazole	C		
				Cipramil (Citalopram Hydrobromide)	C		

Date:07/07/04ISR Number: 4395286-6Report Type:Expedited (15-DaCompany Report #ZANA001315
Age:38 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 2 MG DAILY		Dehydration Fatigue	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Liver Function Test	Professional				
		Abnormal Somnolence		Baclofen (Baclofen)	C		
				Oxybutynin (Oxybutynin)	C		
				Carbamazepine (Carbamazepine)	C		
				Pyridoxine (Pyridoxine)	C		
				Isoniazid (Isoniazid)	C		
				Ascorbic Acid (Ascorbic Acid)	C		
				Warfarin (Warfarin)	C		
				Zinc Sulphate (Zinc Sulphate)	C		

Date:07/07/04ISR Number: 4395287-8Report Type:Expedited (15-DaCompany Report #ZANA001320
Age:84 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Disease Progression Hyperhidrosis	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
4 MG BID ORAL		Pneumonia Vomiting	Professional Other				

Date:07/13/04ISR Number: 4398016-7Report Type:Direct Company Report #CTU 222670
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
4 MG 1 TID		Pharmaceutical Product Complaint		Zanaflex 4 Mg 1 Tid	PS		

Date:07/14/04ISR Number: 4398090-8Report Type:Direct Company Report #CTU 222795
Age: Gender:Male I/FU:I

Outcome
Life-Threatening
Hospitalization -
Initial or Prolonged
22-Aug-2005 12:09 PM
Page: 206

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Required Intervention to Prevent Permanent Dose Duration Impairment/Damage	PT	Report Source	Product	Role	Manufacturer	Route
4 MG	Acute Myocardial Infarction Angina Unstable		Zanaflex	PS		

Date:07/14/04ISR Number: 4399990-5Report Type:Expedited (15-DaCompany Report #ZANA001322
Age:59 YR Gender:Male I/FU:I

Outcome Dose Duration Hospitalization - Initial or Prolonged ORAL	PT	Report Source	Product	Role	Manufacturer	Route
ORAL	C-Reactive Protein - Increased	Foreign Literature	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
ORAL	Erythema Multiforme Hepatic Function Abnormal	Health Professional	Tegretol (Carbamazepine)	SS		ORAL
	Human Herpes Virus 6 Serology Positive Hypersensitivity Interleukin Level Increased Leukocytosis Lymphocyte Stimulation Test Positive Pyrexia Skin Test Positive Therapy Non-Responder White Blood Cell Count Increased	Other	Loxonin (Loxoprofen Sodium)	C		

Date:07/15/04ISR Number: 4406699-8Report Type:Expedited (15-DaCompany Report #ZANA001323
Age: Gender:Male I/FU:I

Outcome Dose Duration Other ORAL	PT	Report Source	Product	Role	Manufacturer	Route
ORAL	Visual Disturbance	Foreign Health Professional	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL

Other

Date:07/16/04ISR Number: 4406642-1Report Type:Expedited (15-DaCompany Report #DRON00204002327

Age:50 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Circulatory Collapse	Foreign	Marinol (Dronabinol)	PS		ORAL
2.5 MG BID,		Confusional State	Study				
PO		Somnolence	Health	Amitripytline			
		Speech Disorder	Professional	(Amitriptyline)	SS		ORAL
200 MG DAILY			Other				
PO				Baclofen (Baclofen)	SS		ORAL
70 MG DAILY							
PO				Tizanidine			
				(Tizanidine)	SS		ORAL
32 MG DAILY							
PO							

22-Aug-2005 12:09 PM

Page: 207

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/20/04ISR Number: 4405375-5Report Type:Expedited (15-DaCompany Report #ZANA001314
Age:28 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Pressure Decreased	Foreign Consumer	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY		Dizziness					
ORAL		Jaundice	Other				
		Tachycardia					

Date:07/26/04ISR Number: 4407380-1Report Type:Expedited (15-DaCompany Report #PHBS2004US09673
Age:32 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Life-Threatening		Haemoglobin Decreased	Health Professional	Baclofen	PS	Novartis Sector: Pharma	
Other		Haemolysis		Zanaflex \$El	SS		ORAL
36 mg/d				Neurontin	C		
UNKNOWN				Ditropan	C		
UNKNOWN							

Date:07/29/04ISR Number: 4412075-4Report Type:Direct Company Report #CTU 223860
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
FOOT DROP		Drug Ineffective		Zanaflex 4 Mg	PS		
LEFT FOOT		Pharmaceutical Product					
MUSCLE SPASM		Complaint					

Date:07/29/04ISR Number: 4413578-9Report Type:Expedited (15-DaCompany Report #ZANA001324
Age:27 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Dyspnoea Sensation Of Foreign Body	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY			Professional				
ORAL			Other	Panadol (Paracetamol)	SS		ORAL
250 MG DAILY				Mercilon (Desogestrel) Beklometasone Dipropionate (Beclometasone Dipropionate)	C C		

Date:07/30/04ISR Number: 4411586-5Report Type:Expedited (15-DaCompany Report #PHBS2003JP01063
Age:29 YR Gender:Female I/FU:F

Outcome	PT
Life-Threatening	Alanine Aminotransferase
Hospitalization -	Increased
Initial or Prolonged	Aspartate Aminotransferase Increased Blood Alkaline Phosphatase Increased Gamma-Glutamyltransferase Increased Hepatic Function Abnormal

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Hypogammaglobulinaemia Multiple Sclerosis Myotonia					
200 mg, BID	36000MIN	Pneumonia Productive Cough		Tegretol	PS	Novartis Sector: Pharma	ORAL
200 mg, TID	5760 MIN	Pyrexia Rash Generalised		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, QID	25920MIN	Upper Respiratory Tract Infection		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, TID	60480MIN			Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, BID	40320MIN			Gaster	SS		
UNKNOWN				Ternelin	SS		
UNKNOWN				Predonine	C		ORAL
15 mg/day				Selbex	C		ORAL
150 mg/day				Rize	C		ORAL
5 mg/day							

Date:08/05/04ISR Number: 4422425-0Report Type:Expedited (15-DaCompany Report #PHBS2004US09673
Age:32 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Glucose-6-Phosphate Dehydrogenase Deficiency Haemoglobin Decreased	Foreign Health Professional	Zanaflex \$E1 (Tizanidine Hydrochloride)	PS		ORAL
36 MG/D		Haemolysis	Other	Baclofen (Baclofen) Neurontin (Gabapentin) Ditropan (Oxybutynin Hydrochloride)	SS C C		

Date:08/06/04ISR Number: 4416952-XReport Type:Expedited (15-DaCompany Report #PHBS2003JP01063
 Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Eosinophilia		Tegretol	PS	Novartis Sector: Pharma	ORAL
Hospitalization -	Erythema					
200 mg, BID	36000MIN					
Initial or Prolonged	Hepatic Function Abnormal		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, TID	5760 MIN					
	Hypogammaglobulinaemia					
	Lung Infiltration		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, QID	25920MIN					
	Pneumonia					
	Productive Cough		Tegretol	SS	Novartis Sector: Pharma	
200 mg, TID	60480MIN					
	Pyrexia					
	Rales		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, BID	40320MIN					
	Rash Generalised					
	Skin Exfoliation		Gaster	SS		
UNKNOWN						
	Upper Respiratory Tract		Ternelin	SS		
UNKNOWN						
	Infection		Predonine	C		ORAL
15 mg/day						
			Selbex	C		ORAL
150 mg/day						
			Rize	C		ORAL
5 mg/day						

Date:08/11/04ISR Number: 4426146-XReport Type:Expedited (15-DaCompany Report #ZANA001325
 Age:44 YR Gender:Male I/FU:I

Outcome	PT
Hospitalization -	Acute Myocardial
Initial or Prolonged	Infarction

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Angina Unstable Back Pain Chest Pain					
4 MG DAILY		Condition Aggravated Coronary Artery Disease	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Muscle Spasms					
		Nerve Compression Pain Pain In Jaw Treatment Noncompliance		Vicodin (Paracetamol) Accupril (Quinapril) Zoloft (Sertraline) Klonopin (Clonazepam)	C C C C		

Date:08/18/04ISR Number: 4432526-9Report Type:Expedited (15-DaCompany Report #ZANA001328
Age:69 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Amnesia Angiopathy	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
4 MG ORAL Other		Blood Creatine Phosphokinase Increased Carotid Artery Stenosis Confusional State Encephalopathy Mental Status Changes Overdose Sleep Disorder Urinary Tract Infection	Other	Copaxone (Glatiramer Acetate)	SS		

Date:08/18/04ISR Number: 4432541-5Report Type:Expedited (15-DaCompany Report #ZANA001332
Age:63 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Depression General Physical Health Deterioration	Literature Health Professional	Zanaflex (Tizanidine Hydrochloride) Hydrocodone (Hydrocodone)	PS C		
Other		Hip Fracture					

Orthostatic Hypotension

Acetaminophen	
(Paracetamol)	C
Carbamazepine	
(Carbamazepine)	C
Aspirin	
(Acetylsalicylic Acid)	C
Unspecified	
Antihypertensive	
(Unspecified	
Antihypertensive)	C

Date:08/23/04ISR Number: 4432952-8Report Type:Expedited (15-DaCompany Report #ZANA001335

Age:23 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization - 32 MG DAILY		Drug Screen Positive Respiratory Depression	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Initial or Prolonged ORAL		Urinary Tract Infection	Professional	Methadone (Methadone)	SS		

50 MG DAILY

22-Aug-2005 12:09 PM

Page: 210

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Rivotril
 (Clonazepam) C
 Coumadin (Warfarin) C
 Vioxx (Rofecoxib) C
 Neurontin
 (Gabapentin) C
 Baclofen (Baclofen) C
 Bactrim
 (Sulfamethoxazole) C
 Phencyclidine
 (Phencyclidine) C

Date:08/23/04ISR Number: 4432954-1Report Type:Expedited (15-DaCompany Report #ZANA001333
 Age:71 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 6 MG ORAL		Hospitalisation	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
			Professional Other	Baclofen (Baclofen) Ranitidine (Ranitidine) Paracetamol (Paracetamol) Atorvastatin (Atorvastatin) Oxybutynin (Oxybutynin) Amitriptyline (Amitriptyline) Warfarin (Warfarin) Zopiclone (Zopiclone) Carbamazepine (Carbamazepine)	C C C C C C C C C		

Date:08/23/04ISR Number: 4432955-3Report Type:Expedited (15-DaCompany Report #ZANA001157
 Age:29 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening Hospitalization -	Alanine Aminotransferase Increased

Initial or Prolonged

Aspartate
Aminotransferase
Increased
B-Lymphocyte
Abnormalities
Eosinophilia
Extensor Plantar Response
Gamma-Glutamyltransferase
Increased
Hepatic Enzyme Increased
Hepatic Function Abnormal
Hyperreflexia
Hypoaesthesia
Hypogammaglobulinaemia
Immunodeficiency
Multiple Sclerosis
Pneumonia
Rash Generalised

22-Aug-2005 12:09 PM

Page: 211

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Outcome	Report Source	Product	Role	Manufacturer	Route
400 MG DAILY		Skin Exfoliation Upper Respiratory Tract Infection	Foreign Literature Health Professional	Ternelin (Tizanidine Hydrochloride) Tegretol (Carbamazepine)	PS SS		ORAL
ORAL		Upper Respiratory Tract Inflammation	Other	Gaster (Famotidine) Predonine (Prednisolone) Selbex (Teprenone) Rize (Clotiazepam)	SS C C C		

Date:08/23/04ISR Number: 4433088-2Report Type:Expedited (15-DaCompany Report #ZANA001328
Age:69 YR Gender:Female I/FU:I

Dose	Duration	Outcome	Report Source	Product	Role	Manufacturer	Route
4 MG ORAL		Hospitalization - Initial or Prolonged	Health Professional	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
Other		Phosphokinase Increased Carotid Artery Stenosis	Other	Copaxone (Glatiramer Acetate)	SS		
SUBCUTANEOUS	20 MG DAILY,	Confusional State					
SUBCUTANEOUS		Delirium		Baclofen (Baclofen)	SS		ORAL
14 TO 20 MG		Encephalopathy					
TABLETS, ORAL		Mental Status Changes Overdose Pain In Extremity Urinary Tract Infection					

Date:08/25/04ISR Number: 4433560-5Report Type:Direct
Age:53 YR Gender:Male I/FU:I

Company Report #CTU 225635

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	1 TWICE DAILY	Discomfort		Zanaflex 4 Mg	PS		
Hospitalization - Initial or Prolonged Other		Loss Of Consciousness Myocardial Infarction Pain					
Required Intervention to Prevent Permanent Impairment/Damage		Thrombosis					

Date:09/01/04ISR Number: 4441807-4Report Type:Expedited (15-DaCompany Report #ZANA001338
Age:79 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening	2 MG DAILY	Hypotension	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Professional				
			Other	Brufen (Ibuprofen)	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/01/04ISR Number: 4443131-2Report Type:Expedited (15-DaCompany Report #ZANA001323
Age:40 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Visual Disturbance	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
8 MG DAILY			Professional				
ORAL			Other				

Date:09/02/04ISR Number: 4441090-XReport Type:Direct Company Report #CTU 226225
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Disability		Drug Ineffective		Zanaflex 8 Mg Tid - Qid	PS		
8 MG TID -		Pharmaceutical Product					
QID		Complaint		Ultracet	C		

Date:09/03/04ISR Number: 4440511-6Report Type:Expedited (15-DaCompany Report #PHBS2004US11398
Age:16 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Depressed Level Of Consciousness	Health Professional	Baclofen	PS	Novartis Sector: Pharma	
UNKNOWN		Dizziness		Tizanidine Hydrochloride	SS		
UNKNOWN		Tachycardia		Nortriptyline Hydrochloride	SS		
UNKNOWN				Gabapentin	SS		
UNKNOWN				Phenelzine	SS		

UNKNOWN Ketorolac SS
 UNKNOWN Bethanechol SS
 UNKNOWN Olanzapine SS

Date:09/03/04ISR Number: 4444842-5Report Type:Expedited (15-DaCompany Report #2004PK01436
 Age:33 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required		Confusional State	Foreign	Seroquel	PS		ORAL
700 MG DAILY							
Intervention to		Coordination Abnormal	Health				
PO							
Prevent Permanent		Drug Interaction	Professional	Sirdalud	SS		ORAL
4 MG DAILY PO							
Impairment/Damage			Other	Entumin	SS		ORAL
80 MG DAILY							
PO							
				Orfiril	SS		ORAL
1 G DAILY PO							
				Lorazepam	SS		ORAL
4.5 MG DAILY							
PO							

Date:09/03/04ISR Number: 4445304-1Report Type:Expedited (15-DaCompany Report #ZANA001342
 Age:65 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Blood Pressure Systolic	Foreign	Ternelin (Tizanidine			
Initial or Prolonged		Decreased	Health	Hydrochloride)	PS		ORAL
3 MG ORAL							
		Heart Rate Decreased	Professional	Loxonin (Loxoprofen			
			Other	Sodium)	SS		ORAL
180 MG							
				Mucosta(Rebamipide)	SS		ORAL
300 MG ORAL							

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/08/04ISR Number: 4444172-1Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009

Age:60 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -	8 DAY	Alanine Aminotransferase	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged		Increased	Professional	Diclofenac Sodium	SS		ORAL
		Aspartate		Tizanidine			
		Aminotransferase		Hydrochloride	SS		ORAL
	3 DAY	Increased		Herbs (Unspecified)	C		ORAL
		Blood Alkaline					
		Phosphatase Increased					
		Bradycardia					
		Gamma-Glutamyltransferase					
		Increased					

Date:09/14/04ISR Number: 4448421-5Report Type:Expedited (15-DaCompany Report #PHBS2004CH11775

Age:60 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Alanine Aminotransferase		Voltaren	PS	Novartis Sector:	
Initial or Prolonged		Increased				Pharma	
UNKNOWN		4320 MIN					
Other		Aspartate		Sirdalud	SS		
UNKNOWN	6 mg/day	4320 MIN					
		Aminotransferase		Vioxx	SS		
UNKNOWN		4320 MIN					
		Increased		Herbal Extracts Nos	SS		
		Blood Alkaline					
		Phosphatase Increased					
		Bradycardia					
		Chest Discomfort					
		Diarrhoea					
		Drug Interaction					
		Dyspnoea					
		Fibrin D Dimer Increased					
		Gamma-Glutamyltransferase					
		Increased					
		Haemangioma Of Liver					
		Hepatic Enzyme Increased					
		Hepatic Lesion					
		Hyperhidrosis					

Liver Disorder
Pleural Effusion
Pulmonary Hypertension
Vomiting

Date:09/14/04ISR Number: 4450215-1Report Type:Expedited (15-DaCompany Report #ZANA001322
Age:59 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged ORAL		Biopsy Skin Abnormal C-Reactive Protein	Foreign Literature	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Increased Eosinophilia	Health Professional	Tegretol (Carbamazepine)	SS		ORAL
		Erythema Multiforme Hepatic Function Abnormal Human Herpes Virus 6 Serology Positive Hypersensitivity Leukocytosis Lymphocyte Stimulation Test Positive Purpura	Other	Loxonin (Loxoprofen Sodium) Prednisolone	C C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/14/04ISR Number: 4450216-3Report Type:Expedited (15-DaCompany Report #ZANA001290
Age:74 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		False Positive Laboratory Result	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
2 MG DAILY							
ORAL		Hepatitis Cholestatic	Professional				
		Laboratory Test Abnormal Lymphocyte Stimulation Test Positive Urticaria	Other	Mucosta (Rebamipide) Osteluc (Etodolac) Nitrendipine Bayaspirina (Acetylsalicylic Acid) Resplen (Eprazinone Hydrochloride) Empynase (Pronase) Spelear (Fudosteine) Nitorol (Isosorbide Dinitrate)	SS C C C C C C C		

Date:09/14/04ISR Number: 4450218-7Report Type:Expedited (15-DaCompany Report #ZANA001344
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Pressure Decreased Dehydration	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
ORAL			Professional	Depromel (Fluvoxamine)	C		
			Other	Wypax (Lorazepam) Amoxan (Amoxapine)	C C		

Date:09/15/04ISR Number: 4452325-1Report Type:Expedited (15-DaCompany Report #ZANA001309
Age:32 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Confusional State	Foreign	Sirdalud (Tizanidine			

2-4 MG/DAY	Coordination Abnormal	Health	Hydrochloride)	PS	ORAL
ORAL	Depressive Delusion	Professional			
40-80 MG/DAY	Disease Recurrence	Other	Entumin (Clotiapine)	SS	ORAL
ORAL	Disorientation				
4.5 MG/DAY	Drug Interaction		Lorazepam		
ORAL	Gait Disturbance		(Lorazepam)	SS	ORAL
	Sleep Disorder				
100 - 700			Seroquel (Quetiapine		
MG/DAY ORAL			Fumarate)	SS	ORAL
50 MG DAILY			Nozinan		
ORAL			(Levomepromazine)	SS	ORAL
1000 MG/DAY			Orfiril (Valproate		
ORAL			Sodium)	SS	ORAL

Date:09/15/04ISR Number: 4452379-2Report Type:Expedited (15-DaCompany Report #ZANA001345
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization -	Hepatitis Acute	Foreign
Initial or Prolonged		Health

22-Aug-2005 12:09 PM
Page: 215

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Professional
Other

Dose	Duration	Product	Role	Manufacturer	Route
3	TABLETS/DAY, ORAL	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
3	TABLETS/DAY, ORAL	Cerocral (Ifenprodil Tartrate)	SS		ORAL
		Methycobal (Mecobalamin)	C		

Date:09/17/04ISR Number: 4456374-9Report Type:Expedited (15-DaCompany Report #DSA_24963_2004
Age:33 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 4.5 MG Q DAY		Confusional State	Foreign	Temesta	PS		ORAL
PO 700 MG Q DAY		Coordination Abnormal	Health				
PO 4 MG Q DAY PO		Sleep Disorder	Professional	Seroquel	SS		ORAL
			Other	Sirdalud	SS		ORAL
80 MG Q DAY				Entumin	SS		ORAL
PO 1 G QD PO				Orfiril "Desitin"	SS		ORAL

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Aggression	Literature	Cyclobenzaprine			
Hospitalization - Initial or Prolonged		Aspiration	Health	(Cyclobenzaprine			
Other		Drug Interaction	Professional	Hydrochloride)			
300 MG, 1 IN		Potentiation		Unknown	PS		ORAL
1 DAY, ORAL		Drug Screen Positive					
30 G/3 G		Drug Toxicity		Acetaminophen/Tramad			
		Lung Disorder		ol (Tramadol/Apap)	SS		
700 MG, 1 IN		Multiple Drug Overdose		Amitriptyline			
		Sedation		(Amitriptyline)	SS		ORAL
1 DAY, ORAL		Self-Medication					
120 MG, 1 IN		Suicide Attempt		Tizanidine			
		Vomiting		(Tizanidine)	SS		ORAL
1 DAY, ORAL							
750 MG, 1 IN				Rofecoxib			
				(Rofecoxib)	SS		ORAL
1 DAY, ORAL							
300 MG, 1 IN				Omeprazole			
				(Omeprazole)	SS		ORAL
1 DAY, ORAL							

Outcome
 Death
 Hospitalization -
 Initial or Prolonged

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Other

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Aggression Aspiration Completed Suicide Depressed Level Of	Health Professional	Vioxx Acetaminophen And Tramadol Hydrochloride	PS	Merck & Co., Inc	ORAL
UNKNOWN		Consciousness Drug Toxicity Intentional Misuse Vomiting		Elavil Tizanidine Hydrochloride Flexeril Omeprazole	SS SS SS SS		ORAL ORAL ORAL ORAL

Date:09/24/04ISR Number: 4462090-XReport Type:Direct
Age:9 YR Gender:Male I/FU:I

Company Report #CTU 228006

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 2 MG BID		Muscle Spasticity		Tizanidine 2mg	PS		
		Pharmaceutical Product Complaint Retching Vomiting		Baclofen	C		

Date:09/28/04ISR Number: 4462613-0Report Type:Expedited (15-DaCompany Report #200412698GDS
Age:71 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 500 MG, BID, ORAL		Blood Creatinine Increased	Foreign Health	Ciproxine (Ciprofloxacin)	PS		ORAL
		Bradycardia	Professional				
20 MG, BID, ORAL		Electrocardiogram Qt Prolonged	Other	Propranolol	SS		ORAL
4 MG, TOTAL		Hypotension		Tizanidine	SS		ORAL

Sinus Arrest

DAILY, ORAL

Aspirin	C
Irbesartan	C
Simvastatin	C
Oxazepam	C
Dextran Sulfate	C
Tramadol	C

Date:09/30/04ISR Number: 4465441-5Report Type:Expedited (15-DaCompany Report #ZANA001349

Age:54 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Blood Pressure Systolic Increased	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
3 TABLETS		Epilepsy	Professional				
DAILY ORAL			Other	Luvox (Fluvoxamine Maleate)	C		
				Myslee (Zolpidem Tartrate)	C		
				Gasmotin (Mosapride Citrate)	C		
				Promac (Polaprezinc)	C		

22-Aug-2005 12:09 PM

Page: 217

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:09/30/04ISR Number: 4465452-XReport Type:Expedited (15-DaCompany Report #ZANA001348

Age:74 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Cardiac Enzymes Increased	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
ORAL		Cardiac Failure	Professional Other				

Date:09/30/04ISR Number: 4465453-1Report Type:Expedited (15-DaCompany Report #ZANA001347

Age:81 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization - Initial or Prolonged		Alanine Aminotransferase Increased	Foreign Health	Ternelin (Tizanidine Hydrochloride)	PS		ORAL
3 MG DAILY		Aspartate	Professional				
ORAL		Aminotransferase	Other	Ketas (Ibudilast)	SS		ORAL
30 MG DAILY		Increased					
ORAL		Blood Alkaline Phosphatase Increased		Gasmotin (Mosapride Citrate)	SS		ORAL
15 MG DAILY		Blood Lactate					
ORAL		Dehydrogenase Increased		Chinese Medication	C		
		Gamma-Glutamyltransferase Increased					
		Hypoaesthesia					
		Liver Disorder					
		Therapy Non-Responder					

Date:10/04/04ISR Number: 4467946-XReport Type:Expedited (15-DaCompany Report #200412698GDS

Age:71 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Blood Creatinine Increased

Bradycardia
Delirium
Drug Level Increased
Electrocardiogram Qrs
Complex Prolonged
Electrocardiogram Qt
Prolonged
Fall
General Physical Health
Deterioration
Haemoglobin Decreased
Headache
Hypotension
Loss Of Consciousness
Mental Disorder Due To A
General Medical Condition
Myoclonus
Psychomotor Retardation
Pulse Absent
Sinus Arrest
Sinus Bradycardia
Somnolence
Therapeutic Agent
Toxicity
Thirst
Traumatic Brain Injury

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Tremor
Urinary Tract Infection

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
500 MG, BID, ORAL		Foreign Health Professional	Ciproxine (Ciprofloxacin)	PS		ORAL
20 MG, BID, ORAL		Other	Inderal (Propranolol Hydrochloride)	SS		ORAL
4 MG, TOTAL DAILY, ORAL			Sirdalud (Tizanidine Hydrochloride)	SS		ORAL
			Aspirin Cardio	C		
			Coaprovel	C		
			Simcora	C		
			Quilinorm	C		
			Surmontil	C		
			Seresta	C		
			Neurontin	C		
			Celebrex	C		
			Tramal	C		
			Phlebodril N	C		

Date:10/05/04ISR Number: 4469462-8Report Type:Expedited (15-DaCompany Report #ZANA001350
Age:70 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 4 MG DAILY ORAL		Blood Creatinine Increased	Foreign Health Professional	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
40 MG DAILY ORAL		Delirium	Other	Inderal (Propranolol Hydrochloride)	SS		ORAL
		Electrocardiogram Qrs Complex Prolonged					
		Electrocardiogram Qt					

1000 MG DAILY

Prolonged Electrocardiogram	Ciproxin (Ciprofloxacin)	SS
Repolarisation Abnormality Fall	Aspirin (Acetylsalicylic Acid)	C
General Physical Health Deterioration	Coaprovel (Irbesartan)	C
Haemoglobin Decreased	Simvastatin	C
Headache	(Simvastatin)	C
Hypotension	Seresta (Oxazepam)	C
Loss Of Consciousness	Phlebodril N (Ruscus Aculeatus Melilotus Officinalis)	C
Myoclonus	Tramal (Tramadol Hydrochloride)	C
Personality Change	Quilonorm (Lithium Acetate)	C
Polydipsia	Surmontil (Trimipramine Maleate)	C
Pulse Absent	Neurontin (Gabapentin)	C
Pyrexia	Celebrex (Celecoxib)	C
Sinus Arrest	Cipralext (Escitalopram)	C
Sinus Bradycardia	Lithium (Lithium)	C
Somnolence		
Therapeutic Agent		
Toxicity		
Tremor		
Urine Abnormality		

22-Aug-2005 12:09 PM

Page: 219

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/05/04ISR Number: 4470593-7Report Type:Expedited (15-DaCompany Report #ZANA001346
Age:60 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged 6 MG DAILY		Alanine Aminotransferase Increased	Foreign Health	Sirdalud (Tizanidine Hydrochloride)	PS		ORAL
Other ORAL		Aspartate	Professional				
		Aminotransferase Increased	Other	Voltaren (Diclofenac Sodium)	SS		
		Blood Alkaline		Vioxx (Rofecoxib)	SS		
		Phosphatase Increased		Herbal Extracrs Nos			
		Bradycardia		(Herbal Extracts Nos)	SS		
		Chest Discomfort					
		Diarrhoea					
		Drug Interaction					
		Drug Level Increased					
		Dyspnoea					
		Fibrin D Dimer Increased					
		Gamma-Glutamyltransferase Increased					
		Haemangioma					
		Hepatic Enzyme Increased					
		Hyperhidrosis					
		Hypoperfusion					
		Pleural Effusion					
		Pulmonary Hypertension					
		Vomiting					

Date:10/06/04ISR Number: 4470653-0Report Type:Direct Company Report #CTU 228942
Age:46 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 4 MG FOR QJS	6 MON	Pharmaceutical Product Complaint		Zanaflex (Tizanidine)	PS		
				Flexent	C		
				Clonazepam	C		
				Wellbutrin Sr	C		
				Gabitol	C		
				Duragesic	C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Abnormal Chest Sound	Literature	Elavil	PS		ORAL
700 MG DAILY; Hospitalization - PO		Aggression	Health				
Initial or Prolonged 750 MG DAILY; Required PO		Aspiration	Professional	Vioxx	SS		ORAL
Intervention to 300 MG DAILY; Prevent Permanent PO Impairment/Damage 30 G		Completed Suicide					
		Depressed Level Of Consciousness		Flexeril	SS		ORAL
		Drug Toxicity		Acetaminophen	SS		
		Intentional Misuse Sedation		Tramadol Hydrochloride	SS		
3G		Vomiting		Tizanidine Hydrochloride	SS		ORAL
120 MG DAILY; PO							
300 MG DAILY; PO				Omeprazole	SS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/07/04ISR Number: 4471850-0Report Type:Expedited (15-DaCompany Report #ZANA001353
Age:41 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Bradycardia Nausea	Foreign Health	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
16 MG DAILY							
ORAL		Orthostatic Hypotension	Professional				
		Vomiting Weight Decreased	Other	Avonex (Interferon) Sandostatin (Octreotide)	C C		

Date:10/12/04ISR Number: 4475626-XReport Type:Expedited (15-DaCompany Report #ST-2004-008072
Age:72 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Anorexia	Foreign	Olmotec	PS		ORAL
20 MG QD PO							
Initial or Prolonged		Dizziness	Health	Diovan	SS	Novartis	ORAL
80 MG QD PO							
		Hepatic Function Abnormal	Professional	Niflan	SS		ORAL
7.5 MG TID PO							
		Malaise	Company	Enchinin	SS		ORAL
1 MG TID PO							
			Representative	Iotrol	C		
			Other	Renivace	C		
				Halcion	C		
				Methycool	C		
				Norvasc	C		

Date:10/12/04ISR Number: 4475637-4Report Type:Expedited (15-DaCompany Report #ZANA001352
Age:18 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Agitation Hepatic Enzyme Increased	Foreign Other	Zanaflex (Tizanidine Hydrochloride)	PS		ORAL
1 MG DAILY							
ORAL		Liver Disorder					

Pyrexia
Rash Erythematous

Baclofen (Baclofen) C
Heparin (Heparin) C
Risperidone
(Risperidone) C

Date:10/12/04ISR Number: 4476942-8Report Type:Expedited (15-DaCompany Report #KII-2004-0013534
Age:43 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Other		Aggression Agitation Alkalosis Areflexia Back Pain Blood Ph Decreased Coma Headache Muscle Twitching Myocardial Infarction Neck Pain Pericarditis Pneumonia Aspiration Pyrexia Restlessness Viral Infection	Study Health Professional Other	Morphine Sulfate (Morphine Sulfate) Other Hypnotics And Sedatives () Muscle Relaxants () Tizanidine (Tizanidine) Cyclobenzaprine (Cyclobenzaprine) Benzodiazepine Derivatives () Amitriptyline (Amitriptyline)	PS SS SS SS SS SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/12/04ISR Number: 4477557-8Report Type:Expedited (15-DaCompany Report #2004070988

Age:43 YR Gender:Unknown I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Cardio-Respiratory Arrest	Literature	Doxepin (Caps)	PS		
Other		Completed Suicide	Health Professional	Oxycodone (Oxycodone)	SS		
				Tizanidine (Tizanidine)	SS		
				All Other Therapeutic Products (All Other Therapeutic Products)	SS		

Date:10/13/04ISR Number: 4474169-7Report Type:Direct

Company Report #CTU 229457

Age:37 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required		Nausea		Tizanidine	PS		
4 MG 1 - 1							
Intervention to		Rash					
1/2 Q 6 H							
Prevent Permanent Impairment/Damage		Stomach Discomfort					

Date:10/14/04ISR Number: 4475455-7Report Type:Direct

Company Report #CTU 229593

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Condition Aggravated		Tizanidine	PS		
CHANGE TO		Muscle Spasms					
ZANAFLEX BMN							

[LIFETIME]

Date:10/14/04ISR Number: 4678669-6Report Type:Direct Company Report #CTU 239853
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
4 MG DAILY		Drug Ineffective		Tizanidine 4 Mg	PS		
		Therapeutic Response Unexpected With Drug Substitution					

Date:10/15/04ISR Number: 4476649-7Report Type:Direct Company Report #CTU 229667
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other NIGHTLY		Depressed Level Of Consciousness Hallucination Hallucination, Visual Nightmare		Zanaflex 4 Mg	PS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/20/04ISR Number: 4482108-8Report Type:Expedited (15-DaCompany Report #ACO_0006_2004
Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 3 TAB QDAY PO	Hepatitis Acute	Foreign	Ternelin	PS		ORAL
Initial or Prolonged 3 TAB QDAY PO	Malaise	Health	Cerocral	SS		ORAL
		Professional	Methycobal	C		

Date:10/20/04ISR Number: 4483459-3Report Type:Expedited (15-DaCompany Report #ACO_0007-2004
Age:74 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 2 MG QDAY PO	Myocardial Infarction	Health	Sirdalud	PS		ORAL
Initial or Prolonged		Professional				

Date:10/21/04ISR Number: 4486099-5Report Type:Expedited (15-DaCompany Report #HQWYE706312OCT04
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Life-Threatening Hospitalization - Initial or Prolonged 40 MG 1X PER	Blood Creatinine Increased Bradycardia	Health Professional Other	Inderal (Propranolol Hydrochloride, Tablet)	PS		ORAL
Other 1 DAY ORAL 7 DAY	Drug Interaction					
	Electrocardiogram Qt Prolonged		Ciproxin (Ciprofloxacin,)	SS		ORAL
1 G 1X PER 1 DAY 4 DAY	Hypotension					
	Loss Of Consciousness Sinus Arrest		Sirdalud - Slow Release (Tizanidine Hydrochloride,)	SS		ORAL
4 MG 1X PER 1 DAY ORAL			Aspirin "Bayer"			

(Acetylsalicylic Acid)	C
Coaprovel (Irbesartan/Hydrochl orothiazide)	C
Simvastatin (Simvastatin)	C
Seresta (Oxazepam)	C
Phlebodril (Ascorbic Acid/Hesperidin Methyl Chalcone/Ruscus Aculeatus)	C
Tramal (Tramadol Hydrochloride)	C
Lithium (Lithium)	C
Gabapentin (Gabapentin)	C
Celecoxib (Celecoxib)	C
Trimipramine (Trimipramine)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:10/22/04ISR Number: 4484597-1Report Type:Expedited (15-DaCompany Report #2004AL000677

Age:30 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Multiple Drug Overdose	Literature	Tizanidine Hydrochloride Tablets, 2 Mg And 4 Mg (Purepac)	PS	Purepac	ORAL
PO				Valproic Acid	SS		ORAL

Date:10/22/04ISR Number: 4484598-3Report Type:Expedited (15-DaCompany Report #2004AL000709

Age:39 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Multiple Drug Overdose	Literature	Tizanidine Hydrochloride Tablets, 2 Mg And 4 Mg (Purepac)	PS	Purepac	ORAL
PO				Paroxetine	SS		ORAL

Date:10/22/04ISR Number: 4484604-6Report Type:Expedited (15-DaCompany Report #2004AL000683

Age:43 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Multiple Drug Overdose	Literature	Tizanidine Hydrochloride Tablets, 2 Mg And 4 Mg (Purepac)	PS	Purepac	ORAL
PO				Doxepin	SS		ORAL
PO				Oxycodone	SS		ORAL

Date:10/26/04ISR Number: 4486575-5Report Type:Direct
Age:94 YR Gender:Female I/FU:I

Company Report #CTU 230473

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Dysphagia		Tizanidine	PS		

Date:10/26/04ISR Number: 4489914-4Report Type:Expedited (15-DaCompany Report #ACO_0008_2004
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Overdose Somnolence	Foreign Health Professional Other	Ternelin	PS		

Date:10/27/04ISR Number: 4489642-5Report Type:Expedited (15-DaCompany Report #FLUV00304003016
Age:67 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Dizziness Postural Drug Interaction Dysstasia	Foreign Health Professional	Depromel 25 (Fluvoxamine Maleate)	PS		ORAL
50 MILLIGRAM (S) BID ORAL		Fall	Other				
1 MILLIGRAM (S) TID ORAL		Muscular Weakness Orthostatic Hypotension		Ternelin (Tizanidine Hydrochloride)	SS		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Meilax (Ethyl
Loflazepate) C
Dogmatyl (Sulpiride) C
Lendormin
(Brotizolam) C
Gosha-Jinki-Gan
(Gosha-Jinki-Gan) C

Date:10/28/04ISR Number: 4490060-4Report Type:Expedited (15-DaCompany Report #2004082345
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Cutaneous Lupus Erythematosis Fibromyalgia Rheumatoid Arthritis Sjogren'S Syndrome	Consumer	Neurontin (Gabapentin) Zoloft (Sertraline) Methotrexate (Methotrexate) Infliximab (Infliximab) Hydroxychloroquine Phosphate (Hydroxychloroquine Phosphate) Tizanidine Hydrochloride (Tizanidine Hydrochloride) Morphine Sulfate (Morphine Sulfate)	PS SS SS SS SS SS SS C		

Date:11/02/04ISR Number: 4491034-XReport Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01708
Age:21 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Aggression		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Aspiration		Flexeril	SS		ORAL
Initial or Prolonged		Completed Suicide		Acetaminophen And			
Other		Depressed Level Of Consciousness		Tramadol Hydrochloride	SS		
UNKNOWN		Drug Toxicity		Omeprazole	SS		ORAL

Intentional Misuse
Vomiting

Elavil
Tizanidine
Hydrochloride

SS
SS

ORAL
ORAL

Date:11/03/04ISR Number: 4494900-4Report Type:Expedited (15-DaCompany Report #ACO_0009_2004
Age:30 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide	Literature	Tizanidine			
DF		Multiple Drug Overdose	Health	Hydrochloride	PS		
DF			Professional	Valproic Acid	SS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/03/04ISR Number: 4495377-5Report Type:Expedited (15-DaCompany Report #ACO_0011_2004

Age:39 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Intentional Misuse	Literature Health Professional	Tizanidine Hydrochloride Paroxetine	PS SS		

Date:11/03/04ISR Number: 4495383-0Report Type:Expedited (15-DaCompany Report #ACO_0010_2004

Age:43 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Intentional Misuse	Literature Health Professional	Tizanidine Hydrochloride Oxycodone Doxepin	PS SS SS		

Date:11/05/04ISR Number: 4493790-3Report Type:Expedited (15-DaCompany Report #US-ABBOTT-04P-163-0279307-00

Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide		Valproic Acid Tizanidine	PS SS		ORAL ORAL

Date:11/08/04ISR Number: 4495564-6Report Type:Expedited (15-DaCompany Report #US-ROCHE-384009

Age:54 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability SUBCUTANEOUS		Vertigo		Pegasys Copegus Topamax Zanaflex Flomax	PS SS SS SS C	Roche Roche	ORAL ORAL ORAL

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged	Areflexia Cerebral Haemorrhage Cerebrovascular Accident		Prinivil Tizanidine Hydrochloride	PS SS	Merck & Co., Inc	ORAL
UNKNOWN	Coma		Amlodipine Besylate	C		
UNKNOWN	Corneal Reflex Decreased		Ofloxacin	C		
UNKNOWN	Decerebration		Biofermin	C		
UNKNOWN	Depressed Level Of Consciousness		Theophylline Nimodipine	C C		
UNKNOWN	Drug Interaction Hypertension		Labetalol Hydrochloride	C		
	Hypotension Movement Disorder Muscle Rigidity Opisthotonus Respiratory Failure Sepsis					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/11/04ISR Number: 4499275-2Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908829

Age:21 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Aggression		Ultracet	PS		
OROPHARINGEAL		Aspiration		Cyclobenzaprine	SS		
OROPHARINGEAL		Completed Suicide		Amitriptyline	SS		
OROPHARINGEAL		Depressed Level Of Consciousness		Tizanidine	SS		
		Drug Toxicity		Rofecoxib	SS		
		Intentional Misuse		Omeprazole	SS		
		Lung Crepitation					
		Sedation					
		Vomiting					

Date:11/12/04ISR Number: 4503023-7Report Type:Expedited (15-DaCompany Report #ACO_0013_2004

Age:47 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Dry Mouth	Foreign	Zanaflex	PS		ORAL
2 MG QDAY PO		Fatigue	Health	Ibuprofen	C		
		Headache	Professional	Cialis	C		
		Insomnia	Other				
		Muscle Spasms					
		Nightmare					
		Somnolence					

Date:11/15/04ISR Number: 4500819-2Report Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00025

Age:24 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
		Dermatitis Bullous		Tizanidine			
		Pyrexia		Hydrochloride	SS		ORAL

Date:11/16/04ISR Number: 4504376-6Report Type:Expedited (15-DaCompany Report #ACO_0015_2004
Age:46 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening 360 MG ONCE	Blood Pressure Decreased	Literature	Tizanidine	PS		ORAL
PO	Coma	Health				
	Drug Ineffective Heart Rate Decreased Miosis Overdose	Professional				

Date:11/16/04ISR Number: 4504452-8Report Type:Expedited (15-DaCompany Report #ACO_0016_2004
Age:30 YR Gender:Female I/FU:I

Outcome	PT
Life-Threatening	Blood Pressure Decreased Blood Pressure Systolic Increased Depressed Level Of Consciousness Drug Ineffective Heart Rate Decreased Heart Rate Increased

22-Aug-2005 12:09 PM
Page: 227

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
30 TAB ONCE		Hypotension Miosis Overdose	Literature	Tizanidine	PS		ORAL
PO		Respiratory Depression	Health Professional				

Date:11/16/04ISR Number: 4504993-3Report Type:Expedited (15-DaCompany Report #ACO_0014_2004
Age:35 YR Gender:Female I/FU:I

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
2000 MG QDAY		Life-Threatening	Foreign	Tizandine	PS		ORAL
Hospitalization - PO		Convulsion	Literature				
Initial or Prolonged 12 MG QDAY PO		Delirium	Health	Tizanidine	SS		ORAL
7500 MG QDAY		Drug Withdrawal Syndrome	Professional	Zolpidem	SS		ORAL
PO		Hypotonia	Other				
DF QDAY PO		Medication Error		Zolpidem	SS		ORAL
100 MG QDAY		Muscle Spasms		Xylometazoline	SS		
DF QDAY		Paraesthesia		Xylometazoline	SS		
		Treatment Noncompliance					

Date:11/17/04ISR Number: 4503821-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0411CHE00026
Age:83 YR Gender:Male I/FU:I

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
21 DAY		Hospitalization -	Health	Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 44 DAY		Drug Interaction	Professional	Celecoxib	SS		ORAL

6	MON	Renal Failure Acute	Buthiazide	SS	ORAL
44	DAY		Tizanidine Hydrochloride	SS	ORAL
6	YR		Oxprenolol Hydrochloride	SS	ORAL
UNKNOWN			Ascorbic Acid And Vitamin B (Unspecified)	C	
UNKNOWN			Enterococcus Faecium (As Drug)	C	

Date:11/17/04ISR Number: 4506997-3Report Type:Expedited (15-DaCompany Report #2004-BP-11398YA
Age:41 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged 0.2 MG PO	Alanine Aminotransferase Increased	Foreign Health	Harnal (Tamsulosin)	PS		ORAL
25 MG PO	Aspartate Aminotransferase	Professional Other	Dantrium (Dantrolene Sodium)	SS		ORAL
5 MG PO	Increased Blood Bilirubin Increased		Lioresal (Dantrolene Sodium)	SS		ORAL
1 MG PO	Blood Lactate Dehydrogenase Increased		Ternelin (Tizanidine Hydrochloride)	SS		ORAL
	Gamma-Glutamyltransferase Increased Hepatic Function Abnormal		Vitamedin (Benfotiamine/B6/B12) Diazepam (Diazepam)	C C		ORAL

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:11/18/04ISR Number: 4507134-1Report Type:Expedited (15-DaCompany Report #B0349830A
Age:39 YR Gender:Unknown I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Drug Level	Literature Health Professional	Proxetine Hydrochloride Tablet-Controlled Release (Generic) (Paroxetine)	PS		ORAL
ORAL				Tizanidine (Formulation Unknown) (Tizanidine)	SS		ORAL

Date:11/23/04ISR Number: 4512376-5Report Type:Expedited (15-DaCompany Report #ACO_0018_2004
Age:34 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	3 MG QDAY PO	Blood Pressure Decreased	Foreign	Ternelin	PS		ORAL
	150 MG QDAY PO	Blood Pressure Systolic Increased	Health Professional	Fluvoxamine Maleate	SS		ORAL
		Dehydration	Other	Lorazepam	C		
		Dialysis		Amoxan	C		
		Dialysis Disequilibrium Syndrome		Allopurinol	C		
		Dizziness		Lansoprazole	C		
		Nausea		Mosapride Citrate	C		
		Somnolence		Alfacalcidol	C		
				Calcium Carbonate	C		

Date:11/23/04ISR Number: 4512401-1Report Type:Expedited (15-DaCompany Report #ACO_0017_2004
Age:81 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -	2 MG QDAY PO	Alanine Aminotransferase	Foreign	Ternelin	PS		ORAL

Initial or Prolonged 30 MG QDAY PO	Increased	Health	Ketas	SS	ORAL
15 MG QDAY PO	Aspartate	Professional	Gasmotin	SS	ORAL
	Aminotransferase Increased Blood Alkaline Phosphatase Increased Blood Lactate Dehydrogenase Increased Gamma-Glutamyltransferase Increased Hypoaesthesia Limb Discomfort Liver Disorder	Other	Chinese Medicine	C	

Date:11/24/04ISR Number: 4514139-3Report Type:Expedited (15-DaCompany Report #2003AP02691
Age:47 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required		Drug Interaction	Foreign	Zestril	PS		ORAL
10 MG DAILY							
Intervention to PO		Hypotension	Literature				
Prevent Permanent 2 MG DAILY PO			Health	Sirdalud	SS		ORAL
Impairment/Damage			Professional	Senokot	C		
			Other	Magnesium Oxide	C		
				Amikin	C		
				Trandate	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Nimotop	C
Well-Well	C
Glycerol	C
Mucosolvan	C
Clincin	C
Ofloxacin	C
Amlodipine	C
Nimodipine	C
Labetalol	C

Date:12/09/04ISR Number: 4524021-3Report Type:Expedited (15-DaCompany Report #ACO_0028_2004
Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 2 MG ONCE PO Initial or Prolonged	Blood Pressure Decreased	Foreign	Tizanidine	PS		ORAL
	Depressed Level Of Consciousness	Health Professional Other	Labetalol Amlodipine Nimodipine Lisinopril	C C C C		

Date:12/14/04ISR Number: 4528889-6Report Type:Expedited (15-DaCompany Report #HQWYE762806DEC04
Age:17 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged	Serotonin Syndrome	Health Professional Other	Tazobac (Piperacillin/Tazoba ctam Injection)	PS		
INTRAVENOUS 1 DAY 400 MG 3X PER 1 DAY	4.5 G 3X PER 25 DAY		Brufen (Ibuprofen)	SS		ORAL
INTRAVENOUS 30 MG 2X PER			Garamycin (Gentamicin Sulfate)	SS		DRIP

1 DAY

Nexium
(Esomeprazole) SS

40 MG DAILY

Sirdalud (Tizanidine
Hydrochloride) SS

ORAL

3 MG DAILY

Tramal (Tramadol
Hydrochloride) SS

50 MG 4X PER

1 DAY

Bactrim
(Sulfamethoxazole/Tr
imethoprim) SS

Zoloft (Sertraline
Hydrochloride) SS

ORAL

50 MG

Neurontin
(Gabapentin) C

Rivotril
(Clonazepam) C

Fraxiparin
(Heparin-Fraction,
Calcium Salt) C

Benerva (Thiamine
Hydrochloride) C

Temesta (Lorazepam) C

Becozyme Forte
(Biotin/Calcium
Pantothenate/Cyanoco

Freedom Of Information (FOI) Report

balamin/Nicotinamide
 /Pyridoxine/ C
 Mst (Morphine
 Sulfate) C
 Dafalgan
 (Paracetamol) C

Date:12/14/04ISR Number: 4529397-9Report Type:Expedited (15-DaCompany Report #2004PK02050
 Age:17 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Required 40 MG DAILY		Agitation	Foreign	Nexium	PS		
Intervention to 200 MG DAILY		Asthenia	Health	Tramal	SS		ORAL
Prevent Permanent PO		Coordination Abnormal	Professional				
Impairment/Damage 8 MG DAILY PO		Dysaesthesia	Other	Sirdalud	SS		ORAL
		Hyperaesthesia		Zoloft	SS		
		Motor Dysfunction		Brufen	SS		ORAL
1200 MG DAILY		Pain In Extremity					
PO		Postoperative Infection		Tazobac	SS		
INTRAVENOUS	13.5 G	DAILY Pseudomonas Infection					
IV		Pyrexia		Gentamicine	SS		
INTRAVENOUS	160 MG	DAILY Sedation					
IV		Serotonin Syndrome		Neurontin	C		
		Skin Necrosis		Rivotril	C		
		Somnolence		Mst	C		
		Tremor		Dafalgan	C		
				Temesta	C		
				Bactrim	C		
				Fraxiparin	C		
				Benerva	C		
				Becozyne Forte	C		

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - Initial or Prolonged	Chromaturia Diarrhoea Jaundice	Health Professional	Mirapex Tablets (Pramipexole Dihydrochloride)	PS		ORAL
PO (THERAPY DATES: ABOUT ONE YEAR AGO - NR)	Nausea Vomiting		Metformin (Metformin) Estrogen Zanaflex (Tizanidine Hydrochloride) Rebif (Interferon Beta)	SS SS SS SS		

Outcome	PT
Other	Agitation Asthenia Coordination Abnormal Diarrhoea Dysaesthesia

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Adverse Event	Report Source	Product	Role	Manufacturer	Route
		Hyperaesthesia Myoclonus Neuralgia					
(50 MG), ORAL		Pain	Foreign	Zoloft (Sertraline)	PS		ORAL
		Postoperative Infection Pseudomonas Infection	Health Professional	Gentamicin (Gentamicin)	SS		
INTRAVENOUS	INTRAVENOUS	Serotonin Syndrome Somnolence Tremor		Pip/Tazo (Piperacillin Sodium, Tazobactam Sodium) Ibuprofen (Ibuprofen) Tizanidine Hydrochloride (Tizanidine Hydrochloride) Tramadol Hydrochloride (Tramadol Hydrochloride) Doxorubicin (Doxorubicin) Esomeprazole (Esomeprazole) Gabapentin (Gabapentin) Clonazepam (Clonazepam) Morphine Sulfate (Morphine Sulfate) Paracetamol (Paracetamol) Lorazepam (Lorazepam) Bactrim (Sulfamethoxazole, Trimethoprim) Heparin-Fraction, Calcium Salt (Heparin-Fraction, Calcium Salt) Thiamine Hydrochloride (Thiamine	SS SS SS SS C C C C C C C C C C C		

Hydrochloride) C
Becozyme (Magnesium
Carbonate, Potassium
Iodide, Silicic
Acid, Vitamins Nos) C

Date:12/21/04ISR Number: 4537410-8Report Type:Expedited (15-DaCompany Report #MK200412-0137-1
Age:43 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Multiple Drug Overdose	Literature Health Professional	Oxycodone Hcl Tabets Doxepine Tizanidine	PS SS SS		

22-Aug-2005 12:09 PM
Page: 232

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/22/04ISR Number: 4538886-2Report Type:Expedited (15-DaCompany Report #ACO_0030_2004

Age:64 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - DF PO	Duration Fall	Health	Zanaflex	PS		ORAL
Initial or Prolonged	Loss Of Consciousness Lower Limb Fracture	Professional				

Date:12/27/04ISR Number: 4541188-1Report Type:Expedited (15-DaCompany Report #2004-BP-11398YA

Age:41 YR Gender:Male I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 0.2 MG PO	Duration Alanine Aminotransferase Increased	Foreign Health	Harnal (Tamsulosin)	PS		ORAL
25 MG PO	Aspartate Aminotransferase Increased	Professional Other	Dantrium (Dantrolene Sodium)	SS		ORAL
1 MG TIS (TID) PO	Blood Bilirubin Increased Blood Lactate Dehydrogenase Increased Gamma-Glutamyltransferase Increased Liver Disorder Malaise		Ternelin (Tizanidine Hydrochloride) Vitamedin (Benfotiamine/B6/B12) Diazepam (Diazepam)	SS C C		ORAL

Date:12/27/04ISR Number: 4541330-2Report Type:Expedited (15-DaCompany Report #ACO_0018_2004

Age:34 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Other 3 MG QDAY PO	Duration Balance Disorder	Foreign	Ternelin	PS		ORAL
150 MG QDAY	Blood Pressure Decreased	Health	Fluvoxamine Maleate	SS		ORAL

PO

Dehydration

Professional

Dizziness

Other

Lorazepam

C

Nausea

Amoxan

C

Somnolence

Allopurinol

C

Lansoprazole

C

Mosapride Citrate

C

Alfacalcidol

C

Calcium Carbonate

C

Date:12/27/04ISR Number: 4541332-6Report Type:Expedited (15-DaCompany Report #ACO_0028_2004

Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 2 MG ONCE PO Initial or Prolonged	Blood Pressure Decreased	Foreign	Tizanidine	PS		ORAL
	Depressed Level Of Consciousness	Health Professional Other	Labetalol Amlodipine Nimodipine Lisinopril	C C C C		

Date:12/27/04ISR Number: 4541346-6Report Type:Expedited (15-DaCompany Report #ACO_0006_2004

Age:53 YR Gender:Female I/FU:I

Outcome	PT	Report Source
Hospitalization - Initial or Prolonged	Hepatitis Acute	Foreign Health Professional

22-Aug-2005 12:09 PM

Page: 233

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Other

Dose	Duration	Product	Role	Manufacturer	Route
3 TAB QDAY PO		Ternelin	PS		ORAL
3 TAB QDAY PO		Cerocral	SS		ORAL
		Methycobal	C		

Date:12/27/04ISR Number: 4541347-8Report Type:Expedited (15-DaCompany Report #ACO_0008_2004
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Overdose Somnolence	Foreign Health Professional Other	Ternelin	PS		

Date:12/27/04ISR Number: 4541351-XReport Type:Expedited (15-DaCompany Report #ACO_0013_2004
Age:47 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability 2 MG QDAY PO		Dry Mouth	Foreign	Zanaflex	PS		ORAL
		Fatigue Headache Insomnia Muscle Spasms Nightmare Somnolence	Health Professional Other	Ibuprofen Cialis	C C		

Date:12/27/04ISR Number: 4541354-5Report Type:Expedited (15-DaCompany Report #ACO_0014_2004
Age:35 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening 2000 MG QDAY		Abnormal Behaviour	Foreign	Tizanidine	PS		ORAL

Hospitalization - PO	Anxiety	Literature			
Initial or Prolonged 12 MG QDAY PO	Convulsion	Health	Tizanidine	SS	ORAL
Required 7500 MG QDAY	Delirium	Professional	Zolpidem	SS	ORAL
Intervention to PO	Drug Withdrawal Syndrome	Other			
Prevent Permanent DF QDAY PO	Hypotonia		Zolpidem	SS	ORAL
Impairment/Damage 100 MG QDAY	Muscle Spasms		Xylometazoline	SS	
DF QDAY	Paraesthesia		Xylometazoline	SS	
	Social Avoidant Behaviour				
	Treatment Noncompliance				

Date:12/27/04ISR Number: 4541358-2Report Type:Expedited (15-DaCompany Report #ACO_0017_2004
Age:81 YR Gender:Female I/FU:I

Outcome PT
Hospitalization - Alanine Aminotransferase
Initial or Prolonged Increased
Aspartate
Aminotransferase
Increased
Blood Alkaline
Phosphatase Increased
Blood Lactate
Dehydrogenase Increased
Discomfort

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Gamma-Glutamyltransferase Increased					
		Hypoaesthesia					
3 MG QDAY PO		Liver Disorder	Foreign	Ternelin	PS		ORAL
30 MG QDAY PO			Health	Ketas	SS		ORAL
15 MG QDAY PO			Professional	Gasmotin	SS		ORAL
			Other	Chinese Medicine	C		

Date:12/27/04ISR Number: 4542153-0Report Type:Expedited (15-DaCompany Report #ACO_0016_2004
Age:30 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Blood Pressure Increased	Literature	Tizanidine	PS		ORAL
30 TAB ONCE		Depressed Level Of	Health				
PO		Consciousness	Professional				
		Drug Ineffective					
		Heart Rate Decreased					
		Hypotension					
		Intentional Misuse					
		Miosis					
		Respiratory Depression					
		Treatment Noncompliance					

Date:12/27/04ISR Number: 4542155-4Report Type:Expedited (15-DaCompany Report #ACO_0015_2004
Age:46 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Blood Pressure Decreased	Literature	Tizanidine	PS		ORAL
360 MG ONCE		Coma	Health				
PO		Drug Ineffective	Professional				
		Heart Rate Decreased					
		Miosis					
		Overdose					

Date:12/27/04ISR Number: 4542157-8Report Type:Expedited (15-DaCompany Report #ACO_0007_2004
Age:74 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 2 MG DAILY PO		Cardiac Enzymes Increased	Health	Sirdalud	PS		ORAL
Initial or Prolonged		Myocardial Infarction	Professional				

Date:12/27/04ISR Number: 4542249-3Report Type:Expedited (15-DaCompany Report #ACO_0011_2004
Age:39 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Overdose	Literature Health Professional	Tizanidine Hydrochloride Paroxetine	PS SS		

Date:12/27/04ISR Number: 4542417-0Report Type:Expedited (15-DaCompany Report #ACO_0009_2004
Age:30 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Multiple Drug Overdose	Literature Health	Tizanidine Hydrochloride	PS		
DF			Professional	Valproic Acid	SS		
DF							

22-Aug-2005 12:09 PM
Page: 235

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:12/27/04ISR Number: 4542420-0Report Type:Expedited (15-DaCompany Report #ACO_0010_2004

Age:43 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Completed Suicide Multiple Drug Overdose	Literature Health Professional	Tizanidine Hydrochloride Oxycodone Doxepin	PS SS SS		

Date:12/29/04ISR Number: 4542433-9Report Type:Expedited (15-DaCompany Report #2004AP000937

Age:59 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Chest Pain Depressed Level Of Consciousness	Consumer	Tizanidine Hydrochloride Tablets	PS		ORAL
8 MG; EVERY DAY (DAILY); ORAL		Dizziness Dizziness Postural					
		Dysstasia Hallucination, Visual Overdose Pharmaceutical Product Complaint Sedation		Donnatal Extentabs Ibuprofen	C C		

Date:12/30/04ISR Number: 4541726-9Report Type:Expedited (15-DaCompany Report #JP-SOLVAY-00304004443

Age:70 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Anuria		Fluvoxamine	PS		ORAL
Daily dose: 150 milligram(s) UNKNOWN		Body Temperature Decreased					
	Daily dose:	Drug Interaction		Zopiclone	C		

unknown	Dry Mouth					
UNKNOWN	Heart Rate Decreased		Flunitrazepam		C	
unknown	Daily dose:					
UNKNOWN			Candesartan		C	
unknown	Daily dose:					
UNKNOWN			Famotidine		C	
unknown	Daily dose:					
UNKNOWN			Carbamazepine		C	
unknown	Daily dose:					
UNKNOWN			Bezafibrate		C	
unknown	Daily dose:					
UNKNOWN			Ticlopidine		C	
unknown	Daily dose:					
UNKNOWN			Benidipine		C	
unknown	Daily dose:					
UNKNOWN			Tizanidine		I	
unknown	Daily dose: 3					
milligram(s)						

Date:12/30/04ISR Number: 4544292-7Report Type:Expedited (15-DaCompany Report #ACO_0034_2004
Age:49 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Aphasia	Foreign Health	Sirdalud - Slow Release	PS		ORAL
Other		Drug Interaction					
6 MG DAILY PO		Epilepsy	Professional	Sirdalud	SS		ORAL
4 MG DAILY PO			Other	Zocor "Merck"	SS	Merck	ORAL
80 MG QDAY PO							

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Pyrexia Serotonin Syndrome	Health Professional Other	Tazobac (Piperacillin/Tazoba ctam, Injection)	PS		
INTRAVENOUS	4.5 G 3X PER						
1 DAY							
INTRAVENOUS	25 DAY			Brufen (Ibuprofen)	SS		ORAL
400 MG 3X PER							
1 DAY ORAL							
INTRAVENOUS				Garamycin (Gentamicin Sulfate)	SS		DRIP
30 MG 2X PER							
1 DAY							
INTRAVENOUS							
DRIP				Nexium (Esomeprazole)	SS		
40 MG DAILY							
3 MG DAILY				Sirdalud (Tizanidine Hydrochloride)	SS		ORAL
ORAL							
50 MG 4X PER				Tramal (Tramadol Hydrochloride)	SS		ORAL
1 DAY ORAL							
				Zoloft (Sertraline			

Freedom Of Information (FOI) Report

50 MG ORAL	Hydrochloride)	SS	ORAL
	Neurontin (Gabapentin)	C	
	Rivortil (Clonazepam)	C	
	Mst (Morphine Sulfate)	C	
	Dafalgan (Paracetamol)	C	
	Bactrim (Sulfamethoxazole/Tr imethoprim)	C	
	Fraxiparin (Heparin-Fraction, Calcium Salt)	C	
	Benerva (Thiamine Hydrochloride)	C	
	Becozyme Forte (Biotin/Calcium Pantothenate/Cyanoco balamin/Nicotinamide /Pyridoxine/Riboflav	C	
	Temesta (Lorazepam)	C	

Date:01/10/05ISR Number: 4551309-2Report Type:Expedited (15-DaCompany Report #ACO_0037_2004
Age:27 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Interaction	Foreign	Ternelin	PS		ORAL
DF QDAY PO		Respiratory Disorder	Health	Ternelin	SS		ORAL
DF QDAY PO		Serotonin Syndrome	Professional	Paxil	SS		ORAL
DF PO		Therapy Non-Responder Tremor	Other				

Date:01/12/05ISR Number: 4552849-2Report Type:Direct Company Report #CTU 236460
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							

Other Drug Ineffective Zanaflex PS ORAL
4MG TID PO

Pharmaceutical Product
Complaint

Date:01/18/05ISR Number: 4555504-8Report Type:Direct Company Report #CTU 237070
Age:59 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Nephrolithiasis		Tizanidine	PS		

Date:01/21/05ISR Number: 4558654-5Report Type:Direct Company Report #CTU 237527
Age:37 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Required		Nausea		Tizandine	PS		
2-(3 X A DAY							
Intervention to		Pharmaceutical Product					
)(PRN)							
Prevent Permanent		Complaint					
Impairment/Damage		Rash					
		Stomach Discomfort					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:01/24/05ISR Number: 4563646-6Report Type:Expedited (15-DaCompany Report #ACO_0036_2004
Age:27 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 3 MG QDAY PO	Alanine Aminotransferase	Foreign	Ternelin	PS		ORAL
Initial or Prolonged 75 MG QDAY PO	Increased	Health	Voltaren	SS		ORAL
300 MG QDAY PO	Aspartate Aminotransferase	Professional Other	Mucosta	SS		ORAL
	Increased Back Pain Liver Disorder Lymphocyte Stimulation Test Positive		Mecobalamin	C		

Date:01/25/05ISR Number: 4563233-XReport Type:Expedited (15-DaCompany Report #CH-2005-000910
Age:67 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged 80 MG, 2X/DAY, ORAL	Delirium Hallucination, Auditory	Foreign Health Professional	Sotalol (Sotalol Hydrochloride) Tablet	PS		ORAL
4 MG, 1X/DAY, ORAL		Other	Sirdalud (Tizanidine Hydrochloride)	SS		ORAL
			Transtec Tts (Buprenorphine)	C		
			Torem (Torasemide)	C		
			Plavix (Clopidogrel Sulfate)	C		
			Dafalgan	C		
			Zestril (Lisinopril)	C		
			Temgesic (Buprenorphine)	C		
			Aspirin Cardio			

(Acetylsalicylic
Acid)

C

Date:01/26/05ISR Number: 4566551-4Report Type:Direct
Age: Gender:Male I/FU:I

Company Report #CTU 238193

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Muscle Spasms		Tizanidine	PS		
CHANGE TO							

ZANAFLEX 73

MN [LIFETIME]

Date:01/31/05ISR Number: 4568451-2Report Type:Expedited (15-DaCompany Report #ACO_0028_2004
Age:48 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization -	Cerebral Haemorrhage
Initial or Prolonged	Cerebral Ventricle Dilatation Cerebrovascular Accident Coma Decerebration Drug Interaction Hypertension Hypotension

22-Aug-2005 12:09 PM
Page: 239

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Jaw Disorder Opisthotonus Pain					
2 MG ONCE PO		Respiratory Failure	Foreign	Tizanidine	PS		ORAL
10 MG QDAY PO			Literature	Lisinopril	SS		ORAL
			Health Professional	Labetalol	C		
			Other	Amlodipine	C		
				Nimodipine	C		

Date:02/01/05ISR Number: 4601995-3Report Type:Periodic Company Report #ACO_0029_2004
 Age:56 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Alanine Aminotransferase		Zanaflex	PS		ORAL
4 MG TID PO	1 YR	Increased		Aminopyridine	C		
Initial or Prolonged		Aspartate		Rebif	C		
		Aminotransferase		Mirapex	C		
		Increased		Estrogen	C		
		Blood Bilirubin Increased					
		Chromaturia					
		Jaundice					
		Nausea					
		Vomiting					

Date:02/01/05ISR Number: 4601997-7Report Type:Periodic Company Report #ACO_0019_2004
 Age:42 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Accidental Overdose	Consumer	Zanaflex	PS		
DF		Coma		Baclofen	SS		
Initial or Prolonged							
DF		Respiratory Distress		Xanax	SS		
DF							

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - PO		Cerebral Infarction	Foreign	Sirdalud	PS		ORAL
Initial or Prolonged Disability		Condition Aggravated Hypotension Memory Impairment	Health Professional Other	Ciproxin	SS		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other DF QDAY PO		Convulsion	Foreign	Ternelin	PS		ORAL
DF QDAY PO		Disease Recurrence	Health	Ternelin	SS		ORAL
35 MG QDAY PO		Drug Interaction	Professional	Paxil	SS		ORAL
DF		Dyspnoea	Other	Lexotan	SS		
		Epilepsy Hyperventilation Myoclonus Oxygen Saturation Decreased Serotonin Syndrome Therapy Non-Responder Tremor					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/07/05ISR Number: 4576742-4Report Type:Expedited (15-DaCompany Report #ACO_0122_2005

Age:10 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - DF	Depressed Level Of Consciousness	Literature Health	Zanaflex	PS		
Initial or Prolonged DF PO	Heart Rate Increased Hypotension Musculoskeletal Stiffness Pallor Somnolence	Professional	Lisinopril Valproic Acid Valium Clonazepam	SS C C C		ORAL

Date:02/08/05ISR Number: 4576909-5Report Type:Expedited (15-DaCompany Report #05-02-0156

Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 10MG QD ORAL	Depressed Level Of Consciousness	Foreign Literature	Lisinopril Tablets	PS		ORAL
Initial or Prolonged 2 MG Other	Drug Interaction Hypotension		Tizanidine Amlodipine Nimopidine Labetalol	SS C C C		

Date:02/08/05ISR Number: 4579159-1Report Type:Direct Company Report #CTU 239730

Age:28 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Other 1/2 AT NIGHT	Blood Pressure Decreased Heart Rate Decreased Loss Of Consciousness		Zanaflex	PS		ORAL

Date:02/09/05ISR Number: 4577958-3Report Type:Expedited (15-DaCompany Report #ACO_0123_2005

Age:65 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 4 MG QDAY PO		Hallucination, Auditory	Foreign	Sirdalud	PS		ORAL
Initial or Prolonged 160 MG QDAY			Health	Sotalex	SS		ORAL
PO			Professional				
			Other	Buprenorphine	C		
				Torem	C		
				Plavix	C		
				Dafalgan	C		
				Zestril	C		
				Temgesic "Essex Pharma"	C		
				Aspirin Compound	C		

Date:02/09/05ISR Number: 4578634-3Report Type:Direct Company Report #CTU 239962
Age:51 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged Required		Jaundice Myalgia Nausea		Tizanidine	PS		
Intervention to Prevent Permanent Impairment/Damage		Vomiting		Zolpidem	C		
				Venlafaxine	C		
				Propranolol	C		
				Levothyroxine	C		
				Ropinirole	C		
				Loratidine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:02/10/05ISR Number: 4579812-XReport Type:Expedited (15-DaCompany Report #2005PK00214

Age:23 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Dissociative Disorder	Foreign	Zomig	PS		ORAL
4 DF DAILY PO							
Initial or Prolonged		Drug Abuser	Health	Sirdalud	SS		ORAL
4 DF DAILY PO							
		Intentional Misuse	Professional	Diflucan	SS		ORAL
1 DF DAILY PO							
		Somnolence	Other	Benzodiazepines	SS		
		Stupor					
		Tachycardia					

Date:02/10/05ISR Number: 4579912-4Report Type:Expedited (15-DaCompany Report #2004AL000677

Age:30 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Bradycardia	Literature	Tizanidine			
Hospitalization -		Cardio-Respiratory Arrest	Health	Hydrochloride			
Initial or Prolonged		Coma	Professional	Tablets, 4 Mg			
PO		Completed Suicide		(Purepac)	PS	Purepac	ORAL
		Haemodialysis		Valproic Acid	SS		ORAL
PO							
		Hypotension					
		Intentional Misuse					
		Mental Status Changes					

Date:02/16/05ISR Number: 4589351-8Report Type:Expedited (15-DaCompany Report #ACO_0128_2005

Age:39 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Confusional State	Foreign	Sirdalud	PS		ORAL
20 MG QDAY PO							
Initial or Prolonged		Gait Disturbance	Health	Oxaprozin	C		
		Vertigo	Professional	Kenacort	C		
			Other				

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Effect Decreased		Tizanidine	PS	Apo Ti-4	ORAL
4MG AND 8MG		Dry Mouth					
BID ORAL		Fatigue		Copaxone	C		
		Muscle Spasticity		Prevacid	C		
		Pharmaceutical Product		Wellbutrin Sr	C		
		Complaint		Femhrt	C		
				Tizanidine	C		

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Dissociative Disorder	Foreign	Diffucan Tablets			
Initial or Prolonged		Drug Abuser	Health	(Fluconazole)	PS		ORAL
ORAL		Heart Rate Increased	Professional	Tizanidine			
		Muscle Contracture		Hydrochloride			
		Somnolence		(Tizanidine			
		Stupor		Hydrochloride)	SS		ORAL
16 MG (4 MG,							
1 IN 1							
D),ORAL				Zolmitriptan			

Freedom Of Information (FOI) Report

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
10 MG (2.5 MG, 1 IN 1 D), ORAL				(Zolmitriptan)	SS		ORAL
				Benzodiazepine Derivatives (Benzodiazepine Derivatives)	SS		
Date:02/23/05ISR Number: 4595107-2Report Type:Expedited (15-DaCompany Report #JP-SHR-03-002988 Age:51 YR Gender:Female I/FU:F							
Other		Haemolytic Anaemia Leukopenia Neutropenia	Foreign Study Health	Betaferon (Interferon Beta-1b) Injection	PS		
SUBCUTANEOUS	SEE IMAGE	Relapsing-Remitting Multiple Sclerosis Therapy Non-Responder	Professional Other	Ternelin (Tizanidine Hydrochloride) Tablet	SS		ORAL
2 MG, 1X/DAY, ORAL				Zantac (Ranitidine Hydrochloride) Tablet	SS		ORAL
300 MG, 1X/DAY, ORAL				Mucosta (Rebamipide) Tablet	SS		ORAL
300 MG, 1X/DAY, ORAL				Tegretol (Carbamazepine) Tablet	SS		ORAL
SEE IMAGE				Takepron (Lansoprazole) Solu-Medrol (Methylprednisolone Sodium Succinate)	C C		

Glyceol (Glycerol,	C
Fructose)	C
Predonine	C
Iscotin (Isoniazid)	C
Mucodyne	
(Carbocisteine)	C
Mucosolvan	C
Rimactane	
(Rifampicin)	C
Vitamedin	
(Benfotiamine)	C
Voltaren (Diclofenac	
Sodium)	C
Gaster D	
(Famotidine)	C

Date:03/01/05ISR Number: 4598348-3Report Type:Direct
 Age: Gender:Female I/FU:I

Company Report #CTU 241765

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Chest Pain		Tizanidine 4mg	PS		ORAL
PO ONCE QID						
	Dyspnoea		Tizanidine 4mg	SS		
	Feeling Abnormal		Klonopin	C		
	Syncope		Neurontin	C		
			Soma	C		
			Lortabs	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Zomig C

Date:03/03/05ISR Number: 4599864-0Report Type:Expedited (15-DaCompany Report #ACO_0130_2005

Age:23 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 16 MG QD PO	Conversion Disorder	Foreign	Sirdalud	PS		ORAL
Initial or Prolonged 1 TAB QDAY PO	Dissociative Disorder	Health	Diflucan	SS		ORAL
4 TAB QDAY PO	Drug Abuser	Professional	Zomig	SS		ORAL
	Dysphonia Muscle Contracture Somnolence Stupor Tachycardia	Other	Benzodiazepines	SS		

Date:03/03/05ISR Number: 4600212-8Report Type:Expedited (15-DaCompany Report #2005-00682

Age:48 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Required 10 MG, DAILY, Intervention to ORAL	Drug Interaction	Foreign	Lisinopril	PS	Watson Laboratories	ORAL
Prevent Permanent Impairment/Damage 2 MG, SINGLE	Potentiation	Literature				
	Hypotension	Health	Tizanidine			
	Idiosyncratic Drug	Professional	(Tizanidine)	SS		
	Reaction	Other	Amlodipine (Amlodipine) Nimodipine (Nimodipine) Labetalol (Labetalol) Ofloxacin (Ofloxacin) Theophylline Biofermin (Lactobacillus Acidophilus,	C C C C C C		

Bacillus Subtilis,
Streptococcus C

Date:03/07/05ISR Number: 4603071-2Report Type:Expedited (15-DaCompany Report #ACO_0127_2005
Age:27 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Lymphocyte Stimulation	Foreign	Ternelin	PS		ORAL
PO		Test Positive	Health	Peon	SS		
		Toxic Skin Eruption	Professional	Marzulene S	SS		
		Urticaria	Other				

Date:03/09/05ISR Number: 4602775-5Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20040908829
Age:21 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Death		Completed Suicide	Health	Ultracet	PS		
OROPHARINGEAL	30g/3 g						
Hospitalization -			Professional	Cyclobenzaprine	SS		
Initial or Prolonged				Amitriptyline	SS		
OROPHARINGEAL				Tizanidine	SS		
				Rofecoxib	SS		
				Omeprazole	SS		

22-Aug-2005 12:09 PM
Page: 244

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/10/05ISR Number: 4608969-7Report Type:Expedited (15-DaCompany Report #2004-BP-11398YA
Age:41 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 0.2 MG (NR)		Alanine Aminotransferase	Foreign	Harnal (Tamsulosin)	PS		ORAL
Initial or Prolonged PO		Increased	Health				
Other 25 MG (NR) PO		Aspartate Aminotransferase	Professional	Dantrium (Dantrolene Sodium) (Nr)	SS		ORAL
		Increased Blood Bilirubin Increased		Lioresal (Dantrolene Sodium) (Nr)	SS		ORAL
6 DF (NR) PO		Blood Lactate Dehydrogenase Increased		Ternelin (Tizanidine Hydrochloride) (Nr)	SS		ORAL
1 MG TID (NR, TID) PO		Gamma-Glutamyltransferase					
		Increased Liver Disorder Lymphocyte Stimulation Test Positive Malaise		Vitamedin (Benfotiamine/B6/B12) (Nr) Diazepam (Diazepam) (Nr)	C C		

Date:03/15/05ISR Number: 4611182-0Report Type:Direct Company Report #CTU 243250
Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose 2 MG		Drug Ineffective Pharmaceutical Product		Zanaflex - Generic Form	PS		
		Complaint					

Date:03/15/05ISR Number: 4613238-5Report Type:Expedited (15-DaCompany Report #2005040174
Age:47 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Abdominal Pain	Foreign	Triazolam Tablet			

Initial or Prolonged 2.5 MG, ORAL	Acute Prerenal Failure	Literature	(Triazolam)	PS	ORAL
Other	Blood Pressure Systolic Increased	Health Professional	Flunitrazepam (Flunitrazepam)	SS	ORAL
ORAL	Body Temperature Decreased		Phenobarbital (Phenobarbital)	SS	ORAL
ORAL	Dehydration Haemodialysis Intentional Misuse		Lorazepam (Lorazepam) (Lorazepam)	SS	ORAL
ORAL	Rhabdomyolysis Suicide Attempt Vomiting		Tizanidine Hydrochloride (Tizanidine Hydrochloride)	SS	ORAL
ORAL			Zopiclone (Zopiclone)	SS	ORAL

Date:03/17/05ISR Number: 4611206-0Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01708
Age:21 YR Gender:Female I/FU:F

Outcome	PT
Death	Aggression
Hospitalization -	Aspiration
Initial or Prolonged	Completed Suicide
Other	Depressed Level Of Consciousness Drug Interaction Drug Screen Positive Drug Toxicity

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
		Foreign Body Aspiration Intentional Misuse Lung Crepitation				
		Lung Disorder	Vioxx	PS	Merck & Co., Inc	ORAL
		Sedation	Flexeril	SS		ORAL
		Self-Medication	Ultracet	SS		
UNKNOWN		Vomiting	Omeprazole	SS		ORAL
			Elavil	SS		ORAL
			Tizanidine Hydrochloride	SS		ORAL

Date:03/17/05ISR Number: 4611425-3Report Type:Expedited (15-DaCompany Report #PHBS2004JP16522
Age:27 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization - Initial or Prolonged		Alanine Aminotransferase Increased		Voltaren	PS	Novartis Sector: Pharma	ORAL
75 mg/day	43200MIN	Aspartate		Ternelin	SS		ORAL
3 mg/day	43200MIN	Aminotransferase		Mucosta	SS		ORAL
300 mg/day	43200MIN	Increased		Mecobalamin	C		ORAL
1000 ug/day		Back Pain Condition Aggravated Gamma-Glutamyltransferase Increased Liver Disorder Lymphocyte Stimulation Test Positive					

Date:03/17/05ISR Number: 4619026-8Report Type:Direct Company Report #CTU 243514
Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
		Blood Pressure Systolic Decreased Dizziness		Sirdalud -Tizanidine-	PS		

Drug Effect Increased
Drug Interaction
Drug Interaction
Inhibition
Drug Level Increased
Hypotension
Nervous System Disorder
Somnolence

Date:03/18/05ISR Number: 4613530-4Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 243721

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
ZANAFLEX	2MG	Muscle Spasms Pharmaceutical Product		Zanaflex - Generic Form 2mg	PS		
		Complaint					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:03/23/05ISR Number: 4620308-4Report Type:Direct
 Age: Gender:Male I/FU:I

Company Report #CTU 244097

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 4MG 1 TID Initial or Prolonged PRN ORAL		Delirium		Tizanidine Hcl	PS		ORAL
		Drug Withdrawal Syndrome					
		Overdose Psychotic Disorder					

Date:03/24/05ISR Number: 4617527-XReport Type:Expedited (15-DaCompany Report #PHBS2005BE04067
 Age:47 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other UNKNOWN tablets = 336 tablets 8 packages of 100 Sirdalud 4 mg tablets	6 x 56	Drug Abuser Medication Error		Lamisil	PS	Novartis Sector: Pharma	
				Sirdalud	SS		
				Sirdalud	SS		
				Methadone	SS		

tablets		Serenase	SS
UNKNOWN	3 x 50		
tablets = 150			
tablets		Temgesic	SS
UNKNOWN	50 DF,		
ONCE/SINGLE			
UNKNOWN	9 x 28 or 56	Ranitidine	SS
tablets			
UNKNOWN	500 mg,	Amoxicillin	SS
ONCE/SINGLE			
UNKNOWN	400 mg,	Brufen	SS
ONCE/SINGLE			
UNKNOWN	3 x 20	Ciproxine	SS
tablets = 60			
tablets			

Date:03/24/05ISR Number: 4620084-5Report Type:Expedited (15-DaCompany Report #2005040174
Age:47 YR Gender:Male I/FU:F

Outcome	PT
Hospitalization -	Abdominal Pain
Initial or Prolonged	Acute Prerenal Failure
Other	Aphagia
	Blood Chloride Decreased
	Blood Pressure Systolic
	Increased
	Blood Sodium Decreased
	Dehydration
	Haemodialysis
	Hepatic Function Abnormal
	Intentional Misuse
	Rhabdomyolysis
	Suicide Attempt

Freedom Of Information (FOI) Report

Vomiting

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
0.25 MG (0.25 MG,)	ORAL	Foreign Literature	Halcion (Triazolam)	PS		ORAL
		Health Professional	Lorazepam (Lorazepam) (Lorazepam)	SS		ORAL
1 MG (1 MG, QD),	ORAL		Phenobarbital (Phenobarbital)	SS		ORAL
	ORAL		Zopiclone (Zopiclone)	SS		ORAL
	ORAL		Vegetamin(Chlorpromazine Hydrochloride, Phenobarbital, Promethazine Hydrochloride)	SS		ORAL
	ORAL		Tizanidine Hydrochloride (Tizanidine Hydrochloride)	SS		ORAL
2 MG (2 MG, QD),	ORAL		Flunitrazepam (Flunitrazepam)	C		ORAL
			All Other Therapeutic Products (All Other Therapeutic Products)	C		

Outcome
Hospitalization -
Initial or Prolonged

PT
Abdominal Pain
Alanine Aminotransferase
Increased
Aspartate
Aminotransferase
Increased
Blood Calcium Increased
Blood Lactate
Dehydrogenase Increased
Blood Potassium Increased
Blood Pressure Systolic
Increased
Blood Sodium Decreased
Body Temperature
Decreased
Dry Skin
Glasgow Coma Scale
Abnormal
Haemodialysis
Intentional Misuse
Oedema Peripheral
Oral Intake Reduced
Renal Failure Acute
Rhabdomyolysis

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Somnolence Suicide Attempt Vomiting	Report Source	Product	Role	Manufacturer	Route
20 MG ONCE PO			Foreign	Ternelin	PS		ORAL
46 MG ONCE PO			Health	Rohypnol	SS		ORAL
2.5 MG ONCE PO			Professional	Halcion	SS		ORAL
			Other				
20 MG ONCE PO				Wypax	SS		ORAL
75 MG ONCE PO				Slowheim	SS		ORAL
600 MG ONCE PO				Vegetamin A	SS		ORAL

Date:04/01/05ISR Number: 4628375-9Report Type:Expedited (15-DaCompany Report #ACO_0133_2005
Age:46 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 4 MG PO		Amnesia	Health	Zanaflex	PS		ORAL
Initial or Prolonged 100 MG PO		Confusional State Depression	Professional	Trazodone Hydrochloride	SS		ORAL
		Insomnia		Dilaudid	SS		
		Lethargy		Xanax	SS		
		Muscular Weakness		Quinapril	SS		
				Valium	SS		

Date:04/05/05ISR Number: 4626981-9Report Type:Expedited (15-DaCompany Report #PHBS2005BE04067
Age:47 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Drug Abuser		Lamisil	PS	Novartis Sector:	

Medication Error

Pharma

UNKNOWN 6 x 56

tablets = 336

tablets

Sirdalud

SS

8 packages

of 100

Sirdalud 4 mg

tablets 92160MIN

Sirdalud

SS

UNKNOWN 32 packages

of 100

Sirdalud 4 mg

tablets 106 DAY

Methadone

SS

UNKNOWN 10 x 60

tablets = 600

tablets

Serenase

SS

UNKNOWN 3 x 50

tablets = 150

tablets

Temgesic

SS

UNKNOWN 50 DF,

ONCE/SINGLE

Ranitidine

SS

UNKNOWN 9 x 28 or 56

tablets

Amoxicillin

SS

UNKNOWN 500 mg,

ONCE/SINGLE

Brufen

SS

UNKNOWN 400 mg,

ONCE/SINGLE

Ciproxine

SS

UNKNOWN 3 x 20

tablets = 60

tablets

22-Aug-2005 12:09 PM

Page: 249

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/05/05ISR Number: 4629414-1Report Type:Expedited (15-DaCompany Report #ACO_0135_2005

Age:43 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Condition Aggravated Dyskinesia Muscle Spasms Speech Disorder	Foreign Consumer Other	Zanaflex Inhaler	PS C		

Date:04/07/05ISR Number: 4708207-0Report Type:Direct Company Report #USP 57197

Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
TABLET		Drug Dispensing Error		Gabitril	PS	Cephalon	
TABLET		Medication Error		Zanaflex	SS		

Date:04/08/05ISR Number: 4633338-3Report Type:Expedited (15-DaCompany Report #ACO-0127_2005

Age:27 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other PO		Generalised Erythema	Foreign	Ternelin	PS		ORAL
		Lymphocyte Stimulation Test Positive	Health Professional	Peon Marzulene S	SS SS		
		Pigmentation Disorder	Other	Dan Rich	SS		
		Rash		Over-The - Counter			
		Toxic Skin Eruption		Antitussives (Nos)	SS		
		Urticaria					

Date:04/12/05ISR Number: 4633339-5Report Type:Expedited (15-DaCompany Report #ACO_0036_2004

Age:27 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 3 MG QDAY PO		Alanine Aminotransferase	Foreign	Ternelin	PS		ORAL

Initial or Prolonged 75 MG QDAY PO	Increased	Health	Voltaren	SS	ORAL
	Aspartate	Professional	Mucosta	SS	ORAL
300 MG QDAY PO	Aminotransferase	Other			
	Increased Back Pain Gamma-Glutamyltransferase Abnormal Liver Disorder Lymphocyte Stimulation Test Positive		Mecobalamin	C	

Date:04/14/05ISR Number: 4636804-XReport Type:Expedited (15-DaCompany Report #ACO_0137_2005
Age:64 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose Disability		Confusional State Dyspnoea Loss Of Consciousness Quadripareisis Rales	Foreign Health Professional Other	Sirdalud	PS		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:04/14/05ISR Number: 4636807-5Report Type:Expedited (15-DaCompany Report #ACO_0138_2005

Age:47 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Drug Abuser	Foreign	Zanaflex	PS		ORAL
4 MG PO							
			Health Professional	Lamisil	SS		
25 MG PO	5 MON			Methadone	SS		ORAL
			Other	Serenase	SS		ORAL
2.5 MG PO							
				Temgesic			
0.2 MG PO				Schering-Plough	SS	Schering-Plough	ORAL
				Ranitidine	SS		ORAL
300 MG PO							
				Amoxicillin	SS		ORAL
500 MG PO							
				Brufen Abbott	SS	Abbott	ORAL
400 MG PO							
				Ciproxine	SS		ORAL
500 MG PO							

Date:04/14/05ISR Number: 4636822-1Report Type:Expedited (15-DaCompany Report #DSA_26193_2005

Age:40 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Abdominal Pain	Foreign	Wypax	PS		ORAL
20 MG ONCE PO							
Initial or Prolonged		Blood Potassium Increased	Health Professional	Halicion	SS		ORAL
2.5 MG ONCE							
		Blood Pressure Systolic					
PO			Other	Rohypnol	SS		ORAL
DF ONCE PO		Increased					
		Body Temperature		Ternelin	SS		ORAL
20 MG ONCE PO							
		Decreased		Vegetamin A	SS		ORAL
600 MG ONCE							
		Depression					
PO							
		Dry Skin		Slowheim	SS		ORAL
75 MG ONCE PO							

DF UNK PO	Glasgow Coma Scale	Wypax	SS	ORAL
DF UNK PO	Abnormal	Halcion	SS	ORAL
DF UNK PO	Haemodialysis	Rohypnol	SS	ORAL
DF UNK PO	Hepatic Function Abnormal	Ternelin	SS	ORAL
DF UNK PO	Intentional Misuse	Vegetamin A	SS	ORAL
DF UNK PO	Oedema Peripheral	Slowheim	SS	ORAL
DF UNK PO	Renal Failure Acute Rhabdomyolysis Suicide Attempt			

Date:04/21/05ISR Number: 4643078-2Report Type:Expedited (15-DaCompany Report #ACO_0135_2005
Age:43 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Hospitalization - 4 MG Q6HR PO	Back Pain	Foreign	Tizanidine	PS		ORAL
Initial or Prolonged	Dyskinesia Muscle Spasms Speech Disorder Torticollis	Consumer Other	Inhaler (Name Unknown)	C		

Date:04/21/05ISR Number: 4643080-0Report Type:Expedited (15-DaCompany Report #ACO_0141_2005
Age:53 YR Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Duration Other DF	Chest Pain	Foreign	Ternelin	PS		
	Peripheral Coldness	Health Professional Other				

Other	Corrected Interval Prolonged Hypotension	(Similar To Nda 20-553) (Oxycodone Hydrochloride)	PS	ORAL
ORAL	Lethargy Mental Status Changes	Tizanidine (Tizanidine)	SS	ORAL
ORAL	Renal Failure Acute	Benzodiazepine Derivatives (Benzodiazepine Derivatives)	SS	ORAL
ORAL		Hydrochlorothiazide (Hydrochlorothiazide)	SS	ORAL
ORAL		Ace Inhibitor Nos (Ace Inhibitor Nos)	SS	ORAL

Date:05/05/05ISR Number: 4656450-1Report Type:Expedited (15-DaCompany Report #S05-SWI-01568-01
Age:33 YR Gender:Female I/FU:I

Outcome PT
Other Burning Sensation
Condition Aggravated
Dizziness
Dyspnoea
Fatigue

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Muscular Weakness Somnolence Tongue Disorder	Report Source	Product	Role	Manufacturer	Route
10 MG QD PO			Foreign Health	Ciprallex (Escitalopram)	PS		ORAL
			Professional Other	Sirdalud (Tizanidine Hydrochloride)	SS		
				Felden (Piroxicam)	C		
				Ponstan (Mefenamic Acid)	C		
				Xefo (Lornoxicam)	C		

Date:05/06/05ISR Number: 4656778-5Report Type:Expedited (15-DaCompany Report #2005PK00757
Age:26 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Required Intervention to Prevent Permanent Impairment/Damage	20 MG DAILY PO	Convulsion Sleep Disorder	Foreign Health	Nolvadex Astrazeneca	PS	Astrazeneca	ORAL
	100 MG DAILY PO		Professional Other	Tramal	SS		ORAL
	2 MG DAILY PO			Sirdalud	SS		ORAL

Date:05/09/05ISR Number: 4658145-7Report Type:Expedited (15-DaCompany Report #2005061462
Age: Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other	20 MG (20 MG, 1 IN 1 D),	Activities Of Daily Living Impaired Crying	Consumer	Bextra (Valdecoxib)	PS		ORAL
ORAL							

1 IN 1 D,	Drug Ineffective	Celebrex (Celecoxib)	SS	ORAL
ORAL	Exostosis			
	Fatigue	Tizanidine		
	Herpes Simplex	Hydrochloride		
	Intervertebral Disc	(Tizanidine		
	Disorder	Hydrochloride)	SS	
	Memory Impairment			
	Oral Mucosal Blistering			
	Pain			
	Pruritus			
	Rash Pruritic			
	Scar			
	Skin Disorder			
	Skin Reaction			
	Somnolence			
	Stress			

Date:05/09/05ISR Number: 4658772-7Report Type:Expedited (15-DaCompany Report #ACO_0143_2005
Age:71 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Anaemia
Initial or Prolonged	Balance Disorder
	Blindness Transient
	Blood Pressure Increased
	Bradycardia
	Cardiomegaly
	Carotid Bruit

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
3 MG QDAY PO	33 DAY	Coronary Artery Stenosis Dizziness Drug Interaction	Foreign	Tizanidine	PS		ORAL
100 MG TID PO		Electrocardiogram Poor R-Wave Progression	Literature	Ticlopidine	SS		ORAL
		Electrocardiogram St-T Change Glycosylated Haemoglobin Increased Pulse Absent Reflexes Abnormal Sinus Arrhythmia Sinus Bradycardia Ventricular Hypertrophy	Health Professional Other				

Date:05/12/05ISR Number: 4660036-2Report Type:Expedited (15-DaCompany Report #US-2004-BP-12563BP
Age:56 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - Initial or Prolonged		Chromaturia Diarrhoea Jaundice Nausea Vomiting		Mirapex Tablets	PS	B.I. Pharmaceuticals, Inc. /Ridgefield	ORAL
				Metformin	SS		
				Estrogen	SS		
				Zanaflex	SS		
				Rebif	SS		

Date:05/13/05ISR Number: 4663254-2Report Type:Expedited (15-DaCompany Report #ACO_0144_2005
Age:33 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 4 TAB QDAY PO		Burning Sensation	Foreign	Sirdalud	PS		ORAL
10 MG NIGHTLY PO		Dizziness	Health	Cipralext	SS		ORAL
		Dyspnoea	Professional				
		Muscular Weakness	Other	Felden	C		

Somnolence
Sudden Onset Of Sleep
Tongue Disorder

Ponstan
Xefo

C
C

Date:05/16/05ISR Number: 4664015-0Report Type:Direct
Age: Gender:Female I/FU:I

Company Report #CTU 248634

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
ZANAFLEX	2MG	Condition Aggravated Drug Effect Decreased Muscle Spasms Therapeutic Response Unexpected		Zanaflex Generic Form 2mg	PS		

Date:05/25/05ISR Number: 4673499-3Report Type:Expedited (15-DaCompany Report #PHBS2005JP06867
Age:62 YR Gender:Female I/FU:F

Outcome	PT
Hospitalization - Initial or Prolonged	Anaphylactic Shock Blood Pressure Decreased Confusional State Erythema

22-Aug-2005 12:09 PM
Page: 254

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	Vomiting	Report Source	Product	Role	Manufacturer	Route
75 mg/day				Voltaren Sr	PS	Novartis Sector: Pharma	ORAL
2 mg/day				Ternelin	SS		ORAL
2 DF/day				Mucosta	SS		ORAL

Date:06/02/05ISR Number: 4679968-4Report Type:Expedited (15-DaCompany Report #PHFR2005GB01965
 Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening Hospitalization -	40 mg, QD	Blood Creatinine Increased		Baclofen	PS	Novartis Sector: Pharma	ORAL
Initial or Prolonged	36mg/day	Drug Level Increased		Tizanidine	SS		ORAL
Other UNKNOWN	400 mg, BID	Epilepsy		Gabapentin	SS		
2.5mg/day		Glasgow Coma Scale		Bendrofluazide	C		ORAL
		Abnormal Hallucination Loss Of Consciousness Overdose Renal Failure Acute Urinary Tract Infection					

Date:06/02/05ISR Number: 4681511-0Report Type:Expedited (15-DaCompany Report #ZICO001221
 Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Anaemia	Health Professional	Prialt (Ziconotide Intrathecal Infusion)	PS		
Initial or Prolonged		Anxiety					
INTRATHECAL	0.1 MCG/HR	Blood Albumin Decreased					

Blood Creatine

Phosphokinase Increased

Blood Creatine

Phosphokinase Mb

Increased

Dyspnoea

Headache

Pulmonary Oedema

Zanaflex

(Tizanidine)

SS

Neurontin

(Gabapentin)

C

Restoril (Temazepam)

C

Wellbutrin

(Amfebutamone

Hydrochloride)

C

Dilaudid

(Hydromorphone

Hydrochloride)

C

Oxybutryn

(Oxybutryn)

C

Protonix (Pantoprazol
e)

C

Zoloft (Sertraline

Hydrochloride)

C

Procrit

(Erythropoeitin)

C

Hydrochlorothiazid

(Hydrochlorothiazide

)

C

Levaquin

(Levofloxacin)

C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/02/05ISR Number: 4682499-9Report Type:Direct
Age:57 YR Gender:Female I/FU:I

Company Report #CTU 250170

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
3 PER DAY; 1		Drug Effect Decreased		Tizanidine 4 Mg	PS		
3 TIMES PER		Dry Mouth					
DAY		Headache					
		Insomnia					
		Pharyngitis Streptococcal					

Date:06/06/05ISR Number: 4682504-XReport Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009
Age:60 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY							
Initial or Prolonged		Hepatic Enzyme Increased		Tizanidine			
1 DAY				Hydrochloride	SS		ORAL
				Tizanidine			
1 DAY				Hydrochloride	SS		ORAL
				Tizanidine			
1 DAY				Hydrochloride	SS		ORAL
				Diclofenac Sodium	SS		ORAL
				Herbs (Unspecified)	C		ORAL

Date:06/09/05ISR Number: 4688149-XReport Type:Expedited (15-DaCompany Report #430015M05USA
Age:41 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Hospitalization -		Idiopathic	Health	Novantrone			
Initial or Prolonged		Thrombocytopenic Purpura	Professional	(Mitoxantrone			
25 MG/M2, 3				Hydrochloride)	PS		

Effexor (Venlafazine Hydrochloride)	SS
Zanaflflex (Tizanidine Hydrochloride)	SS
Neurontin (Gabapentin)	C
Provigil (Modafinil)	C
Inderal (Propranolol Hydrochoride)	C
Clonazepam (Clonazepam)	C
Naprilan (Enalapril)	C
Ambien (Zolipen (Enalapril)	C
Imitrex (Sumatriptan Succinate)	C
Urocholine (All Other Non-Therapeutic Products)	C
Trileptal (Oxycarbazepine)	C

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/09/05ISR Number: 4688206-8Report Type:Expedited (15-DaCompany Report #ACO_0162_2005

Age:40 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Depression	Health	Zanaflex	PS		ORAL
DF PO		Paranoia	Professional	Effexor-Xr	SS		ORAL
37.5 MG ONCE							
PO				Lexapro	C		
				Duragesic	C		
				Zonegran	C		
				Clonidine	C		
				Ultram	C		

Date:06/14/05ISR Number: 4691907-9Report Type:Expedited (15-DaCompany Report #ACO_0163_2005

Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Alanine Aminotransferase	Health	Tizanidine	PS		ORAL
DF PO							
Initial or Prolonged		Increased	Professional	Prialt/Ziconotide	SS		
INTRATHORACIC	DF IT	Anaemia		Neurontin	C		
		Anxiety		Restoril	C		
		Aspartate					
		Aminotransferase					
		Increased					
		Band Neutrophil					
		Percentage Decreased					
		Blood Alkaline					
		Phosphatase Increased					
		Blood Calcium Decreased					
		Blood Creatine					
		Phosphokinase Increased					
		Blood Creatine					
		Phosphokinase Mb					
		Increased					
		Blood Glucose Increased					
		Blood Iron Decreased					
		Blood Lactate					
		Dehydrogenase Increased					

Drug Screen Positive
Dyspnoea
Haematocrit Decreased
Haemoglobin Decreased
Haptoglobin Increased
Headache
Laboratory Test Abnormal
Lymphocyte Percentage
Decreased
Mean Cell Haemoglobin
Concentration Decreased
Mean Cell Haemoglobin
Decreased
Mean Cell Volume
Increased
Neutrophil Count Abnormal
Neutrophil Percentage
Increased
Pulmonary Oedema
Red Cell Distribution
Width Increased
White Blood Cell Count
Increased

22-Aug-2005 12:09 PM

Page: 257

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/14/05ISR Number: 4692043-8Report Type:Expedited (15-DaCompany Report #HQWYE133802JUN05
Age:41 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - Initial or Prolonged	Idiopathic Thrombocytopenic Purpura	Health Professional	Novantrone (Mitoxantrone Hydrochloride, Injection)	PS		
25 MG/M2 EVERY 3 MONTHS			Effexor (Venlafaxine Hydrochloride, Tablet)	SS		
			Zanaflex (Tizanidine Hydrochloride,)	SS		
			Neurontin (Gabapentin)	C		
			Inderal (Propranolol Hydrochloride)	C		
			Clonazepam (Clonazepam)	C		
			Naprilene (Enalapril Maleate)	C		
			Ambien (Zolpidem Tartrate)	C		
			Imitrex (Sumatriptan Succinate)	C		
			Trileptal (Oxcarbazepine)	C		
			Provigil (Modafinil)	C		

Date:06/14/05ISR Number: 4692169-9Report Type:Expedited (15-DaCompany Report #TZD20050003
Age:71 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - 3 MG DAILY PO Initial or Prolonged	Anaemia Areflexia Balance Disorder Blindness Transient	Foreign Literature Health Professional	Tizanidine Hcl Ticlopidine Hcl	PS C		ORAL

Blood Pressure Diastolic
Decreased
Blood Pressure Systolic
Increased
Cardiomegaly
Carotid Bruit
Coronary Artery Stenosis
Dizziness
Drug Level Increased
Electrocardiogram Poor
R-Wave Progression
Electrocardiogram St-T
Change
Glycosylated Haemoglobin
Increased
Pulse Absent
Sinus Arrhythmia
Sinus Bradycardia
Ventricular Hypertrophy

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/15/05ISR Number: 4690435-4Report Type:Expedited (15-DaCompany Report #PHBS2004CH11775

Age:60 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Life-Threatening	Abdominal Pain Upper		Voltaren	PS	Novartis Sector:	
Hospitalization -	Alanine Aminotransferase				Pharma	
UNKNOWN	50 mg/d	4320 MIN				
Initial or Prolonged	Increased		Sirdalud	SS		ORAL
6 mg/day	4320 MIN					
Other	Aspartate		Vioxx	SS		
UNKNOWN	25 mg/d	4320 MIN				
	Aminotransferase		Herbal Extracts Nos	SS		
	Increased					
	Brain Natriuretic Peptide					
	Increased					
	Chest Discomfort					
	Chest Pain					
	Diarrhoea					
	Drug Interaction					
	Dyspnoea					
	Fibrin D Dimer Increased					
	Gamma-Glutamyltransferase					
	Increased					
	Haemangioma Of Liver					
	Hepatic Enzyme Increased					
	Hepatic Lesion					
	Hepatotoxicity					
	Hyperhidrosis					
	Nausea					
	Pleural Effusion					
	Pulmonary Hypertension					
	Right Ventricular Failure					
	Sinus Bradycardia					
	Vomiting					

Date:06/16/05ISR Number: 4693790-4Report Type:Expedited (15-DaCompany Report #ACO_0166_2005

Age:62 YR Gender:Female I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose	Duration					
Hospitalization -	Exanthem	Foreign	Ternelin	PS		ORAL
2 MG QDAY PO						
Initial or Prolonged	Hypotension	Health	Voltaren	SS		ORAL
75 MG QDAY PO						

Other

Date:06/17/05ISR Number: 4695028-0Report Type:Expedited (15-DaCompany Report #ACO_0167_2005

Age:59 YR Gender:Female I/FU:I

Outcome	PT
Hospitalization -	Acute Right Ventricular
Initial or Prolonged	Failure
Required	Alanine Aminotransferase
Intervention to	Increased
Prevent Permanent	Angiopathy
Impairment/Damage	Aspartate
	Aminotransferase
	Increased
	Blood Pressure Systolic
	Increased
	Bradycardia
	Drug Interaction
	Gamma-Glutamyltransferase
	Increased
	Haemangioma Of Liver

22-Aug-2005 12:09 PM

Page: 259

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Hepatic Cyst Liver Function Test Abnormal					
VAR QDAY PO	3 DAY	Pulmonary Hypertension	Foreign	Sirdalud	PS		ORAL
25 MG QDAY PO		Tachycardia	Literature	Vioxx	SS		ORAL
		Ventricular Extrasystoles	Health Professional Other	Voltaren Phytotherapeutics	C C		

Date:06/21/05ISR Number: 4697993-4Report Type:Expedited (15-DaCompany Report #2005084736
Age:53 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Abasia	Foreign	Serlain (Sertraline)	PS		ORAL
50 MG (50 MG, 1 IN 1 D), ORAL		Drug Interaction	Health				
		Feeling Abnormal	Professional				
				Sirdalud (Tizanidine Hydrochloride)	SS		ORAL

Date:06/22/05ISR Number: 4699425-9Report Type:Expedited (15-DaCompany Report #ACO_0170_2005
Age: Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Blood Pressure Systolic	Foreign	Ternelin	PS		ORAL
20 DF ONCE PO		Decreased Intentional Misuse Overdose Somnolence	Health Professional Other	Alcohol	SS		

Date:06/22/05ISR Number: 4699426-0Report Type:Expedited (15-DaCompany Report #ACO_0171_2005
Age:8 MON Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 32 MG ONCE PO		Accidental Drug Intake By	Foreign	Sirdalud	PS		ORAL
Initial or Prolonged		Child Bradycardia Depressed Level Of Consciousness	Other				

Date:06/22/05ISR Number: 4699427-2Report Type:Expedited (15-DaCompany Report #ACO_0169_2005

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 36 MG PO		Epilepsy	Foreign	Zanaflex	PS		ORAL
Initial or Prolonged 800 MG PO		Glasgow Coma Scale	Health	Gabapentin	SS		ORAL
40 MG PO		Abnormal	Professional	Baclofen	SS		ORAL
		Hallucination Intentional Misuse Loss Of Consciousness Overdose Renal Failure Acute Urinary Tract Infection	Other	Ciprofloxacin Bendrofluazide	C C		

22-Aug-2005 12:09 PM

Page: 260

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:06/27/05ISR Number: 4701637-2Report Type:Expedited (15-DaCompany Report #2005084736
Age:53 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Disability		Abasia	Foreign	Serlain (Sertraline)	PS		ORAL
50 MG (50 MG,		Depression	Health				
1 IN 1 D),		Drug Interaction	Professional				
ORAL		Feeling Abnormal		Sirdalud (Tizanidine Hydrochloride)	SS		ORAL
ORAL							

Date:06/29/05ISR Number: 4702901-3Report Type:Expedited (15-DaCompany Report #US-JNJFOC-20050606116
Age:24 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Intentional Misuse		Flexeril	PS		
Initial or Prolonged		Loss Of Consciousness		Zanaflex	SS		
				Klonopin	SS		
				No-Doz	SS		
				No-Doz	SS		
				Lexapro	C		
				Depakote	C		

Date:06/29/05ISR Number: 4702997-9Report Type:Expedited (15-DaCompany Report #PHBS2003JP01063
Age:29 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Life-Threatening		Eosinophilia		Tegretol	PS	Novartis Sector:	
Hospitalization -		Generalised Erythema				Pharma	ORAL
200 mg, BID	3600MIN						
Initial or Prolonged		Hepatic Function Abnormal		Tegretol	SS	Novartis Sector:	
		Hypogammaglobulinaemia				Pharma	ORAL
200 mg, TID	5760 MIN						
		Immunodeficiency		Tegretol	SS	Novartis Sector:	
		Lung Infiltration				Pharma	ORAL
200 mg, QID	25920MIN						
		Myotonia		Tegretol	SS	Novartis Sector:	

200 mg, TID	60480MIN	Pneumonia			Pharma	
		Productive Cough	Tegretol	SS	Novartis Sector:	
		Pyrexia			Pharma	ORAL
200 mg, BID	40320MIN	Rales	Gaster	SS		
UNKNOWN		Rash Generalised	Ternelin	SS		
UNKNOWN		Skin Exfoliation	Predonine	C		ORAL
15 mg/day		Upper Respiratory Tract	Selbex	C		ORAL
150 mg/day		Infection	Rize	C		ORAL
5 mg/day		Upper Respiratory Tract Inflammation				

Date:07/05/05ISR Number: 4708794-2Report Type:Expedited (15-DaCompany Report #ACO_0172_2005
Age:61 YR Gender: I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Lethargy	Foreign	Zanaflex	PS		ORAL
2 MG TID PO							
		Myalgia	Health	Zanaflex	SS		ORAL
2 MG QWK PO							
			Professional	Evening Primrose	C		
			Other	Vitamin C	C		
				Ibuprfen	C		
				Imipramine	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/07/05ISR Number: 4708246-XReport Type:Expedited (15-DaCompany Report #PHBS2003JP01063

Age:29 YR Gender:Female I/FU:F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Life-Threatening	Duration Eosinophilia		Tegretol	PS	Novartis Sector: Pharma	ORAL
Hospitalization - 200 mg, BID	36000MIN Generalised Erythema					
Initial or Prolonged 200 mg, TID	5760 MIN Hepatic Function Abnormal Hypogammaglobulinaemia		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, QID	25920MIN Lung Infiltration Pneumonia		Tegretol	SS	Novartis Sector: Pharma	ORAL
200 mg, TID	60480MIN Productive Cough Pyrexia		Tegretol	SS	Novartis Sector: Pharma	
200 mg, BID	40320MIN Rales Rash Generalised		Tegretol	SS	Novartis Sector: Pharma	ORAL
UNKNOWN	Upper Respiratory Tract		Gaster	SS		
UNKNOWN	Infection		Ternelin	SS		
15 mg/day			Predonine	C		ORAL
150 mg/day			Selbex	C		ORAL
5 mg/day			Rize	C		ORAL

Date:07/07/05ISR Number: 4709528-8Report Type:Expedited (15-DaCompany Report #ACO_0173_2005

Age: Gender:Male I/FU:I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route
Dose Hospitalization - DF PO	Duration Drug Screen Positive		Zanaflex	PS		ORAL
Initial or Prolonged DF PO	Feelings Of Worthlessness		Klonopin	SS		ORAL
DF PO	Loss Of Consciousness		Flexeril	SS		
DF PO	Multiple Drug Overdose		No-Doz	SS		ORAL
DF PO	Polysubstance Abuse		Lexapro	C		

Somnolence
Suicidal Ideation

Date:07/08/05ISR Number: 4710995-4Report Type:Expedited (15-DaCompany Report #ACO_0166_2005
Age:62 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Erythema	Health	Ternelin	PS		ORAL
2 MG QDAY PO							
Initial or Prolonged		Exanthem	Professional	Voltaren	SS		ORAL
75 MG QDAY PO							
		Hypotension		Mucosta	SS		
2 DF QDAY		Vomiting					

Date:07/08/05ISR Number: 4711002-XReport Type:Expedited (15-DaCompany Report #ACO_0174_2005
Age:48 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other		Difficulty In Walking	Foreign	Tizanidine	PS		ORAL
2 MG QDAY PO							
		Dizziness	Health	Propranol	C		
		Dry Mouth	Professional	Losartan Potassium			
		Feeling Abnormal	Other	W/Hydrochlorothiazid			
		Speech Disorder		e	C		
				Euthyrox	C		

Date:07/13/05ISR Number: 4715469-2Report Type:Expedited (15-DaCompany Report #KII-2005-0017347
Age:41 YR Gender:Female I/FU:I

Outcome
Hospitalization -
Initial or Prolonged

22-Aug-2005 12:09 PM
Page: 262

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Other

Dose	Duration	PT	Report Source	Product	Role	Manufacturer	Route
SEE TEXT,		Intentional Misuse Multiple Drug Overdose	Study Health	Morphine Sulfate (Morphine Sulfate)	PS		ORAL
ORAL		Oxygen Saturation	Professional				
SEE TEXT,		Decreased Polysubstance Abuse	Other	Tizanidine (Tizanidine)	SS		ORAL
ORAL		Respiratory Rate					
SEE TEXT,		Decreased		Diazepam (Diazepam)	SS		ORAL
ORAL		Respiratory Rate					
SEE TEXT,		Increased Sinus Tachycardia		Clonazepam (Clonazepam)	SS		ORAL
ORAL		Somnolence					
RESPIRATORY				Marijuana (Cannabis)	SS		
(INHALATION)	INHALATION						

Date:07/19/05ISR Number: 4718975-XReport Type:Expedited (15-DaCompany Report #ACO_0175_2005
Age:83 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Body Temperature	Foreign	Ternelin	PS		ORAL
1 MG QDAY; PO Hospitalization - 50 MG QDAY; Initial or Prolonged PO		Decreased	Health	Solantal	SS		ORAL
		Drug Interaction	Professional				
		Myocardial Infarction	Other	Marzulene	C		

Date:07/20/05ISR Number: 4718400-9Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009
Age:60 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization - 8 DAY		Abdominal Discomfort		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged 1 DAY		Abdominal Pain Acute Right Ventricular		Tizanidine Hydrochloride	SS		ORAL
1 DAY		Failure Bradycardia		Tizanidine Hydrochloride	SS		ORAL
1 DAY		Diarrhoea Hepatic Cyst		Tizanidine Hydrochloride	SS		ORAL
		Hepatic Enzyme Increased Hyperhidrosis Nausea Pulmonary Hypertension Sinus Bradycardia Vomiting		Diclofenac Sodium Herbs (Unspecified)	SS C		ORAL ORAL

Date:07/20/05ISR Number: 4719189-XReport Type:Expedited (15-DaCompany Report #S05-CAN-02441-01
Age:50 YR Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Other 40 MG QD		Aggression Drug Withdrawal Syndrome	Foreign Health	Citalopram (Hydrobromide)	PS		
UNKNOWN 100 MG QD	UNK	Personality Change Psychotic Disorder	Professional Other	Marijuana (Cannabis) Topimax (Topiramate)	SS SS		
12 MG QD		Speech Disorder		Zanaflex (Tizanidine Hydrochloride) Diphenhydramine	SS C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:07/29/05ISR Number: 4733536-4Report Type:Expedited (15-DaCompany Report #ZANA001129
 Age:61 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Myocardial Infarction	Foreign	Zanaflex	PS		ORAL
4 MG QDAY PO		Rash	Health	Zanaflex	SS		ORAL
4 MG QDAY PO		Respiratory Tract	Professional	Zanaflex	SS		ORAL
0.01 MG TID		Infection	Other				
PO	38 DAY	Ventricular Fibrillation		Vancocyn	C		
				Flagyl	C		
				Tylenol	C		
				Neurontin	C		
				Ativan	C		
				Valium	C		
				Diovol	C		
				Lovenox	C		

Date:08/01/05ISR Number: 4733326-2Report Type:Direct Company Report #CTU 254997
 Age:60 YR Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
		Drug Ineffective		Zanaflex	PS		ORAL
4 MG PO BID		Pharmaceutical Product Complaint					

Date:08/02/05ISR Number: 4736410-2Report Type:Expedited (15-DaCompany Report #ACO_0170_2005
 Age: Gender: I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Blood Pressure Systolic	Foreign	Ternelin	PS		ORAL
20 TAB ONCE		Decreased	Health				
Initial or Prolonged		Coma	Professional	Alcohol	SS		
PO		Intentional Misuse	Other				

Intentional Self-Injury
Overdose
Somnolence

Date:08/02/05ISR Number: 4736412-6Report Type:Expedited (15-DaCompany Report #ACO_0141_2005
Age:56 YR Gender:Male I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Chest Pain	Foreign	Ternelin	PS		
Other		Hypoaesthesia	Health				
DF		Peripheral Coldness	Professional				
			Other				

Date:08/03/05ISR Number: 4735833-5Report Type:Direct Company Report #CTU 255403
Age: Gender:Male I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose		Pharmaceutical Product		Zanaflex	PS		
Other		Complaint		Baclofen	C		
4MG TID		Vomiting		Artane	C		

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Date:08/15/05ISR Number: 4744888-3Report Type:Expedited (15-DaCompany Report #US-MERCK-0409USA01708

Age:21 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Death		Abnormal Chest Sound		Vioxx	PS	Merck & Co., Inc	ORAL
Hospitalization -		Aggression		Flexeril	SS		ORAL
Initial or Prolonged		Aspiration		Ultracet	SS		
UNKNOWN							
Other		Completed Suicide		Omeprazole	SS		ORAL
		Depressed Level Of		Elavil	SS		ORAL
		Consciousness		Tizanidine			
		Drug Interaction		Hydrochloride	SS		ORAL
		Drug Screen Positive					
		Drug Toxicity					
		Intentional Misuse					
		Lung Crepitation					
		Lung Disorder					
		Sedation					
		Self-Medication					
		Vomiting					

Date:08/16/05ISR Number: 4746208-7Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009

Age:60 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -		Abdominal Pain		Vioxx	PS	Merck & Co., Inc	ORAL
8 DAY							
Initial or Prolonged		Alanine Aminotransferase		Tizanidine			
		Increased		Hydrochloride	SS		ORAL
1 DAY							
		Aspartate		Tizanidine			
		Aminotransferase		Hydrochloride	SS		ORAL
1 DAY							
		Increased		Tizanidine			
		Back Pain		Hydrochloride	SS		ORAL
1 DAY							
		Blood Alkaline		Diclofenac Sodium	SS		ORAL
		Phosphatase Increased		Herbs (Unspecified)	C		ORAL
		Bradycardia					
		Chest Discomfort					
		Diarrhoea					
		Drug Interaction					
		Dyspnoea					

Fibrin D Dimer Increased
Gamma-Glutamyltransferase
Increased
Haemangioma Of Liver
Hepatic Cyst
Hepatic Lesion
Hyperhidrosis
Liver Disorder
Liver Function Test
Abnormal
Pleural Effusion
Pulmonary Hypertension
Right Ventricular Failure
Sinus Bradycardia
Vomiting

Date:08/18/05ISR Number: 4747990-5Report Type:Expedited (15-DaCompany Report #US-SANOFI-SYNTHELABO-A03200500832
Age: Gender:Female I/FU:F

Outcome PT
Other Abdominal Discomfort
Gastrointestinal

22-Aug-2005 12:09 PM

Page: 265

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Haemorrhage

Dose	Duration	Report Source	Product	Role	Manufacturer	Route
UNK			Ambien	PS		ORAL
UNK			Plavix	SS		ORAL
UNK			Carafate	SS		ORAL
UNK			Metoclopramide	SS		ORAL
UNK			Darvocet	SS		ORAL
UNK			Mycelelex	SS		
UNKNOWN	UNK		Promethazine	SS		ORAL
UNK			Lasix	SS		ORAL
UNK			Tizanidine	SS		ORAL

Date:08/18/05ISR Number: 4748218-2Report Type:Expedited (15-DaCompany Report #200516252US

Age: Gender:Female I/FU:I

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Dose							
Other		Abdominal Discomfort Gastrointestinal		Lasix	PS	Aventis Pharmaceuticals Inc.	ORAL
dose: UNKNOWN		Haemorrhage		Ambien	SS		ORAL
dose: UNKNOWN				Plavix	SS		ORAL
dose: UNKNOWN				Carafate	SS		ORAL
dose: UNKNOWN				Metoclopramide	SS		ORAL
dose: UNKNOWN				Darvocet-N	SS		ORAL
dose: UNKNOWN				Mycelelex	SS		
dose: UNKNOWN				Promethazine	SS		ORAL

dose: UNKNOWN

Tizanidine

SS

ORAL

Date:08/19/05ISR Number: 4749387-0Report Type:Expedited (15-DaCompany Report #CH-MERCK-0409CHE00009

Age:60 YR Gender:Female I/FU:F

Outcome	Duration	PT	Report Source	Product	Role	Manufacturer	Route
Hospitalization -	8 DAY	Bradycardia		Vioxx	PS	Merck & Co., Inc	ORAL
Initial or Prolonged	1 DAY	Hepatic Enzyme Increased		Tizanidine Hydrochloride	SS		ORAL
	1 DAY			Tizanidine Hydrochloride	SS		ORAL
	1 DAY			Tizanidine Hydrochloride	SS		ORAL
				Diclofenac Sodium	SS		ORAL
				Herbs (Unspecified)	C		ORAL

Summary report for FOI selections:

Selection by inexact search of active ingredient:

TIZANIDINE%

Selection by inexact search of Tradename/Verbatim:

ZANAFLEX%

Total number of reports: 1,065

From: 01-NOV-1997

To: Present

